

Curriculum Vitae

Natasha Leighl

A. Date Curriculum Vitae is Prepared: 2024 September 27

B. Personal Information

Correspondence language: English
Sex: Female
Date of Birth: 9/23
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Primary Office	Department of Medical Oncology & Hematology Princess Margaret Cancer Centre/UHN 700 University Avenue, Suite 7-913 Toronto, Ontario, Canada M5G 1Z5
Telephone	416 946 4645
Fax	416 946 6546
Email	natasha.leighl@uhn.ca

1. EDUCATION

Degrees

2001	MMedSc, (Master of Medical Science) Clinical Epidemiology, Faculty of Health and Medicine, University of Newcastle, Australia
1994	MD, Dept of Medicine, University of Toronto
1992	BSc, with Distinction, Life Sciences, Queen's University at Kingston, Kingston, Ontario

Postgraduate, Research and Specialty Training

2000 - 2001	Clinical Oncology Fellow, Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Supervisor(s): Prof. MHN Tattersall, Dr. MJ Boyer
1999 - 2000	Clinical Research Fellow, Division of Medical Oncology & Hematology, Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada, Supervisor(s): Dr. FA Shepherd
1997 - 1999	Medical Oncology Residency Training, Division of Medical Oncology and Hematology, University of Toronto, Toronto, Ontario, Canada, Supervisor(s): Dr. Ronald Burkes
1994 - 1997	Internal Medicine Residency Training, Internal Medicine, The University of Calgary, Calgary, Alberta, Canada

Qualifications, Certifications and Licenses

1998 - present	Independent Practice License, Medical Oncology, College of Physicians and Surgeons of Ontario, Ontario, Canada, License / Membership #: 69795
----------------	---

Natasha LEIGHL

2009 - 2019	Board Certification, Medical Oncology, The American Board of Internal Medicine, United States
1999 - 2009	Board Certification, Medical Oncology, The American Board of Internal Medicine, United States
1999	Specialist Certification, Medical Oncology, Royal College of Physicians and Surgeons of Canada, Canada
1998	FRCPC, Internal Medicine, Royal College of Physicians and Surgeons of Canada, Canada
1997	Board Certification, Internal Medicine, The American Board of Internal Medicine, United States

2. EMPLOYMENT

Current Appointments

2016 Jul - present	Professor, Medicine, Faculty of, University of Toronto, Canada
2011 Sep - present	Lung Site Lead, Princess Margaret Cancer Centre
2001 - present	Staff Physician, Medicine, Division of Medical Oncology & Hematology, Princess Margaret Hospital, Canada
2001 - present	Courtesy privileges, Mount Sinai Hospital, Canada

Previous Appointments

HOSPITAL

1998 - 2000	Assistant Physician (part-time), Departments of Medicine, Medical Oncology/Hematology, Sunnybrook and Women's College Health Sciences Centre, Canada <i>(both sites)</i>
-------------	---

RESEARCH

2012 - 2022	OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development, Princess Margaret Cancer Foundation, Medicine, University of Toronto, Toronto, Ontario, Canada
-------------	---

UNIVERSITY

2013 Jul 1 - 2015	Associate Graduate Faculty, Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
-------------------	--

UNIVERSITY - RANK

2010 Jul - 2016 Jun	Associate Professor, University of Toronto, Canada
2003 - 2010	Assistant Professor, Medicine, University of Toronto, Canada

OTHER

2017 Jul - 2023 Jun 30	Professor, Status-Only, Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada <i>Clinical Epidemiology & Health Research Program</i>
------------------------	---

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

INTERNATIONAL

Received

Natasha LEIGHL

2018 - present **Fellow of ASCO**, American Society of Clinical Oncology. (Credential)
2019 **ASCO Special Awards: 2019 Excellence in Teaching Award**, American Society of Clinical Oncology, Chicago, Illinois, United States. (Distinction)
2003 **Young Investigator Award**, International Association for the Study of Lung Cancer. (Research Award)
2002 - 2005 **Career Development Award**, American Society of Clinical Oncology. (Research Award)
Total Amount: 170,000 USD
2001 **Merit Award**, American Society of Clinical Oncology. (Research Award)
2001 **Young Investigator Award**, American Society of Clinical Oncology. (Research Award)
Total Amount: 35,000 USD
2000 **Merit Award**, American Society of Clinical Oncology. (Research Award)
1999 **Fellow travel award**, ASCO/AACR Workshop: Methods in Clinical Cancer Research, Vail, United States. (Research Award)

Nominated

2023 Jan - 2023 Dec **Daniel C. Ihde Lectureship Award for Medical Oncology**, International Association for the Study of Lung Cancer. (Distinction)
2015 Oct America's Best Physicians

NATIONAL

Received

2019 - present **Honorary Lifetime Board Member**, Lung Cancer Canada. (Distinction)
2016 Nov **HOPE Award**, Lung Cancer Canada. (Distinction)
Awarded for outstanding contributions to awareness, education and support of lung cancer patients and families.
2005 **Annual Honoree**, Sikh Centennial Foundation. (Distinction)

Nominated

2023 **Distinguished Service Award**, Canadian Association of Medical Oncology. (Distinction)

PROVINCIAL / REGIONAL

Received

1993 **PAIRO Trust Fund Citizenship Award**, Professional Association of Internes and Residents of Ontario. (Distinction)
1991 **Ontario Breast Cancer Foundation Award**, Ontario Breast Cancer Foundation. (Research Award)
1988 **Ontario Scholarship**. (Distinction)

LOCAL

Received

2020 Feb **Best Poster #2 (2020 Cancer AI and Big Data: Success through Global Collaboration)**, Senior Responsible Author, Joint Princess Margaret/International Cancer Expert Corps. (Research Award)

Natasha LEIGHL

Using AI to Improve Precision Medicine: Real-world impact of biomarker testing in advanced lung cancer.

2017 Mar - 2022 Mar

OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development, Princess Margaret Cancer Program, University Health Network and University of Toronto, Toronto, Ontario, Canada. (Research Award, Specialty: Medical Oncology)
Research Chair for drug development in lung cancer. Total Amount: 500,000 CAD

2012 Jun

Young Investigator Award, Division of Medical Oncology, University of Toronto. (Research Award)

2012 Mar - 2017 Mar

OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development, Princess Margaret Cancer Program, University Health Network and University of Toronto, Toronto, Ontario, Canada. (Research Award, Specialty: Medical Oncology)
Research Chair for drug development in lung cancer. Total Amount: 500,000 CAD

2010 Jun

Young Investigator Award, Division of Medical Oncology, Mount Sinai/University Health Network. (Research Award)

2000

Research Presentation Award, Division of Medical Oncology, University of Toronto. (Research Award)

1999

Research Presentation Award, Annual Research Day, Division of Medical Oncology, University of Toronto. (Research Award)

1999

Rhone-Poulenc-Rorer Fellowship in Lung Cancer Award, Rhone-Poulenc-Rorer Fellowship. (Research Award)

1994

Alumni Association Award, University of Toronto Faculty of Medicine. (Distinction)

1994

Robert P. Orange Medal, Faculty of Medicine, University of Toronto. (Distinction)

1993

Honor Award, University of Toronto Medical Society. (Distinction)

1990

Summer Studentship, Ontario Cancer Institute. (Distinction)

1988

Longstaffe Scholarship, Queen's University. (Distinction)

Teaching and Education Awards

INTERNATIONAL

Received

Excellence in Teaching Award, American Society of Clinical Oncology

LOCAL

Received

2006

Outstanding Teacher Award, Medical Oncology Training Program, Oncology (Medical), Dept of Medicine, Faculty of Medicine, University of Toronto, Canada. (Postgraduate MD)

2004

Outstanding Teacher Award, Medical Oncology Training Program, Oncology (Medical), Dept of Medicine, Faculty of Medicine, University of Toronto, Canada. (Postgraduate MD)

2003 - 2005

Excellent Teacher Citation, Medical Oncology Ambulatory Rotation, Dept of Medicine, Faculty of Medicine, Internal Medicine On-site Review, Canada

Nominated

2020 Jun

2019-2020 University of Toronto MOTP Outstanding Teaching Award, Oncology (Medical), Dept of Medicine, Faculty of Medicine, DMOH-Princess Margaret Cancer Centre. (Postgraduate MD)

Student/Trainee Awards

INTERNATIONAL

Received

- 2022 Feb **IASLC TT Education Award**, Senior Responsible Author, Awardee Name: Miguel Garcia. International Association for the Study of Lung Cancer, United States
Total Amount: 2,000 USD
- 2021 Jun **Novartis Oncology Young Canadian Investigator Award (ASCO)**, Senior Responsible Author, Awardee Name: Carly Barron. Novartis, United States
Total Amount: 5,000 CAD
- 2019 **CCF/ASCO Merit Award**, Supervisor, Awardee Name: Dr. Kirstin Perdrizet. Conquer Cancer Foundation
Use of Comprehensive NGS in advanced NSCLC patients in a publicly funded healthcare system. Total Amount: 1,000 USD
- 2018 **CCF/ASCO Merit Award**, Awardee Name: Dr. Doreen Ezeife. Conquer Cancer Foundation
Financial toxicity among patients with lung cancer in a publicly funded health care system (Quality Care Symposium).
- 2016 Jul - 2016 Dec **ESMO 2016 Travel Grant for Young Oncologists**, Senior Responsible Author, Awardee Name: Mark Doherty. European Society of Medical Oncology (ESMO)
*Selected for abstract: *Unsung Heroes in Lung Cancer*. Total Amount: 600 EUR*
- 2013 **2013 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research**, Awardee Name: Donna Graham. 2013 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research
Selected for Workshop with Participant Funding for protocol MEK162 in combination with pemetrexed/platinum in KRAS mutant lung carcinoma. Total Amount: 3,000 EUR
- 2012 **2012 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research**, Awardee Name: Olusola Faluyi. 2012 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research
Selected for Workshop with Participant Funding for protocol preoperative metformin in early stage lung cancer. Total Amount: 3,000 EUR
- 2011 **ASCO Merit Award**, Awardee Name: Dr. Adrian Sacher. American Society of Clinical Oncology
Shifting patterns of "positive" trials in advanced NSCLC.
- 2008 **ASCO Merit Award**, Awardee Name: Penny Bradbury. American Society of Clinical Oncology
Cost effectiveness analysis and cost - utility of erlotinib 2nd and 3rd line after chemotherapy failure in advanced NSCLC, NCIC CTG BR.21.
- 2008 **ASCO Merit Award**, Awardee Name: Raymond Jang. American Society of Clinical Oncology
Q-TwiST analysis of BR. 10 adjuvant therapy in NSCLC.
- 2006 **2006 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research**, Awardee Name: Antonio Visbal. 2006 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research
Selected for Workshop with Participant Funding for protocol preoperative erlotinib in early stage lung cancer (SELECT).
- 2004 **2004 AACR-ASCO Workshop on Methods in Clinical Cancer Research**, Awardee Name: Anthony Joshua. 2004 AACR-ASCO Workshop on Methods in Clinical Cancer Research
Selected for Workshop with Participant Funding for protocol preoperative gefitinib in early stage lung cancer (NIFTEE).

NATIONAL

Received

- 2019 **Novartis Young Canadian Investigator Award**, Supervisor, Awardee Name: Dr. Kirstin Perdrizet. Novartis
Use of Comprehensive NGS in advanced NSCLC patients in a publicly funded healthcare system. Total Amount: 10,000 CAD
- 2017 Jul - 2018 Jun **Medical Oncology Fellowship Award**, Supervisor, Awardee Name: Doreen Ezeife. Canadian Association of Medical Oncologists (CAMO)
Fellowship Award for Project to Develop Prioritization Framework for Oncology Drug Funding Decisions. Total Amount: 75,000 CAD
- 2017 Jan **Betty Rice Award**, Supervisor, Awardee Name: Charles Lim. Canadian Lung Cancer Conference
Awarded for research into biomarker testing and delays in patient care in lung cancer. Total Amount: 3,000 CAD
- 2016 Jun - 2016 Dec **Lung Cancer Canada Summer Studentship Award**, Supervisor, Awardee Name: Mike Sung. Lung Cancer Canada
Awarded for project examining role of neutrophil lymphocyte ratio in immunotherapy treated NSCLC patients. Total Amount: 5,000 CAD
- 2014 **Canadian Association of Medical Oncology 2014 Annual Meeting Best Resident Abstract Award**, Awardee Name: Charles Lim. 2014 CAMO annual meeting, Canada
Best Resident Abstract for "Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)"-Certificate and Honorarium. Total Amount: 1,000 CAD
- 2013 Jul - 2014 Jun **Canadian Cancer Society Research Institute Travel Award**, Awardee Name: Kitman Wong. Canadian Cancer Society Research Institute
Travel Award to present cost analysis of gene signature in NCIC CTG adjuvant JBR.10 trial. Total Amount: 2,000 CAD
- 2012 **Novartis Oncology Young Canadian Investigator Award**, Awardee Name: Adrian Sacher. Novartis Canada
Pharmacoeconomic outcomes of advance NSCLC therapy in Ontario.
- 2011 Jul - 2011 Dec **PSI Foundation Award**, Awardee Name: Tina Hsu. Physician Services Incorporated Foundation
Awarded for her study: Objective markers of chemotherapy toxicity in the elderly. Total Amount: 4,000
- 2011 Jul **Canadian Association for Population Therapeutics Annual Meeting Best Student Presentation**, Awardee Name: Ilia Ferrusi. Canadian Association for Population Therapeutics
A cost-effectiveness analysis of targeted therapy for HER-2 positive breast cancer based on Canadian practice patterns.
- 2011 **Novartis Oncology Young Canadian Investigator Award**, Awardee Name: Adrian Sacher. Novartis
Patterns in outcomes of clinical trials in advanced NSCLC.
- 2008 Jul **PSI Resident Research Prize**, Awardee Name: Raymond Jang. PSI Foundation
Q-TwiST analysis of NCIC CTG BR. 10 clinical trial of adjuvant therapy in NSCLC.
- 2008 **Novartis Oncology Young Canadian Investigator Award**, Awardee Name: Penny Bradbury. Novartis Canada
Cost effectiveness analysis and cost- utility of erlotinib 2nd and 3rd line after chemotherapy failure in advanced NSCLC, NCIC CTG BR.21.
- 2008 **Novartis Oncology Young Canadian Investigator Award**, Awardee Name: Raymond Jang. Novartis Canada
Q-TwiST analysis of BR.10 adjuvant therapy for NSCLC.
- 2006 May **Novartis Oncology Young Canadian Investigator Award**, Medical Oncology, Supervisor, Awardee Name: Dr. Raymond Ng. Novartis Oncology Canada
Total Amount: 5,000 CAD

PROVINCIAL / REGIONAL

Received

- 2018 Aug - 2019 Jul **Postgraduate Ontario Student Opportunity Trust Funds Award**, Supervisor, Awardee Name: Kirstin Perdrizet. University of Toronto Division of Medical Oncology
Total Amount: 10,000 CAD
- 2017 Aug - 2018 Jul **Postgraduate Ontario Student Opportunity Trust Funds Award**, Supervisor, Awardee Name: Doreen Ezeife. University of Toronto Division of Medical Oncology
Total Amount: 10,000 CAD
- 2013 **OCI Travel Award**, Clinical Research Fellow, Medical Oncology, Awardee Name: Donna Graham
To support ECCO-AACR-EORTC-ESMO Workshop costs. Total Amount: 1,600 CAD
- 2012 **OCI Travel Award**, Clinical Research Fellow, Medical Oncology, Awardee Name: Olusola Faluyi
To support ECCO-AACR-EORTC-ESMO Workshop costs. Total Amount: 1,600 CAD

LOCAL

Received

- 2021 Jul - 2022 Jun **Fellowship Award (Research)**, Medical Oncology, Senior Responsible Author, Awardee Name: Miguel Garcia. Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Total Amount: 25,000 CAD
- 2020 Jun **2nd Place Oral Abstract Presentation**, Supervisor, Awardee Name: Maisam Makarem. 2020 CAMO Virtual AGM and Oral Abstract Presentations
"Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System".
- 2020 Jun **MACK Foundation Bursary**, Supervisor, Awardee Name: Maisam Makarem. UHN- Post Graduate Medicine, Toronto, Ontario, Canada
"Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System". Expense reimbursement for presentation at CAMO. Total Amount: 700 CAD
- 2015 **2015 University of Toronto Division of Medical Oncology Annual Division Research Award**, Awardee Name: Charles Lim. University of Toronto
Patients with advanced non-small cell lung cancer: Are research biopsies a barrier to participation in clinical trials.
- 2012 **2012 University of Toronto Division of Medical Oncology Annual Division Research Award**, Awardee Name: Adrian Sacher. University of Toronto
Pharmacoeconomic outcomes of advanced NSCLC therapy in Ontario.
- 2011 Jun **Annual Research Day Award - 1st Prize**, Awardee Name: Adrian Sacher. University of Toronto Division of Medical Oncology
awarded to Dr. Adrian Sacher for his presentation: Patterns in outcomes of clinical trials in advanced NSCLC.
- 2011 May - 2011 Aug **Comprehensive Research Experience for Medical Students Award**, Medical Oncology, Awardee Name: Rick Chen. Faculty of Medicine, University of Toronto, Ontario, Canada
Total Amount: 2,750 CAD
- 2010 **McMaster Faculty of Health Science Excellence Award**, Awardee Name: Ilia Ferrusi
Thesis topic: A cost-effectiveness analysis of targeted therapy for HER-2 positive breast cancer based on Canadian practice patterns.
- 2009 **1st Prize- University of Toronto Medical Oncology Annual Research & Awards Day**, Awardee Name: Robert Goldberg
Willingness to pay for VEGF inhibitors in advanced NSCLC.

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Administrative Activities

INTERNATIONAL

Other Organizations

2022 Dec - 2022 Dec 30 Data Monitoring Committee- Abbie Study -ABBV-647- DECLINED

AbbVie Global Medical Affairs

2022 Dec Member of Solid Tumor Advisory Council- DECLINED

American Society of Clinical Oncology

2023 Nov 3 - present 2024 ASCO Breakthrough Program Committee
2023 Oct 30 - present ASCO Special Awards Committee
2016 - present **Member**, ASCO Thoracic Cancer Guideline Advisory Group
Systemic Therapy for Stage IV NSCLC Guideline Expert Panel.
2018 - 2019 **Member**, Clinical Practice Guidelines Committee
Lung Cancer Follow Up Guideline Panel.
2017 - 2019 **Member**, Clinical Practice Guidelines Committee
Management of Immune-Mediated Side Effects Guideline Panel.
2017 - 2019 **Member**, Clinical Practice Guidelines Committee
Update: Lung Cancer Biomarker Testing Guideline Panel.
2017 **Reviewer**, ASCO Educational Book 2017, Faculty of Medicine, Dept of Medicine
2016 - 2019 **Member**, Clinical Practice Guidelines Committee
ASCO CPGC Methodology Subcommittee.
2016 - 2019 **Member**, Clinical Practice Guidelines Committee
Management of Stage IV NSCLC Guideline Panel.
2015 - 2017 **Member**, Clinical Practice Guidelines Committee
ASCO Guideline Program.
2014 - 2018 **Member**, ASCO Thoracic Cancer Guideline Advisory Group
ASCO Guideline Program.
2013 2013 Best of ASCO Faculty, Faculty of Medicine, Dept of Medicine, United States.
2013 **Mentor**, International Development and Education Award (IDEA)
2012 - 2014 **Member**, ASCO Thoracic Cancer Guideline Advisory Group
ASCO Guideline Program.
2012 - 2013 **Track Leader**, Cancer Education Committee - Lung Cancer Track, Faculty of Medicine, Dept
of Medicine
*ASCO Annual Meeting Lung Sessions Design/Planning; Peer review of ASCO abstracts
(~500 per year).*
2011 Jun - 2012 Jun **Participant**, Leadership Development Program
2011 - 2016 **Cancer Education Committee Liaison**, Multidisciplinary Cancer Management Course
Working Group
2011 - 2012 **Associate Editor**, ASCO Educational Book 2012, Faculty of Medicine, Dept of Medicine
2010 Jun - 2013 Jun Continuing Medical Education Reviewer, Faculty of Medicine, Dept of Medicine
2010 - 2013 **Member**, Cancer Education Committee - Lung Cancer Track, Faculty of Medicine, Dept of
Medicine
*ASCO Annual Meeting Lung Sessions Design/Planning; Peer review of ASCO abstracts
(~500 per year).*

Natasha LEIGHL

2010 - 2011 **Associate Editor**, ASCO Educational Book 2011
2009 - 2011 **Member**, International Affairs Committee (IAC) Steering Committee
2008 - 2011 Jun **Member**, International Affairs Committee (IAC)
2006 - 2009 **Member**, Bylaws Committee

Americas Health Foundation

2017 Nov - present Board of Directors
2017 Nov - present Advisory Committee

Amgen

2023 Mar - present Amgen 20210004 Clinical Trial Steering Committee

ARIAD Pharmaceuticals ALTA AP26113-13-201 International Trial

2014 - 2016 **Member**, International Phase III Trial Steering Committee (ALTA AP26113-13-201)

Astra Zeneca

2021 Apr Lung External Advisory Steering Council, United States.

AstraZeneca

2020 Oct - present Steering Committee-LUMINANCE Clinical Trial

ATTRACT-2 Clinical Trial

2009 - 2012 **Member**, International Phase III Study Steering Committee (Novartis ASA404A2302)

BioAlta- Conditionally Active CTLA-4 in NSCLC

2023 Nov IDMC Participation-DECLINED

Boehringer Ingelheim Global

2010 - 2014 **Member (Uncompensated)**, Global Advisory Board Vargatef (Nintedanib)

Bristol Myers Squibb

2022 Feb Global HTA Advisory Board - Declined for conflicts

Canadian Cancer Trials Group

2016 - present **Chair**, BR.34 Study Chair
2016 - present **Principal Investigator S1400F Substudy**, BRC.6 (SWOG S1400) Study Chair
2016 - present **Chair**, BRC.6 (SWOG S1400) Study Chair
2014 - present **Member**, BR.31 International Trial Steering Committee

Conquer Cancer Foundation

2015 - 2019 Grants Selection Committee (CDA Grants Selection), Alexandria, United States.

Conquer Cancer Foundation (ASCO)

2021 Aug - 2022 Jun **Reviewer**, Grants and Awards Program
International Innovation Grant Panel.
2021 Jun - 2022 Jun **Reviewer**, Grants and Awards Program

Natasha LEIGHL

Gateway Discovery Grant Panel.

Daiichii Sankyo

2022 Apr Member, IDMC HERTHENA-Lung02 Phase III RCT HER3-DxD

EMD Serono Medical Affairs Department

2021 Apr NSCLC Journal Club Moderator - DECLINED DUE TO TIME CONSTRAINTS, Continuing Education, United States.

ESMO 2020

2020 Jul Scientific Steering Committee

European Lung Cancer Congress 2021

2020 Sep - present Scientific Committee - Targeted Therapy Co-Chair, Lugano, Switzerland.

European Society for Medical Oncology

2022 Dec - 2024 Apr Co-Chair 2024 European Lung Cancer Congress

European Society of Medical Oncology

2022 May - present Lines of Therapy (LoT) Thoracic Subcommittee Member

2021 Aug - 2022 Dec **Subject Editor**, ESMO Guidelines Committee
Lung & Chest Tumours (localized disease).

2021 Apr - 2022 Apr Expert Consensus Statement Lead 4 - metastatic EGFR mutated NSCLC

2021 Apr - 2022 Apr **Member**, Metastatic NSCLC Track
Scientific Committee, European Lung Cancer Congress 2022.

2021 Jan - 2021 Dec **Chair**, Education Committee
Virtual Advanced Course on KRAS mutant NSCLC - Co-chair and developer.

2021 - 2022 Dec **Member**, Metastatic NSCLC Track
Scientific Committee ESMO 2022 Annual Meeting.

2020 Apr - 2021 Apr **Member**, Metastatic NSCLC Track
Scientific Committee, European Lung Cancer Congress 2021.

2020 Mar - 2024 Dec **Faculty Coordinator**, Metastatic NSCLC Track
Educational Committee.

2020 Jan - 2021 Oct **Member**, Metastatic NSCLC Track
Scientific Committee ESMO 2021 Annual Meeting.

2019 Apr - 2020 Apr **Targeted Therapies Track Co-Lead**, Metastatic NSCLC Track
Scientific Committee, European Lung Cancer Congress 2020.

2019 Mar - 2020 Sep **Chair**
NSCLC Metastatic Chair ESMO 2020 Annual Meeting.

2019 - 2020 **Chair**, Metastatic NSCLC Track
Scientific Committee ESMO 2020 Annual Meeting.

Federation of Latin American Cancer Societies/American Society of Clinical Oncology

2013 Jul - 2014 Jun Multidisciplinary Cancer Management Course Faculty, Faculty of Medicine, Dept of Medicine, Uruguay.

Genentech

2016 Global Advisory Board: Atezolizumab

Natasha LEIGHL

Global Asia Institute- National University of Singapore

2023 Dec Medical Reviewer-DECLINED

GSK

2023 Nov Steering Committee- Belrestotug- DECLINED

Helsinn Healthcare

2021 Apr Member, IDMC HM06-19-26 (NCT04683250)

Imagene

2023 Jul - present **Medical Advisor**, Scientific Advisory Board, Pennsylvania, United States.

International Association for the Study of Lung Cancer

2022 Feb - present IASLC Academy Mentorship Faculty

2019 Feb - present LCFA/ILCF Young Investigator Award Reviewer

2016 Feb - present Quality and Value Taskforce

2012 - present **Editorial Board Member**, Journal of Thoracic Oncology

2022 Oct - 2023 Sep IASLC WCLC 2023 Track Committee

2022 Jan - 2022 Dec IASLC Academy, Academic Faculty, Faculty Development

2021 Mar - 2021 Sep **Program Track Member**, World Conference on Lung Cancer 2021 Program Committee
Liquid Biopsy Track.

2021 Feb - 2021 Aug **Abstract Reviewer**, World Conference on Lung Cancer 2021 Program Committee

2019 Feb - 2020 Oct Liquid Biopsy Meeting 2020 Faculty

2019 Feb - 2020 Aug **Member**, World Conference on Lung Cancer 2020 Program Committee

2014 - 2018 19th World Conference on Lung Cancer Congress Co-President, Continuing Education

2012 - 2016 **Web Editor**, Journal of Thoracic Oncology

2012 - 2015 **Member**, Career Development Committee

2012 - 2015 **Member**, Continuing Medical Education Subcommittee

2007 - 2011 **Member**, Communications Committee

Janssen

2023 Mar - present Janssen EGFR NSCLC Real-World Evidence Publication Steering Committee

2022 Jun - present PALOMA-2 Steering Committee

2022 Apr - present PALOMA-3 Steering Committee

2021 Dec - present MARIPOSA-2 Steering Committee

Janssen Inc

2023 Oct 16 - present 2024 Medical Education Steering Committee for Lung Cancer

Jazz Pharmaceuticals

2021 Jul - present Lurbinectidin Global Thoracic Oncology Steering Committee

Journal of Thoracic Disease

2023 Jun Editorial Board Member-DECLINED

Natasha LEIGHL

Lung Cancer Foundation of America

2016 Feb - present Scientific Advisory Board Member

Lung Cancer International

2016 Jul - 2018 Editorial Board Member

Lung Cancer Research Foundation

2024 Feb Scientific Advisory Board-DECLINED

Lung Cancer U.S. Intergroup

2004 - 2006 **Member**, Limited Stage Small Cell Lung Cancer Committee

Merck Sharp & Dohme

2020 Jun - present MK-7902 LEAP Lung Steering Committee

Merck Sharp Dohme

2016 - present EMEAC Lung Cancer Advisory Board (uncompensated)

Mirati Therapeutics

2020 Oct Member, IDMC MRTX549-012 (KRYSTAL-12)

Multinational Association of Supportive Care in Cancer

2003 - 2006 **Member**, Organizing Committee, 2006 Annual Meeting

National Cancer Institute

2005 **Member**, Phase II Common Data Elements (CDEs) Lung Cancer Committee, Cancer Therapy Evaluation Program

2005 **Member**, Phase II Common Data Elements (CDEs) Breast Cancer Committee, Cancer Therapy Evaluation Program

National Cancer Institute Center for Cancer Research

2021 Dec - present Office of Sponsor and Regulatory Oversight PD-L1 Committee DSMB, United States.

NCIC Clinical Trials Group

2012 - present **Member**, BR.26 International Trial Steering Committee

2010 - present **Chair**, BRC.2 Study Chair (International Cooperative Group Trial US NCI E1505)

2010 - present **Chair**, BRC.2E Study Chair (International Cooperative Group Clinical Trial US NCI E1505)

2001 - present **Chair**, BR.18 International Study Chair

Novartis

2021 Jul - present Capmatinib Steering Committee

Oncogenex (US)

2006 - 2007 **Member**, Data Safety Monitoring Board, OGX011 plus gemcitabine/cisplatin in advanced NSCLC; PI Dr. J. Laskin, BCCA

Natasha LEIGHL

PrIME Oncology

2016 - present Young Investigator Forum Faculty

Regeneron

2023 Oct 19 - 2023 Oct 20 **Medical Advisor**, Regeneron Lung Cancer Portfolio Advisory Board
2021 Nov - 2022 Dec Cemiplimab Publication Steering Committee

Southwest Oncology Group

2016 - present **Chair**, Lung MAP S1400F SubStudy Principal Investigator

The International Lung Cancer Foundation

2020 Jul - 2020 The International Lung Cancer Foundation's Research Awards Review Committee

Young Investigators Forum in Lung Cancer- Faculty

2021 Oct 8 - 2021 Oct 9 **Faculty**, Atlanta, Georgia, United States.
2020 May 14 - 2020 May 16 **Faculty**, Atlanta, Georgia, United States.

NATIONAL

Anti-Angiogenesis in Cancer Education Program (Oncology.ca sponsor/organizer)

2007 - 2008 **Member**, Organizing Committee
(> 20 hrs).

Canadian Association of Medical Oncologists

2007 - 2008 **Co-Chair**, 2008 Annual Scientific Committee and Symposium
May 1, 2008.

Canadian Association of Medical Oncology

2021 Sep - present **Mentor**, National Virtual Mentorship Program

Canadian Cancer Real-world Evaluation (CCRE) Platform

2023 Nov Clinical Advisory Group-DECLINED

Canadian Cancer Society Research Institute

2017 - 2018 **Co-Chair**, Quality of Life Grants Committee
2016 - 2017 **Co-Chair**, Quality of Life Grants Committee
2015 - 2016 **Co-Chair**, Quality of Life Grants Committee
2013 - 2014 **Co-Chair**, Quality of Life Grants Committee
2012 - 2013 **Co-Chair**, Quality of Life Grants Committee

Canadian Cancer Trials Group

2004 - present **Member**, Committee on Economic Analysis (formerly Working Group on EA)
2007 - 2019 **Member**, Lung Cancer Executive Committee
2007 - 2018 **Chair**, Committee on Economic Analysis (formerly Working Group on EA)

Canadian Centre for Applied Research in Cancer Control (ARCC)

Natasha LEIGHL

2012 - present **Member**, ARCC Network

Canadian Lung Cancer Conference

2014 Jan - present Executive Committee CLCCO, Continuing Education

Canadian Partnership Against Cancer

2011 - present **Member**, Pan-Canadian Lung Cancer Screening Initiative

Canadian Task Force on Preventative Health Care

2020 Dec - present Lung Cancer Screening Guideline Working Group, Canada.

Canadian Task Force on Preventive Healthcare

2020 Jul 1 - present Lung Cancer Screening - Clinical Expert, Canada.

CHESTMATE SUMMIT (sponsored by Lilly Oncology; Faculty Chair Dr. Barb Melosky)

2006 Oct 24 **Member**, Program Committee

CPD MEDSCAPE Non-Small Cell Lung Cancer Educational Program

2003 Sep - 2005 May **Member**, Planning Committee
(40 hrs).

Dalhousie University

2014 **External Reviewer**, Faculty of Medicine Promotions Committee, Faculty of Medicine, Dept of Medicine

Exactis

2021 Jan - present **Chair**, Exactis-01 Advisory Committee
Exactis-01 Advisory Committee.

Health Canada Therapeutic Drugs Directorate

2009 - present **Ad Hoc Member**, Scientific Advisory Committee on Oncology Therapies

Lung Cancer Canada

2017 - 2018 **Co-chair, Advocacy Commit**, Board

2016 - 2019 **Past President**, Board

2009 - 2016 **President**, Board

2008 - 2011 **Chair**, Medical Advisory Committee

2007 - 2019 **Director**, Board

NCIC Clinical Trials Group

2012 - present **Chair**, IND.196 Study Chair

Next Generation Sequencing Coalition- Member

2020 Jul 5 - present

Novartis Young Canadian Investigator Awards (NOYCIA)

Natasha LEIGHL

2015 Apr - 2017 Jun NOYCIA Panel Judge

Pan-Canadian Oncology Drug Review

2019 - 2020 **Member**, Clinical Expert Panel
Clinical Panel Larotrectinib review, Clinical Expert Panel
2016 - 2017 **Clinical Lead Osimertinib Review**, Clinical Expert Panel
Member, Economic Panel

Royal College of Physicians and Surgeons of Canada

2007 - 2011 **Member**, Examination Board for Medical Oncology, Faculty of Medicine, Dept of Medicine

The University of Alberta

2010 **External Reviewer**, Faculty of Medicine Promotions Committee, Faculty of Medicine, Dept of Medicine

The University of British Columbia

2008 **External Reviewer**, Faculty of Medicine Promotions Committee, Faculty of Medicine, Dept of Medicine

The University of Ottawa

2014 **External Reviewer**, Faculty of Medicine Promotions Committee, Faculty of Medicine, Dept of Medicine

PROVINCIAL / REGIONAL

Cancer Care Ontario

2016 - present Lung Drug Advisory Committee, Ontario, Canada.
2007 - present **Member**, Provincial Lung Disease Site Group
Practice Guidelines Initiative.
2016 - 2019 CCO Working Group on Immune Therapy Toxicity
2012 Jul - 2019 Systemic Treatment Program, Ontario, Canada.
2010 - 2012 **Reviewer**, Case-by-Case Review Program
Member, Lung Drug Advisory Committee

Cancer Care Ontario Program in Evidence Based Care

2013 - 2014 Survivorship Program Guideline Author: Follow-up and surveillance of curatively treated lung cancer patients
2013 - 2014 Pathology Guideline Working Group Author: Best Practices for Oncologic Pathology
Secondary Review: Lung Cancer

EXON 20 Honorary Chair

2020 Feb - present

First Ontario Thoracic Cancer Conference

2005 - 2006 **Member**, Organizing Committee

Ministry of Health

Natasha LEIGHL

2007 - 2012 **Member**, Joint Committee to Evaluate Drugs and Cancer Care Ontario (CED/CCO) Subcommittee (Advisory Group to JODR re Cancer Drug Funding), Ontario, Canada.

Ontario Clinical Oncology Group

2003 - 2009 **Member**, Steering Committee, PET Imaging in Stage III Non-small Cell Lung Cancer Trial

Peel Public Health

2007 **External Reviewer**, Lay Health Educator Breast Cancer Screening Program Curriculum

LOCAL

Other Organizations

2022 Oct - 2022 Oct 30 PM Catalyst and Invest in Research Grants Review Committee- DECLINED

CHOICE - Interactive Non-small Cell Lung Cancer Educational Program (Sponsored by Rx Media; Faculty Chair: Dr. Barb Melosky)

2007 - 2008 **Member**, Program Committee

Princess Margaret Cancer Centre, University of Toronto

2015 - 2016 **Co-Chair**, Personalizing Cancer Medicine Conference 2016

Princess Margaret Cancer Centre/University Health Network

2020 Jul - present Co-Chair, Sytemic Therapy Steering Committee, Toronto, Ontario, Canada.

2020 - present Member, Global Cancer Program Advisory Group, Toronto, Ontario, Canada.

2011 Sep - present Division of Medical Oncology Lung Site Lead

2021 Jan - 2021 Feb Thoracic Surgery Chair Search Committee (Hospital Head, Division Chair), Toronto, Ontario, Canada.

Princess Margaret Hospital/University Health Network

2013 - present **Member**, Medical Advisory Committee Tissue Subcommittee

2009 **Member**, Organizing Committee – 9th Annual Princess Margaret Hospital Conference

2006 **Member**, Search Committee, Division Head Hematology/Oncology

2006 **Member**, Breast Site Group Tissue Bank Committee

2006 **Member**, Search Committee, Director Medical Oncology Services

2005 - 2006 **Member**, Organizing Committee - 6th Annual Princess Margaret Hospital Conference

2005 **Member**, Breast Quality Accreditation Team

2003 - 2009 **Member**, Data Safety Monitoring Board, Preoperative esophageal chemoradiation study *Trial PI - Darling, Wong, Knox.*

2003 - 2007 **Member**, Comprehensive Breast Centre Quality Team

2003 - 2007 **Member**, Breast Tumour Board, Faculty of Medicine, Dept of Medicine, Continuing Education ~ 4 x/yr/ ~2hrs/yr.

2002 - 2005 **Member**, Research Ethics Board C (Oncology)

University Health Network

2009 **Member**, Postgraduate Advisory Council

University of Toronto

Natasha LEIGHL

2020 Continuing Appointment Review (Dr. D. Shultz), Faculty of Medicine, Dept of Radiation Oncology, Toronto, Ontario, Canada.

2005 - 2019 **Faculty Advisor**, Lung Section, Medical Oncology Training Program Half-Day, Faculty of Medicine, Dept of Medicine, Postgraduate MD

2005 - 2013 **Rotation Coordinator**, Medical Oncology Training Program Committee, Faculty of Medicine, Dept of Medicine, Postgraduate MD

2004 - 2013 **Faculty Coordinator**, Pathobiology of Disease Course, Faculty of Medicine, Dept of Medicine, Undergraduate MD

2001 - 2004 **Dept. Medicine representative**, Task Force on Palliative Care in Undergraduate Medical Education, Faculty of Medicine, Dept of Medicine, Undergraduate MD

2001 - 2004 **Division of Medical Oncology Representative**, Department of Medicine Undergraduate Education Committee, Faculty of Medicine, Dept of Medicine, Undergraduate MD

University of Toronto Department of Radiation Oncology

2020 Jul 1 - 2021 Jun 30 Promotion Review: Dr. Alexander Louie

University of Toronto Division of Thoracic Surgery

2019 Feb - 2019 Jun 30 Program Committee Toronto Thoracic Surgery Refresher Conference

OTHER

Amgen

2022 Jan - present Global Thoracic Executive Advisory Council

AstraZeneca Sponsored Education Program- Advanced EGFRm NSCLC

2024 Feb Faculty Member- DECLINED

Daiichi Sankyo

2022 May - 2022 Jun 30 DMC Physician Expert for U304 Study- DECLINED

Editorial Board of Current Oncology- DECLINED

2022 Sep - 2022 Sep 30

Peer Review Activities

ASSOCIATE OR SECTION EDITING

Editor

2021 Aug Pearson's Textbook of Thoracic Surgery - Thoracic Medical Oncology Section

2021 Aug Therapeutic Advances in Medical Oncology (Associate Editor)

2019 Jan - 2019 Dec The Oncologist/Lung Cancer Section Editor, Number of Reviews: 94

2012 Jul - 2022 Mar The Oncologist/Lung Cancer Section Editor, Number of Reviews: 85

2012 Jul - 2021 Aug Current Oncology/Pharmacoeconomics and Outcomes Section Editor, Number of Reviews: 28

EDITORIAL BOARDS

Editor

Natasha LEIGHL

2015 Jul - present Journal of Thoracic Oncology, Number of Reviews: 83
2020 Jul AME College, AME Medical Journal- DECLINED INVITATION to join Editorial Team
2016 - 2018 Fondazione IRCCS Istituto Tumori Milano, Tumori Journal
2016 Translational Cancer Research, Translational Cancer Research
Member
2018 Mar - present British Journal of Cancer, Number of Reviews: 18
2019 - 2021 Frontiers in Oncology, Number of Reviews: 12
2015 Jul 1 - 2016 Jun 30 Journal of Thoracic Disease - DECLINED DUE TO TIME CONSTRAINTS
Deputy Editor
2023 - present Elsevier, Critical Reviews in Oncology/Hematology
Member
2009 - 2014 Journal of Clinical Oncology

GRANT REVIEWS

External Grant Reviewer

2021 Nov - 2022 Feb Breakthrough Cancer Research Ireland, Breakthrough Cancer Research Ireland, Number of Reviews: 1
2020 Nov Juravinski Hospital and Cancer Centre Grant Review Panel, "Pulmonary Function Tests to Detect Immune Checkpoint Inhibitor Associated Autoimmune Pneumonitis in Advanced Solid Tumors: A Pilot Observational Study." INVITATION DECLINED
2020 Jan - 2020 Dec Terry Fox Research Institute, International Scientific Program Review - DECLINED DUE TO TIME CONSTRAINTS
2019 Flanders Innovation & Entrepreneurship, Industrial R&D, Number of Reviews: 1
2018 LUNGeVity ALK-Positive Award Program, Number of Reviews: 6
2016 - 2018 Associazione Italiana Oncologia Medica, Number of Reviews: 3
2016 American University of Beirut
2016 Cancer Research UK
2014 Sep - 2014 Nov United States Department of Defence, Congressionally-Directed Medical Research Program Lung Cancer Research Program, Number of Reviews: 2
2014 Mar - 2014 Apr Research Grants Council of Hong Kong, General Research Fund, Number of Reviews: 1
Member
2004 - 2007 National Cancer Institute of Canada, Grants Review Panel "I"
2003 - 2004 Canadian Breast Cancer Foundation, Ontario Chapter, Project Grant Review Panel

MANUSCRIPT REVIEWS

Reviewer

2010 - present The Oncologist, Number of Reviews: 5
2022 Mar Annals of Oncology, Number of Reviews: 1
2022 Feb Clinical Cancer Research, Number of Reviews: 1
2022 Jan ImmunoOncology Technology, Number of Reviews: 1
2022 Jan Lancet Oncology, Number of Reviews: 1
2021 Jul - 2021 Jul 30 BMC Cancer, Number of Reviews: 1
2021 Jul - 2021 Jul 30 Journal of Immunotherapy of Cancer, Number of Reviews: 1
2021 Jul - 2021 Jul 30 Molecular Diagnosis and Therapy, Number of Reviews: 1
2021 Lancet Oncology, Number of Reviews: 1
2020 Jan - 2020 Dec British Journal of Cancer, Number of Reviews: 3

2020 Cancer, Number of Reviews: 2
2020 Clinical Cancer Research, Number of Reviews: 2
2020 Clinical Lung Cancer, Number of Reviews: 3
2020 Critical Reviews in Oncology/Hematology, Number of Reviews: 1
2020 JNCI Cancer Spectrum, Number of Reviews: 2
2020 Journal of Clinical Oncology, Number of Reviews: 1
2020 Journal of Clinical Oncology Precision Oncology, Number of Reviews: 1
2020 Journal of Thoracic Oncology, Number of Reviews: 4
2020 Journal of Thoracic Oncology Clinical Research Reports, Number of Reviews: 1
2020 Lancet Oncology, Number of Reviews: 1
2020 Lung, Number of Reviews: 1
2020 Nature Clinical Reviews in Oncology, Number of Reviews: 3
2019 Jul Nature, Number of Reviews: 2
2019 Future Oncology, Number of Reviews: 1
2019 Immunotherapy, Number of Reviews: 1
2019 Lancet Oncology, Number of Reviews: 1
2017 Jul JNCI Cancer Spectrum, Number of Reviews: 2
2017 - 2019 Annals of Oncology (Top Reviewer of 2017), Number of Reviews: 4
2017 European Respiratory Journal, Number of Reviews: 2
2015 Oct Canadian Respiratory Journal
2014 Targeted Oncology, Number of Reviews: 1
2021 Cancer, Number of Reviews: 2
2021 Lung Cancer, Number of Reviews: 1
2019 Cancer, Number of Reviews: 3
2019 Clinical Cancer Research, Number of Reviews: 2
2019 Clinical Lung Cancer, Number of Reviews: 14
2019 Journal of Clinical Oncology, Number of Reviews: 46
2019 Journal of Oncology Practice, Number of Reviews: 4
2019 Journal of Thoracic Oncology, Number of Reviews: 25
2019 Lung Cancer, Number of Reviews: 11
2019 Lung Cancer International, Number of Reviews: 2
2018 Therapeutics and Clinical Risk Management, Number of Reviews: 2
American Journal of Managed Care, Number of Reviews: 1
Annals of Oncology, Number of Reviews: 5
Asia-Pacific Journal of Oncology, Number of Reviews: 1
Biology of Blood and Bone Marrow Transplant, Number of Reviews: 1
Cancer Chemotherapy and Pharmacology, Number of Reviews: 1
Cancer Investigation, Number of Reviews: 1
Clinical Oncology, Number of Reviews: 3
Current Oncology, Number of Reviews: 5
Disease Management & Health Outcomes, Number of Reviews: 1
Drugs, Number of Reviews: 1
European Journal of Health Economics, Number of Reviews: 1
Expert Opinion on Pharmacotherapy, Number of Reviews: 1
Expert Opinion on Therapeutic Patents, Number of Reviews: 1

Natasha LEIGHL

Expert Reviews in Molecular Medicine, Number of Reviews: 1
Expert Reviews in Respiratory Medicine, Number of Reviews: 1
Future Oncology, Number of Reviews: 1
Health-Related Quality of Life, Number of Reviews: 1
Journal of Oncology Practice, Number of Reviews: 2
Journal of Palliative Care, Number of Reviews: 1
Journal of the National Cancer Institute, Number of Reviews: 4
Molecular Cancer Therapeutics, Number of Reviews: 1
Oncogene, Number of Reviews: 1
Patient Education and Counselling, Number of Reviews: 1
Pharmacoeconomics, Number of Reviews: 3
Quality of Life Research, Number of Reviews: 1
Therapeutic Advances in Medical Oncology, Number of Reviews: 1

Faculty Reviewer

2009 Textbook, The Essentials of Oncology. Carlo Hojilla, James Kennedy (eds), 2009. Number of Reviews: 3

PRESENTATION REVIEWS

Reviewer

2013 Jul - 2014 Jun University of Toronto, Medical Oncology Training Program PGY4 Research Month, Number of Reviews: 5

ABSTRACT REVIEWER

Reviewer

2017 ARCC 2017 Conference

CLINICAL TRIAL PROPOSAL REVIEW

External Grant Reviewer

2010 Jul - 2015 Jun 30 European Organisation for Research and Treatment of Cancer Protocol Review Committee, Number of Reviews: 2

DRUG REIMBURSEMENT REVIEWS- LAROTRECTINIB

Reviewer

2020 Nov 18 The Canadian Agency for Drugs and Technologies in Health (CADTH), INVITATION DECLINED

FACULTY PROMOTION

External Referee

2017 Dec Dept. of Radiology, University of Toronto Faculty of Medicine, Number of Reviews: 1
2017 Oct Cumming School of Medicine, University of Calgary, Number of Reviews: 1

PROTOCOL REVIEW COMMITTEE

External Grant Reviewer

2016 European Organization for Research and Treatment of Cancer, Number of Reviews: 4

Natasha LEIGHL

SCIENTIFIC REVIEW COMMITTEE

Reviewer

2013 Apr - 2013 Oct International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer

YOUNG INVESTIGATOR AWARD PANEL REVIEWER

Reviewer

2013 Nov - 2016 Novartis Oncology Young Investigator Awards Panel, Number of Reviews: 90

OTHER

Editor

2014 Jul 1 - 2015 Jun 30 memo inOncology - DECLINED FOR TIME CONSTRAINTS

Editorial Author

2020 Nov Ontario Thoracics Reviews (OTR)
INVITATION DECLINED

C. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

FUNDED

2024 Jul - 2025 Jun **Co-Principal Investigator.** University of Toronto Temerty Faculty of Medicine. Hold'em for Life Oncology Fellowship. Collaborator(s): Matthew Hall. 50,000 CAD. [Grants]

2024 May - 2025 May **Principal Investigator.** DISCOVERing New Targets with Liquid Biopsy in Patients with Lung Cancer. Lung Cancer Canada. Lung Ambition Alliance. 50,000 CAD. [Grants]

2022 Sep - 2023 Dec **Principal Applicant.** Expanding the Lung Cancer Molecular Diagnostics Program (Liquid Biopsy, Precision Medicine Navigator). Pfizer Canada ULC. Quality Improvement Grants. 75522193. PI: **Leighl, Natasha**. 128,000 CAD. [Grants]

2022 Jun - 2024 Jul **Co-Investigator.** Development of a pharmacoeconomic modeling framework to evaluate the cost effectiveness of novel therapeutics for advanced lung cancer. University of Toronto, Division of Medical Oncology. Strategic Innovation Grant. PI: Ambika Parmar. Collaborator(s): Alex Louie; Kelvin Chan; **Natasha Leighl**; Geoffrey Liu; William Wong; Daniel Yokom. 30,000 CAD. [Grants]

2022 Jan - 2022 Dec **Principal Investigator.** Accelerating Lung Cancer Diagnosis through Liquid Biopsy. Princess Margaret Cancer Foundation. Invest in Research. Collaborator(s): Kasia Czarnecka; Ming Tsao; Patrik Rogalla; Prodipto Pal; Thomas Waddell; Tracy Stockley. 100,000 CAD. [Grants]

2021 Nov - 2023 Sep **Principal Applicant.** Right Person, Right Treatment, Right Time. Pfizer Canada ULC. Global

Quality Improvement Grants. 68742627. PI: **Leighl, Natasha**. Collaborator(s): Ming Tsao; Tracy Stockley. 195,000 CAD. [Grants]

- 2021 Oct - 2024 Oct **Principal Investigator.** From Liquid Biopsy to Cure: Using ctDNA detection of minimal residual disease to identify patients for curative therapy after lung cancer resection. Ontario Institute for Cancer Research. Clinical Translation Pathway CATA. Collaborator(s): Michael Ko; Najib Safieddine; Scott Bratman; Thomas Waddell. 1,274,747 CAD. [Grants]
- 2021 Sep - 2022 Aug **Principal Investigator.** Accelerating Lung Cancer Diagnosis through Liquid Biopsy. MaRS Discovery District. Lung Cancer Innovation Challenge. 50,000 CAD. [Grants]
- 2020 Dec - 2022 Jun **Principal Investigator.** Intercept Cancer: using liquid biopsy to increase cure in early stage lung cancer. Princess Margaret Cancer Foundation. Grand Challenge 2: Intercept Cancer. Collaborator(s): Bratman S, Waddell T, Stockley T, Tsao M, Liu G. 500,000 CAD. [Grants]
- 2020 Dec - 2022 Jun **Co-Principal Investigator.** Beyond Chemotherapy: combination immunotherapy with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer. Princess Margaret Cancer Foundation. Grand Challenge: Beyond Chemotherapy. PI: co-PIs **Leighl, Natasha** and Sacher, Adrian. Collaborator(s): Pamela Ohashi; Ming Sound Tsao; Geoffrey Liu; Ben Wang. 500,000 CAD. [Grants]
- 2020 Jul - 2021 Jun **Principal Investigator.** Accelerating Lung Cancer Diagnosis through Liquid Biopsies. Lung Health Foundation. Breathing as One NSCLC Research Award. Collaborator(s): Waddell, Tom; Czarnecka, Kasia; Stockley, Tracy; Pal, Prodipto; Rogalla, Patrik. 40,000 CAD. [Grants]
- 2020 Jun - 2022 Jul **Co-Investigator.** Frailty screening as a predictor for functional decline, quality of life, and early death in older patients receiving palliative chemotherapy for lung cancer. University of Toronto, Division of Medical Oncology. Strategic Innovation Grant. PI: Ines Menjak. Collaborator(s): **Natasha Leighl**; Shabir Alibhai; Camilla Wong; Rajin Mehta; Ronita Lee. 30,000 CAD. [Grants]
- 2018 May - 2019 Apr **Co-Investigator.** Advancing Cancer Clinical Molecular Diagnostics with Artificial Intelligence. University of Toronto McLaughlin Centre. 2018 Accelerator Grants in Genomic Medicine. PI: Stockley, Tracy. Collaborator(s): Kamel-Reid, Suzanne; **Leighl, Natasha**; Malkin, David; Schuh, Andre; Shlien, Adam; Stickle, Natalie; Villani, Anita; Virtanen, Carl. 60,000 CAD. [Grants]
- 2017 Sep - 2018 Mar **Principal Investigator.** Evaluating Financial Toxicity in Canadian Cancer Patients. Cancer Care Ontario. Planning and Regional Programs. Collaborator(s): Ezeife, Doreen; Chan, Kelvin. 67,000 CAD. [Grants]
- 2017 Feb - 2022 Jan **Co-Investigator.** Canadian Cancer Trials Group Program Grant. Canadian Cancer Society Research Institute. Major Program Grant. PI: Dancey, Janet. Collaborator(s): Seymour L, Shepherd L, Parulekar W, O'Callaghan C, Richardson H, Hay A, Vera-Badillo- F, Tu D, Chen B, Ding K, Mason W, Gelmon K, Whelan T, Jonker D, Chi K, Fleshner N, Hirte H, Fung Kee Fung M, Crump M, Coupon S, Laurie S, Bedarf P, Goss G, Ung Y, Petrella T, Spatz A, Alcindor T, Nielsen T, Wong R, Brundage M, Ringash J, Tsao MS, **Leighl N**, Mittmann N. 25,586,666 CAD. [Grants]
- 2016 Dec - 2017 Dec **Co-Investigator.** Optimizing the methods for economic evaluation embedded in phase III clinical trials. Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC Seed Grant Program. N/A. PI: Cheung, Matthew. Collaborator(s): Mittmann, Nicole; **Leighl Natasha**; Hay, Annette; Pater, Joseph. 15,000 CAD. [Grants]

Natasha LEIGHL

- 2015 Feb - 2020 Feb **Co-Investigator.** REAL-PDX: Resistance modeling in EGFR and ALK lung cancer patient-derived xenografts for personalized post-progression therapy. Canadian Cancer Society Research Institute (CCSRI). Impact Grant. PI: Liu, Geoffrey. Collaborator(s): Tsao, Ming; Shepherd, Frances; **Leighl, Natasha**; Yasufuku, Kazuhiro; Pintilie, Melania; Lupien; Haibe-Kains; Bradbury, Penelope; Shah. 1,249,999 CAD. [Grants]
- 2015 Feb - 2018 Feb **Co-Investigator.** Identifying the most effective multi-attribute utility instruments to guide cancer funding decisions in Canada. Canadian Cancer Society Research Institute (CCSRI). Quality of Life Grants. 703548. PI: Peacock, Stuart. Collaborator(s): Hoch, Jeffrey; **Leighl, Natasha**; Mittmann, Nicole; Regier, Dean. 297,350 CAD. [Grants]
- 2014 Apr - 2019 Feb **Co-Investigator.** NCI Experimental Therapeutics Trials Network with Phase 1 Emphasis (ET-CTN) (UM1) Princess Margaret Phase 1 Consortium (PMP1C). NCI. 1UM1-CA-186644-01. PI: Siu LL, Sullivan D, Hotte S, Chi K. Collaborator(s): Aparicio S, Bedard P, Cheiken R, Degendorfer P, Hedley D, Hiret H, Huntsman D, Jones S, Kamel-Reid S, Kavsak P, Lush R, Magliococco A, Mahipal A, Marra M, Moore M, Oza A, Pond G, Pugh T, Razak A, Roehri M, Renouf D, Schell M, Tsao M, Valliant J, Almhanna D, Antonio S, Bramson J, Butler M, Chen E, Chia S, Dalton W, DeCarvalho D, Dick J, Gelmon K, Ghai S, Gillies R, Jaffray D, Joshua A, Juergens R, Kollmannsberger C, Lancet J, **Leighl N**, Liu G, Lupien M, Mak T, McLeod H, McWhirter E, Metser U. 1,756,985 USD. [Grants]
- 2014 Mar - 2019 Feb **Co-Investigator.** NCIC CTG - Canadian Collaborating Clinical Trials Network (NCTN). National Institutes of Health/National Cancer Institute (NIH/NCI). Major Program Grant. CA180863. PI: Dancey, Janet. Collaborator(s): Seymour L; Shepherd L; Parulekar W; O'Callaghan C; Hay A; Tu D; Ding K; Chen B; Richardson H; Mason W; Gelmon K; Whelan T; Jonker D; Chi K; Fleshner N; Hirte H; Fung Kee Fung M; Crump M; Couban S; Goss G; Ung Y; Petrella T; Spatz A; Alcindor T; Nielsen T; Wong R; Brundage M; Ringash J; Tsao M; **Leighl N**; Mittmann N. 15,115,295 CAD. [Grants]
- 2014 - 2018 **Co-Investigator.** Administrative Databases for Oncology Case Costing in Ontario - Phase 2. Ontario Institute for Cancer Research. PI: Mittmann, Nicole. Collaborator(s): **Leighl N**, Hoch J, Evans W, Cheung M, Dainty K, Trudeau M, Earle C, Chan K. 840,000 CAD. [Grants]
- 2013 Oct - 2016 Mar **Co-Investigator.** The Canadian Prostate Cancer Biomarker Network (Phase II). The Terry Fox Research Institute. PI: Saad, Fred. 10,600 CAD. [Grants]
Substudy Lead (Leighl N).
- 2013 Aug - 2015 Jul **Co-Investigator.** What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, cancer specialist and family physician? Canadian Cancer Society Research Institute. Innovation Grant. PI: Puts, Martine. Collaborator(s): Shabbir Alibhai, Eitan Amir, Margaret Fitch, Anthony Joshua, Monika Krzyzanowska, **Natasha Leighl**, Anne Tourangeau, Pdraig Warde. 74,722 CAD. [Grants]
- 2013 Jul - 2014 Jun **Principal Investigator.** Clinical Impact of Epidermal Growth Factor Receptor (EGFR) Mutation Fraction and Tumour Sample Cellularity on Clinical Outcomes. University of Toronto Department of Medicine. 2013/14 Medical Oncology Strategic Planning Innovation Fund. Collaborator(s): Cheng, Susanna. 30,000 CAD. [Grants]
- 2013 - 2014 **Principal Investigator.** Predicting the impact of adjuvant chemotherapy on early stage non-small cell lung cancer using a 15-gene expression signature. Canadian Centre for Applied Research in Cancer Control. Collaborator(s): Nicole Mittmann, Keyue Ding, Ralph Meyer, Penelope Bradbury, Frances Shepherd, Ming-Sound Tsao. 21,000 CAD. [Grants]
- 2012 Nov - 2013 Jun **Co-Investigator.** Understanding risk-benefit trade-offs of genomic testing in chemotherapy

treatment decisions for breast cancer. Canadian Centre for Applied Research in Cancer Control. PI: Marshall, Deborah. Collaborator(s): Ken Deal, Maureen Trudeau, **Natasha Leighl**. 38,625 CAD. [Grants]

- 2012 Aug - 2013 Nov **Principal Investigator**. Improving molecular testing and personalized medicine in lung cancer. Cancer Care Ontario. Health Services Research Network. Collaborator(s): Ming Tsao, Suzanne Kamel-Reid, Gilda Santos, Harman Sekhon, Ron Carter, JC Cutz. 100,000 CAD. [Grants]
- 2012 Jul - 2013 Jul **Co-Investigator**. Systematic Review of factors influencing older adults decision to accept or refuse cancer treatment proposed by their physician. Canadian Institutes of Health Research. Knowledge Synthesis Grant. 262568. PI: Puts, Maria and Alibhai, Shabbir. Collaborator(s): M Fitch, D Howell, M Krzyzanowska, **N Leighl**, J Monette, D Wan-Chow-Wah. 51,835 CAD. [Grants]
- 2011 Nov - 2013 Oct **Co-Investigator**. A pilot trial of a self-management intervention for breathlessness in lung cancer. National Lung Cancer Partnership, Oncology Nursing Society Foundation. PI: Howell, Doris. Collaborator(s): A Bezzak, S Sidani, **N Leighl**, C Zimmerman, D Dudgeon, R Goldstein. 50,000 USD. [Grants]
- 2011 Jul - 2016 Jun **Co-Investigator**. On-PROST: Ontario Patient Reported Outcomes of Symptoms and Toxicity. Cancer Care Ontario. Advanced Clinical Research Unit (ACRU). PI: Liu, Geoff and Howell, Doris. Collaborator(s): M Brundage, A Hope, G Rodin, L Barbera, P Bradbury, R Hung, R Kim, **N Leighl**, M Li, N Mittmann, J Waldron, R Wong, C Zimmerman. 1,182,500 CAD. [Grants]
- 2011 Jul - 2016 Jun **Co-Investigator**. Personalized Medicine with Targeted and Genome-Wide Sequencing. Cancer Care Ontario. ACRU. PI: Neel, Ben. Collaborator(s): L Siu, N Onetto, S Ghai, K Murphy, M Haider, D Jaffray, P Shaw, S Asa, MS Tsao, S Kamel-Reid, J McPherson, L Stein, I Jurisica, M Moore, A Oza, F Shepherd, **N Leighl**, G Liu, E Chen, D Hedley, M Tsao P Bedard, M Minden, V Stambolic, B Wouters, M Reedijk, FF Liu, R Bristow, S Hotte, G Goss, E Winquist. 1,182,500 CAD. [Grants]
- 2011 Jan - 2011 Dec **Co-Investigator**. Understanding risk-benefit trade-offs of genetic testing in chemotherapy treatment decisions for breast cancer. OICR/CCO Research Network. PI: Marshall, Deborah. Collaborator(s): Y Bombard, **N Leighl**, M Trudeau, K Deal. 192,300 CAD. [Grants]
- 2010 Aug - 2017 Feb **Co-Investigator**. CCS Clinical Trials Group. Canadian Cancer Society Research Institute (CCSRI). Major Program Grant. 021039. PI: Dancey, Janet. Collaborator(s): Seymour L; Shepherd L; Parulekar W; O'Callaghan C; Hay A; Tu D; Ding K; Chen B; Richardson H; Mason W; Gelmon K; Whelan T; Jonker D; Chi K; Fleshner N; Hirte H; Fung Kee Fung M; Crump M; Couban S; Goss G; Ung Y; Petrella T; Spatz A; Alcindor T; Nielsen T; Wong R; Brundage M; Ringash J; Tsao M; **Leighl N**; Mittmann N. 25,586,666 CAD. [Grants]
- 2010 Jun - 2013 May **Co-Investigator**. Influence of beliefs about symptoms on symptom intensity, distress and patient's participation in self-management behaviours in lung cancer. Canadian Institutes of Health Research. Operating Grant. 220136. PI: Howell, Doris. Collaborator(s): A Bezzak, G Devins, L Gagliese, **N Leighl**, G Rodin, C Zimmerman. 243,334 CAD. [Grants]
- 2009 Jul - 2012 Jun **Co-Investigator**. Novel therapeutic targets for non-small cell lung cancer. Ontario Institute for Cancer Research. PI: Tsao, Ming Sound. Collaborator(s): F Shepherd, **N Leighl**, T John. 677,548 CAD. [Grants]
- 2009 Jul - 2011 Jun **Co-Investigator**. Early palliative care intervention in patients with metastatic cancer: a cluster randomized trial. Canadian Cancer Society Research Institute. 020509. PI:

Zimmerman, Camilla. Collaborator(s): G Rodin, M Moore, A Oza, A Bezbek, **N Leighl**, M Krzyzanowska, A Donner, A Rydall. 405,496 CAD. [Grants]

- 2009 Jul - 2010 Jun **Co-Investigator.** The impact of adherence to guidelines on clinical outcomes and the use of cancer care services: testing treatment and monitoring guidelines in patients with early stage breast cancer. Ontario Institute for Cancer Research. PI: Marshall, Deborah. Collaborator(s): C Earle, M Trudeau, J Hoch, **N Leighl**. 115,000 CAD. [Grants]
- 2009 - 2012 **Co-Investigator.** Case Costing in Oncology using Administrative Databases. Ontario Institute for Cancer Research. PI: Mittmann, Nicole. Collaborator(s): **N. Leighl**, WK Evans, M. Cheung. 700,000 CAD. [Grants]
- 2008 - 2015 **Co-Investigator.** Early Lung Cancer Screening: A Pan-Canadian Study. Terry Fox Research Institute. PI: Lam, Stephen; Tsao, Ming-Sound. Collaborator(s): A. McWilliams, J. Mayo, S. Peacock, R. Finley, J. Yee, K. Evans, D. Sin, W. Tan; A. Tremblay, P. Burrowes, P. MacEachern; M. Tammemagi, H. Roberts, F. Shepherd, G. Liu, K. Sophrati, J. Thenganatt, **N. Leighl**, J. Goffin, S. Puksa, L. Stewart, W.K. Evans, G. Nicholas, G. Goss, J.M. Seely, K. Amjadi; S. Martel, F. Laberge, M. Gingras; M. Johnston, D. Manos. 8,128,851 CAD. [Grants]
- 2008 - 2011 **Co-Investigator.** Mass spectrometry analysis of aberrant epidermal growth factor receptor signaling in non-small cell lung carcinoma. Ontario Institute for Cancer Research. PI: Moran, Michael. Collaborator(s): Ming-Sound Tsao, **Natasha Leighl**, Thomas Waddell. 641,453 CAD. [Grants]
- 2006 - 2009 **Co-Investigator.** Randomized controlled trial of a palliative care team intervention for patients with metastatic cancer. National Cancer Institute of Canada (NCIC). Canadian Cancer Society Research Grant. PI: Zimmermann, Camilla. Collaborator(s): Gary Rodin, Malcolm Moore, Amit Oza, Monika Krzyzanowska, Andrea Bezbek, **Natasha Leighl**, Allan Donner, Anne Rydall. 415,856 CAD. [Grants]
- 2005 - 2006 **Principal Investigator.** Preoperative gefitinib in clinical stage 1A non-small cell lung cancer. Princess Margaret Hospital Foundation (The). Ontario Cancer Research Network Infrastructure Grant. Collaborator(s): Co-PI Waddell T, Associate Investigators: Tsao MS, Roberts H, Shepherd FA, Keshavjee S. 20,000 CAD. [Grants]
Personnel funding of approximately \$20,000 x 1 year.
- 2005 - 2006 **Principal Investigator.** Randomized trial to investigate the impact of a computer generated quality of life assessment program on treatment patterns for advanced non-small cell lung cancer patients. Princess Margaret Hospital Foundation (The). Ontario Cancer Research Network Infrastructure Grant. Collaborator(s): Associate Investigators: Shepherd F, Feld R, Kassam F. 30,000 CAD. [Grants]
Personnel funding approximately \$30,000 x 1 year.
- 2004 - 2005 **Principal Investigator.** Preoperative gefitinib in clinical stage 1A non-small cell lung cancer. Princess Margaret Hospital Foundation (The). Ontario Cancer Research Network Infrastructure Grant. Collaborator(s): Co-PI Waddell T, Associate Investigators: Tsao MS, Roberts H, Shepherd FA, Keshavjee S. 60,000 CAD. [Grants]
Personnel funding approximately \$60,000 x 1 year.
- 2003 - 2009 **Collaborator.** Impact of positron emission tomography (PET) Imaging in Stage III Nonsmall Cell Lung Cancer: A prospective randomized trial. Cancer Care Ontario Provincial Lung Cancer Disease Site Group. Ministry of Ontario Health and Long-term Care. PI: Ung, Y. Collaborator(s): Steering Committee: W Evans, G Darling, **N Leighl**, et al. [Grants]
- 2003 - 2009 **Co-Investigator.** Tobacco Use in Special Populations Research Training Program.

Canadian Institutes of Health Research (CIHR). PI: Selby P. Collaborator(s): Associate Investigators: Bercovitz K, Brands B, Brewster J, Busto U, Favolden P, Ferrence R, Kahan M, **Leighl N**, McDonald PW, Midmer D, Oh P, Rahman S, Smith P, Tyndale R, Young K, Zack M, Zipursky R. 300,000 CAD. [Grants]
Budget: \$50,000 annually x 6 years.

NON-PEER-REVIEWED GRANTS

FUNDED

- 2024 Jan - present **Principal Site Investigator. Trial Steering Committee.** Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304). Amgen. [Clinical Trials]
- 2023 Nov - present **Principal Site Investigator.** A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark). Janssen. [Clinical Trials]
- 2023 Jul - present **Principal Site Investigator. Trial Steering Committee.** A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations (FURMO 002). Arrivent. [Clinical Trials]
- 2023 Jun - present **Principal Investigator.** DISCOVERing New Targets with Liquid Biopsy in Patients with Lung Cancer. Princess Margaret Cancer Foundation. [Clinical Trials]
- 2022 May - present **Principal Site Investigator.** Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98). [Clinical Trials]
- 2021 Dec - present **Principal Investigator.** Investigator Initiated. Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT). Princess Margaret Cancer Foundation; Ontario Institute for Cancer Research; Bristol Myers Squibb. [Clinical Trials]
- 2021 Oct - present **Principal Site Investigator.** A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies. Janssen Pharmaceuticals. [Clinical Trials]
- 2021 Jul - present **Principal Site Investigator.** Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. F. Hoffmann-la Roche Ltd. (Basel, Switzerland). [Clinical Trials]
- 2021 Jul - present **Principal Investigator.** Investigator Initiated. Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection (ctDNA Detect). Princess Margaret Cancer Foundation; Ontario Institute for Cancer Research. [Clinical Trials]
- 2021 Jan - present **Principal Investigator.** Investigator Initiated. Accelerating Lung Cancer Diagnosis Through Liquid Biopsy (ACCELERATE). Grant funded (PMCF, Lung Health Foundation, Mars Innovation Challenge). [Clinical Trials]
- 2020 Dec - present **Principal Site Investigator. Safety Review Committee Member.** SPARTA - Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met

Dysregulation Advanced Solid Tumors. Appollomics. [Clinical Trials]

- 2020 Feb - present **Principal Site Investigator. Trial Steering Committee.** LEAP 008: Randomized trial of lenvatinib plus pembrolizumab versus docetaxel after prior immunotherapy and chemotherapy. [Clinical Trials]
- 2019 Dec - present **Principal Investigator.** Investigator Initiated Trial: Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer. PMC Foundation plus Pfizer (drug supply in kind value \$2,299,640). [Clinical Trials]
- 2019 Nov - present **Principal Investigator.** Investigator Initiated Trial: Phase I/Ib Study of Binimetinib, a MEK Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Array BioPharma. 290,000 USD. [Clinical Trials]
- 2019 Nov - present **Principal Site Investigator.** A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC391 Administered Orally to Subjects with Solid Tumours. [Clinical Trials]
- 2019 Jun - present **Principal Site Investigator.** Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. [Clinical Trials]
- 2018 Dec - present **Principal Investigator.** Investigator Initiated. Achieving Value in Cancer Diagnostics: blood versus tissue molecular profiling - a prospective Canadian study (VALUE). Guardant Health. Collaborator(s): Desiree Hao; Janessa Laskin; Jason Agulnik; Rosalyn Juergens; Scott Laurie; Doreen Ezeife. 149,500 USD. [Clinical Trials]
- 2017 Oct - present **Principal Site Investigator.** BO29554 (B-FAST): A phase II/III multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable somatic mutations detected in blood. Hoffman LaRoche. [Clinical Trials]
- 2017 Jul - present **Principal Site Investigator.** CEGF816X2102: Phase I Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC. [Clinical Trials]
- 2016 Jul - present **Study Chair.** CCTG BRC.6. SWOG Intergroup S1400 Lung MAP trial - Biomarker-driven master protocol for previously treated squamous cell lung cancer. [Clinical Trials]
- 2016 Jul - present **Study Chair.** CCTG BRC.6 S1400F: SWOG Intergroup S1400 Lung MAP trial - durvalumab plus tremelimumab in PD-1 refractory/resistant squamous lung carcinoma. [Clinical Trials]
- 2016 - present **Trial Steering Committee Member.** A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy (PI: A Sun, PMH). [Clinical Trials]
- 2014 - present **Principal Site Investigator.** AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA). Astra Zeneca. [Clinical Trials]
- 2014 - present **Principal Site Investigator.** CEGF816X2101: Phase I/II, open label study of EGFRmut-TKI EGF816, administered orally in EGFRmut solid malignancies. Novartis. per case funding. 41,101.5 CAD. [Clinical Trials]

- 2014 - present **Principal Site Investigator.** Open-label, randomized Phase III trial of Nivolumab vs. Investigator's choice chemotherapy as first line therapy for stage IV or recurrent PD-L1+NSCLC. Bristol-Myers Squibb. 13,848 CAD. [Clinical Trials]
- 2008 - present **Study Co-Chair, Principal Site Investigator.** A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 CM) - IIIA Non-Small Cell Lung Cancer. National Cancer Institute of Canada (NCIC). CTG. NCIC CTG BRC.2, BRC.2E. [Clinical Trials]
- 2006 - present **Chair.** NCIC CTG BRC.2E: Economic Analysis of adjuvant randomized trial of cisplatin-based chemotherapy +/- bevacizumab after complete resection of NSCLC. National Cancer Institute of Canada (NCIC). CTG. NCIC CTG BRC.2E. [Clinical Trials]
- 2021 Jan - 2022 Nov **Principal Applicant.** Lung Cancer Molecular Profiling Program. Novartis Canada Ltd. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy. 70,000 CAD. [Grants]
- 2020 Dec - 2022 Nov **Principal Applicant.** Lung Cancer Molecular Profiling Program. Eli Lilly. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy. 450,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Hoffmann-la Roche Limited, Canada. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 100,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Amgen Canada Inc (Mississauga, ON). PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 100,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Astra Zeneca Canada. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 25,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Takeda Pharmaceuticals Inc. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy. 25,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Pfizer Canada Inc. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 70,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. Bayer (Canada) Inc. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 20,000 CAD. [Grants]
- 2020 Oct - 2021 Sep **Principal Applicant.** Lung Cancer Molecular Profiling Program. EMD Serono. PI: **Leighl, Natasha.** Collaborator(s): Stockley, Tracy; Princess Margaret Cancer Foundation. 50,000 CAD. [Grants]
- 2019 Nov - 2020 Dec **Principal Site Investigator.** Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-Small Cell Lung Cancer or Urothelial Cancer. [Clinical Trials]
- 2018 Dec - 2020 Dec **Principal Site Investigator.** Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant

Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789). [Clinical Trials]

2018 Dec - 2020 Dec

Principal Investigator. Investigator Initiated Multicentre Trial: Achieving Value in Cancer Diagnostics: blood versus tissue molecular profiling – a prospective Canadian study (VALUE). Guardant Health; Princess Margaret Foundation. 149,500 USD. [Clinical Trials]

2018 Jan - 2018 Dec

Principal Site Investigator. BP29435 (CEA): A Phase 1b, Open-Label, Multi-Center, Dose-Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of an Immunocytokine, which consists of a variant of Interleukin-2 (IL-2v), that targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an antibody that targets Programmed Death-Ligand 1 (Pd-L1), administered in combination intravenously, in patients with advanced and/or metastatic Solid Tumors. F. Hoffmann-la Roche Ltd. (Basel, Switzerland). [Clinical Trials]

2017 Jul - 2020 Feb

Principal Site Investigator. Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer. [Clinical Trials]

2017 Jul - 2019 Apr

Principal Site Investigator. Ad/MG1-MAGEA3-001: A phase 1/2, multicenter, open-label trial of MG1 maraba expressing MAGE-A3 (MG1-MAGEA3), with adenovirus vaccine (Ad-MAGEA3), in combination with pembrolizumab in patients with previously treated metastatic NSCLC. Turnstone Biologics. [Clinical Trials]

2017 May - 2020 Feb

Principal Site Investigator. CA209-207: An open-label, single-arm phase II safety study of nivolumab in participants with advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemic regimen. Bristol-Myers Squibb. [Clinical Trials]

2016 Dec - 2020 Dec

Study Chair. BR.34 Study of immunotherapy (durvalumab and tremelimumab) with or without chemotherapy in advanced NSCLC. CCTG. [Clinical Trials]

2016 Jul - 2018

Principal Site Investigator. Multicenter open label Phase I dose finding and expansion study of RO7051790. [Clinical Trials]

2016 May - 2018 Aug

Principal Site Investigator. HM-EMSI-202: A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694 in after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Hanmi Pharmaceuticals. [Clinical Trials]

2015 Jun - 2020 Feb

Principal Site Investigator. GH03-001 (NILE): Non-invasive versus Invasive Lung Evaluation. Guardant Health. [Clinical Trials]

2015 - 2020

Principal Site Investigator. CheckMate 153: A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen. [Clinical Trials]

2015 - 2020 Dec

Principal Investigator. Investigator Initiated trial: MEK162 in combination with pemetrexed/carboplatin first-line chemotherapy in advanced nonsmall cell lung cancer - a phase I study. Novartis Canada Ltd. Investigator Initiated Trial. 30,000 CAD. [Grants]

2015 - 2020 Feb

Principal Site Investigator. Phase I/II trial of BMS-986012 in Relapsed/Refractory SCLC. [Clinical Trials]

2015 - 2016

Principal Site Investigator. Study of INC280 in Patients With c-MET Dependent Advanced

Solid Tumors - Lung Expansion Cohort. Novartis. [Clinical Trials]

- 2014 - 2016 **Principal Site Investigator.** Open-Label Phase Ib/II, Multicentre Study of the Combination RO5479599 with Carboplatin and Paclitaxel in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC. Hoffman LaRoche. PI: **Leighl, Natasha.** [Clinical Trials]
\$36000 per patient plus \$9000 start-up.
- 2014 - 2016 **Principal Site Investigator.** A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation. Clovis Oncology. PI: **Leighl, Natasha.** [Clinical Trials]
\$25000 per patient plus \$9000 start-up.
- 2013 - 2018 **Principal Site Investigator.** Double blind, randomized, Phase II/III study of Nintedanib with pemetrexed and cisplatin followed by Nintedanib monotherapy vs placebo with pemetrexed and cisplatin followed by placebo monotherapy for unresectable MPM. Boehringer-Ingelheim. 24,910.1 CAD. [Clinical Trials]
- 2013 - 2018 **Principal Site Investigator.** MK-3475-010: Phase II/III, randomized trial of two doses of MK-3475 vs. docetaxel in previously treated NSCLC. Merck. 48,134.07 CAD. [Clinical Trials]
- 2013 - 2016 **Principal Site Investigator.** DOVE-M: Phase II study of dovitinib in advance MPM after progression in platinum-antifolate chemotherapy. OCOG. 6,410 CAD. [Clinical Trials]
- 2013 - 2016 **Principal Site Investigator.** Phase Ib/II study of carboplatin and paclitaxel with or without BKM120 in previously untreated metastatic squamous NSCLC. Novartis. 30,991.5 CAD. [Clinical Trials]
- 2013 - 2015 **Principal Site Investigator.** Randomized, Phase III study of Ganetespib with docetaxel vs docetaxel alone in lung adenocarcinoma. Synta Pharmaceuticals. 33,436 CAD. [Clinical Trials]
- 2013 - 2014 **Principal Site Investigator.** Phase Ib study of selumetinib in previously treated or untreated advanced/metastatic NSCLC plus standard chemotherapy. National Cancer Institute of Canada (NCIC). [Clinical Trials]
NCIC CTG IND.215.
- 2013 **Principal Investigator.** SELECT: Surgery for Early Lung Cancer with Preoperative Erlotinib: A Clinical Phase II Trial. Roche Canada. 30,000 CAD. [Grants]
(investigator initiated study, unrestricted educational grant).
- 2012 - 2016 **Principal Site Investigator.** MEK113486: Open-label, Phase I/Ib, dose escalation study of GSK1120212 plus chemotherapy or erlotinib in advanced solid tumors. GlaxoSmithKline. 13,547 CAD. [Clinical Trials]
- 2012 - 2014 **Principal Site Investigator.** OAM4971g: Randomized, Phase III, double-blind study of MetMAb or placebo with erlotinib in Met-positive NSCLC after chemotherapy for advanced/metastatic disease. Genentech. 10,478 CAD. [Clinical Trials]
- 2012 - 2014 **Principal Site Investigator.** Single arm, Phase II study of Ganetespib in advance ALK-positive NSCLC. Synta Pharmaceutical. 23,744 CAD. [Clinical Trials]

Natasha LEIGHL

- 2011 Jul - 2014 Mar **Principal Site Investigator.** Randomized Phase III double-blind study of farletuzumab (MorAB003) or placebo plus platinum-based chemotherapy in folate receptor alpha-expressing lung adenocarcinoma. Morphotek. 23,192 CAD. [Clinical Trials]
- 2011 Jul - 2012 Jun **Principal Site Investigator.** Phase II study of BKM120 (PI3Ka inhibitor) in PIK3CA mutant or PTEN mutant/deficient NSCLC. Novartis. [Clinical Trials]
- 2011 - 2014 **Principal Site Investigator.** Randomized trial of Erlotinib first-line in EGFR mutant NSCLC +/- OSI906, (IGF1R- and IR-TKI). Astellas. 23,322 CAD. [Clinical Trials]
- 2009 - 2014 **Study Chair.** A Phase I/II study of GSK1363089 in patients with previously treated NSCLC receiving standard erlotinib therapy. National Cancer Institute of Canada (NCIC). CTG. NCIC CTG IND.196. [Clinical Trials]
Pending.
- 2009 - 2014 **Principal Site Investigator.** Randomized, open-label, Phase II trial of BI6727 monotherapy and BI6727 in combination with pemetrexed compared to pemetrexed monotherapy in second line NSCLC. Boehringer Ingelheim. 11,459 CAD. [Clinical Trials]
- 2009 - 2013 **Principal Site Investigator.** Randomized phase III study of maintenance TFGbeta vaccine, LUCANIX, after first-line platinum based chemotherapy in NSCLC. NovaRx Pharmaceuticals. 29219.07. [Clinical Trials]
- 2009 - 2012 **Principal Site Investigator.** Randomized trial of Minocycline for Erlotinib skin toxicity in advanced NSCLC patients. Roche. PI: Melosky, Barb. [Clinical Trials]
Pending. Investigator Initiated.
- 2009 - 2012 **Principal Site Investigator.** Timing study of erlotinib in advanced NSCLC. Investigator. PI: Bjarnason, Georg. [Clinical Trials]
Pending.
- 2009 - 2011 **Principal Site Investigator.** A phase II, double blind, randomized, placebo-controlled study to assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone in 2nd line patients with KRAS mutation positive, locally advanced or metastatic non-small cell lung cancer (stage III-IV). Astra Zeneca Inc. [Clinical Trials]
- 2009 - 2011 **Principal Site Investigator.** Randomized phase II study of pemetrexed/cisplatin +/- aflibercept in advanced adenocarcinoma of the lung. Regeneron Pharmaceuticals Inc (USA). [Clinical Trials]
- 2008 - 2012 **Co-Investigator.** NCI CTEP Phase 2 Consortium trial: Phase II study of AZD0530, src inhibitor, in previously treated advanced NSCLC. National Cancer Institute (USA). CTEP. PI: Laurie, Scott. [Clinical Trials]
Co-Investigator, Institutional PI.
- 2008 - 2010 **Principal Site Investigator.** CA031: Phase III randomized trial of paclitaxel/carboplatin versus nab-paclitaxel (Abraxane™)/carboplatin in advanced non-small cell lung cancer. Abraxis Bio. 13,709 USD. [Clinical Trials]
Canadian PI, Institutional PI.
- 2008 - 2010 **Principal Site Investigator.** Phase II randomized trial of Paclitaxel/Carboplatin/Bevacizumab +/- Apomab first-line in advanced nonsmall cell lung cancer. Genentech Inc. [Clinical Trials]
- 2008 **Principal Site Investigator.** Phase II study of ABT-869 in previously treated NSCLC. Abbott.

13,463 CAD. [Clinical Trials]

- 2007 - 2012 **Principal Investigator.** SELECT: Surgery for Early Lung Cancer with Preoperative Erlotinib: A Clinical Phase II Trial. Roche Canada. 290,000 CAD. [Grants]
(investigator initiated study, unrestricted educational grant).
- 2007 - 2011 **Principal Site Investigator.** Phase I/II study of RAD-001 plus Erlotinib second-line in advanced NSCLC. Novartis. 13,890 CAD. [Clinical Trials]
- 2007 - 2010 **Principal Site Investigator.** Phase III study of ZD6474 versus placebo after failure of chemotherapy and EGFR TKI in advanced NSCLC. AstraZeneca. [Clinical Trials]
- 2007 - 2009 **Study Chair.** NCI CTEP Phase II study of pazopanib in advanced or recurrent breast cancer. National Cancer Institute (USA). CTEP. 14,000 USD. [Clinical Trials]
(Original Study Chair: Kathy Pritchard, TSRCC).
- 2007 - 2009 **Principal Site Investigator.** Phase III randomized trial of Myocet plus trastuzumab versus paclitaxel plus trastuzumab in first-line therapy of patients with metastatic Her-2-neu overexpressing breast cancer. Sopherion. [Clinical Trials]
- 2007 - 2008 **Principal Site Investigator.** Phase II randomized trial of erlotinib with or without satraplatin first line in patients 70 and older with advanced NSCLC. GPC Biotech. [Clinical Trials]
Canadian PI and Institutional PI.
- 2006 - 2017 **Principal Investigator.** Economic and Quality of Life Substudies, TORCH trial (Tarceva or Chemotherapy for first-line advanced NSCLC), PMH. Roche. [Clinical Trials]
Investigator Initiated study.
- 2006 - 2016 **Principal Site Investigator.** NSABP B38: a randomized trial of dose dense AC-paclitaxel, TAC or dose dense AC-paclitaxel/gemcitabine. The National Surgical Adjuvant Breast and Bowel Project. [Clinical Trials]
- 2006 - 2012 **Principal Site Investigator.** NCI CTEP Consortium Phase II AZD2171 in pleural mesothelioma. National Cancer Institute (USA). CTEP. PI: Kindler, Hedy. [Clinical Trials]
- 2006 - 2010 **Principal Site Investigator.** NCI CTEP Consortium Phase II docetaxel + bortezomib second line in NSCLC. National Cancer Institute (USA). CTEP. PI: Lara, Primo. [Clinical Trials]
- 2006 - 2008 **Principal Investigator.** NCI CTEP Consortium Phase II study of radiotherapy followed by chemotherapy plus bevacizumab in NSCLC patients at high risk of bleeding. National Cancer Institute (USA). CTEP. 2,000 USD. [Clinical Trials]
- 2006 - 2008 **Principal Site Investigator.** Phase II study of VEGF-trap 3rd line in advanced NSCLC. Sanofi Aventis. [Clinical Trials]
- 2006 - 2007 Phase 2 study of lapatinib in patients with HER2+ breast cancer and brain metastases. GlaxoSmith Kline. [Clinical Trials]
- 2005 - 2010 **Co-Investigator.** National Cancer Institute Phase II study of UCN-01 in combination with Topotecan in patients with SCLC who relapsed or progressed > 3 months after completing first-line platinum-based chemotherapy. Princess Margaret Hospital Consortium, Toronto, Canada. National Cancer Institute (USA). CTEP. PI: Goss, Glen. 12,000 USD. [Clinical Trials]

Co-Investigator, Institutional PI.

- 2005 - 2008 **Principal Site Investigator.** AVAIL. Phase III randomized trial of first-line Gemcitabine/cisplatin +/- bevacizumab in advanced NSCLC. PMH. Roche Pharmaceuticals. [Clinical Trials]
- 2005 - 2007 **Principal Investigator.** Economic analysis of the BR.10 trial of adjuvant vinorelbine/cisplatin vs. observation in completely resected NSCLC. [Clinical Trials]
Investigator funded. Investigator initiated.
- 2005 - 2007 **Principal Investigator.** NIFTEE: Phase I/II Study of Single Agent Gefitinib in Patients with Clinical Stage IA NSCLC. AstraZeneca. 152,500 CAD. [Grants]
(investigator initiated trial, unrestricted educational grant).
- 2005 - 2007 **Principal Investigator.** NIFTEE: Phase I/II Study of Single Agent Gefitinib in Patients with Clinical Stage IA NSCLC (unrestricted educational grant). AstraZeneca. Collaborator(s): Surgical PI Waddell T. [Clinical Trials]
Budget: \$185,000 plus drug.
- 2005 - 2006 **Principal Site Investigator.** Randomized Phase II study of neoadjuvant letrozole +/- RAD001 in postmenopausal patients with operable breast cancer. PMH. Novartis. 5,087.85 CAD. [Clinical Trials]
- 2004 - 2008 **Co-Investigator.** Feasibility, Reliability, and Validity Testing of a Computer-Generated Quality of Life Assessment and Scoring Program for Patients with Lung Cancer (LCSS-QL). COMET, Ontario, Canada. Sanofi Aventis. PI: Gralla, Richard. [Clinical Trials]
Co-investigator, Institutional PI. Investigator initiated study.
- 2004 - 2006 **Principal Site Investigator.** Phase III study of CCI-779 versus placebo in combination with letrozole as first-line therapy in hormone receptor positive metastatic breast cancer. Wyeth Pharma. [Clinical Trials]
- 2004 - 2006 **Principal Site Investigator.** PK study of CTI-2030 plus carboplatin first-line in advanced NSCLC patients. Cell Therapeutics Inc. [Clinical Trials]
- 2003 - 2006 **Principal Investigator.** Phase I/II study of GTI-2040 in combination with docetaxel in advanced nonsmall cell lung cancer. Princess Margaret Hospital Consortium, Toronto, Canada. National Cancer Institute (USA). CTEP. 34,000 USD. [Clinical Trials]
- 2003 - 2005 **Principal Site Investigator.** Phase I Study of targretin, vinorelbine and cisplatin as first-line therapy in advanced non-small cell lung cancer. PMH. LIGAND Pharma. [Clinical Trials]
- 2003 - 2004 **Principal Site Investigator.** Randomized trial of CTI-2030/carboplatin versus paclitaxel/carboplatin in PS2 patients with advanced non-small cell lung cancer. Cell Therapeutics Inc. [Clinical Trials]
- 2002 - 2006 **Principal Investigator.** Phase II study of perifosine in advanced breast cancer. National Cancer Institute (USA). CTEP. 12,000 USD. [Clinical Trials]
- 2002 - 2004 **Co-Investigator.** Phase I study of Gleevec in combination with irinotecan and cisplatin in extensive stage small cell lung cancer. Princess Margaret Hospital Consortium, Toronto, Canada. National Cancer Institute (USA). CTEP. PI: Vincent, Mark. 8,000 USD. [Clinical Trials]
Co-Investigator, Institutional PI.

2002 - 2004

Principal Site Investigator. TALENT: randomized double blind trial of OSI774 plus combination chemotherapy (gemcitabine/cisplatin) versus combination chemotherapy alone in advanced non-small cell lung cancer. Roche Pharmaceuticals. [Clinical Trials]

D. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Kuang S, Chen K, Sayal S, Prabahan G, Rabey MR, Le LW, Seto A, Shepherd FA, Liu G, Bradbury P, Sacher AG, Law JH, Sabatini P, Stockley TL, Tsao MS, **Leighl NB**. Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience. *Curr Oncol*. 2024 Aug 3;31(8):4476-4485. Impact Factor: 3.11. **Senior Responsible Author.**
2. **Leighl NB**. Osimertinib in Stage III *EGFR*-Mutated NSCLC - Game, Set, Match. *N Engl J Med*. 2024 Aug 15;391(7):652-654. Impact Factor: 96.2. **Principal Author.**
3. Barghout SH, Zhan LJ, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, Kasymjanova G, Proulx-Rocray F, Chan SWS, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Goldshtein D, Cleary-Gosine J, Gibson AJ, Hubley L, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd FA, **Leighl N**, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. Treatment patterns and outcomes in KRAS^{G12C}-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study. *Lung Cancer*. 2024 Aug;194:107898. **Coauthor or Collaborator.**
4. Priantti JN, Vilbert M, de Moraes FCA, Madeira T, de Lima Santiago EM, **Leighl NB**, Cavalcante L, Karim NFA. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2024 Jul 22;16(14):2611. Impact Factor: 5.2. **Coauthor or Collaborator.**
5. **Leighl NB**, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Nahit Şendur MA, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory *EGFR*-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. *J Clin Oncol*. 2024 Jun 10;JCO2401001. Impact Factor: 42.1. **Coauthor or Collaborator.**
6. Schmid S, Zhan L, Garcia M, Dietrich K, Khan K, Chowdhury M, Herman M, Patel D, Zaeimi F, **Leighl NB**, Sacher A, Feld R, Shepherd FA, Donahoe L, de Perrot M, Cho BCJ, Liu G, Bradbury PA. Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma. *Clin Lung Cancer*. 2024 Apr 20;S1525-7304(24)00066-4. Impact Factor: 4.2. **Coauthor or Collaborator.**
7. Owen DH, Ismaila N, Freeman-Daily J, Roof L, Singh N, Velazquez AI, **Leighl NB**. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. *J Clin Oncol*. 2024 Jul 10;42(20):e44-e59. **Senior Responsible Author.**
8. Ghazali N, **Leighl NB**. Current Uses and Pitfalls of Liquid Biopsy in NSCLC. *Canadian Oncology Today*. 2024 Jun 20;1(2):12-18. Available from: <https://doi.org/10.58931/cot.2024.1221>. **Co-Principal Author.**

9. **Leighl NB**, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Filip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Nahit Şendur MA, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A, PALOMA-3 Investigators. Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. *J Clin Oncol*. 2024 Jun 10;JCO2401001. **Principal Author**.
10. Phillips WJ, **Leighl NB**, Blais N, Wheatley-Price P. Traitement ciblé oral contre le cancer du poumon non à petites cellules. *CMAJ*. 2024 Jun 9;196(22):E770-E774. Impact Factor 14.6. **Coauthor or Collaborator**.
11. Li Y, Wong M, Zhan L, Corke L, Brown MC, Cheng S, Khan K, Balatnaram K, Chowdhury M, Sabouhanian A, Herman J, Walia P, Strom E, Patel D, García-Pardo M, Schmid S, Eng L, Sacher AG, **Leighl N**, Bradbury PA, Shepherd FA, Shultz D, Liu G. Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort. *Lung Cancer*. 2024 Jun 1;192:107823. **Coauthor or Collaborator**.
12. Malapelle U, **Leighl N**, Addeo A, Hershkovitz D, Hochmair MJ, Khorshid O, Länger F, de Marinis F, Peled N, Sheffield BS, Smit EF, Viteri S, Wolf J, Venturini F, O'Hara RM Jr, Rolfo C. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. *Br J Cancer*. 2024 May 15. **Coauthor or Collaborator**.
13. Melosky B, Prabaharan G, Laskin J, Humphreys M, Finn N, **Leighl N**, Wang Y, Blais N. Clinical Experience with Tepotinib for the Treatment of Patients with non-Small Cell Lung Cancer with MET Exon 14 Skipping Alterations in Canada. *Current Oncol*. 2024 May. In Press. **Coauthor or Collaborator**.
14. Phillips WJ, **Leighl NB**, Blais N, Wheatley-Price P. Oral targeted therapy for the treatment of non-small cell lung carcinoma. *CMAJ*. 2024 Apr 28;196(16):E558-E561. **Coauthor or Collaborator**.
15. Schmid S, Zhan L, Garcia M, Dietrich K, Khan K, Chowdhury M, Herman M, Patel D, Zaeimi F, **Leighl NB**, Sacher A, Feld R, Shepherd FA, Donahoe L, de Perrot M, Cho BCJ, Liu G, Bradbury PA. Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma. *Clin Lung Cancer*. 2024 Apr 20. **Coauthor or Collaborator**.
16. Jaiyesimi IA, **Leighl NB**, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. *J Clin Oncol*. 2024 Apr 10;42(11):e1-e22. **Coauthor or Collaborator**.
17. Jaiyesimi IA, **Leighl NB**, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. *J Clin Oncol*. 2024 Apr 10;42(11):e23-e43. Epub 2024 Feb 28. **Coauthor or Collaborator**.
18. Owen DH, Jaiyesimi IA, **Leighl NB**, Ismaila N, Florez N, Puri S, Schenk EL, Schneider BJ, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights. *JCO Oncol Pract*. 2024 Apr 8:OP2400177. **Coauthor or Collaborator**.
19. Chow R, Drkulec H, Im JHB, Tsai J, Nafees A, Kumar S, Hou T, Fazelzad R, **Leighl NB**, Krzyzanowska M, Wong P, Raman S. The Use of Wearable Devices in Oncology Patients: A Systematic Review. *Oncologist*. 2024 Apr 4;29(4):e419-e430. Impact Factor 5.8. **Coauthor or Collaborator**.
20. Moulson R, Law J, Sacher A, Liu G, Shepherd FA, Bradbury P, Eng L, Iczkovitz S, Abbie E, Elia-Pacitti J, Ewara EM, Mokriak V, Weiss J, Pettengell C, **Leighl NB**. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence. *Curr Oncol*. 2024 Apr 2;31(4):1947-1960. **Senior Responsible Author**.

21. Torrado C, Feng J, MD, Faour E, **Leighl NB**. Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report. *JTO Clin Res Rep*. 2024 Apr;5(4):100647. Available from: <https://doi.org/10.1016/j.jtocrr.2024.100647>. Impact Factor 2.4. **Senior Responsible Author**.
22. Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. *Nat Commun*. 2024 Mar 26;15(1):2568. Impact Factor 17.694. **Coauthor or Collaborator**.
23. Pillay J, Rahman S, Klarenbach S, Reynolds DL, Tessier LA, Thériault G, Persaud N, Finley C, **Leighl N**, McInnes MDF, Garritty C, Traversy G, Tan M, Hartling L. Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care. *Syst Rev*. 2024 Mar 16;13(1):88. **Coauthor or Collaborator**.
24. Kim TM, Girard N, **Leighl NB**, Sabari J, Rahhali N, Schioppa CA, Diels J, Sermon J, Chandler C, Kapetanakis V, Jain R, Li T, Sanden SV. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer. *Future Oncol*. 2024 Mar 1;20(8):447-458. Epub 2023 Oct 26. Impact Factor 3.3. **Coauthor or Collaborator**.
25. Majem M, Basch E, Cella D, Garon EB, Herbst RS, **Leighl NB**. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. *Lung Cancer*. 2024 Jan 1;187:107419. Impact Factor 5.705. **Coauthor or Collaborator**.
26. Huang RS, Mihalache A, Nafees A, Hasan A, Ye XY, Liu Z, **Leighl NB**, Raman S. The Impact of Multidisciplinary Cancer Conferences on Overall Survival: A Meta-Analysis. *J Natl Cancer Inst*. 2023 Dec 20. Impact Factor 10.3. **Coauthor or Collaborator**.
27. Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, **Leighl N**, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. *Lancet*. 2023 Dec 16;402(10419):2295-2306. Impact Factor 168.9. **Coauthor or Collaborator**.
28. Tankel J, Spicer J, Chu Q, Fiset PO, Kidane B, **Leighl NB**, Joubert P, Maziak D, Palma D, McGuire A, Melosky B, Snow S, Bahig H, Blais N. Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process. *Curr Oncol*. 2023 Dec 6;30(12):10363-10384. Impact Factor 2.257. **Coauthor or Collaborator**.
29. Chow R, Drkulec H, Im JHB, Tsai J, Nafees A, Kumar S, Hou T, Fazelzad R, **Leighl NB**, Krzyzanowska M, Wong P, Raman S. The Use of Wearable Devices in Oncology Patients: A Systematic Review. *Oncologist*. 2023 Nov 16. Impact Factor 5.8. **Coauthor or Collaborator**.
30. Zhan LJ, Barghout S, Raptis S, Al-Agha F, Popovacki A, Esfahanian, Kasymianova G, Proulx-Rocray, Chan S, Richardson M, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Cleary-Gosine J, Gibson AJ, Hubley N, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd F, **Leighl N**, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. EP12.03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). *J Thorac Oncol*. 2023 Nov;18(11, Suppl). Impact Factor 20.4. **Coauthor or Collaborator**.
31. Kim TM, Girard N, **Leighl NB**, Sabari J, Rahhali N, Schioppa CA, Diels J, Sermon J, Chandler C, Kapetanakis V, Jain R, Li T, Sanden SV. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer. *Future Oncol*. 2023 Oct 26. Impact Factor 3.3. **Coauthor or Collaborator**.
32. Lau SCM, Perdrizet K, Fung AS, Mata DGMM, Weiss J, Holzapfel N, Liu G, Bradbury PA, Shepherd FA, Sacher AG, Feilotter H, Sheffield B, Hwang D, Tsao MS, Cheng S, Cheema P, **Leighl NB**. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies. *JTO Clin Res Rep*. 2023 Oct 1;4(10):100562. **Senior Responsible Author**.

33. Fares AF, Li Y, Jiang M, Brown MC, Lam ACL, Aggarwal R, Schmid S, **Leighl NB**, Shepherd FA, Wang Z, Diao N, Wenzlaff AS, Xie J, Kohno T, Caporaso NE, Harris C, Ma H, Barnett MJ, Leal LF, Fernandez-Tardon G, Pérez-Ríos M, Davies MPA, Taylor F, Schöttker B, Brennan P, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Brenner H, Andrew A, Cox A, Field JK, Ruano-Ravina A, Shete SS, Tardon A, Wang Y, Le Marchand L, Reis RM, Schabath MB, Chen C, Shen H, Ryan BM, Landi MT, Shiraishi K, Zhang J, Schwartz AG, Tsao MS, Christiani DC, Yang P, Hung RJ, Xu W, Liu G. Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies. *Lancet Public Health*. 2023 Sep 1;8(9):e691-e700. Impact Factor 50. **Coauthor or Collaborator**.
34. Choudhury NJ, Lavery JA, Brown S, de Bruijn I, Jee J, Tran TN, Rizvi H, Arbour KC, Whiting K, Shen R, Hellmann M, Bedard PL, Yu C, **Leighl N**, LeNoue-Newton M, Micheel C, Warner JL, Ginsberg MS, Plodkowski A, Girshman J, Sawan P, Pillai S, Sweeney SM, Kehl KL, Panageas KS, Schultz N, Schrag D, Riely GJ, AACR GENIE BPC Core Team. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2023 Sep 1;29(17):3418-3428. Impact Factor 13.801. **Coauthor or Collaborator**.
35. Fong CH, Meti N, Kruser T, Weiss J, Liu ZA, Takami H, Narita Y, de Moraes FY, Dasgupta A, Ong CK, Yang JCH, Lee JH, Kosyak N, Pavlakis N, Kongkham P, Doherty M, **Leighl NB**, Shultz DB. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice. *J Thorac Dis*. 2023 Aug 31;15(8):4367-4378. Impact Factor 2.5. **Coauthor or Collaborator**.
36. Raphael J, Richard L, Lam M, Blanchette P, **Leighl NB**, Rodrigues G, Trudeau M, Krzyzanowska MK. Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice. *J Natl Cancer Inst*. 2023 Aug 8;115(8):949-961. Impact Factor 10.3. **Coauthor or Collaborator**.
37. Chayab L, Konstantelos N, **Leighl NB**, Tadrus M, Wong WWL. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). *Pharmacoeconomics*. 2023 Aug 1;41(8):945-980. Impact Factor 4.579. **Coauthor or Collaborator**.
38. Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, **Leighl NB**, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. *Curr Oncol*. 2023 Jul 6;30(7):6473-6496. Impact Factor 2.257. **Coauthor or Collaborator**.
39. Garcia-Pardo M, Czarnecka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, Waddell TK, Yasufuku K, Liu G, Donahoe LL, Pierre A, Le LW, Gunasegaran T, Ghumman N, Shepherd FA, Bradbury PA, Sacher AG, Schmid S, Corke L, Feng J, Stockley T, Pal P, Rogalla P, Pipinikas C, Howarth K, Ambasager B, Mezquita L, Tsao MS, **Leighl NB**. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. *JAMA Netw Open*. 2023 Jul 3;6(7):e2325332. Impact Factor 13.353. **Coauthor or Collaborator**.
40. Gosney JR, Paz-Ares L, Jänne P, Kerr KM, **Leighl NB**, Lozano MD, Malapelle U, Mok T, Sheffield BS, Tufman A, Wistuba II, Peters S. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. *ESMO Open*. 2023 Jun 23;8(4):101587. Impact Factor 5.329. **Coauthor or Collaborator**.
41. Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, **Leighl NB**, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). *J Thorac Oncol*. 2023 Jun 1;18(6):813-819. Impact Factor 20.4. **Coauthor or Collaborator**.
42. Singh N, Jaiyesimi IA, Ismaila N, **Leighl NB**, Mamdani H, Phillips T, Owen DH. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1. *J Clin Oncol*. 2023 May 20;41(15):e51-e62. Impact Factor 45.3. **Coauthor or Collaborator**.

43. Singh N, Jaiyesimi IA, Ismaila N, **Leighl NB**, Mamdani H, Phillips T, Owen DH. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1. *J Clin Oncol*. 2023 May 20;41(15):e42-e50. Impact Factor 45.3. **Coauthor or Collaborator**.
44. Kohan A, Kulanthaivelu R, Hinzpeter R, Liu ZA, Ortega C, **Leighl N**, Metser U, Veit-Haibach P, AACR Project GENIE BPC Core Team. Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database. *Cancers (Basel)*. 2023 Mar 31;15(7). Impact Factor 5.2. **Coauthor or Collaborator**.
45. Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, **Leighl NB**, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2. *J Clin Oncol*. 2023 Feb 10;41(5):e10-e20. Impact Factor 45.3. **Coauthor or Collaborator**.
46. Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, **Leighl NB**, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2. *J Clin Oncol*. 2023 Feb 10;41(5):e1-e9. Impact Factor 45.3. **Coauthor or Collaborator**.
47. Popat S, Ahn MJ, Ekman S, **Leighl NB**, Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL, Yang JC. Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. *Target Oncol*. 2023 Jan 18. Impact Factor 4.864. **Coauthor or Collaborator**.
48. Subramanian J, **Leighl NB**, Choi YL, Chou TY, Gregg J, Hui R, Marchetti A, Silvey M, Makin R, Gillespie-Akar L, Taylor A, Kahangire DA, Bailey T, Chau M, Navani N. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study. *Lung Cancer*. 2023 Jan 1;175:47-56. Impact Factor 5.705. **Coauthor or Collaborator**.
49. Schmid S, Cheng S, Chotai S, Garcia M, Zhan L, Hueniken K, Balaratnam K, Khan K, Patel D, Grant B, Raptis R, Brown MC, Xu W, Moriarty P, Shepherd FA, Sacher AG, **Leighl NB**, Bradbury PA, Liu G. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2023 Jan 1;24(1):40-50. Impact Factor 3.6. **Coauthor or Collaborator**.
50. Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, **Leighl NB**, Sacher AG, Snow S, Juergens R, Liu G. Presentation and outcomes of KRAS(G12C) mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. *Cancer Treat Res Commun*. 2023 Jan 1;37:100774. Impact Factor 1.985. **Coauthor or Collaborator**.
51. Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F, AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. *Sci Rep*. 2022 Nov 9;12(1):19055. Impact Factor 4.6. **Coauthor or Collaborator**.
52. Chu Q, **Leighl NB**, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N. BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. *JTO Clin Res Rep*. 2022 Nov 1;3(11):100400. **Coauthor or Collaborator**.
53. Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, **Leighl NB**, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. *J Clin Oncol*. 2022 Oct 1;40(28):3323-3343. Impact Factor 45.3. **Coauthor or Collaborator**.
54. Tan DSW, Kim SW, Ponce Aix S, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, Grohé C, **Leighl NB**, Riely G, Cui X, Zou M, Ghebremariam S, O'Sullivan-Djentuh L, Belli R, Giovannini M, Kim DW. Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. *Eur J Cancer*. 2022 Sep 1;172:276-286. Impact Factor 10.002. **Coauthor or Collaborator**.

55. Raphael J, Richard L, Lam M, Blanchette PS, **Leighl NB**, Rodrigues G, Trudeau ME, Krzyzanowska MK. Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. *Oncologist*. 2022 Aug 5;27(8):675-684. Impact Factor 5.8. **Coauthor or Collaborator**.
56. Kuang S, Fung AS, Perdrizet KA, Chen K, Li JJN, Le LW, Cabanero M, Karsaneh OAA, Tsao MS, Morganstein J, Ranich L, Smith AC, Wei C, Cheung C, Shepherd FA, Liu G, Bradbury P, Pal P, Schwock J, Sacher AG, Law JH, Stockley TL, **Leighl NB**. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. *Curr Oncol*. 2022 Jun 22;29(7):4428-4437. Impact Factor 2.257. **Senior Responsible Author**.
57. McTaggart-Cowan H, King MT, Norman R, Costa DSJ, Pickard AS, Viney R, Peacock SJ, Canadian MAUCa Team. The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. *Health Qual Life Outcomes*. 2022 Jun 16;20(1):97. Impact Factor 2.278. **Coauthor or Collaborator**.
58. Gauthier MP, Law JH, Le LW, Li JJN, Zahir S, Nirmalakumar S, Sung M, Pettengell C, Aviv S, Chu R, Sacher A, Liu G, Bradbury P, Shepherd FA, **Leighl NB**. Automating Access to Real-World Evidence. *JTO Clin Res Rep*. 2022 Jun 1;3(6):100340. **Senior Responsible Author**.
59. García-Pardo M, Makarem M, Li JJN, Kelly D, **Leighl NB**. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. *Br J Cancer*. 2022 Mar 26. Impact Factor 9. **Senior Responsible Author**.
60. Udayakumar S, Parmar A, **Leighl NB**, Everest L, Arciero VS, Santos SD, Rahmadian A, Doherty MK, Chan KKW. Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. *Crit Rev Oncol Hematol*. 2022 Mar 24;173:103660. Impact Factor 6.2. **Coauthor or Collaborator**.
61. Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, Chouaid C, Dechev H, Dowlati A, Fernández Núñez N, Ivashchuk O, Kiladze I, Kortua T, **Leighl N**, Luft A, Makharadze T, Min Y, Quantin X, DISTINCT study investigators. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. *Lung Cancer*. 2022 Mar 4;166:135-142. Impact Factor 5.705. **Coauthor or Collaborator**.
62. Kuehne N, Hueniken K, Xu M, Shakik S, Vedadi A, Pinto D, Brown MC, Bradbury PA, Shepherd FA, Sacher AG, **Leighl NB**, Xu W, Lok BH, Liu G, O'Kane GM. Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. *Clin Lung Cancer*. 2022 Mar 1;23(2):e154-e164. Online, ahead of print. Impact Factor 4.2. **Coauthor or Collaborator**.
63. Perdrizet K, Stockley TL, Law JH, Smith A, Zhang T, Fernandes R, Shabir M, Sabatini P, Youssef NA, Ishu C, Li JJ, Tsao MS, Pal P, Cabanero M, Schwock J, Ko HM, Boerner S, Ruff H, Shepherd FA, Bradbury PA, Liu G, Sacher AG, **Leighl NB**. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. *Cancer Treat Res Commun*. 2022 Feb 18;31:100534. Impact Factor 1.985 (Trainee publication). **Senior Responsible Author**.
64. Passaro A, **Leighl N**, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Filip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. *Ann Oncol*. 2022 Feb 14. Impact Factor 51.77. **Coauthor or Collaborator**.
65. Castro PP, de Perrot M, Chua YC, Bezjak A, **Leighl N**, Darling G, Pierre A, Yasufuku K, Cypel M, Waddell T, Donahoe L, Yeung J, Keshavjee S. Importance of tumor size in resectable stage III-N2 non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2022 Feb 11. Impact Factor 5.209. **Coauthor or Collaborator**.
66. Schmid S, Garcia M, Cheng S, Zhan L, Chotai S, Balaratnam K, Khan K, Patel D, Catherine Brown M, Sachdeva R, Xu W, Shepherd FA, Sacher A, **Leighl NB**, Bradbury P, Moriarty P, Sara Kuruvilla M, Liu G. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. *Lung Cancer*. 2022 Feb 3;166:58-62. Impact Factor 5.705. **Coauthor or Collaborator**.

67. Eggen AC, Richard NM, Bosma I, Jalving M, **Leighl NB**, Liu G, Mah K, Higazy R, Shultz DB, Reyners AKL, Rodin G, Edelstein K. Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. *Neurooncol Pract*. 2022 Feb 1;9(1):50-58. Impact Factor 2.7. **Coauthor or Collaborator**.
68. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, **Leighl NB**, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERA-VOLT study group. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry. *J Thorac Oncol*. 2022 Jan 24. Impact Factor 20.4. **Coauthor or Collaborator**.
69. Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, Li JJ, Fernandes R, Shokoohi A, Lanman RB, **Leighl NB**. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. *Ther Adv Med Oncol*. 2022 Jan 1;14:17588359221112696. e-collection publication. **Senior Responsible Author**.
70. Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, Corke L, Waddell TK, Yasufuku K, Donahoe LL, Pierre A, Le LW, Ghumman N, Liu G, Shepherd FA, Bradbury P, Sacher A, Stockley T, Pal P, Rogalla P, Tsao MS, **Leighl NB**. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. *Ther Adv Med Oncol*. 2022 Jan 1;14:17588359221126151. Impact Factor 4.9. **Senior Responsible Author**.
71. Schmid S, Zhan L, Dietrich K, Khan K, Chowdhury M, Herman M, Patel D, Zaeimi F, **Leighl NB**, Sacher A, Feld R, Shepherd FA, Donahoe L, de Perrot M, Cho BCJ, Liu G, Bradbury PA. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. *Clin Lung Cancer*. 2022 Jan 1;23(1):e43-e53. Impact Factor 4.2. **Coauthor or Collaborator**.
72. Patel YP, Husereau D, **Leighl NB**, Melosky B, Nam J. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. *Curr Oncol*. 2021 Dec 11;28(6):5278-5294. Impact Factor 2.048. **Coauthor or Collaborator**.
73. Sung MR, Tomasini P, Le LW, Kamel-Reid S, Tsao MS, Liu G, Bradbury PA, Shepherd FA, Li JJN, Feld R, **Leighl NB**. Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. *JTO Clin Res Rep*. 2021 Dec 4;3(2):100259. Impact Factor 15.609 (Trainee publication). **Senior Responsible Author**.
74. Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, **Leighl NB**, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. *Ann Oncol*. 2021 Dec 1;32(12):1597-1607. Impact Factor 32.98. **Coauthor or Collaborator**.
75. Lau SCM, Ryan M, Weiss J, Fares AF, Garcia M, Schmid S, Kuang S, Kelly D, Tsao MS, Bradbury PA, Cho BCJ, Sun A, Raman S, Hope A, Giuliani M, Lok BH, Bezjak A, Liu G, **Leighl NB**, Shepherd FA, Sacher AG. Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy. *JTO Clin Res Rep*. 2021 Dec 1;2(12):100251. **Coauthor or Collaborator**.
76. Saraon P, Snider J, Schormann W, Rai A, Radulovich N, Sánchez-Osuna M, Coulombe-Huntington J, Huard C, Mohammed M, Lima-Fernandes E, Thériault B, Halabelian L, Chan M, Joshi D, Drecun L, Yao Z, Pathmanathan S, Wong V, Lyakisheva A, Aboualzadeh F, Niu L, Li F, Kiyota T, Subramanian R, Joseph B, Aman A, Prakesch M, Isaac M, Mamai A, Poda G, Vedadi M, Marcellus R, Uehling D, **Leighl N**, Sacher A, Samaržija M, Jakopović M, Arrowsmith C, Tyers M, Tsao MS, Andrews D, Al-Awar R, Stagljar I. Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. *J Mol Biol*. 2021 Nov 19;433(23):167294. Impact Factor 5.469. **Coauthor or Collaborator**.

77. Cheema PK, Banerji SO, Blais N, Chu QS, Desmeules P, Juergens RA, **Leighl NB**, Sheffield BS, Wheatley-Price PF, Melosky BL. Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. *Curr Oncol*. 2021 Nov 9;28(6):4552-4576. Impact Factor 2.048. **Coauthor or Collaborator**.
78. Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS, AACR Project GENIE Consortium. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. *JAMA Oncol*. 2021 Nov 4. Impact Factor 31.78. **Coauthor or Collaborator**.
79. Makarem M, García-Pardo M, **Leighl NB**. Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. *Cancers (Basel)*. 2021 Oct 22;13(21). Impact Factor 6.639. **Senior Responsible Author**.
80. Torres FS, Akbar S, Raman S, Yasufuku K, Schmidt C, Hosny A, Baldauf-Lenschen F, **Leighl NB**. End-to-End Non-Small-Cell Lung Cancer Prognostication Using Deep Learning Applied to Pretreatment Computed Tomography. *JCO Clin Cancer Inform*. 2021 Oct 1;5:1141-1150. **Senior Responsible Author**.
81. Zimmermann C, Pope A, Hannon B, Krzyzanowska MK, Rodin G, Li M, Howell D, Knox JJ, **Leighl NB**, Sridhar S, Oza AM, Prince R, Lheureux S, Hansen AR, Rydall A, Chow B, Herx L, Booth CM, Dudgeon D, Dhani N, Liu G, Bedard PL, Mathews J, Swami N, Le LW. Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer. *J Natl Compr Canc Netw*. 2021 Sep 7:1-10. Impact Factor 11.91. **Coauthor or Collaborator**.
82. Perdrizet K, Sutradhar R, Li Q, Liu N, Earle CC, **Leighl NB**. Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. *J Thorac Dis*. 2021 Sep 1;13(9):5419-5429. Impact Factor 2.365. **Senior Responsible Author**.
83. Makarem M, Ezeife DA, Smith AC, Li JJN, Law JH, Tsao MS, **Leighl NB**. Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System. *Curr Oncol*. 2021 Aug 25;28(5):3268-3279. Impact Factor 2.048. **Senior Responsible Author**.
84. Park K, Haura EB, **Leighl NB**, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol*. 2021 Aug 2;JCO2100662. Impact Factor 44.544. **Coauthor or Collaborator**.
85. Ezeife DA, Morganstein BJ, Yip S, Ryan M, Law JH, Guan AY, Le LW, Hansen AR, Sacher A, Bjarnason GA, Doherty MK, **Leighl NB**. The financial impact of cancer care on renal cancer patients. *Can J Urol*. 2021 Aug 1;28(4):10762-10767. Impact Factor 5.157. **Senior Responsible Author**.
86. Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, **Leighl N**, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocchi S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM. Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort. *J Thorac Oncol*. 2021 Jul 23:S1556-0864(21)02321. Impact Factor 13.357. **Coauthor or Collaborator**.
87. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, **Leighl NB**, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2021 Jul 15. Impact Factor 31.777. **Coauthor or Collaborator**.
88. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, **Leighl N**, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). *J Thorac Oncol*. 2021 Jul 8. Impact Factor 13.357. **Coauthor or Collaborator**.

89. Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, Schrag D, Panageas KS, American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. *JAMA Netw Open*. 2021 Jul 1;4(7):e2117547. Impact Factor 8.483. **Coauthor or Collaborator**.
90. Fung AS, Graham DM, Chen EX, Stockley TL, Zhang T, Le LW, Albaba H, Pisters KM, Bradbury PA, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendi S, Gill S, Sawczak M, Law JH, **Leighl NB**. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. *Lung Cancer*. 2021 Jul 1;157:21-29. Impact Factor 4.702. **Senior Responsible Author**.
91. Herman M, Liu Z, Shepherd FA, **Leighl N**, Liu G, Bradbury PA. The effect of prior cancer on non-small cell lung cancer trial eligibility. *Cancer Med*. 2021 Jun 18. Impact Factor 3.362. **Coauthor or Collaborator**.
92. Lau SCM, Poletes C, Le LW, Mackay KM, Fares AF, Bradbury PA, Shepherd FA, Tsao MS, **Leighl NB**, Liu G, Shultz D, Sacher AG. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. *Lung Cancer*. 2021 Jun 1;156:76-81. Impact Factor 4.702. **Coauthor or Collaborator**.
93. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, **Leighl NB**, Al Baghdadi T, Lara P Jr, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. *Clin Lung Cancer*. 2021 May 1;22(3):187-194.e1. Online, ahead of print. Impact Factor 3.55. **Coauthor or Collaborator**.
94. Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, **Leighl NB**, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). *Clin Lung Cancer*. 2021 May 1;22(3):170-177. Impact Factor 3.55. **Coauthor or Collaborator**.
95. Cheung MC, Chan KK, Golden S, Hay A, Pater J, Prica A, Chen BE, **Leighl N**, Mittmann N. Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. *Clin Trials*. 2021 Apr 19;17407745211005045. Impact Factor 2.715. **Coauthor or Collaborator**.
96. Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, **Leighl NB**, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, Singh N, Spigel DR, Tashbar J, Masters G. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *J Clin Oncol*. 2021 Mar 20;39(9):1040-1091. Impact Factor 32.956. **Coauthor or Collaborator**.
97. **Leighl NB**, Nirmalakumar S, Ezeife DA, Gyawali B. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. *Am Soc Clin Oncol Educ Book*. 2021 Mar 1;41:1-12. Impact Factor 1.564. **Principal Author**.
98. Cho BCJ, Donahoe L, Bradbury PA, **Leighl N**, Keshavjee S, Hope A, Pal P, Cabanero M, Czarnecka K, McRae K, Tsao MS, de Perrot M. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. *Lancet Oncol*. 2021 Feb 1;22(2):190-197. Epub 2021 Jan 12. Impact Factor 33.752. **Coauthor or Collaborator**.
99. Vedadi A, Shakik S, Brown MC, Lok BH, Shepherd FA, **Leighl NB**, Sacher A, Bradbury PA, Xu W, Liu G, O'Kane GM. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. *Qual Life Res*. 2021 Feb 1;30(2):445-454. Impact Factor 2.392. **Coauthor or Collaborator**.
100. Kuang S, **Leighl NB**. Lorlatinib in ALK-Rearranged Lung Cancer. *Cancer Cell*. 2021 Jan 11;39(1):25-27. Impact Factor 22.602. **Senior Responsible Author**.

101. Chan SWS, Smith E, Aggarwal R, Balaratnam K, Chen R, Hueniken K, Fazelzad R, Weiss J, Jiang S, Shepherd FA, Bradbury PA, Sacher AG, **Leighl NB**, Xu W, Brown MC, Eng L, Liu G. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. *Clin Lung Cancer*. 2021 Jan 10;S1525-7304(21)00005. Online ahead of print. Impact Factor 3.55. **Coauthor or Collaborator**.
102. Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, Liu G, **Leighl NB**, Sacher AG. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. *Clin Lung Cancer*. 2021 Jan 7;S1525-7304(21)00003-. Online ahead of print. Impact Factor 3.55. **Coauthor or Collaborator**.
103. Benjamin DM, Mandel DR, Barnes T, Krzyzanowska MK, **Leighl N**, Tannock IF, Kimmelman J. Can Oncologists Predict the Efficacy of Treatments in Randomized Trials? *Oncologist*. 2021 Jan 1;26(1):56-62. Impact Factor 5.025. **Coauthor or Collaborator**.
104. Cheema PK, Gomes M, Banerji S, Joubert P, **Leighl NB**, Melosky B, Sheffield BS, Stockley T, Ionescu DN. Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer. *Curr Oncol*. 2020 Dec 1;27(6):321-329. Impact Factor 2.257. **Coauthor or Collaborator**.
105. Tse BC, Said BI, Fan ZJ, Hueniken K, Patel D, Gill G, Liang M, Razooqi M, Brown MC, Sacher AG, Bradbury PA, Shepherd FA, **Leighl NB**, Xu W, Howell D, Liu G, O'Kane G. Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. *Curr Oncol*. 2020 Dec 1;27(6):e552-e559. Impact Factor 2.257. **Coauthor or Collaborator**.
106. Li JJN, Karim K, Sung M, Le LW, Lau SCM, Sacher A, **Leighl NB**. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. *Lung Cancer*. 2020 Dec 1;150:159-163. Impact Factor 4.702. **Senior Responsible Author**.
107. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, **Leighl NB**, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. *J Clin Oncol*. 2020 Nov 20;38(33):3863-3873. Impact Factor 32.956. **Coauthor or Collaborator**.
108. Trama A, Proto C, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Mazieres J, Soo RA, **Leighl NB**, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J. Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. *Cancer Cell*. 2020 Nov 9;38(5):602-604. Impact Factor 26.602. **Coauthor or Collaborator**.
109. Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Price PW, Jao K, Schellenberg DD, Juergens R, **Leighl N**, Chu Q. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. *Oncologist*. 2020 Nov 1;25(11):981-992. Impact Factor 5.025. **Coauthor or Collaborator**.
110. Nadjafi M, Sung MR, Santos GDC, Le LW, Hwang DM, Tsao MS, **Leighl NB**. Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre. *Curr Oncol*. 2020 Oct 1;27(5):244-249. Impact Factor 2.257. **Senior Responsible Author**.
111. Young K, Jiang H, Marquez M, Yeung J, Shepherd FA, Renner E, Keshavjee S, Kim J, Ross H, Aliev T, Liu G, **Leighl NB**, Feld R, Bradbury P. Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients. *Lung Cancer*. 2020 Sep 1;147:214-220. Impact Factor 4.702. **Coauthor or Collaborator**.
112. Schmid S, Li JJN, **Leighl NB**. Mechanisms of osimertinib resistance and emerging treatment options. *Lung Cancer*. 2020 Sep 1;147:123-129. **Senior Responsible Author**.
113. Schmid S, Stewart EL, Martins-Filho SN, Cabanero M, Wang A, Bao H, Wu X, Patel D, Chen Z, Law JH, Bradbury PA, Shepherd FA, **Leighl N**, Tsao MS, Pugh T, Bratman SV, Sacher A, Liu G. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. *Clin Lung Cancer*. 2020 Sep 1;5:e488-e492. **Coauthor or Collaborator**.

114. Eggen AC, Reyners AKL, Shen G, Bosma I, Jalving M, **Leighl NB**, Liu G, Richard NM, Mah K, Shultz DB, Edelstein K, Rodin G. Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. *J Pain Symptom Manage*. 2020 Aug 1;60(2):422-429.e1. Impact Factor 3.249. **Coauthor or Collaborator**.
115. Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, **Leighl NB**, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. *Lung Cancer*. 2020 Aug 1;146:78-85. Impact Factor 4.702. **Coauthor or Collaborator**.
116. Fares AF, Lok BH, Zhang T, Cabanero M, Lau SCM, Stockley T, Patel D, Bradbury PA, Sacher A, Yasufuku K, Morash BA, Sabatini PJB, Nguyen LN, **Leighl NB**, Tsao MS, Shepherd FA, Liu G, Martins-Filho SN, Pal P. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. *Lung Cancer*. 2020 Aug 1;146:350-354. **Coauthor or Collaborator**.
117. Hao D, Sengupta A, Ding K, Ubeydullah ER, Krishnaiah S, **Leighl NB**, Shepherd FA, Seymour L, Weljie A. Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy. *Cancers (Basel)*. 2020 Jul 16;12(7). Impact Factor 5.742. **Coauthor or Collaborator**.
118. Makarem M, **Leighl NB**. Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma-first” approach? *Cancer*. 2020 Jul 15;126(14):3176-3180. **Senior Responsible Author**.
119. Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, **Leighl NB**, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. *Lung Cancer*. 2020 Jul 1;145:144-151. Impact Factor 4.702. **Coauthor or Collaborator**.
120. Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Soo RA, **Leighl NB**, Peters S, Wakelee H, Garassino MC, Horn L. TERA-VOLT: Thoracic Cancers International COVID-19 Collaboration. *Cancer Cell*. 2020 Jun 8;37(6):742-745. Impact Factor 26.602. **Coauthor or Collaborator**.
121. **Leighl NB**, Kamel-Reid S, Cheema PK, et al. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. *JCO Precision Oncology* 2020. 2020 May 15;4:520-533. DOI: 10.1200/PO.19.00335; Published on-line May 15, 2020. **Principal Author**.
122. Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, Xiao X, Han Y, Gorlova O, Hung RJ, Brhane Y, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Byun J, Dragnev KH, Field JK, Kiemeny LF, Lazarus P, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Diao N, Su L, Song L, Zhang R, **Leighl N**, Johansen JS, Mellemegaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, Heijden EHF MV, Kim JH, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Goodman GE, Cox A, Taylor F, Woll P, Wichmann E, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Butler LM, Offit K, Sriniv. Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nat Commun*. 2020 May 11;11(1):2220. Impact Factor 12.121. **Coauthor or Collaborator**.
123. Hanna NH, Schneider BJ, Temin S, Baker S Jr, Brahmer J, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, **Leighl NB**, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Singh N, Spigel DR, Stabler JO, Tashbar J, Masters G. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *J Clin Oncol*. 2020 May 10;38(14):1608-1632. Impact Factor 32.956. **Coauthor or Collaborator**.
124. Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, **Leighl N**, Oza AM, Parsons JA, Hansen AR. Cancer patients' experiences with immune checkpoint modulators: A qualitative study. *Cancer Med*. 2020 May 1;9(9):3015-3022. Impact Factor 3.362. **Coauthor or Collaborator**.

125. Saraon P, Snider J, Kalaidzidis Y, Wybenga-Groot LE, Weiss K, Rai A, Radulovich N, Drecun L, Vučković N, Vučetić A, Wong V, Thériault B, Pham NA, Park JH, Datti A, Wang J, Pathmanathan S, Aboualizadeh F, Lyakisheva A, Yao Z, Wang Y, Joseph B, Aman A, Moran MF, Prakesch M, Poda G, Marcellus R, Uehling D, Samaržija M, Jakopović M, Tsao MS, Shepherd FA, Sacher A, **Leighl N**, Akhmanova A, Al-Awar R, Zerial M, Stagljar I. A drug discovery platform to identify compounds that inhibit EGFR triple mutants. *Nat Chem Biol*. 2020 May 1;16(5):577-586. Impact Factor 12.587. **Coauthor or Collaborator**.
126. Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Liu G, **Leighl NB**. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. *J Thorac Dis*. 2020 May 1;12(5):2706-2712. Impact Factor 2.046. **Senior Responsible Author**.
127. Wakeam E, Adibfar A, Stokes S, **Leighl NB**, Giuliani ME, Varghese TK Jr, Darling GE. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. *J Thorac Cardiovasc Surg*. 2020 May 1;159(5):2043-2054.e9. Impact Factor 4.88 (Trainee publication). **Coauthor or Collaborator**.
128. Ramotar M, Barnes S, Moraes F, Dasgupta A, Laperriere N, Millar BA, Berlin A, Conrad T, van Prooijen M, Damyanovich A, Heaton R, Cho YB, Coolens C, Liu G, Shepherd FA, Bradbury P, **Leighl N**, Bernstein M, Zadeh G, Kongkham P, Doherty M, Shultz DB. Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. *Adv Radiat Oncol*. 2020 May 1;5(3):350-357. Impact Factor 1.95. **Coauthor or Collaborator**.
129. Ezeife DA, Dionne F, Fares AF, Cusano ELR, Fazelizad R, Ng W, Husereau D, Ali F, Sit C, Stein B, Law JH, Le L, Ellis PM, Berry S, Peacock S, Mitton C, Earle CC, Chan KKW, **Leighl NB**. Value assessment of oncology drugs using a weighted criterion-based approach. *Cancer*. 2020 Apr 1;126(7):1530-1540. Impact Factor 6.102 (Trainee publication). **Senior Responsible Author**.
130. Kuo JC, Graham DM, Salvarrey A, Kassam F, Le LW, Shepherd FA, Burkes R, Hollen PJ, Gralla RJ, **Leighl NB**. A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer. *Curr Oncol*. 2020 Apr 1;27(2):e156-e162. Impact Factor 2.257. **Senior Responsible Author**.
131. Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, **Leighl N**, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. *Cancer*. 2020 Apr 1;126(7):1550-1558. Impact Factor 6.126. **Coauthor or Collaborator**.
132. Melosky B, Banerji S, Blais N, Chu Q, Juergens R, **Leighl NB**, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. *Curr Oncol*. 2020 Apr 1;27(2):e146-e155. Impact Factor 2.257. **Coauthor or Collaborator**.
133. Fung AS, **Leighl NB**. Advancing the systemic therapy of lung cancer: quality or quantity? *Lancet Oncol*. 2020 Mar 1;21(3):322-324. **Senior Responsible Author**.
134. Puri S, Lok BH, **Leighl N**, Gray JE. Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. *Front Oncol*. 2020 Jan 1;10:1783. **Co-Senior Responsible Author**.
135. **Leighl NB**, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Rydén A, Novello S. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. *Eur J Cancer*. 2020 Jan 1;125:49-57. [Epub ahead of print]. Impact Factor 6.68. **Principal Author**.
136. Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, Earle CC, Cheung MC, **Leighl NB**, Coburn NG, DeAngelis C, Evans WK. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. *CMAJ Open*. 2020 Jan 1;8(1):E191-E198. Impact Factor 7.7. **Coauthor or Collaborator**.

137. Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, **Leighl NB**, Shepherd FA, Xu W, Liu G, Hurry M, O’Kane GM. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. *Cancer Med*. 2019 Dec 1;8(18):7542-7555. Impact Factor 3.362. **Coauthor or Collaborator**.
138. Fiset PO, Labbé C, Young K, Craddock KJ, Smith AC, Tanguay J, Pintilie M, Wang R, Torlakovic E, Cheung C, da Cunha Santos G, Ko HM, Boerner SL, Hwang DM, **Leighl NB**, Tsao MS. Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center’s results in population-based reflex testing. *Cancer*. 2019 Nov 15;125(22):4043-4051. Impact Factor 6.072. **Coauthor or Collaborator**.
139. Lee MJ, Kuehne N, Hueniken K, Liang S, Rai S, Sorotsky H, Herman M, Shepshelovich D, Bruce J, Liang M, Patel D, Cheng D, Chen Z, Eng L, Brown MC, Cho J, **Leighl NB**, de Perrot M, Reisman D, Xu W, Bradbury PA, Liu G. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. *Mol Carcinog*. 2019 Nov 1;58(11):1960-1973. Impact Factor 4.004. **Coauthor or Collaborator**.
140. Fung AS, **Leighl NB**. Improving the Management of Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer. *J Oncol Pract*. 2019 Nov 1;15(11):571-572. Impact Factor 2.828 (Trainee publication). **Senior Responsible Author**.
141. Mittmann N, Cheng SY, Liu N, Seung SJ, Saxena FE, DeAngelis C, Hong NJL, Earle CC, Cheung MC, **Leighl N**, Coburn N, Evans WK. The generation of two specific cancer costing algorithms using Ontario administrative databases. *Curr Oncol*. 2019 Oct 1;26(5):e682-e692. Impact Factor 2.048. **Coauthor or Collaborator**.
142. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, **Leighl NB**, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. *J Clin Oncol*. 2019 Oct 1;37(28):2518-2527. Impact Factor 26.303. **Coauthor or Collaborator**.
143. Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, **Leighl NB**, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). *J Thorac Oncol*. 2019 Sep 1;14(9):1628-1639. Impact Factor 12.46. **Coauthor or Collaborator**.
144. Lau SCM, **Leighl NB**. Hyperprogressive disease with immunotherapy: new directions. *J Thorac Dis*. 2019 Sep 1;11(Suppl 15):S1877-S1880. Impact Factor 2.027 (Trainee publication). **Senior Responsible Author**.
145. Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, **Leighl NB**, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. *Curr Oncol*. 2019 Aug 1;26(4):e551-e557. Impact Factor 2.048. **Coauthor or Collaborator**.
146. **Leighl NB**, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. *Clin Cancer Res*. 2019 Aug 1;25(15):4691-4700. Impact Factor 10.199. **Principal Author**.
147. Melosky B, Juergens R, McLeod D, **Leighl N**, Brade A, Card PB, Chu Q. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. *Lung Cancer*. 2019 Aug 1;134:259-267. Impact Factor 4.806. **Coauthor or Collaborator**.
148. Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, **Leighl N**, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. *ESMO Open*. 2019 Jul 22;4(4):e000532. **Coauthor or Collaborator**.

149. Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, **Leighl N**, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. Lung Cancer. 2019 Jul 1;133:48-55. Impact Factor 4.806. **Coauthor or Collaborator.**
150. Kachuri L, Helby J, Bojesen SE, Christiani DC, Su L, Wu X, Tardón A, Fernández-Tardón G, Field JK, Davies MP, Chen C, Goodman GE, Shepherd FA, **Leighl NB**, Tsao MS, Brhane Y, Brown MC, Boyd K, Shepshelovich D, Sun L, Amos CI, Liu G, Hung RJ. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Jul 1;28(7):1228-1237. Impact Factor 4.125. **Coauthor or Collaborator.**
151. O’Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, **Leighl NB**, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G. The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist. 2019 Jul 1;24(7):e501-e509. Impact Factor 4.54. **Coauthor or Collaborator.**
152. Soldera SV, Kavanagh J, Pintilie M, **Leighl NB**, de Perrot M, Cho J, Hope A, Feld R, Bradbury PA. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Oncologist. 2019 Jul 1. 24(7):e510-e517. Impact Factor 2.6 (Trainee publication). **Coauthor or Collaborator.**
153. Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, **Leighl NB**. Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. Clin Lung Cancer. 2019 Jul 1. Impact Factor 4.117 (Trainee publication). **Senior Responsible Author.**
154. Hoch JS, Hay A, Isaranuwachai W, Thavorn K, **Leighl NB**, Tu D, Trenaman L, Dewa CS, O’Callaghan C, Pater J, Jonker D, Chen BE, Mittmann N. Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. BMC Cancer. 2019 Jun 7;19(1):552. Impact Factor 3.288. **Coauthor or Collaborator.**
155. Marshall DA, Ferrusi IL, Trudeau M, **Leighl NB**, Hoch JS, Grazziotin LR, Khong H, Pullenayegum E, Earle CC. Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. J Oncol Pharm Pract. 2019 Jun 2;1078155219850299. Impact Factor 1.908 (Trainee publication). **Coauthor or Collaborator.**
156. Melosky B, Juergens R, Hirsh V, McLeod D, **Leighl N**, Tsao MS, Card PB, Chu Q. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 2019 May 28. Impact Factor 5.252. **Coauthor or Collaborator.**
157. O’Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, **Leighl NB**. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. Lung Cancer. 2019 May 1;131:86-89. Impact Factor 4.806 (Trainee publication). **Senior Responsible Author.**
158. Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, **Leighl NB**, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 May 1. 20(30):e338-e345. Impact Factor 4.117 (Trainee publication). **Coauthor or Collaborator.**
159. Zhang C, **Leighl NB**, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019 Apr 25;12(1):45. Impact Factor 8.731. **Coauthor or Collaborator.**
160. Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, **Leighl N**, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. Cancer. 2019 Apr 15;125(8):1341-1349. Epub ahead of print. Impact Factor 6.537. **Coauthor or Collaborator.**

161. Cheung WY, Kornelsen EA, Mittmann N, **Leighl NB**, Cheung M, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. *Curr Oncol*. 2019 Apr 1;26(2):89-93. Impact Factor 2.048. **Coauthor or Collaborator**.
162. **Leighl NB**, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. *Lancet Respir Med*. 2019 Apr 1;7(4):347-357. Impact Factor 21.466. **Principal Author**.
163. Li Y, Xiao X, Bossé Y, Gorlova O, Gorlov I, Han Y, Byun J, **Leighl N**, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Han J, Siminovitch K, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orłowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Liu G, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. *Oncotarget*. 2019 Mar 5;10(19):1760-1774. Impact Factor 5.168. **Coauthor or Collaborator**.
164. Sung MR, **Leighl NB**. Improving lung cancer diagnosis: the evolving role of patients and care providers. *J Thorac Dis*. 2019 Mar 1;11(Suppl 3):S422-S424. Impact Factor 2.365 (Trainee publication). **Senior Responsible Author**.
165. Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakakis N, Drilon A, Rudin CM, Arcila ME, **Leighl NB**, Shepherd FA, Kris MG, Mazières J, Li BT. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. *Eur J Cancer*. 2019 Mar 1;109:28-35. Epub 2019 Jan 24. Impact Factor 5.417. **Coauthor or Collaborator**.
166. Perdrizet K, **Leighl NB**. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. *Curr Treat Options Oncol*. 2019 Feb 18;20(3):21. Impact Factor 3.562. **Senior Responsible Author**.
167. Young K, da Cunha Santos G, Card P, **Leighl N**. The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. *Cancer Cytopathol*. 2019 Feb 1. 127(2):72-78. Impact Factor 3.818 (Trainee publication). **Senior Responsible Author**.
168. Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, **Leighl N**, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. *Curr Oncol*. 2019 Feb 1;26(1):e81-e93. Impact Factor 2.018. **Coauthor or Collaborator**.
169. Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, **Leighl NB**, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. *Eur J Cancer*. 2019 Jan 1;107:1-7. Impact Factor 7.191. **Coauthor or Collaborator**.
170. Ferreira CG, Nicolini A, Dalurzo L, Stefani S, Teich V, **Leighl N**. The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy. *Curr Drug Targets*. 2019 Jan 1;20(1):81-86. Impact Factor 3.112. **Senior Responsible Author**.
171. Shen SY, Singhanian R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, **Leighl N**, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. *Nature*. 2018 Nov 1;563(7732):579-583. Impact Factor 41.577. **Coauthor or Collaborator**.
172. Ezeife DA, Kirk V, Chew DS, Nixon NA, Lee R, Le LW, Chan KK, **Leighl NB**. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. *Lung Cancer*. 2018 Nov 1;125:1-7. Impact Factor 4.486. **Senior Responsible Author**.

173. Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, **Leighl NB**. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. *Curr Oncol*. 2018 Oct 1;25(5):e385-e390. Impact Factor 10.336. **Senior Responsible Author**.
174. Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, **Leighl NB**, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. *Lung Cancer*. 2018 Sep 1;123:22-29. Impact Factor 4.486. **Coauthor or Collaborator**.
175. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Feld R, Liu G, Iazzi M, Zawisza D, Nouriany N, **Leighl NB**. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2018 Sep 1;19(5):426-434.e1. Impact Factor 4.204. **Senior Responsible Author**.
176. Raman S, Bissonnette JP, Warner A, Le L, Bratman S, **Leighl N**, Bezjak A, Palma D, Schellenberg D, Sun A. Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461). *Clin Lung Cancer*. 2018 Sep 1;19(5):e699-e703. Impact Factor 4.204. **Coauthor or Collaborator**.
177. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, **Leighl N**, Hodge R, McKeown A, Brown AP, Rukazenkova Y, Ramalingam SS, Vansteenkiste J. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2018 Aug 28;JCO2018783118. Impact Factor 26.303. **Coauthor or Collaborator**.
178. Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemenev LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, **Leighl N**, Johansen JS, Mellemegaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHF, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. *Nat Commun*. 2018 Aug 13;9(1):3221. **Coauthor or Collaborator**.
179. Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, **Leighl NB**, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH. Additional germline findings from a tumor profiling program. *BMC Med Genomics*. 2018 Aug 9;11(1):65. Impact Factor 3.3. **Coauthor or Collaborator**.
180. Zer A, Cutz JC, Sekhon H, Hwang DM, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, da Cunha Santos G, Patel M, Carter RF, **Leighl NB**. Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing. *J Thorac Oncol*. 2018 Jul 1;13(7):1004-1011. Impact Factor 10.336. **Senior Responsible Author**.
181. O'Kane GM, **Leighl NB**. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. *CNS Drugs*. 2018 Jun 1;32(6):527-542. Impact Factor 4.206. **Senior Responsible Author**.
182. Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, **Leighl N**, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. *Lung Cancer*. 2018 Jun 1;120:142-148. Impact Factor 4.486. **Coauthor or Collaborator**.
183. O'Kane GM, Barnes TA, **Leighl NB**. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. *Curr Oncol*. 2018 Jun 1;25(Suppl 1):S28-S37. Impact Factor 2.473. **Senior Responsible Author**.

184. Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, **Leighl NB**, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA. Lung cancer in never smokers from the Princess Margaret Cancer Centre. *Oncotarget*. 2018 Apr 27;9(32):22559-22570. Impact Factor 5.168. **Coauthor or Collaborator**.
185. Melosky B, Chu Q, Juergens RA, **Leighl N**, Ionescu D, Tsao MS, McLeod D, Hirsh V. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. *Cancer Treat Rev*. 2018 Apr 1;65:65-77. Impact Factor 8.122. **Coauthor or Collaborator**.
186. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, **Leighl NB**, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomaso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018 Feb 14;JCO2017776385. Epub ahead of print. Impact Factor 24.008. **Coauthor or Collaborator**.
187. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, **Leighl NB**, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. *J Clin Oncol*. 2018 Feb 5;JCO2017767293. Impact Factor 24.008. **Coauthor or Collaborator**.
188. Lau SC, **Leighl NB**, Liu SV. Pembrolizumab-chemotherapy combination in non-small cell lung cancer: Too soon to be Standard? *Medicine Matters - Oncology*. 2018 Jan 23. Epub available online 23 Jan 2018 (Trainee publication). **Senior Responsible Author**.
189. O'Kane G, **Leighl NB**. Targeting lung cancer CNS metastases with molecularly targeted agents. *CNS Drugs*. 2018 Jan 17. CNSA-D-18-00009 (Trainee publication). **Senior Responsible Author**.
190. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenzov Y, Ramalingam SS, FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Jan 11;378(2):113-125. Impact Factor 72.406. **Coauthor or Collaborator**.
191. Dudani S, Zhu X, Yokom DW, Yamada A, Ho C, Pantarotto JR, **Leighl NB**, Zhang T, Wheatley-Price P. Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. *Clin Lung Cancer*. 2018 Jan 1;19(1):e11-e18. Impact Factor 3.434. **Coauthor or Collaborator**.
192. Sattar S, Alibhai SMH, Fitch M, Krzyzanowska M, **Leighl N**, Puts MTE. Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study. *J Geriatr Oncol*. 2018 Jan 1;9(1):47-52. pii: S1879-4068(17)30143-1. Impact Factor 2.852. **Coauthor or Collaborator**.
193. Ezeife DA, **Leighl NB**. Personalized medicine for non-small cell lung cancer: where are we now and where can we go? *Expert Rev Respir Med*. 2017 Dec 5;12(2):81-82. Epub 5 Dec 2017. Impact Factor 2.176. **Senior Responsible Author**.
194. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, **Leighl NB**, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH, ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2017 Dec 1;18(12):1610-1623. Impact Factor 33.9. **Coauthor or Collaborator**.
195. Albaba H, Lim C, **Leighl NB**. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. *Pharmacoeconomics*. 2017 Dec 1;35(12):1195-1209. Impact Factor 3.338. **Senior Responsible Author**.

196. Smith TJ, Hanna N, Johnson D, Baker S Jr, Biermann WA, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, **Leighl NB**, Riely GJ, Schiller JH, Schneider BJ, Tashbar J, Temin S, Masters G. Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. *J Oncol Pract*. 2017 Dec 1;13(12):780-783. Impact Factor 1.85. **Coauthor or Collaborator**.
197. Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, Liu G, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrows P, MacEachern P, Urbanski S, Sin DD, Tan WC, **Leighl NB**, Shepherd FA, Evans WK, Tsao MS, Lam S, PanCan Study Team. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. *Lancet Oncol*. 2017 Nov 1;18(11):1523-1531. Impact Factor 33.9. **Coauthor or Collaborator**.
198. Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, **Leighl NB**, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. *J Clin Oncol*. 2017 Nov 1;35(31):3591-3600. Impact Factor 24.008. **Coauthor or Collaborator**.
199. Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, **Leighl N**, Hodge R, McKeown A, Brown AP, Rukazenzov Y, Ramalingam S. CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. *Ann Oncol*. 2017 Nov 1;28(suppl_10). Impact Factor 13.926. **Coauthor or Collaborator**.
200. Li Y, Xiao X, Han Y, Gorlova O, Qian D, **Leighl N**, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Liu G, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemenev LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. *Carcinogenesis*. 2017 Oct 20. Impact Factor 5.334. **Coauthor or Collaborator**.
201. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, **Leighl NB**, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2017 Oct 20;35(30):3484-3515. Impact Factor 24.008. **Coauthor or Collaborator**.
202. **Leighl NB**, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. *Oncotarget*. 2017 Sep 19;8(41):69651-69662. Impact Factor 5.168. **Principal Author**.
203. Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, **Leighl NB**, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). *Lung Cancer*. 2017 Sep 1;111:23-29. Impact Factor 4.294. **Coauthor or Collaborator**.
204. Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, **Leighl N**, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C. Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. *Oncotarget*. 2017 Aug 22;8(34):57528-57536. Impact Factor 5.168. **Coauthor or Collaborator**.

205. Cheng S, McDonald EJ, Cheung MC, Arciero VS, Qureshi M, Jiang D, Ezeife D, Sabharwal M, Chambers A, Han D, **Leighl N**, Sabarre KA, Chan KKW. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? *J Clin Oncol*. 2017 Aug 20;35(24):2764-2771. Impact Factor 24.008. **Coauthor or Collaborator**.
206. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, **Leighl NB**, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. *J Clin Oncol*. 2017 Aug 1;35(22):2490-2498. Impact Factor 24.008. **Coauthor or Collaborator**.
207. Cressman S, Peacock SJ, Tammemägi MC, Evans WK, **Leighl NB**, Goffin JR, Tremblay A, Liu G, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Mayo JR, Yee J, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrowes P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, Lam S. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. *J Thorac Oncol*. 2017 Aug 1;12(8):1210-1222. Impact Factor 6.595. **Coauthor or Collaborator**.
208. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, **Leighl NB**, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. *J Thorac Oncol*. 2017 Aug 1;12(8):1183-1209. pii: S1556-0864(17)30427-6. Impact Factor 6.595. **Coauthor or Collaborator**.
209. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, Liu G, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, **Leighl N**, Johansen JS, Mellemegaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlo. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet*. 2017 Jul 1;49(7):1126-1132. Impact Factor 31.616. **Coauthor or Collaborator**.
210. Wakeam E, Acuna SA, **Leighl NB**, Giuliani ME, Finlayson SRG, Varghese TK, Darling GE. Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival. *Lung Cancer*. 2017 Jul 1;109:78-88. Impact Factor 4.294. **Coauthor or Collaborator**.
211. Wakeam E, Varghese TK Jr, **Leighl NB**, Giuliani M, Finlayson SRG, Darling GE. Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer. *Lung Cancer*. 2017 Jul 1;109:117-123. Impact Factor 4.294. **Coauthor or Collaborator**.
212. O’Kane GM, Bradbury PA, Feld R, **Leighl NB**, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. Uncommon EGFR mutations in advanced non-small cell lung cancer. *Lung Cancer*. 2017 Jul 1;109:137-144. Impact Factor 4.294. **Coauthor or Collaborator**.
213. Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O’Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, **Leighl NB**, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. *Clin Lung Cancer*. 2017 Jul;18(4):388-395. Impact Factor 3.03. **Coauthor or Collaborator**.

214. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017 Jun 22;376(25):2415-2426. Impact Factor 72.406. **Coauthor or Collaborator**.
215. Martin P, **Leighl NB**. Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. *Ther Adv Med Oncol*. 2017 Jun 1;9(6):405-414. **Senior Responsible Author**.
216. Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce JP, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss GD, **Leighl NB**, Hung RJ, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman D. BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial. *Clin Cancer Res*. 2017 May 15;23(10):2460-2470. Impact Factor 8.738. **Coauthor or Collaborator**.
217. Sung MR, Patel MV, Djalalov S, Le LW, Shepherd FA, Burkes RL, Feld R, Lin S, Tudor R, **Leighl NB**. Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade. *Clin Lung Cancer*. 2017 May 1;18(3):274-280.e6. Epub ahead of print. Impact Factor 3.434. **Senior Responsible Author**.
218. Wakeam E, Giuliani M, **Leighl NB**, Finlayson SRG, Varghese TK, Darling GE. Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. *Ann Thorac Surg*. 2017 May 1;103(5):1647-1653. ANNALS-16-11350R1. Impact Factor 3.849. **Coauthor or Collaborator**.
219. Hui R, Garon EB, Goldman JW, **Leighl NB**, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. *Ann Oncol*. 2017 Apr 1;28(4):874-881. Epub ahead of print. Impact Factor 11.855. **Coauthor or Collaborator**.
220. O'Brien MA, Dhesy-Thind S, Charles C, Hammond Mobilio M, **Leighl NB**, Grunfeld E. Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists. *Curr Oncol*. 2017 Apr 1;24(2):e138-e145. Impact Factor 2.048. **Coauthor or Collaborator**.
221. Lim C, Sekhon HS, Cutz JC, Hwang DM, Kamel-Reid S, Carter RF, Santos GDC, Waddell T, Binnie M, Patel M, Paul N, Chung T, Brade A, El-Maraghi R, Sit C, Tsao MS, **Leighl NB**. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. *Curr Oncol*. 2017 Apr 1;24(2):103-110. Impact Factor 2.048. **Senior Responsible Author**.
222. Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, **Leighl NB**, Chung C, Shepherd FA. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. *Radiother Oncol*. 2017 Mar 28;pii: S0167-8140(17):30103-2. Impact Factor 4.817. **Coauthor or Collaborator**.
223. Soldera SV, **Leighl NB**. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. *Front Oncol*. 2017 Mar 27;7:50. Impact Factor 6.4. **Senior Responsible Author**.
224. Puts MT, Sattar S, McWatters K, Lee K, Kulik M, MacDonald ME, Jang R, Amir E, Krzyzanowska MK, **Leighl N**, Fitch M, Joshua AM, Warde P, Tourangeau AE, Alibhai SM. Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. *Support Care Cancer*. 2017 Mar 1;25(3):879-886. Impact Factor 2.59. **Coauthor or Collaborator**.
225. Gandara DR, **Leighl N**, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017 Mar 1;12(3):556-566. Impact Factor 6.595. **Coauthor or Collaborator**.
226. de Perrot M, Dong Z, Bradbury P, Patsios D, Keshavjee S, **Leighl NB**, Hope A, Feld R, Cho J. Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma. *Eur Respir J*. 2017 Mar 1;49(3). ERJ-01428-2016.R1. Impact Factor 8.332. **Coauthor or Collaborator**.

227. Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, **Leighl NB**, Liu G, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd FA. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. *Clin Lung Cancer*. 2017 Mar 1;18(2):156-161. Impact Factor 3.434. **Coauthor or Collaborator**.
228. Warner E, **Leighl NB**. Curing Early-Stage Lung Cancer: Is There an Easy Way Out? *J Oncol Pract*. 2017 Feb 1;13(2):63-65. Impact Factor 1.85. **Senior Responsible Author**.
229. Laurie SA, Hao D, **Leighl NB**, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. *Lung Cancer*. 2017 Feb 1;104:65-69. Impact Factor 4.294. **Coauthor or Collaborator**.
230. Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziusko R, Ettinger D, Fellnel D, Kerr K, Lechevalier T, **Leighl N**, Papotti M, Pazares I, Perol M, Peters S, Pirker R, Quoix E, REck M, Smit E, Vokes E, Vanzandwijk N. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. *ESMO OPEN*. 2017 Jan 13;1(6). esmooopen-2016-000118. **Coauthor or Collaborator**.
231. O'Kane GM, Labbé C, Doherty MK, Young K, Albaba H, **Leighl NB**. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. *Oncologist*. 2017 Jan 1;22(1):70-80. Impact Factor 4.789. **Senior Responsible Author**.
232. Barnes TA, O'Kane GM, Vincent MD, **Leighl NB**. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. *Front Oncol*. 2017 Jan 1;7:113. Impact Factor 6.4. **Senior Responsible Author**.
233. McDonald J, Swami N, Hannon B, Lo C, Pope A, Oza A, **Leighl N**, Krzyzanowska M, Rodin G, Le LW, Zimmermann C. Impact of early Palliative Care on Caregivers of Patients with Advanced Cancer: Cluster Randomised Trial. *Ann Oncol*. 2017 Jan 1;28(1):163-168. Impact Factor 6.578. **Coauthor or Collaborator**.
234. Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, **Leighl NB**. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2017 Jan 1;18(1):e41-e47. T15-52SR R1. Impact Factor 4.54 (Trainee publication). **Senior Responsible Author**.
235. **Leighl NB**, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. *Clin Lung Cancer*. 2017 Jan;18(1):34-42. Impact Factor 3.22. **Principal Author**.
236. O'Kane GM, **Leighl NB**. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. *Transl Lung Cancer Res*. 2016 Dec 1;5(6):628-636. **Senior Responsible Author**.
237. Tomasini P, Walia P, Labbe C, Jao K, **Leighl NB**. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. *Oncologist*. 2016 Dec 1;21(12):1450-1460. T15-84R1 (Trainee publication). **Senior Responsible Author**.
238. Barnes TA, **Leighl NB**. Expanding Therapies for Crizotinib Refractory ALK-Rearranged Non-Small Cell Lung Cancer. *Translational Cancer Research*. 2016 Oct 28;5(Suppl 3):S458-S461. **Senior Responsible Author**.
239. Stockley TL, Oza AM, Berman HK, **Leighl NB**, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. *Genome Med*. 2016 Oct 25;8(1):109. Impact Factor 5.7. **Coauthor or Collaborator**.
240. Hannon B, Swami N, Pope A, **Leighl N**, Rodin G, Krzyzanowska M, Zimmermann C. Early Palliative Care and Its Role in Oncology: A Qualitative Study. *Oncologist*. 2016 Jul 22. (Epub ahead of print). Impact Factor 4.54. **Coauthor or Collaborator**.

241. Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, **Leighl NB**. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2016 Jul 9. (Epub ahead of print). **Senior Responsible Author**.
242. MacDonald KV, Bombard Y, Deal K, Trudeau M, **Leighl N**, Marshall DA. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy. *Eur J Cancer*. 2016 Jul 1;61:85-93. Impact Factor 4.819. **Coauthor or Collaborator**.
243. Marshall DA, Deal K, Bombard Y, **Leighl N**, MacDonald KV, Trudeau M. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment. *BMJ Open*. 2016 Jun 2;6(6):e010981. **Coauthor or Collaborator**.
244. Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, **Leighl N**, Tsao MS, de Perrot M, Xu W, Liu G. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2016 Jun 1;11(6):900-9. pii:S1556-0864(16)00408-1 [Epub ahead of print]. Impact Factor 5.8. **Coauthor or Collaborator**.
245. Sung MR, Ellis PM, Verma S, Duncan E, **Leighl NB**. Approach to biomarker testing: perspectives from various specialties. *Curr Oncol*. 2016 Jun 1;23(3):178-83. accepted 5 Jan 2016. Impact Factor 1.643 (Trainee publication). **Senior Responsible Author**.
246. Melosky B, Chu Q, Juergens R, **Leighl N**, McLeod D, Hirsh V. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. *J Clin Oncol*. 2016 May 10;34(14):1676-88. Epub ahead of print. 2016 Feb 16. pii:JCO6308049. Impact Factor 20.982. **Coauthor or Collaborator**.
247. Zimmermann C, Swami N, Krzyzanowska M, **Leighl N**, Rydall A, Rodin G, Tannock I, Hannon B. Perceptions of palliative care among patients with advanced cancer and their caregivers. *CMAJ*. 2016 Apr 18. CMAJ-15-1171.R1. **Coauthor or Collaborator**.
248. Dudani S, **Leighl NB**, Ho C, Pantarotto JR, Zhu X, Zhang T, Wheatley-Price P. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists. *Lung Cancer*. 2016 Apr 1;94:74-80. Impact Factor 3.737 (Trainee publication). **Coauthor or Collaborator**.
249. Peters S, Bexelius C, Munk V, **Leighl N**. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. *Cancer Treat Rev*. 2016 Apr 1;45:139-62. Impact Factor 6.466. **Senior Responsible Author**.
250. Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, **Leighl NB**, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. *Cancer Epidemiol*. 2016 Apr 1;41:50-6. Impact Factor 3.737 (Trainee publication). **Coauthor or Collaborator**.
251. Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, Liu G, Tsao M, **Leighl NB**. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. *Oncotarget*. 2016 Mar 25. Paper#: 004725. Impact Factor 6.578 (Trainee publication). **Senior Responsible Author**.
252. Brade A, MacRae R, Laurie SA, Bezjak A, Burkes R, Chu Q, Goffin JR, Cho J, Hope A, Sun A, **Leighl N**, Capobianco S, Feld R, Mahalingam E, Hossain A, Iscoe N, Shepherd FA. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2016 Mar 1;17(2):133-41. pii:S1525-7304(15)00302-2. Impact Factor 3.22. **Coauthor or Collaborator**.

253. Martin P, Shiao C, Pasic M, Tsao M, Kamel-Reid S, Lin S, Tudor R, Cheng S, Higgins B, Burkes R, Ng M, Arif S, Ellis P, Hubay S, Kuruvilla S, Laurie S, Li J, Shepherd FA, Le LW, **Leighl NB**. Clinical impact of epidermal growth factor receptor (EGFR) mutation fraction and tumour cellularity in EGFR mutation positive NSCLC. *British Journal of Cancer*. 2016 Feb 18. CL/2015/2023R2 [Epub ahead of print]. Impact Factor 4.817 (Trainee publication). **Senior Responsible Author**.
254. Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, **Leighl NB**. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. *Curr Oncol*. 2016 Feb 1;23(Suppl 1):S7-S13. Impact Factor 4.901. **Senior Responsible Author**.
255. Lim C, Sung M, Shepherd FA, Nouriany N, Sawczak M, Paul T, Perera-Low N, Foster A, Zawisza D, Feld R, Liu G, **Leighl NB**. Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? *J Thorac Oncol*. 2016 Jan 1;11(1):79-84. accompanying media release <http://www.medicalnewstoday.com/releases/304698.php>. Impact Factor 5.8 (Trainee publication). **Senior Responsible Author**.
256. Karim S, **Leighl N**. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. *Future Oncol*. 2016 Jan 1;12(1):9-23. Epub 2015 Dec 3. Impact Factor 2.611 (Trainee publication). **Senior Responsible Author**.
257. Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, **Leighl N**, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. *ESMO Open*. 2016 Jan 1;1(6):e000118. **Coauthor or Collaborator**.
258. Hsu T, Chen R, Lin SC, Djalalov S, Horgan A, Le LW, **Leighl N**. Pilot of three objective markers of physical health and chemotherapy toxicity in older adults. *Curr Oncol*. 2015 Dec 1;22(6):385-91. CO/2623. Impact Factor 1.643. **Senior Responsible Author**.
259. Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Goyert N, **Leighl NB**, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC, Mittmann N. A population-based study of the epidemiology of pancreatic cancer: a brief report. *Curr Oncol*. 2015 Dec 1;22(6):e478-84. Impact Factor 2.05. **Coauthor or Collaborator**.
260. Ferrusi I, Kulin NA, Goeree R, **Leighl NB**, Pullenayegum E, Phillips KA, Marshall DA. Cost-utility analysis of new human epidermal growth factor receptor-2 (HER2) test to target trastuzumab in early-stage breast cancer. *Value in Health*. 2015 Nov 24. VIH-2015-617 (Trainee publication). **Coauthor or Collaborator**.
261. Sung MR, Patel M, Djalalov S, Le L, Shepherd FA, Burkes RL, Feld R, Lin S, Tudor R, **Leighl NB**. Evolution of the Physical and Psychosocial Impact of Advanced Lung Cancer over a Decade. *Clin Lung Cancer*. 2015 Nov 20. CLC-D-15-00398 accepted with Revisions Jan 2016 (Trainee publication). **Senior Responsible Author**.
262. Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, Ho C, Lam W, Lee CW, **Leighl NB**, Murray N, Sun S, Winston R, Laskin JJ. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. *J Clin Oncol*. 2015 Nov 19. Epub ahead of print. Impact Factor 17.879. **Coauthor or Collaborator**.
263. Ellis PM, **Leighl NB**, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2015 Nov 1;16(6):457-65. S1525-7304(15)00142-4. doi: 10.1016/j.clc.2015.05.010 (Epub ahead of print). Impact Factor 3.22. **Coauthor or Collaborator**.
264. Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R, Tsao MS, **Leighl N**, Bezjak A, Keshavjee S, de Perrot M. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. *J Thorac Dis*. 2015 Nov 1;7(11):1898-906. **Coauthor or Collaborator**.

265. Fares AF, Araujo DV, **Leighl NB**. Anti EGFR therapy in squamous cell lung cancer: swimming with or against the tide? *The ASCO Post*. 2015 Oct 25;25 Oct 2015. Available from: <http://www.ascopost.com/issues/october-25-2015/anti-egfr-therapy-in-squamous-cell-lung-carcinoma-swimming-with-or-against-the-tide/> (Trainee publication). **Senior Responsible Author**.
266. de Perrot M, Feld R, **Leighl NB**, Hope A, Waddell TK, Keshavjee S, Cho BC. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg*. 2015 Oct 19. Epub ahead of print. Impact Factor 3.991. **Coauthor or Collaborator**.
267. Wong KM, Su S, Coate L, Cuffe L, Espin-Garcia O, Boyd K, Hon H, **Leighl N**, Shepherd FA, Xu W, Liu G. Low Body Mass Index as a Prognostic Factor in Advanced Lung Cancer. *Cancer Epidemiology*. 2015 Oct 5 (Trainee publication). **Coauthor or Collaborator**.
268. Doherty MK, Jao K, Shepherd FA, Hazrati LN, **Leighl NB**. Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. *J Thorac Oncol*. 2015 Oct 1;10(10):e100-1. doi:10.1097/TJO.0000000000000587. Impact Factor 5.8. **Senior Responsible Author**.
269. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, **Leighl NB**, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015 Oct 1;33(28):3199-212. doi:10.1200/JCO.2015.62.3488 (Epub ahead of print). Impact Factor 17.879. **Coauthor or Collaborator**.
270. Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziusko R, Ettinger D, Kerr K, Le Chevalier T, **Leighl N**, Papotti M, Paz Ares L, Perol M, Peters S, Pirker R, Quoix E, Reck M, Smit EF, Vokes EE, VanZandwijk N. Novel active agents in patients with advanced NSCLC who have progressed after first-line chemotherapy. *Annals of Oncology*. 2015 Sep 30. **Coauthor or Collaborator**.
271. Jao K, Labbe C, **Leighl NB**. Ready or not? Lung cancer diagnosis in 2015. *Curr Oncol*. 2015 Aug 1;22(4):239-42. Impact Factor 5.8 (Trainee publication). **Senior Responsible Author**.
272. Jao K, Labbe C, **Leighl NB**. Ready or not? Lung cancer diagnosis in 2015. *Curr Oncol*. 2015 Aug 1;22(4):239-42. Impact Factor 1.643 (Trainee publication). **Senior Responsible Author**.
273. Sacher AG, Le LW, Lau A, Earle CC, **Leighl NB**. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? *Cancer*. 2015 Aug 1;121(15):2562-2569. (CNCR-14-2844.R1);Epub ahead of print. Impact Factor 5.201 (Trainee publication). **Senior Responsible Author**.
274. Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, da Cunha Santos G, **Leighl NB**. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. *Ann Oncol*. 2015 Jul 1;26(7):1415-21. 2015 April 28. pii:mdv208 (Epub ahead of print). Impact Factor 6.578. **Senior Responsible Author**.
275. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, **Leighl NB**, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. *J Clin Oncol*. 2015 Jun 29;33(22):2472-2480. JCO:2014.60.1492 (Epub ahead of print). Impact Factor 17.879 (Trainee publication). **Coauthor or Collaborator**.
276. Korpanty G, Kamel-Reid S, Tsao MS, Hwang DM, Zer A, Liu G, Leigh NB, Feld R, Gill B, Pintilie M, Shepherd F. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. *Journal of Clinical Oncology*. 2015 Jun;33. (suppl: abstr e 19006). **Coauthor or Collaborator**.
277. Garon EB, Rizvi NA, Hui R, **Leighl N**, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015 May 21;372(21):2018-28. DOI: 10.1056. Impact Factor 54.42. **Coauthor or Collaborator**.

278. **Leighl NB**. Sunitinib: the next advance in small-cell lung cancer? *J Clin Oncol*. 2015 May 20;33(15):1637-9. Impact Factor 17.879. **Principal Author**.
279. **Leighl NB**. Sunitinib: the next advance in small-cell lung cancer? *J Clin Oncol*. 2015 May 20;33(15):1637-9. Impact Factor 17.879. **Principal Author**.
280. Leung JM, Mayo J, Tan W, Tammemagi CM, Liu G, Peacock S, Shepherd FA, Goffin J, Goss G, Nicholas G, Tremblay A, Johnston M, Martel S, Laberge F, Bhatia R, Roberts H, Burrowes P, Manos D, Stewart L, Gingras M, Pasian S, Tsao MS, Lam S, Sin DD, Pan-Canadian Early Lung Cancer Study Group. Plasma pro-surfactant protein B and lung function decline in smokers. *Eur Respir J*. 2015 Apr 1;45(4):1037-45. **Coauthor or Collaborator**.
281. Bombard Y, Rozmovits L, Trudeau M, **Leighl NB**, Deal K, Marshall DA. The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment. *Oncologist*. 2015 Apr 1;20(4):351-6. T14-268SR R1 Bombard. Impact Factor 3.737. **Coauthor or Collaborator**.
282. Melosky B, **Leighl NB**, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki-induced dermatologic adverse events. *Curr Oncol*. 2015 Apr 1;22(2):123-32. Impact Factor 1.643. **Coauthor or Collaborator**.
283. Marshall DA, Deal K, Bombard Y, **Leighl N**, Macdonald KV, Trudeau M. The Value of Gene Expression Profiling Based on Benefit-Risk Trade-Offs in Chemotherapy Treatment Decisions. *Canadian Medical Association Journal*. 2015 Mar 30. Impact Factor 5.808. **Coauthor or Collaborator**.
284. Hotta K, Kato Y, **Leighl N**, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. *PLoS One*. 2015 Mar 16;10(3):e0121211. Impact Factor 3.534. **Coauthor or Collaborator**.
285. Di Maio M, Gallo C, **Leighl NB**, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. *J Clin Oncol*. 2015 Mar 10;33(8):910-5. JCO/2014/579334. Impact Factor 17.879. **Coauthor or Collaborator**.
286. Rekhtman N, **Leighl NB**, Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline. *J Oncol Pract*. 2015 Mar 1;11(2):135-6. pii: JOP.2014.002303. [Epub ahead of print] [First 2 authors are co-chairs and equal contributors]. **Co-Principal Author**.
287. Zer A, **Leighl NB**. Reply to G Spitzer and MA Socinski. *J Clin Oncol*. 2015 Jan 12;2015 Feb 10(33(5)):525-6. Impact Factor 17.879 (Trainee publication). **Senior Responsible Author**.
288. Lilenbaum R, **Leighl NB**, Neubauer M. Expectations in the care of lung cancer. *Am Soc Clin Oncol Educ Book*. 2015 Jan 1;35:e420-4. doi: 10.14694/EdBook_AM.2015.35.e420. **Coauthor or Collaborator**.
289. Labbe C, Doherty M, Jao K, Tomasini P, **Leighl NB**. Pathological Subtyping and Molecular Profiling in Non-small Cell Lung Cancer: A Clinician's Perspective. *Can J Pathology*. 2015;6(Suppl 1):158-165. Winter 2015. **Senior Responsible Author**.
290. Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, **Leighl NB**, Springall E, Alibhai SM. A systematic review of factors influencing older adults' decision to accept or decline cancer treatment. *Cancer Treat Rev*. 2014 Dec 26. Impact Factor 6.024. **Coauthor or Collaborator**.
291. Giuliani ME, Lindsay PE, Kwan JY, Sun A, Bezjak A, Le LW, Brade A, Cho J, **Leighl NB**, Shepherd FA, Hope AJ. Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma. *Clin Lung Cancer*. 2014 Dec 2. Impact Factor 2.312. **Coauthor or Collaborator**.

292. Mittmann N, Porter JM, Rangrej J, Seung SJ, Liu N, Saskin R, Cheung MC, **Leighl NB**, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC. Health system costs for stage-specific breast cancer: a population-based approach. *Curr Oncol*. 2014 Dec 1;21(6):281-93. Impact Factor 2.473. **Coauthor or Collaborator**.
293. Lim C, Sergi M, **Leighl NB**. Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. *Lung Cancer Management*. 2014 Dec;3(6):477-489 (Trainee publication). **Senior Responsible Author**.
294. Mittmann N, Seung SJ, Liu N, Porter J, **Leighl N**, Trudeau M, Evans WK, Earle C. Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. *Lung Cancer Management*. 2014 Dec;3(6):439-442. **Coauthor or Collaborator**.
295. Zer A, **Leighl N**. Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. *Front Oncol*. 2014 Nov 25;4:329. doi:10.3389/fonc.2014.00329 eCollection 2014 (Trainee publication). **Senior Responsible Author**.
296. Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, **Leighl NB**, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA, NCIC CTG, Australasian Lung Cancer Trials Group, NCI Naples Clinical Trials Unit. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2014 Nov 1;15(12):1379-88. Impact Factor 25.117. **Coauthor or Collaborator**.
297. Djalalov S, Graham DM, Beca J, Hoch JS, Tsao MS, **Leighl N**. The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer. *Value Health*. 2014 Nov 1;17(7):A642. **Senior Responsible Author**.
298. Marshall D, MacDonald K, Deal K, Trudeau M, **Leighl N**, Bombard Y. The Influence Of Gene Expression Profiling (GEP) On Decisional Conflict In Chemotherapy Treatment Decision-Making For Early-Stage Breast Cancer (BRCA). *Value Health*. 2014 Nov 1;17(7):A569. **Coauthor or Collaborator**.
299. **Leighl NB**, Beca JM, Tsao MS, Hoch JS. Reply to C.G. Azzoli et al and C. Chouaid et al. *J Clin Oncol*. 2014 Nov 1;32(31):3578-9. JCO/2014/572552. Impact Factor 18.038. **Principal Author**.
300. Partridge AH, Seah DS, King T, **Leighl NB**, Hauke R, Wollins DS, Von Roenn JH. Developing a service model that integrates palliative care throughout cancer care: the time is now. *J Clin Oncol*. 2014 Oct 10;32(29):3330-6. doi:10.1200/JCO.2013.54.8149. **Coauthor or Collaborator**.
301. Cressman S, Lam S, Tammemagi MC, Evans WK, **Leighl NB**, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ, Pan-Canadian Early Detection of Lung Cancer Screening with Computed Tomography in Canada. *J Thorac Oncol*. 2014 Oct 1;9(10):1449-58. Impact Factor 17.879. **Coauthor or Collaborator**.
302. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch JS, Evans WK, **Leighl NB**, Trudeau M, Earle CC. Population-based utilization of radiation therapy by a Canadian breast cancer cohort. *Curr Oncol*. 2014 Oct 1;21(5):e715-7. Impact Factor 2.473. **Coauthor or Collaborator**.
303. Graham DM, **Leighl NB**. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. *Front Oncol*. 2014 Sep 22;4:258. doi:10.3389/fonc.2014.0258. eCollection 2014 (Trainee publication). **Senior Responsible Author**.
304. Collaud S, Machuca T, Mercier O, Waddell TK, Yasufuku K, Pierre AF, Darling GE, Cypel M, Rampersaud YR, Lewis SJ, Shepherd FA, **Leighl NB**, Cho JB, Bezjak A, Keshavjee S, de Perrot M. Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet. *Ann Thorac Surg*. 2014 Sep 1;98(3):962-7. Impact Factor 3.631. **Coauthor or Collaborator**.

305. Korpanty GJ, Graham DM, Vincent MD, **Leighl NB**. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. *Front Oncol*. 2014 Aug 11;4:204. doi:10.389/fonc.2014.00204. eCollection 2014 (Trainee publication). **Senior Responsible Author**.
306. **Leighl NB**, Curigliano G. Early-stage lung cancer--what do the experts recommend? *Ann Oncol*. 2014 Aug 1;25(8):1451-3. Impact Factor 6.578. **Principal Author**.
307. Martin P, **Leighl NB**. The use of pretest probability for molecular testing in non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2014 Jul 17. JCO/2014/582460. Impact Factor 17.879 (Trainee publication). **Senior Responsible Author**.
308. de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, **Leighl N**, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, Pallaud C, Lambrechts D. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. *Angiogenesis*. 2014 Jul 11. Epub ahead of print. Impact Factor 4.41. **Coauthor or Collaborator**.
309. Boag AH, Fletcher GG, Falkson CB, Hwang DM, Jones DP, **Leighl NB**, Sekhon HS, Pollett A, Srigley J. Evidence Summary #22-2-7: Best Practices for Oncology Pathology Secondary Review. Cancer Care Ontario Program in Evidence-based Care. 2014 Jul 10. Available from: <https://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/pathlabebcs>. **Coauthor or Collaborator**.
310. Shiau CJ, Babwah JP, da Cunha Santos G, Sykes JR, Boerner SL, Geddie WR, **Leighl NB**, Wei C, Kamel-Reid S, Hwang DM, Tsao MS. Sample features associated with success rates in population-based EGFR mutation testing. *J Thorac Oncol*. 2014 Jul 1;9(7):947-56. doi: 10.1097/JTO. Impact Factor 5.8. **Coauthor or Collaborator**.
311. Cuffe S, Hon H, Qiu X, Tobros K, Wong CK, De Souza B, McFarlane G, Masroor S, Azad AK, Hasani E, Rozanec N, **Leighl N**, Alibhai S, Xu W, Issa AM, Liu G. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. *Pharmacogenet Genomics*. 2014 Jul 1;24(7):348-55. Impact Factor 3.45. **Coauthor or Collaborator**.
312. Lambrechts D, Moisse M, Delmar P, Miles DW, **Leighl N**, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Genetic markers of bevacizumab-induced hypertension. *Angiogenesis*. 2014 Jul 1;17(3):685-94. Impact Factor 4.41. **Coauthor or Collaborator**.
313. Zer A, **Leighl NB**. Second-Line Therapy in Non-Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens. *J Clin Oncol*. 2014 Jun 20;32(18):1874-81. Impact Factor 17.879 (Trainee publication). **Senior Responsible Author**.
314. Bombard Y, Rozmovits L, Trudeau M, **Leighl NB**, Deal K, Marshall DA. Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment. *Curr Oncol*. 2014 Jun 1;21(3):e426-33. doi: 10.3747/co.21.1782. Impact Factor 2.473. **Coauthor or Collaborator**.
315. Azad AK, Qiu X, Boyd K, Kuang Q, Emami M, Perera N, Palepu P, Patel D, Chen Z, Cheng D, Feld R, **Leighl NB**, Shepherd FA, Tsao MS, Xu W, Liu G, Cuffe S. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). *Lung Cancer*. 2014 Jun;84(3):289-94. Impact Factor 3.972. **Coauthor or Collaborator**.
316. Zimmerman C, Swami N, Krzyzanowska M, Hannon B, **Leighl N**, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A, Lo C. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *Lancet*. 2014 May 17;383(9930):1721-30. **Coauthor or Collaborator**.
317. Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, **Leighl N**, Gutierrez E, Dobrow MJ, Coyte PC, Yung T, Bezjak A, Hope A. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non small cell lung cancer. *Journal of Oncology Practice*. 2014 May 4;10(3):130-6. **Coauthor or Collaborator**.
318. Bombard Y, Rozmovits L, Trudeau ME, **Leighl NB**, Deal K, Marshall DA. Patients' perceptions of gene expression profiling in breast cancer treatment decisions. *Curr Oncol*. 2014 Apr 1;21(2):e203-11. Impact Factor 2.473. **Coauthor or Collaborator**.

319. Wong KM, Qiu X, Cheng D, Azad AK, Habbous S, Palepu P, Mirshams M, Patel D, Chen Z, Roberts H, Knox J, Marquez S, Wong R, Darling G, Waldron J, Goldstein D, **Leighl N**, Shepherd FA, Tsao M, Der S, Reisman D, Liu G. Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers. *Cancer Med*. 2014 Apr 1;3(2):426-33. **Coauthor or Collaborator**.
320. Simos D, Sajjady G, Sergi M, Liew MS, Califano R, Ho C, **Leighl N**, White S, Summers Y, Petrcich W and Wheatley-Price P. Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis. *Clin Lung Cancer*. 2014 Mar 14;15(2):110-8. Impact Factor 2.312. **Coauthor or Collaborator**.
321. Cho BC, Feld R, **Leighl N**, Opitz I, Anraku M, Tsao MS, Hwang DM, Hope A, de Perrot M. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. *J Thorac Oncol*. 2014 Mar 1;9(3):397-402. Impact Factor 4.473. **Coauthor or Collaborator**.
322. Mittmann N, Liu N, Porter JM, Isogai PK, Saskin R, Cheung MC, **Leighl NB**, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC. End-of-life home care utilization and costs in patients with advanced colorectal cancer. *J Community Support Oncol*. 2014 Mar 1;12(3):92-8. **Coauthor or Collaborator**.
323. Besse B, **Leighl N**, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V and Johnson BE. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. *Ann Oncol*. 2014 Feb 25;25(2):109-15. Impact Factor 7.384. **Coauthor or Collaborator**.
324. Eng L, Su J, Qiu X, Palepu PR, Hon H, Fadhel E, Harland L, La Delfa A, Habbous S, Kashigar A, Cuffe S, Shepherd FA, **Leighl NB**, Pierre AF, Selby P, Goldstein DP, Xu W, Liu G. Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. *J Clin Oncol*. 2014 Feb 20;32(6):564-70. Impact Factor 17.879. **Coauthor or Collaborator**.
325. Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, **Leighl NB**, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. *Br J Cancer*. 2014 Feb 4;110(3):602-8. Impact Factor 4.817. **Coauthor or Collaborator**.
326. Seruga B, Sadikov A, Cazap EL, Delgado LB, Digumarti R, **Leighl NB**, Meshref MM, Minami H, Robinson E, Yamaguchi NH, Pyle D, Cufer T. Barriers and challenges to global clinical cancer research. *Oncologist*. 2014 Jan 1;19(1):61-7. doi: 10.1634/theoncologist.2013-0290. . Impact Factor 4.54 (Trainee publication). **Coauthor or Collaborator**.
327. Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schowock J, Hirsh V, Oza A, Tsao MS, Wright JJ, **Leighl NB**. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the Princess Margaret Hospital Phase II Consortium. *Clin Lung Cancer*. 2014 Jan;15(1):52-7. **Senior Responsible Author**.
328. Sung M, **Leighl N**. Personalized Medicine in Lung Cancer-The Time is Now. *Ontario Thoracic Reviews*. 2014;27(1):1-2. The Lung Association, Ontario Thoracic Society. **Senior Responsible Author**.
329. Mittmann N, Liu N, Porter J, Seung SJ, Hon, Isogai PK, Saskin R, Cheung MC, **Leighl NB**, Hoch JS, Trudeau M, Evans WK, Dainty KN, Earle CC. Utilization and costs of home care for patients with colorectal cancer: a population-based study. *CMAJ Open*. 2014;2(1):E11-17. Impact Factor 5.808. **Coauthor or Collaborator**.
330. Collaud S, Waddell TK, Yasufuku K, Pierre AF, Darling GE, Cypel M, Rampersaud YR, Lewis SJ, Shepherd FA, **Leighl NB**, Cho J, Bezjak A, Tsao MS, Keshavjee S and de Perrot M. Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine. *J Thorac Oncol*. 2013 Dec;8(12):1538-44. Impact Factor 18.038. **Coauthor or Collaborator**.
331. Hannon B, Swami N, Krzyzanowska MK, **Leighl N**, Rodin G, Le LW and Zimmermann C. Satisfaction with oncology care among patients with advanced cancer and their caregivers. *Qual Life Res*. 2013 Nov;22(9):2341-9. doi: 10.1007/s11136-013-0371-3. Impact Factor 2.864. **Coauthor or Collaborator**.

332. Feld R, Woo MM, **Leighl N**, Shepherd FA, Beck JT, Zhao L, Gazi L, Hengelage T, Porro MG and Nayak A. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2013 Oct;72(4):747-55. doi: 10.1007/s00280-013-2237-3. Epub 2013 Sep 8. Impact Factor 2.571. **Coauthor or Collaborator**.
333. Reaume MN, **Leighl NB**, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA and Evans WK. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). *Lung Cancer*. 2013 Oct;82(1):115-20. doi: 10.1016/j.lungcan.2013.07.012. Epub 2013 Aug 17. [First 2 authors equal contributors noted in publication]. Impact Factor 3.737. **Co-Principal Author**.
334. Ellis PM, Verma S, Sehdev S, Younus J and **Leighl NB**. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. *J Thorac Oncol*. 2013 Sep;8(9):1136-41. doi: 10.1097/JTO.0b013e31829f6a43. Impact Factor 4.473. **Senior Responsible Author**.
335. Martin P, **Leighl NB**, Tsao MS and Shepherd FA. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. *J Thorac Oncol*. 2013 May;8(5):530-42. doi: 10.1097/JTO.0b013e318283d958. Impact Factor 4.473 (Trainee publication). **Coauthor or Collaborator**.
336. Sacher AG, Le LW, **Leighl NB** and Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? *J Thorac Oncol*. 2013 Mar;8(3):366-8. doi: 10.1097/JTO.0b013e31827e2145. [NBL supervised both AGS and LEC in this publication]. Impact Factor 5.8 (Trainee publication). **Senior Responsible Author**.
337. Bar J, Ng D, Moretto P, Goss GD, Sun A, Macrae R, Laurie SA, **Leighl N**, Nicholas G. Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis. *Clin Lung Cancer*. 2013 Mar;14(2):200-4. doi: 10.1016/j.clc.2012.05.008. Epub 2012 Aug 4. Impact Factor 3.22. **Coauthor or Collaborator**.
338. Ferrusi IL, Earle CC, Trudeau M, **Leighl NB**, Pullenayegum E, Khong H, Hoch JS and Marshall DA. Closing the personalized medicine information gap: HER2 test documentation practice. *Am J Manag Care*. 2013 Jan;19(1):838-44. Impact Factor 2.166 (Trainee publication). **Coauthor or Collaborator**.
339. Hollen PJ, Gralla RJ, Stewart JA, Meharchand JM, Wierzbicki R, **Leighl N**. Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). *Support Care Cancer*. 2013 Jan;21(1):165-72. doi: 10.1007/s00520-012-1507-7. Epub 2012 Jun 10. Impact Factor 2.495. **Senior Responsible Author**.
340. Ellis PM, Chu QS, **Leighl N**, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. *Clin Lung Cancer*. 2013 Jan;14(1):19-27. doi: 10.1016/j.clc.2012.04.003. Epub 2012 Jun 1. Impact Factor 3.22. **Coauthor or Collaborator**.
341. Martin P, Owen SP, **Leighl NB**. Gefitinib: re-emerging from the shadows. *Lung Cancer Management*. 2013;2(5):1-15 (Trainee publication). **Senior Responsible Author**.
342. Di Maio M, **Leighl NB**, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C, TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec 1;7(12):1830-44. [First 3 authors equal contributors noted in publication]. Impact Factor 4.473. **Co-Principal Author**.
343. Mittmann N, Isogai PK, Saskin R, Liu N, Porter JM, Cheung MC, **Leighl NB**, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC. Population-based home care services in breast cancer: utilization and costs. *Curr Oncol*. 2012 Dec 1;19(6):e383-91. Impact Factor 2.473. **Coauthor or Collaborator**.

344. Campbell NP, Kunnavakkam R, **Leighl N**, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. *Lung Cancer*. 2012 Oct 1;78(1):76-80. doi: 10.1016/j.lungcan.2012.06.011. Epub 2012 Jul 23. Impact Factor 3.392. **Coauthor or Collaborator**.
345. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, **Leighl N**, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol*. 2012 Aug 20;30(24):3002-11. doi: 10.1200/JCO.2011.41.2056. Epub 2012 Jul 9. Impact Factor 18.038. **Coauthor or Collaborator**.
346. Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak AR, Colevas AD, Shepherd FA, **Leighl NB**, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. *Br J Cancer*. 2012 Aug 7;107(4):604-11. Impact Factor 5.082. **Coauthor or Collaborator**.
347. **Leighl NB**. Positron emission tomography use and stage migration in lung cancer: a false sense of accomplishment? *J Clin Oncol*. 2012 Aug 1;30(22):2710-1. Impact Factor 18.038. **Principal Author**.
348. Horgan AM, **Leighl NB**, Coate L, Liu G, Palepu P, Knox JJ, Perera N, Emami M, Alibhai SM. Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. *Am J Clin Oncol*. 2012 Aug 1;35(4):322-8. [Epub ahead of print]. Impact Factor 2.55 (Trainee publication). **Coauthor or Collaborator**.
349. Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, Bradbury PA, **Leighl NB**, Shepherd FA, Nowatzki J, Demers A, Murphy L. Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. *Horm Cancer*. 2012 Jun 1;3(3):93-100. **Coauthor or Collaborator**.
350. **Leighl NB**. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. *Curr Oncol*. 2012 Jun 1;19(Suppl 1):S52-8. Impact Factor 2.473. **Principal Author**.
351. Vincent MD, Kuruvilla MS, **Leighl NB**, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. *Curr Oncol*. 2012 Jun 1;19(Suppl 1):S33-44. Impact Factor 1.625. **Coauthor or Collaborator**.
352. **Leighl NB**. Personalizing Treatment for Lung Cancer: At What Cost? American Society of Clinical Oncology 2012 Educational Book. 2012 Jun:e103-e106. **Principal Author**.
353. Lara-Guerra H, Chung CT, Schwock J, Pintilie M, Hwang DM, **Leighl NB**, Waddell TK, Tsao MS. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. *Lung Cancer*. 2012 May 1;76(2):235-41. Impact Factor 3.392 (Trainee publication). **Coauthor or Collaborator**.
354. Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, **Leighl NB**, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Taylor SC, Jacobs P, Oh PI. Guidelines for health technologies: specific guidance for oncology products in Canada. *Value In Health*. 2012 May;15(3):580-5. doi: 10.1016/j.jval.2011.12.006. Epub 2012 Feb 16. Impact Factor 2.903. **Coauthor or Collaborator**.
355. Wakelee HA, Middleton G, Dunlop D, Ramlau R, **Leighl N**, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). *Cancer Chemother Pharmacol*. 2012 Mar 1;69(3):815-24. Epub 2011 Nov 6. Impact Factor 2.795. **Coauthor or Collaborator**.
356. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, **Leighl NB**, Shepherd FA, Hope AJ. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. *Radiother Oncol*. 2012 Feb;102(2):263-7. doi: 10.1016/j.radonc.2011.12.009. Epub 2012 Jan 28. Impact Factor 4.52. **Coauthor or Collaborator**.

357. Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, **Leighl N**, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD and Rodon J. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol*. 2012 Feb;69(2):563-71. doi: 10.1007/s00280-011-1772-z. Epub 2011 Nov 6. Impact Factor 2.571. **Coauthor or Collaborator**.
358. Dubinski W, **Leighl NB**, Tsao MS, Hwang DM. Ancillary testing in lung cancer diagnosis. *Pulm Med*. 2012 Jan 1;2012:249082. Epub. doi:10.1155/2012/249082. **Coauthor or Collaborator**.
359. Korpanty G, **Leighl NB**. Challenges in NSCLC molecular testing. *Oncology Exchange*. 2012;11(4):8-10 (Trainee publication). **Senior Responsible Author**.
360. Faluyi OO, **Leighl NB**. Angiogenesis inhibitors in lung cancer: beyond VEGF? *Lung Cancer Management*. 2012;1(1):7-10 (Trainee publication). **Senior Responsible Author**.
361. Cuffe S, **Leighl NB**. Targeting the phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. *J Thorac Oncol*. 2011 Nov;6(11 Suppl 4):S1805-7. Impact Factor 4.473 (Trainee publication). **Senior Responsible Author**.
362. Giuliani ME, Atallah S, Sun A, Bezjak A, Le LW, Brade A, Cho J, **Leighl NB**, Shepherd FA, Hope AJ. Clinical Outcomes of Extensive Stage Small Lung Carcinoma Patients Treated with Consolidative Thoracic Radiotherapy. *Clin Lung Cancer*. 2011 Nov;12(6):375-9. Epub 2011 May 7. Impact Factor 2.312. **Coauthor or Collaborator**.
363. Brown RF, Shuk E, **Leighl N**, Butow P, Ostroff J, Edgerson S, Tattersall M. Enhancing decision making about participation in cancer clinical trials: development of a question prompt list. *Support Care Cancer*. 2011 Aug 1;19(8):1227-38. Impact Factor 2.597. **Coauthor or Collaborator**.
364. Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, **Leighl NB**. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. *Ann Oncol*. 2011 Aug;22(8):1805-11. Epub 2011 Jan 27. Impact Factor 6.425 (Trainee publication). **Senior Responsible Author**.
365. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, Melosky B, Reiman T, Romeo P, Shepherd FA, Tsao MS, **Leighl NB**. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. *J Thorac Oncol*. 2011 Aug;6(8):1379-91. **Senior Responsible Author**.
366. Pallis AG, Fennel D, Szutowicz E, **Leighl NB**, Greillier L, Dziadziuszko R. Biomarkers of clinical benefit from anti-Epidermal Growth Factor Receptor agents in patients with Non-small Cell Lung Cancer. *Br J Cancer*. 2011 Jun 28;105(1):1-8. Impact Factor 5.082. **Coauthor or Collaborator**.
367. Ferrusi I, **Leighl NB**, Kulin N, Marhsall D. Do Economic Evaluations of Targeted Therapy Provide Support for Decision-Makers? *Am J Man Care*. 2011 May;17(5 Suppl):SP61-70. Impact Factor 2.458 (Trainee publication). **Coauthor or Collaborator**.
368. Ferrusi IL, **Leighl NB**, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? *J Oncol Pract*. 2011 May;7(3 Suppl):36s-45s (Trainee publication). **Coauthor or Collaborator**.
369. da Cunha Santos G, Saieg MA, Geddie W, **Leighl N**. EGFR Gene Status in Cytological Samples of Nonsmall Cell Lung Carcinoma. *Cancer Cytopathol*. 2011 Apr 25;119(2):80-91. Impact Factor 3.333. **Senior Responsible Author**.
370. Horgan AM, Knox JJ, Liu G, Sahi C, Bradbury PA, **Leighl NB**. Capecitabine or infusional 5FU for gastroesophageal cancer: a cost-consequence analysis. *Curr Oncol*. 2011 Apr;18(2):e64-70. Impact Factor 2.473 (Trainee publication). **Senior Responsible Author**.
371. Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, **Leighl N**, Brade A, de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA. Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer. *J Thorac Oncol*. 2011 Mar;6(3):537-44. Impact Factor 3.661 (Trainee publication). **Coauthor or Collaborator**.

372. **Leighl NB**, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on-study. *Br J Cancer*. 2011 Feb 1;104(3):413-8. Epub 2011 Jan 18. Impact Factor 5.082. **Principal Author**.
373. Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, **Leighl N**, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. *Clin Lung Cancer*. 2011 Jan;12(1):33-7. Impact Factor 2.312. **Coauthor or Collaborator**.
374. Hasani A, **Leighl NB**. Classification and Toxicities of Vascular Disrupting Agents. *Clin Lung Cancer*. 2011 Jan;12(1):33-7. Impact Factor 2.312 (Trainee publication). **Senior Responsible Author**.
375. Brade A, Bezjak A, Macrae R, Laurie S, Sun A, Cho J, **Leighl N**, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd FA. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIA/B non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1395-401. Epub 2010 Jun 3. Impact Factor 4.524. **Coauthor or Collaborator**.
376. Zimmermann C, Burman D, Swami N, Krzyzanowska MK, **Leighl N**, Moore M, Rodin G, Tannock I. Determinants of quality of life in patients with advanced cancer. *Support Care Cancer*. 2011;19(5):621-9. Epub 2010 March 30. Impact Factor 2.649. **Coauthor or Collaborator**.
377. Coate LM, **Leighl NB**. How affordable are targeted therapies in non-small cell lung cancer? *Curr Treat Options Oncol*. 2011;12:1-11 (Trainee publication). **Senior Responsible Author**.
378. Yu JL, Simmons C, Victor JC, Han D, Hogeveen S, **Leighl N**, Verma S. Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. *Oncologist*. 2011;16(9):1307-15. Epub 2011 Aug 11. Impact Factor 3.91 (Trainee publication). **Coauthor or Collaborator**.
379. Hasani A, **Leighl NB**. Targeting vascular endothelial growth factor in lung cancer. *J Thorac Oncol*. 2010 Dec 1;5(12 Suppl 6):S484-6. Impact Factor 4.473 (Trainee publication). **Senior Responsible Author**.
380. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, **Leighl NB**. Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. *J Thorac Oncol*. 2010 Dec 1;5(12):1953-7. Impact Factor 4.473 (Trainee publication). **Senior Responsible Author**.
381. **Leighl NB**, Zatloukal P, Mezger J, Ramlau R, Moore N, Reck M, Manegold C. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAL). *J Thorac Oncol*. 2010 Dec;5(12):1970-6. **Principal Author**.
382. Giuliani M, Sun A, Bezjak A, Ma C, Le L, Brade A, Cho J, **Leighl N**, Shepherd F, Hope A. Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. *Cancer*. 2010 Dec;116:5694-9. Impact Factor 5.131. **Coauthor or Collaborator**.
383. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, **Leighl N**, Mezger J, Archer V, Moore N, Manegold C, BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAL). *Ann Oncol*. 2010 Sep 1;21(9):1804-9. Impact Factor 6.452. **Coauthor or Collaborator**.
384. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Greci P, Wang L, Oza AM, Ivy P, Pritchard KI, **Leighl NB**. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. *Oncologist*. 2010 Aug 1;15(8):810-8. Impact Factor 5.826 (Trainee publication). **Senior Responsible Author**.
385. Wheatley-Price P, Le Maitre A, Ding K, **Leighl N**, Hirsh V, Seymour L, Bezjak A, Shepherd FA. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials. *Journal of Thoracic Oncology*. 2010 Jul;5(5):640-8. Impact Factor 4.473 (Trainee publication). **Coauthor or Collaborator**.

386. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, **Leighl NB**, Feld R, Cho BCJ, O'Sullivan B, Roberst H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble Mesothelin Related Peptide and Osteopontin as Markers of Response in Malignant Mesothelioma. *Journal of Clinical Oncology*. 2010 May;28:3316-22. Impact Factor 18.97 (Trainee publication). **Coauthor or Collaborator**.
387. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, **Leighl NB**. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. *J Natl Cancer Inst*. 2010 Mar 3. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16. (Trainee publication). **Senior Responsible Author**.
388. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, **Leighl NB**, Ho C, Noble J, Lee CW and Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. *J Clin Oncol*. 2010 Jan 1. 2010 Jan 1;28(1):49-55. doi: 10.1200/JCO.2009.22.9427. Epub 2009 Nov 16. Impact Factor 18.97. **Coauthor or Collaborator**.
389. Cuffe S, **Leighl NB**. Analysis of Adjuvant Chemotherapy in Non-small Cell Lung Cancer. *European Journal of Clinical & Medical Oncology*. 2010. jcm221993.3d 20/4/10. **Senior Responsible Author**.
390. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Tsao MS, **Leighl NB**. Phase II study of preoperative gefitinib in clinical stage I non-small cell lung cancer. *J Clin Oncol*. 2009 Dec 20;27(36):6229-36. Impact Factor 17.879 (Trainee publication). **Principal Author**.
391. Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, **Leighl NB**. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. *J Clin Oncol*. 2009 Sep 10;27(26):4268-73. Impact Factor 18.038 (Trainee publication). **Senior Responsible Author**.
392. Lwin Z, **Leighl N**. Economic evaluation of docetaxel for breast cancer. *Expert Opin Pharmacother*. 2009 Feb. 2009 Feb;10(2):283-90. doi: 10.1517/14656560802653206. Impact Factor 2.018 (Trainee publication). **Senior Responsible Author**.
393. Aljubran A, **Leighl N**, Pintilie M, Burkes R. Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer. *Hematol Oncol Stem Cell Ther*. 2009 Jan 1;2(1):265-71. Impact Factor 3.036. **Coauthor or Collaborator**.
394. Cheung WY, Hwang D, Chung TB, Johnston M, **Leighl NB**. Initial treatment and outcomes for multifocal bronchioloalveolar carcinoma. *Clin Lung Cancer*. 2009;10(30):187-192. (Mentor to Dr. Winson Cheung, medical oncology resident). Impact Factor 2.362. **Senior Responsible Author**.
395. Le Maître A, Ding K, Shepherd FA, **Leighl N**, Arnold A, Seymour L; NCIC Clinical Trials Group. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. *J Thorac Oncol*. 2009;4(5):586-594. Impact Factor 4.547. **Coauthor or Collaborator**.
396. Ferrusi IL, Marshall DA, Kulin NA, **Leighl NB**, Phillips KA. Looking Back at 10 Years of Trastuzumab Therapy: What is the Role of HER2 Testing? A systematic review of health economic analyses. *Personalized Medicine*. 2009;6(2):193-215. Impact Factor 0.798. **Coauthor or Collaborator**.
397. De Perrot M, Feld R, Cho J, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao M, **Leighl N**, Keshavjee S, Johnston MR. Tri-modality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma; the Toronto experience. *J Clin Oncol*. 2009;27(9):1413-1418. Impact Factor 17.793. **Coauthor or Collaborator**.
398. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, **Leighl N**, Mezger J, Archer V, Moore N, Manegold C. Randomized phase III trial of cisplatin/gemcitabine with placebo or with bevacizumab as first-line therapy for non-squamous non-small cell lung cancer (AVAiL). *J Clin Oncol*. 2009;27(8):1227-1234. Impact Factor 17.793. **Coauthor or Collaborator**.

399. Anraku M, Waddell TK, de Perrot M, Lewis SJ, Pierre AF, Darling GE, Johnston MR, Zener RE, Rampersaud YR, Shepherd FA, **Leighl N**, Bezjak A, Sun AY, Hwang DM, Tsao MS, Keshavjee S. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. *J Thor Cardiovasc Surg*. 2009;137(2):441-447. Impact Factor 4.547. **Coauthor or Collaborator**.
400. Goss GD, Shepherd FA, Laurie SA, Gauthier I, **Leighl N**, Chen E, Feld R, Powers L, Seymour L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. *Eur J Cancer*. 2009;45(5):782-788. Impact Factor 4.121. **Coauthor or Collaborator**.
401. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, **Leighl NB**, Shepherd FA, Powers J, Seymour L, Laurie SA. Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. *J Clin Oncol*. 2009;27(3):404-410. Impact Factor 17.793. **Coauthor or Collaborator**.
402. **Leighl N**, Laurie S, Knox J, Ellis P, Shepherd F, Burkes R, Pond G, Zwiebel J, Moore M. Phase 1/2 study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol*. 2009;4(9):1163-1169. (Study Chair). Impact Factor 4.473. **Principal Author**.
403. Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, LeMaitre A, **Leighl NB**, Shepherd FA. Venous Thromboembolism and Non-small cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group Trials. *Cancer*. 2009;115(23):5516-5525. Impact Factor 5.418. **Coauthor or Collaborator**.
404. **Leighl NB**, Shepherd FA, Zawisza D, Burkes RL, Feld R, Waldron J, Sun A, Payne D, Bezjak A and Tattersall MH. Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer. *Br J Cancer*. 2008 Jun 3. 2008 Jun 3;98(11):1769-73. doi: 10.1038/sj.bjc.6604395. Epub 2008 May 27. Impact Factor 4.846. **Principal Author**.
405. Horgan AM, Feld R, **Leighl NB**. Gefitinib: A consideration of cost. *Expert Rev Pharmacoeconomics Outcomes Res*. 2008;8(3):223-232. **Senior Responsible Author**.
406. Ng R, Loreto M, Lee R, **Leighl NB**. Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent-line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. *Lung Cancer*. 2008;61(2):262-265. Impact Factor 2.97. **Senior Responsible Author**.
407. Fischer S, Darling G, Pierre AF, Sun A, **Leighl N**, Waddell TK, Keshavjee S, de Perrot M. Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. *Eur J Cardiothorac Surg*. 2008;33(6):1129-1134. [Epub 2008 Apr 14]. Impact Factor 2.181. **Coauthor or Collaborator**.
408. Howe K, **Leighl NB**. Factors contributing to adjuvant therapy decisions. *J Thorac Oncol*. 2008;3(2):195-196. Impact Factor 3.508 (Trainee publication). **Senior Responsible Author**.
409. Asmis TR, Ding K, Seymour L, Shepherd FA, **Leighl NB**, Winton TL, Whitehead M, Spaans J, Graham BC, Goss GD. Age and co-morbidity as independent prognostic factors in the treatment of non-small cell lung cancer (NSCLC): A review of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials. *J Clin Oncol*. 2008;26(1):54-59. Impact Factor 17.157. **Coauthor or Collaborator**.
410. Chiew KS, Shepherd H, Vardy J, Tattersall MHN, Butow PN, **Leighl NB**. Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. *Health Expect*. 2008;11(1):35-45. Impact Factor 2.397 (Trainee publication). **Senior Responsible Author**.
411. **Leighl NB**, Dent S, Clemons M, Vandenberg T, Tozer R, Warr DG, Crump RM, Dancy JE, Moore MJ. Phase II study of Perifosine in metastatic or advanced breast cancer. *Breast Cancer Res Treat*. 2008;108(1):87-92. (Study Chair). **Principal Author**.
412. **Leighl NB**. Cetuximab in advanced NSCLC. *Oncology Exchange*. 2008;7(4):16-17. **Principal Author**.

413. Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, **Leighl NB**. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2007 Jun 1. 2007 Jun 1;25(16):2256-61. Impact Factor 15.484 (Trainee publication). **Senior Responsible Author**.
414. Kassam F, Shepherd FA, Johnston M, Visbal A, Feld R, Darling G, Keshavjee S, Pierre A, Waddell T, **Leighl NB**. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *J Thorac Oncol*. 2007 Jan 1;2(1):39-43. Impact Factor 1.429 (Trainee publication). **Senior Responsible Author**.
415. Horn L, Visbal A, **Leighl NB**. Docetaxel – impact on quality of life and pharmacoconomics. *Drugs and Aging*. 2007;24(5):411-428 (Trainee publication). **Senior Responsible Author**.
416. Benamore R, Shepherd FA, **Leighl N**, Pintilie M, Patel M, Feld R, Herman S. Does intensive follow-up alter outcome in patients with advanced lung cancer? *J Thorac Oncol*. 2007;2(4):273-81. **Coauthor or Collaborator**.
417. **Leighl NB**, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. For richer, for poorer: Willingness to pay study for oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. *Lung Cancer*. 2006;51(1):115-121. Impact Factor 3.554. **Principal Author**.
418. **Leighl NB**, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA. Phase II study of pegylated liposomal doxorubicin HCl (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. *Lung Cancer*. 2006;52(3):327-32. Impact Factor 3.554. **Principal Author**.
419. Zhang W, **Leighl N**, Zawisza D, Moore MJ, Chen EX. Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2005 Dec 27;829(1-2):45-9. **Coauthor or Collaborator**.
420. **Leighl NB**, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. *J Clin Oncol*. 2005 Apr 20;23(12):2831-9. Impact Factor 11.81. **Principal Author**.
421. **Leighl NB**. Erlotinib- a Viewpoint. *Am J Cancer*. 2005;4(4):253. **Principal Author**.
422. **Leighl NB**. Diagnosis and Management of Lung Cancer in Older Adults. *Geriatrics and Aging*. 2005;8(7):24-32. **Principal Author**.
423. Visbal A, **Leighl N**, Feld R, Shepherd F. Review of adjuvant chemotherapy for early stage non-small cell lung cancer. *Chest*. 2005;128(4):2933-2943. Impact Factor 4.008 (Trainee publication). **Coauthor or Collaborator**.
424. Carolan H, Sun AY, Bezjak A, Yi QL, Payne D, Kane G, Waldron J, **Leighl N**, Feld R, Burkes R, Keshavjee S, Shepherd FA. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation? *Lung Cancer*. 2005;49(1):109-115. Impact Factor 3.172. **Coauthor or Collaborator**.
425. D'Addario G, Pintilie M, **Leighl NB**, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. *J Clin Oncol*. 2005;23:2926-2936. Impact Factor 11.81. **Coauthor or Collaborator**.
426. Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, **Leighl N**, MacLeod C, Tattersall MHN. Communicating with realism and hope: Incurable cancer patient views on the disclosure of prognosis. *J Clin Oncol*. 2005;23(6):1278-88. Impact Factor 11.81. **Coauthor or Collaborator**.
427. Hagerty RG, Butown PN, Ellis PA, Lobb EA, Pendlebury S, **Leighl N**, Goldstein D, Lo SK, Tattersall MHN. Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting. *J Clin Oncol*. 2004;22(9):1721-1730. Impact Factor 9.835. **Coauthor or Collaborator**.

428. **Leighl NB**, Butow PN, Tattersall MHN. Treatment Decision Aids in Advanced Cancer: When the goal is not cure and the answer is not clear. *J Clin Oncol.* 2004;22(9):1759-1762. Impact Factor 9.835. **Principal Author.**
429. Blackhall FH, Pintilie M, Michael M, **Leighl N**, Feld R, Tsao MS, Shepherd FA. Expression and prognostic significance of kit, PKB/Akt and MAPK in patients with small-cell lung cancer. *Clin Cancer Res.* 2003;9:2241-2247. Impact Factor 7.837. **Coauthor or Collaborator.**
430. **Leighl NB**, Burkes RL, Dancey JE, Lopez PH, Higgins BP, Walde PLD, Rudinskas LC, Rahim YH, Rodgers A, and Shepherd FA. A Phase I study of pegylated liposomal doxorubicin hydrochloride (CAELYX[®]) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. *Clin Lung Cancer.* 2003;5:107-112. Impact Factor 2.312. **Principal Author.**
431. **Leighl NB**, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. An economic analysis of the TAX 317 Trial: Docetaxel versus best supportive care as second-line therapy of advanced non-small cell lung cancer. *Journal of Clinical Oncology.* 2002;20(5):1344-1352. Impact Factor 9.868. **Principal Author.**
432. **Leighl NB**, Shepherd FA, Goodwin PJ. Costs of Lung Cancer. *Journal of Clinical Oncology.* 2002;20(17):3751. Impact Factor 9.868. **Principal Author.**
433. **Leighl N**, Gattellari M, Butow P, Brown R, Tattersall MHN. Discussing adjuvant cancer therapy. *Journal of Clinical Oncology.* 2001;20(5):1344-1352. Impact Factor 8.53. **Principal Author.**

Book Chapters

1. Gauthier MP, **Leighl NB**. Chapter 8: First Line Therapy. In: Gillaspie EA, & Horn L, & Cass AS, editor(s). *Lung Cancer 1st Ed: An Evidence-Based Approach to Multidisciplinary Management.* 1. Philadelphia, PA (United States): Elsevier Inc; 2023. p. 172-194. **Senior Responsible Author.**
2. **Leighl N**, Ahn M-J, Gandara D. Liquid Biopsy: Specimen acquisition, testing strategies, and clinical roles. In: Sholl LM, Cooper WA, Kerr KM, Tan DSW, Tsao M-S, Yang JC-H, editor(s). *IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer.* (United States): International Association for the Study of Lung Cancer; 2023. p. 40-50. **Coauthor or Collaborator.**
3. Ross G, **Leighl NB**, Lu S, Nicholson AG, Smith EF. Large Cell Carcinoma of the Lung. In: *WHO Classification of Tumors. 5th Edition- Thoracic Tumors.* 2020. p. 1.3.7.1. The International Agency for Research in Cancer. **Coauthor or Collaborator.**
4. Lau SCM, Barron DA, FRimner A, Lai WV, Chaft JE, **Leighl NB**. Management of Inoperable Non-small Cell Lung Cancer. In: Baumgartner B, Darling G, Mayer J., editor(s). *Society of Thoracic Surgery Cardiothoracic Surgery E-Book.* Pearson's General Thoracic. (United States); 2020. Available from: https://ebook.sts.org/sts/view/Pearsons-General-Thoracic/1418469/all/Management_of_Inoperable_Non_Small_Cell_Lung_Cancer/. **Senior Responsible Author.**
5. Korpanty GJ, **Leighl NB**. Stage II and III Non-small Cell Lung Cancer. In: Markman M, Abutalib S, editor(s). *Cancer Consult: Expertise for Clinical Practice.* 1. 2. Oxford (United Kingdom): Wiley; 2014. p. 493-499. **Senior Responsible Author.**
6. **Leighl NB**, O'Brien MA. Decision Aids in Advanced Cancer. In: Carr B, Steel J, editor(s). *Psychological Aspects of Cancer.* New York (United States): Springer; 2012. p. Chapter 5: pp 75-82. **Principal Author.**
7. **Leighl NB**, Shepherd FA. Chapter 116: Adjuvant chemotherapy for Non-small Cell Lung Cancer. In: Shields TW, LoCicero J III, Reed CE, Feins RH, editor(s). *General Thoracic Surgery.* 7th ed. Baltimore and Philadelphia: Wolters Kluwer/ Lippincott Williams & Wilkins; 2009. p. 1469-1482. **Principal Author.**
8. Teng L, Horn L, **Leighl NB**. Chapter 15: Oncology. In: Jeeshan H. Chowdhury, Shaheed Merani, editor(s). *Essentials for the Canadian Medical Licensing Exam – Review and Prep for MCCQE Part 1.* Baltimore and Philadelphia: Wolters Kluwer/ Lippincott Williams & Wilkins; 2009. p. 445-464. **Senior Responsible Author.**

9. **Leighl NB**, Shepherd FA. Chapter 67: Small Cell Lung Cancer. In: Patterson GA, Cooper JD, Delauriers J, Lerut AEMR, Luketich JD, Rice TW, editor(s). *Pearson's Thoracic Surgery*. 3rd ed. Vol. 1. Philadelphia (Pennsylvania): Churchill Livingstone; 2008. p. 825-840. **Principal Author**.
10. **Leighl NB**, Feld R. Clinical Practical Guidelines in Patients Fever and Neutropenia. In: Rubenstein EB, Rolston KVI, editor(s). *Fever in the Neutropenic Cancer Patient*. London (United Kingdom): Martin Kunitz Ltd; 2001. p. Chap 14: pp 289-299. **Principal Author**.
11. Lau S, Rimner A, Chافت J, **Leighl NB**. Management of Inoperable Non-Small Cell Cancer. In: Darling G, editor(s). *Pearson's General Thoracic Volume. Society of Thoracic Surgeons Cardiothoracic Surgery E-Book*; Chapter 65. **Senior Responsible Author**.
12. Lau S, Rimner A, Chافت J, **Leighl NB**. Management of Inoperable Non-Small Cell Cancer. In: Darling G, editor(s). *Pearson's General Thoracic Volume. Society of Thoracic Surgeons Cardiothoracic Surgery E-Book*; Chapter 65. **Senior Responsible Author**.
13. Gauthier MP, **Leighl NB**. First-Line Therapy for Advanced NSCLC- Chapter 8. In: Leora Horn & Gallaspie, editor(s). *Lung Cancer - An Evidence Based Approach*. 1st Edition. **Senior Responsible Author**.

Editorials

1. Feng J, **Leighl NB**. There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor. *J Thorac Oncol*. 2022 Oct 1;17(10):1175-1177. **Senior Responsible Author**.
2. **Leighl NB**. Meeting Immunotherapy Resistance in Lung Cancer. *J Thorac Oncol*. 2021 Feb 1;16(2):187-190. **Principal Author**.

Abstract

1. Feng J, Hueniken K, Zen F, Corke L, **Leighl NB**, Liu G, Bradbury PA, Sacher AG, Eng L, Stockley T, Tsao MS, Shepherd F. Prognostic effects of TP53 variants co-occurring in patients with HER2-mutated non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2023 Jun. 41 (Suppl 16): e21065. Available from: https://doi.org/10.1200/JCO.2023.41.16_suppl.e21065 (Trainee publication). **Coauthor or Collaborator**.
2. Gaebe K, Erickson AW, Li AY, Ahluwalia MS, Mehta MP, Lok BH, **Leighl NB**, Chan KK, Das S D. Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis. *J Clin Oncol*. 2023 Jun. 41 (Suppl 16): e20636. **Coauthor or Collaborator**.

Clinical Trial, Journal Articles, Multicenter Study

1. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, **Leighl N**, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. *Lancet Oncol*. 2020 Dec 1;21(12):1589-1601. **Coauthor or Collaborator**.

Guideline, Review

1. Melosky BL, **Leighl NB**, Dawe D, Blais N, Wheatley-Price PF, Chu QS, Juergens RA, Ellis PM, Sun A, Schellenberg D, Ionescu DN, Cheema PK. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. *Curr Oncol*. 2023 Jun 30;30(7):6289-6315. **Coauthor or Collaborator**.

Journal Articles, Multicenter Study

1. Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA, **Leighl NB**. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2022 Jan 1;23(1):72-81. Impact Factor 4.2. **Senior Responsible Author**.
2. **Leighl NB**, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). *J Immunother Cancer*. 2021 Aug 1;9(8). Impact Factor 13.751. **Principal Author**.
3. Desilets A, Blanc-Durand F, Lau S, Hakozaiki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, Cohen V, Charbonneau C, Marcoux N, Blais N, **Leighl NB**, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer*. 2021 Jan 1;142:83-91. Impact Factor 7.275. **Coauthor or Collaborator**.
4. Tan DS, **Leighl NB**, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. *Lancet Respir Med*. 2020 Jun 1;8(6):561-572.

Journal Articles, Multicenter Study, Randomized Controlled Trial

1. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenzov Y, Soria JC, FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2020 Jan 2;382(1):41-50.

Journal Articles, Practice Guideline

1. Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, **Leighl NB**, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. *J Clin Oncol*. 2022 Oct 1;40(28):3310-3322. **Coauthor or Collaborator**.
2. Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, **Leighl NB**, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. *J Clin Oncol*. 2020 Mar 1;38(7):753-766. Impact Factor 26.303. **Coauthor or Collaborator**.

Journal Articles, Randomized Controlled Trial

1. Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K, LIBRETTO-431 Trial Investigators (**Leighl N**). First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. *N Engl J Med*. 2023 Nov 16;389(20):1839-1850. **Coauthor or Collaborator**.
2. **Leighl NB**, Laurie SA, Goss GD, Hughes BGM, Stockler M, Tsao MS, Hwang DM, Joubert P, Kulkarni S, Blais N, Joy AA, Mates M, Rana P, Yadav SK, Underhill C, Lee C, Bradbury PA, Hiltz A, Dancey J, Ding K, Vera-Badillo F, Canadian Cancer Trials Group Lung Disease Site and the Australasian Lung Cancer Trials Group. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. *J Thorac Oncol*. 2022 Mar 1;17(3):434-445. Impact Factor 15.609. **Principal Author**.

3. Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, **Leighl NB**, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. *J Thorac Oncol*. 2020 Mar 1;15(3):404-415. Impact Factor 12.46. **Coauthor or Collaborator**.

Journal Articles, Review

1. Lau SCM, Rabindranath M, Weiss J, Li JJN, Fung AS, Mullen D, Alshamlan N, Ruff HM, Tong LCB, Pal P, Cabanero MR, Hsu YR, Sacher AG, Shepherd FA, Liu G, Bradbury PA, Yasufuku K, Czarnecka-Kujawa K, Mi Ko H, Tsao MS, **Leighl NB**, Schwock J. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC. *Lung Cancer*. 2022 Sep 1;171:42-46. **Coauthor or Collaborator**.
2. Corke LK, Li JJN, **Leighl NB**, Eng L. Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. *Curr Oncol*. 2022 Aug 30;29(9):6260-6276. **Co-Principal Author**.
3. Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, **Leighl NB**, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. *JCO Glob Oncol*. 2022 Aug 1;8:e2200123. **Coauthor or Collaborator**.
4. Ionescu DN, Stockley TL, Banerji S, Couture C, Mather CA, Xu Z, Blais N, Cheema PK, Chu QS, Melosky B, **Leighl NB**. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. *Curr Oncol*. 2022 Jul 15;29(7):4981-4997. **Senior Responsible Author**.
5. Melosky B, Wheatley-Price P, Juergens RA, Sacher A, **Leighl NB**, Tsao MS, Cheema P, Snow S, Liu G, Card PB, Chu Q. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. *Lung Cancer*. 2021 Oct 1;160:136-151. **Coauthor or Collaborator**.
6. Melosky B, Cheema P, Juergens RA, **Leighl NB**, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. *Ther Adv Med Oncol*. 2021 Jan 1;13:17588359211056306. Impact Factor 7.03. **Coauthor or Collaborator**.
7. Hoffner B, **Leighl NB**, Davies M. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. *Cancer Treat Rev*. 2020 Apr 1;85:101979.

Letters to Editor, Comment

1. Aggarwal C, **Leighl NB**. Next-generation ctDNA-driven clinical trials in precision immuno-oncology. *J Immunother Cancer*. 2023 Jan 1;11(1). **Senior Responsible Author**.

Randomized Controlled Trial, Journal Articles

1. Zimmermann C, Pope A, Hannon B, Bedard PL, Rodin G, Dhani N, Li M, Herx L, Krzyzanowska MK, Howell D, Knox JJ, **Leighl NB**, Sridhar S, Oza AM, Lheureux S, Booth CM, Liu G, Castro JA, Swami N, Sue-A-Quan R, Rydall A, Le LW. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study. *Support Care Cancer*. 2023 Jun 21;31(7):404. **Coauthor or Collaborator**.

Review, Journal Articles

1. Tsitsias T, Yasufuku K, Pierre A, **Leighl N**, Cho J, Waddell TK, Darling G, Cypel M, Donahoe L, Yeung J, Keshavjee S, de Perrot M. Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors). *J Thorac Cardiovasc Surg*. 2023 May 1;165(5):1710-1719.e3. **Coauthor or Collaborator**.

2. NON-PEER-REVIEWED PUBLICATIONS

Journal Articles

1. **Leighl NB**. Cetuximab in advanced NSCLC. *Oncology Exchange*. 2008;7(4):16-17. **Principal Author**.
2. Bradbury P, **Leighl NB**. Small molecule tyrosine kinase inhibitors and non small cell lung cancer: new hope for a common disease. *Ontario Respiratory Care Society Update*. 2007;23(1):1-6. Winter. (Mentor to Dr. Bradbury, Clinical Fellow). (Trainee publication). **Senior Responsible Author**.
3. **Leighl NB**. Erlotinib – a Viewpoint. *Am J Cancer*. 2005;4(4):253. **Principal Author**.
4. **Leighl NB**. Angiogenesis inhibitors in advanced non-small cell lung cancer. *Thoracic Medicine (The Official Journal of Taiwan Society of Pulmonary and Critical Care Medicine)*. 96:12-15. **Principal Author**.
5. Kassam F, **Leighl NB**. Bone health in lung cancer. *Lung Cancer Connection (Lung Cancer Canada Newsletter)*. Edition 09:07:02:3 (Trainee publication). **Senior Responsible Author**.

Books

1. Ontario Respiratory Care Society. Update on Respiratory Health, Research and Education-Electronic Publication. 2021. DECLINED. **Contributor**.
2. Precision Oncology-Development of Content. 2021. DECLINED. **Contributor**.

Monographs

1. **Leighl NB**. Anti-EGFR Monoclonal Antibody Cetuximab in Combination with Chemotherapy in First-line Treatment of NSCLC. *Novel Agents in the Treatment of Lung Cancer – New Approaches to First-Line Therapy*. Seventh Cambridge Conference Monograph. Cambridge MA. **Principal Author**.
2. **Leighl NB**, Verma S. 2014 Updates in Lung Cancer. *Best of Oncology*. Page 14-15, 2014. **Coauthor or Collaborator**.

Magazine Entries

1. Kassam F, **Leighl NB**. Bone health in Lung Cancer. *Lung Cancer Connection*. *Lung Cancer Canada Newsletter*. **Senior Responsible Author**.

Abstract

1. Wakeam, Elliot; Giuliani, Meredith; **Leighl, N.**; Varghese Jr., Tom; Finlayson, Samuel; Darling, Gail. Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer. *Journal of Thoracic Oncology*. 2017 Jan;12(1):Supplement, S706. Impact Factor 6.595. **Coauthor or Collaborator**.
2. Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, **Leighl NB**, Liu G, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd FA. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. *Journal of Thoracic Oncology*. 2017 Jan;12(1):Suppl, S326-S327. Impact Factor 6.595. **Coauthor or Collaborator**.

E. Presentations and Special Lectures

1. INTERNATIONAL

Invited Lectures and Presentations

- 2024 Apr 12 **Invited Speaker.** Early Stage Lung Cancer- Virtual. AstraZeneca- Brazil. DECLINED.
- 2024 Feb 23 **Speaker.** Peer Pressure: How Well Do You Know Your ADCs, 2024 Edition Cracking the Code for Selectively Targeting Lung Cancer Cells and Delivering Cytotoxic Payloads Through an Antibody-Mediated Process. PVI, PeerView Institute for Medical Education. Santa Monica, California, United States. DECLINED.
- 2024 Feb 21 **Debater.** Targeted Therapies 4: KRAS, BRAF, SHP2, SOS1. IASLC- 2024 -Targeted Therapies of Lung Cancer Meeting. Santa Monica, Connecticut, United States. DECLINED.
- 2024 Jan 28 **Invited Speaker.** Liquid is "Solid" in Advanced NSCLC. Fortis Cancer Summit 2024. Bengaluru, Karnataka, India.
- 2024 Jan 7 **Invited Speaker.** Next-Generation Multiomic Technology Highlights. ASCO Direct Highlight-Breakthrough in Cancer Care Conference. San Francisco, California, United States. DECLINED.
- 2023 Dec 16 **Invited Speaker.** Improving outcomes in EGFR mutant NSCLC with TKIs combination treatment. Cancer Research and Statistic Foundation: 7th Annual Year End Review. Mumbai, India.
- 2023 Dec 15 **Invited Speaker.** How I manage early stage EGFR mutant lung cancer. Care Hospitals of Hyderabad. Hyderabad, India.
- 2023 Dec 15 **Invited Speaker.** Improving outcomes in EGFR mutant NSCLC with TKIs combination treatment. Basavataarakam Indoamerican Cancer Hospital and Research Institute Grand Rounds. Hyderabad, India.
- 2023 Dec 15 **Participant -Virtual Roundtable.** EPICS: Global Perspectives in Current and Future Management of Lung Cancer (Early-Stage NSCLC). Aptitude Health. DECLINED.
- 2023 Dec 14 **Invited Speaker.** How I manage early stage EGFR mutant lung cancer. Rajiv Gandhi Cancer Centre Medical Rounds. Delhi, India.
- 2023 Dec 6 **Presenter.** Phase 3 LEAP-008 Study of Lenvatinib Plus Pembrolizumab Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer That Progressed on a PD-(L)1 Inhibitor and Platinum-Containing Chemotherapy. European Society of Medical Oncology Immuno-Oncology Congress 2023 Preferred Papers (Oral) Session I. Geneva, Genève (fr), Switzerland.
- 2023 Dec 1 **Invited Speaker.** Mentorship, Sponsorship and what to do when it goes wrong. ARTEs Leadership Development Course for Early Career Faculty. United States.
- 2023 Nov 29 **Invited Speaker.** The Primacy of First-line Checkpoint Inhibition in NSCLC. Great Debates and Updates in Lung Cancer. New York, New York, United States.
- 2023 Nov 29 **Invited Speaker.** The Prognostic and Financial Implications of PD-L1 and NGS Testing in Lung cancer. Great Debates and Updates in Lung Cancer. New York, New York, United States.
- 2023 Nov 27 **Invited Speaker.** News from ESMO 2023: Updates in Early Stage Lung Cancer. Sharing Progress In Cancer Care (SPCC) Webinar. Switzerland.
- 2023 Nov 21 **Invited Speaker.** Integrating Tissue and Liquid Biopsy - Do We Need Both? International Society for Liquid Biopsy (Annual Meeting).
- 2023 Nov 20 **Panel Speaker.** Liquid Biopsy in Minimal Residual Disease. International Society for Liquid Biopsy

Natasha LEIGHL

(Annual Meeting).

- 2023 Nov 20 **Speaker.** Lung Cancer: From Prevention to the Treatment of Advanced Disease. IRCCS Istituto Tumori "Giovanni Paola II". Bari, Italy. DECLINED.
- 2023 Nov 19 **Panel Speaker.** Career Development Session. 5th Annual Congress- Liquid Biopsy. Madrid, Spain. DECLINED.
- 2023 Nov 18 **Invited Speaker.** NRG1 as a Target in NSCLC? Masters in Thoracic Oncology Summit. Albuquerque, New Mexico, United States.
- 2023 Nov 18 **Participant.** Global Lung Expert Input Forum. MSD. Lisbon, Portugal. DECLINED.
- 2023 Nov 17 **Speaker.** ESMO in Focus- Lung. Brazilian Society of Clinical Oncology-2023 Brazilian Congress of Clinical Oncology. Rio de Janeiro, Brazil. DECLINED.
- 2023 Nov 17 **Speaker.** Women in Thoracic Oncology. Brazilian Society of Clinical Oncology-2023 Brazilian Congress of Clinical Oncology. Rio de Janeiro, Brazil. DECLINED.
- 2023 Nov 17 **Invited Speaker.** MRD Detected by Liquid Biopsy: Where are we going? Masters in Thoracic Oncology Summit. Albuquerque, New Mexico, United States.
- 2023 Nov 16 **Chair.** ESMO 2023 Scientific Committee- Virtual Plenary. DECLINED.
- 2023 Nov 15 **Speaker.** Going Beyond the Standard of Care, Pembrolizumab Makes a Difference in Clinical Practice for Patients with Non-Small Cell Lung Cancer. Korea Association Tuberculosis & Respiratory Disease International Conference Satellite Symposium. Korea, Republic Of. DECLINED.
- 2023 Nov 14 **Invited Speaker.** Immunotherapy in Advanced NSCLC: The challenge of the non-expressor. Tuen Mun Hospital Medical Oncology Department. Hong Kong, Hong Kong.
- 2023 Nov 13 **Invited Speaker.** Evolving treatment landscape of NSCLC – _From Metastatic to Early-stage. Hong Kong Medical/Thoracic Surgery Roundtable. Hong Kong, Hong Kong.
- 2023 Nov 12 **Invited Speaker.** Evolving treatment landscape of NSCLC – _From Metastatic to Early-stage. Hong Kong Thoracic Society Autumn Respiratory Seminar 2023. Hong Kong, Hong Kong.
- 2023 Nov 11 **Co-Chair and Speaker.** The BEST of ESMO USA. Colorado Springs, Colorado, United States. DECLINED.
- 2023 Nov 9 **Invited Speaker.** Comprehensive genomic testing: right treatment, right patient, right time. US Oncology Network. Houston, Texas, United States.
- 2023 Nov 9 **Invited Speaker.** ESMO 2023 - Updates on Lung Cancer. Clinical Care Options. Houston, Texas, United States.
- 2023 Oct 27 **Invited Speaker.** Progress in Immunotherapy for __Advanced Lung Cancer in 2023. ASCO Direct China. China.
- 2023 Oct 25 **Invited Speaker.** Emerging options to target SCLC: hope on the horizon? Astra Zeneca Lung Summit. Madrid, Spain.
- 2023 Oct 25 **Invited Speaker.** Emerging options in advanced EGFR mutant lung cancer. Astra Zeneca Lung Summit. Madrid, Spain.
- 2023 Oct 23 **Chair and Speaker.** Transforming treatment approaches for patients with EGFR-mutant NSCLC. ESMO Congress 2023. Madrid, Spain.
- 2023 Oct 21 **Invited Speaker.** Immunotherapy re-challenge: Who, when and why. ESMO Congress 2023. Madrid, Spain.
- 2023 Oct 21 **Presenter.** Immunotherapy re-challenge: Who, when and why. European Society of Medical Oncology.

Natasha LEIGHL

Madrid, Spain. Presenter(s): **N Leighl**.

- 2023 Oct 19 **Panelist.** Getting Better, faster: the Case of Optimizing access to Precision Medicine in the Wake of the Cancer Revolution. Collective Oncology Network for Exchange, Cancer Care Innovation, Treatment Access and Education (CONNECTed). Webinars- DECLINED.
- 2023 Oct 7 **Consensus Panel Discussion Lead.** Liquid Biopsy in Lung Cancer: When, Where, and How? Excellence in Oncology Care 2023. Dubayy [Dubai], United Arab Emirates. DECLINED.
- 2023 Oct 7 **Faculty and Invited Speaker.** The Current Utility of Liquid Biopsy. D.C. Lung Cancer Conference. District of Columbia, United States.
- 2023 Oct 7 **Invited Speaker.** The Current Utility of Liquid Biopsy in Lung Cancer. D.C. Lung Cancer Conference 2023. Washington DC, District of Columbia, United States.
- 2023 Sep 29 **Invited Speaker.** New Directions for _Second Line Therapy. EPICS: Global Perspectives in Lung Cancer in 2023. New York, United States.
- 2023 Sep 25 **Invited Speaker.** New Directions for _EGFR-Mutant NSCLC. EPICS: Global Perspectives in Lung Cancer in 2023. New York, United States.
- 2023 Sep 23 **Invited Speaker.** Liquid Biopsy in mNSCLC. Guardant Health. India. DECLINED.
- 2023 Sep 22 **Presenter.** Immunotherapy 101. Lungevity International Lung Cancer Survivorship Conference. virtual conference.
- 2023 Sep 22 **Invited Speaker.** The Primacy of First-line Checkpoint Inhibition in NSCLC. Great Debates and Updates in Lung Cancer. New York, New York, United States.
- 2023 Sep 22 **Invited Speaker.** Targeted Therapy for MET-Dependent Lung Cancer: Have we Met our Match? Great Debates and Updates in Lung Cancer. New York, New York, United States.
- 2023 Sep 14 **Invited Speaker.** Early Stage Lung Cancer, ADAURA/EGFRm +NSCLC-Sharing your Experience/Expertise. AstraZeneca. India. DECLINED.
- 2023 Sep 12 **Invited Speaker.** MRD Interpretation and Implementation. 2023 World Conference on Lung Cancer Astra Zeneca Lung Cancer Summit. Singapore.
- 2023 Sep 11 **Invited Speaker.** Meet the Expert: Upfront NGS Testing Should Be _the Standard of Care in Advanced NSCLC. 2023 World Conference on Lung Cancer (IASLC) MTE12. Singapore.
- 2023 Sep 11 **Invited Speaker.** At A Crossroads: Monotherapy versus Combination Therapy Treatment Considerations. 2023 World Conference on Lung Cancer (IASLC) Symposium. Singapore.
- 2023 Sep 11 **Invited Speaker.** Debate: Upfront NGS testing should be the standard of care in advanced NSCLC. For the proposition. 2023 World Conference on Lung Cancer (IASLC) Symposium. Singapore.
- 2023 Sep 10 **Co-Chair and Moderator.** IASLC 2023-Symposium- TTFIELDS Therapy in Thoracic Oncology. Novocure. Singapore. DECLINED.
- 2023 Aug 30 **Invited Speaker.** First-line treatment in MET altered NSCLC - targeted therapy versus immunotherapy +/- chemotherapy. Lung Cancer Summit (CME sponsor Novartis). Hong Kong, Hong Kong.
- 2023 Aug 23 **Invited Speaker.** How can we use MRD to improve patient outcomes with immunotherapy? Latam Cancer Connection: Evolution of Biomarkers in Lung Cancer. Sao Paulo, Brazil.
- 2023 Aug 19 **Invited Speaker.** ADCs in Lung Cancer. VIII Simposio Internacional de Cancer de Pulmao. Recife, Brazil.
- 2023 Aug 19 **Invited Speaker.** Immunotherapy resistance – how to sequence treatment? VIII Simposio Internacional de Cancer de Pulmao. Recife, Brazil.
- 2023 Aug 10 **Invited Speaker.** Early Stage Guidelines. CHEST. Hawaii, United States. DECLINED FOR TIME

Natasha LEIGHL

CONSTRAINTS.

- 2023 Aug 5 **Presenter.** 2023 AP Lung Cancer Immunotherapy Conference: A Midyear Review (MSD Lung Cancer Standalone Scientific Symposium). MSD. Taipei, Taiwan, Province Of China. DECLINED.
- 2023 Aug 5 **Invited Speaker.** Bridging Innovative Technology with Clinical Practice. ASCO Breakthrough. Yokohama, Japan.
- 2023 Jul 27 **Invited Speaker.** Complementary use of tissue and liquid biopsy in NSCLC. 24th Annual International Lung Cancer Congress. Huntington Beach, California, United States.
- 2023 Jul 19 **Invited Speaker.** Leadership - IASLC Academy. International Association for the Study of Lung Cancer. United States.
- 2023 Jul **Faculty Co-Chair and Invited Speaker.** Complementary Application of Tissue and Liquid Biopsy for Molecular Testing. 24th International Lung Cancer Congress - Jul 27-29, 2023. Huntington Beach, California, United States.
- 2023 Jun 29 **Invited Speaker.** MET Targeting Antibody Drug Conjugates in Lung Cancer. Dava Oncology Hawaii Lung Cancer Meeting. Kona, Hawaii, United States.
- 2023 Jun 28 **Chair.** Hawaii Lung Cancer Meeting. Dava Oncology. Kona, Hawaii, United States.
- 2023 Jun 28 **Invited Speaker.** EGFR Resistance Mechanisms and How to Overcome. Dava Oncology Hawaii Lung Cancer Meeting. Kona, Hawaii, United States.
- 2023 Jun 23 **Invited Speaker.** NSCLC: Disease Progression after Adjuvant Immunotherapy. 9th International Lung Cancer Network Congress. Athens, Greece.
- 2023 Jun 23 **Invited Speaker.** Where to from here? __Molecular targets in _Pulmonary Neuroendocrine Tumors. 9th International Lung Cancer Network Congress. Athens, Greece.
- 2023 Jun 23 **Invited Speaker.** Circulating Tumor DNA _in the Treatment of Patients _with Lung Cancer. 9th International Lung Cancer Network Congress. Athens, Greece.
- 2023 Jun **Faculty Member- Lecturer- recording.** Precision Oncology. International Society of Liquid Biopsy. DECLINED.
- 2023 May 15 **Invited Speaker.** KRAS G12C inhibition in lung cancer: Clinical Insights. EERT Lung Cancer Assembly 2023. Prague, Czech Republic.
- 2023 May 7 **Invited Speaker.** Practical Applications of Liquid Biopsy. 2nd International Summit on Lung Cancer (Istituto Nazionale Tumori di Regina Elena). Rome, Italy.
- 2023 Apr 17 **Invited Speaker.** Updates in the Management of EGFR exon20ins mutant NSCLC. Janssen Post ELCC OME 2023 Satellite Symposium. Denmark.
- 2023 Mar 31 **Invited Speaker.** Latest Advances in Immunotherapy. 2023 European Lung Cancer Congress Satellite Symposium (GSK). Copenhagen, Denmark.
- 2023 Mar 30 **Invited Speaker.** Debate: Adjuvant TKI for more than 3 years. 2023 European Lung Cancer Congress. Copenhagen, Denmark.
- 2023 Mar 29 **Invited Speaker.** The Pros and Cons of Monotherapy or Chemo-immunotherapy: Immunotherapy Alone. 2023 European Lung Cancer Congress Satellite Symposium (Eisai). Copenhagen, Denmark.
- 2023 Mar 24 **Invited Speaker.** Therapeutic strategy in patients with early stage EGFR mutant lung cancer. Lung Cancer Summit (Astra Zeneca Brasil). Rio de Janeiro, Brazil.
- 2023 Mar 24 **Invited Speaker.** The benefit of immunotherapy for the patient with lung cancer. Lung Cancer Summit (Astra Zeneca Brasil). Rio de Janeiro, Brazil.

Natasha LEIGHL

- 2023 Mar 23 **Invited Speaker.** Management of Locally Advanced NSCLC. Dasa Oncologia Inaugural Grand Rounds. Rio de Janeiro, Brazil.
- 2023 Mar 23 **Invited Speaker.** The evolving landscape of early stage NSCLC treatment. Grupo Brasileiro de Oncologia Torácica. Rio de Janeiro, Brazil.
- 2023 Mar 22 **Invited Speaker.** Immunotherapy: SCLC and early stage NSCLC. Evento Horizonti Oncomed. Minas Gerais, Brazil.
- 2023 Mar 22 **Invited Speaker.** NSCLC - early stage - how to manage? Roadshow - Lung Cancer - Astra Zeneca Brasil. Minas Gerais, Brazil.
- 2023 Mar 21 **Invited Speaker.** Clinical research: opportunities, challenges, careers. Institute of Cancer Sao Paulo Brazil (ICESP). Sao Paulo, Brazil.
- 2023 Mar 21 **Invited Speaker.** Preoperative Immunotherapy - Lessons Learned. Lung Cancer Road Show - Astra Zeneca Brasil. Sao Paulo, Brazil.
- 2023 Mar 9 **Invited Speaker.** Current Gaps and Opportunities in Lung Cancer. Astra Zeneca 2023 Partners of Choice Meeting. Cambridge, United Kingdom.
- 2023 Mar 8 **Invited Speaker.** Gender Specific Aspects of Treatment for Lung Cancer. Brazilian Society of Thoracic Surgery/Grupo Brasileiro de Oncologia Thoracica. Rio, Brazil.
- 2023 Mar 4 **Invited Speaker.** Current and Future Applications of Liquid Biopsies in Advanced Lung Cancer. Asan Medical Centre Annual Oncology Symposium. Seoul, Korea, Republic Of. DECLINED.
- 2023 Mar 3 **Plenary:** Emerging paradigms in the treatment practices for NSCLC. Astra Zeneca Global Diagnostics (non promotional). San Jose, Costa Rica.
- 2023 Feb 24 **Invited Speaker.** IO agents in the clinic. International Association for the Study of Lung Cancer Targeted Therapies Meeting 2023. Santa Monica, California, United States.
- 2023 Feb 23 **Chair and Invited Speaker.** Peerview: Redefining Precision Medicine in EGFR mutant Lung Cancer. International Association for the Study of Lung Cancer Targeted Therapies Meeting 2023. Santa Monica, California, United States.
- 2023 Feb **Invited Speaker.** Lung In Focus- Virtual. MDHealth- Brazil. DECLINED.
- 2023 Jan 21 **Invited Speaker.** The importance of using ctDNA to detect minimal residual disease. Florida Society of Clinical Oncology (FLASCO). Hollywood, Florida, United States.
- 2023 Jan 11 **Invited Speaker.** Systemic therapy for non-oncogene addicted NSCLC. ESMO Preceptorship Programme in NSCLC. Singapore, Singapore.
- 2023 Jan 10 **Invited Speaker.** Adjuvant/Neoadjuvant chemotherapy and radiotherapy strategies for resected NSCLC. European Society of Medical Oncology (ESMO) NSCLC Preceptorship Programme. Singapore, Singapore.
- 2023 Jan 10 **Invited Speaker.** Adjuvant/Neoadjuvant Chemotherapy and Radiotherapy Strategies in Resected NSCLC. ESMO Preceptorship Programme in NSCLC. Singapore, Singapore.
- 2023 Jan 8 **Invited Speaker.** Liquid Biopsy. 2023 TASLC International Symposium on Treatment Advances in Lung Cancer. Taipei, Taipei, Taiwan, Province Of China.
- 2022 Dec 13 **Invited Speaker.** The right tools at the right time: Liquid Biopsy enters the clinic. Roche Asia Pacific. Singapore.
- 2022 Dec 9 **Invited Speaker.** Designing and conducting investigator-initiated trials in immuno-oncology: Tips and tricks. ESMO ImmunoOncology 2022 Annual Meeting. Geneva, Switzerland.

Natasha LEIGHL

- 2022 Dec 8 **Invited Speaker.** Satellite Symposium: Clinical Trials of Biomarker Targeted Therapy in Lung Cancer. ESMO ImmunoOncology 2022 Annual Meeting. Geneva, Switzerland.
- 2022 Dec 7 **Invited Discussant (Proffered Papers).** Moving Beyond PD-L1 (KRAS and TGFbeta trap). ESMO ImmunoOncology 2022 Annual Meeting. Geneva, Switzerland.
- 2022 Dec 7 **Invited Speaker.** New Immunotherapy Targets and Treatments in Lung Cancer. ESMO ImmunoOncology 2022 Annual Meeting. Geneva, Switzerland.
- 2022 Dec 1 **Invited Speaker.** Lung Art Forum: Best practices with IO in NSCLC. Axis Sante/MSD France. Paris, France.
- 2022 Nov 29 **Chair, Speaker.** Expert Review in SCLC. ACE Oncology. New York, United States.
- 2022 Nov 11 **Speaker.** Global Lung Expert Input Forum. Merck. United States. DECLINED.
- 2022 Nov 11 **Expert Faculty.** Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum. SITC. Boston, Massachusetts, United States. DECLINED.
- 2022 Nov 11 **Invited Speaker.** Management of Advanced EGFRm NSCLC Patients. AstraZeneca. India. DECLINED.
- 2022 Nov 9 **Invited Speaker.** Tratamiento 1L en CPNM avanzado sin mutaciones drivers. IX Congreso Internacional De Oncología Del Interior. Cordoba, Argentina.
- 2022 Nov 9 **Invited Speaker.** Mecanismos de resistencia en ICI. IX Congreso Internacional De Oncología Del Interior. Cordoba, Argentina.
- 2022 Nov 9 **Invited Speaker.** ICI Rechallenge? IX Congreso Internacional De Oncología Del Interior. Cordoba, Argentina.
- 2022 Nov 5 **Invited Speaker.** The Ideal CGP Approach: Complementary Roles for Tissue-and Blood-Based Comprehensive Genomic Profiling. 9th Hong Kong International Oncology Symposium. Hong Kong. DECLINED.
- 2022 Nov 5 **Invited Speaker.** New Directions for Second-Line Therapy. EPICS Lung Cancer in 2022 and Beyond. New York, United States.
- 2022 Nov 4 **Invited Speaker.** ESMO 2022: Lung Cancer Updates. Sociedad Mexicana de Oncología 9th Congreso Internacional. Chihuahua, Mexico.
- 2022 Nov 4 **Invited Speaker.** EGFR (Less Common Mutations, Including Exon 20 Insertions). EPICS Lung Cancer in 2022 and Beyond. New York, United States.
- 2022 Oct 31 **Keynote Speaker.** METex14 NSCLC - a Canadian Perspective. Brazilian Thoracic Oncology Group/Novartis Masterclass Series. Brazil.
- 2022 Oct 29 **Speaker.** DC Lung Cancer Conference. Georgetown, District of Columbia, United States. DECLINED.
- 2022 Oct 28 **Invited Speaker.** MET Inhibitors in the Treatment of NSCLC. IASCL Asia Symposium. Nara, Japan. DECLINED.
- 2022 Oct 26 **Invited Speaker.** Management of N2 Disease. ESMO Advanced Course on Early Stage NSCLC. Melbourne, Victoria, Australia.
- 2022 Oct 22 **Invited Speaker.** Liquid Biopsy for Monitoring. Excellence in Oncology Care (EIOC). India.
- 2022 Oct 21 **Invited Speaker.** How to Balance Next Generation Tumor Tissue Testing versus Liquid Biopsy Algorithms in the Clinic. International Society for Liquid Biopsy 2022 Annual Meeting. Miami, Florida, United States.
- 2022 Oct 21 **Invited Speaker.** Redefining ctDNA Endpoints in Perioperative Clinical Trials. International Society for Liquid Biopsy 2022 Annual Meeting. Miami, Florida, United States.

Natasha LEIGHL

- 2022 Oct 21 APTITUDE HEALTH- Global Lung Cancer Academy. United States. DECLINED.
- 2022 Oct 20 **Invited Speaker.** How to integrate liquid biopsy into metastatic NSCLC. Astra Zeneca International Advisory Board ISLB 2022. Miami, Florida, United States.
- 2022 Oct 12 **Invited Speaker.** ESMO Precision Oncology 2022 Roundtable. OncologyEducation. Canada.
- 2022 Oct 8 **Invited Speaker.** Complementary Liquid and Tissue Testing in NSCLC. Guardant Mega India Launch Event. New Delhi, India. DECLINED.
- 2022 Sep 25 **Chair, Invited Speaker.** Refining Biomarker Testing and Targeted Treatment of NSCLC with Common and Uncommon EGFR Mutations. PeerVoice: IASLC North American Conference on Lung Cancer 2022. Chicago, Illinois, United States.
- 2022 Sep 21 **Invited Speaker.** EGFR (Less Common Mutations, Including Exon 20 Insertions). EPICS Lung Cancer in 2022 and Beyond. United States. Virtual.
- 2022 Sep 14 **Invited Panelist.** Liquid biopsies. AZ Lung Summit ESMO 2022. Paris, France.
- 2022 Sep 13 **Invited Speaker.** Improving Lung Cancer Detection with Liquid Biopsies. AZ Lung Summit ESMO 2022. Paris, France.
- 2022 Sep 12 **Invited Speaker.** What's Next? Current and next generation immunotherapy agents. ESMO 2022 Annual Meeting. Paris, France.
- 2022 Sep 9 **Invited Speaker.** Update on New Targeted Therapies for Specific NSCLC Subgroups. ESMO 2022 Annual Meeting Satellite Symposium (ACE Oncology). Paris, France.
- 2022 Aug 19 **Keynote Speaker.** Early Stage NSCLC - Patient Management and Future Treatment Options. Medical Oncology Group of Australia 2022 Annual Scientific Meeting. Cairns, Queensland, Australia.
- 2022 Aug 19 **Invited Speaker.** Early Stage NSCLC - Genomics and Targeted Therapy. Medical Oncology Group of Australia 2022 Annual Scientific Meeting. Cairns, Queensland, Australia.
- 2022 Aug 18 **Keynote Speaker.** Testing and Treatment - A Path to Access in the Real World. Medical Oncology Group of Australia 2022 Annual Scientific Meeting. Cairns, Queensland, Australia.
- 2022 Aug 9 **Round Table Moderator.** Women in Thoracic Oncology. IASLC 2022. Vienna, Austria. DECLINED-timing conflict.
- 2022 Aug 7 **Invited Speaker.** KRAS Inhibition in the Clinic. IASLC Satellite Symposium. Vienna, Austria.
- 2022 Jul 29 **Invited Speaker.** Sequencing of ALK TKIs. IASLC Huntington Beach Meeting. Huntington Beach, California, United States.
- 2022 Jul 28 **Invited Speaker.** Management of uncommon EGFR mutations. IASLC Huntington Beach Meeting. Huntington Beach, California, United States.
- 2022 Jul 28 **Invited Speaker.** Clinical Case Scenarios in NSCLC: International Lung Cancer Congress 2022. OncLive. Huntington Beach, California, United States.
- 2022 Jul 27 **Invited Speaker.** Translating Evidence to Practice: Improving Outcomes in SCLC. OncLive. Huntington Beach, California, United States.
- 2022 Jul 19 **Speaker.** Takeda Global Brigatinib ALTA-3 Roundtable Meeting. TRIPTYCH Health Partners. Virtual. DECLINED.
- 2022 Jul 8 **Invited Speaker.** Targeted Therapies in Stage III Unresectable NSCLC. Hawaiian Lung Cancer Summit. Kona, Hawaii, United States.

Natasha LEIGHL

- 2022 Jul 8 **Invited Speaker.** MET-targeting ADCs. Hawaiian Lung Cancer Summit. Kona, Hawaii, United States.
- 2022 Jul 2 **Invited Speaker.** Overcoming EGFR TKI Resistance. Malaysia National Oncology Summit. Kuala Lumpur, Malaysia.
- 2022 Jun 29 **Invited Speaker.** The Evolving State of the Science in EGFR+ NSCLC. Creative Educational Concepts/EQRX. New York, United States.
- 2022 Jun 25 **Invited Speaker.** Novel Liquid Biopsy Platforms for Lung Cancer Screening and Earlier Diagnosis. 17th Annual New Orleans Summer Cancer Meeting. Illinois, Louisiana, United States.
- 2022 Jun 19 **Presenter.** Clinical Use of Liquid Biopsy Approaches. Mount Holyoke College. Massachusetts, United States. DECLINED.
- 2022 Jun 13 **Speaker.** EPICS: Conference Coverage ASCO 2022-Focus on Lung Cancer. Aptitude Health. United States. Presenter(s): Virtual. DECLINED.
- 2022 Jun 10 **Invited Speaker.** ASCO 2022 Expert Quickfire Updates in EGFR mutant Lung Cancer. MEDSCAPE. United States.
- 2022 Jun 4 **Invited Speaker.** The Evolving Immunotherapy Paradigm for non-metastatic NSCLC. Clinical Care Options (ASCO 2022 Satellite Symposium). Chicago, Illinois, United States.
- 2022 May 31 **Keynote Speaker.** The future of lung cancer therapy - immunotherapy and targeted therapy from a gender perspective. Il Curso Medicina de Precision en cancer del pulmon. Spain.
- 2022 May 17 **Oncologic Impact of Multidisciplinary Care in Lung Cancer.** Latin American Workshop (GBOT, SBCT, ALAT): Multidisciplinary management of lung cancer cases. Rio, Brazil.
- 2022 May 10 **Invited Speaker.** Therapy and Prevention of Lung Cancer. Johns Hopkins University 4th Quarter Course: Novel approaches to therapy and prevention. Baltimore, Maryland, United States.
- 2022 May 3 **Invited Speaker.** Liquid biopsy and immuno-oncology: when and where to move forward? EMD Serono Liquid Biopsy Symposium. Germany.
- 2022 Apr 20 **Invited Speaker.** Recent advances in the treatment of patients with exon20 insertion mutant NSCLC. eCancer. United Kingdom.
- 2022 Apr 1 **Invited Speaker.** New Data on the Management of EGFRm Lung Cancer. Oncology Medical Education Forum (Sponsor Janssen).
- 2022 Apr 1 **Invited Lecturer.** Guidelines and Precision Oncology - DECLINED due to time constraints. Cincinnati Precision Oncology Forum. Cincinnati, Ohio, United States.
- 2022 Apr 1 **Keynote Speaker.** EGFRex20. Takeda. Brazil. DECLINED.
- 2022 Mar 31 **Invited Speaker.** EGFR Resistance: Mechanisms and Novel Approaches. European Lung Cancer Congress 2022 Satellite Symposium. Prague, Czech Republic.
- 2022 Mar 30 **Invited Speaker.** Telescreening here we come. European Lung Cancer Congress 2022. Prague, Czech Republic.
- 2022 Mar 30 **Chair.** Telemedicine in Lung Cancer - what's new? European Lung Cancer Congress 2022. Prague, Czech Republic.
- 2022 Mar 30 **Invited Discussant.** Advances in Targeted Therapy: MET, EGFR, ROS-1 (MiniOral Session). European Lung Cancer Congress 2022. Prague, Czech Republic.
- 2022 Mar 28 **Invited Speaker.** Targeting EGFR exon20 insertions in NSCLC: Lessons from the Clinic. 4th International Workshop on Tumor Evolution, Istituto Nazionale Tumori Regina Elena. Rome, Italy.
- 2022 Feb 22 **Chair.** TTLC 2022: EGFR Targeted Therapies Session. International Association for the Study of Lung

- Cancer 2021 Satellite Symposium (Mirati) Targeted Therapies Meeting 2021 Liquid Biopsy Hot Topic Meeting.
- 2022 Jan 28 **Invited Speaker.** Novel Oncogenic Drivers in NSCLC: Beyond Conventional. Indian Society of Medical and Pediatric Oncologists ISMPOCON Annual Meeting 2022. India. Presenter(s): (virtual).
- 2022 Jan 11 **Invited Speaker.** Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the IASLC. International Association for the Study of Lung Cancer Webinar.
- 2022 Jan **Presenter.** Treatment of Non-Small Cell Lung Cancer. Aptitude Health, CORE Meeting. Virtual, United States. DECLINED.
- 2021 Dec 11 **Invited Speaker.** Are We Ready for a Plasma First Approach in Lung Cancer? The 5th Lung Cancer-Year End Review 2021. India.
- 2021 Dec 3 **Invited Speaker.** EGFR (Less Common Mutations, Including Exon 20 Insertions). EPICS Lung Cancer in 2021 and Beyond. Virtual.
- 2021 Nov 23 **Invited Speaker.** Overview of Early-Stage NSCLC. Merck- Current Trends in Immuno-Oncology-Focus n LUNG. Virtual.
- 2021 Nov 16 **Invited Speaker.** Utilization of ctDNA for Risk Assessment and Monitoring in Early Stage NSCLC. Merck-Global ctDNA Scientific Input Engagement. Virtual.
- 2021 Nov 11 **Chair and Speaker.** Mobocertinib Global Medical Advisory Board: "Mobocertinib - recent data in NSCLC". Takeda.
- 2021 Nov 9 **Invited Speaker.** Liquid Biopsy in Lung Cancer. Springer memo inOncology ESMO. Webinar.
- 2021 Nov **Invited Speaker.** On-Line medical training program. Canada China Trade Innovative Alliance (CCTIA). DECLINED.
- 2021 Oct 30 **Invited Speaker.** The "Value" of Liquid Biopsy. International Society of Liquid Biopsy 2021. Virtual.
- 2021 Oct 28 **Invited Speaker.** Sensitizing EGFR Mutations and Resistance. SciEnergy Symposium III. Brazil.
- 2021 Oct 28 **Invited Speaker.** Management of EGFR Ex20 Insertion Mutant NSCLC. SciEnergy Symposium III. Brazil.
- 2021 Oct 26 **Invited Speaker.** Sensitizing EGFR Mutations and Resistance. SciEnergy Symposium II. Brazil.
- 2021 Oct 26 **Invited Speaker.** Management of EGFR Ex20 Insertion Mutant NSCLC. SciEnergy Symposium II. Brazil.
- 2021 Oct 22 **Invited Speaker.** How to balance next generation tumour tissue testing vs. liquid biopsy algorithms in the clinic. 3rd Annual International Society of Liquid Biopsy Congress 2021.
- 2021 Oct 22 **Invited Speaker.** The VALUE of plasma testing in NSCLC: a Canadian Study. 3rd Annual International Society of Liquid Biopsy Congress 2021 Symposium.
- 2021 Oct 22 **Invited Speaker.** Is it Time to Adopt a "blood first" Approach in NSCLC? Excellence in Oncology Care Symposium. Virtual.
- 2021 Oct 21 **Invited Speaker.** Global Precision Medicine Webinar Series: Real World Experience with ROS 1. Pfizer.
- 2021 Oct 21 **Invited Speaker.** Going Beyond PD-1/PDL1 Inhibition. Novartis Global Lung Summit. Virtual.
- 2021 Oct 21 **Invited Speaker.** Sensitizing EGFR Mutations and Resistance. SciEnergy Symposium I. Brazil.
- 2021 Oct 21 **Invited Speaker.** Management of EGFR Ex20 Insertion Mutant NSCLC. SciEnergy Symposium I. Brazil.
- 2021 Oct 19 **Invited Speaker.** Exploring A New Generation of PD-1 Inhibitors for Patients with Advanced Disease. Medscape-NSCLC Learning Bites. Virtual.

Natasha LEIGHL

- 2021 Oct 15 **Chair and Speaker.** Lung Cancer. Best of Precision Oncology 2021-Virtual.
- 2021 Oct 14 **Invited Speaker.** ESMO Virtual Advanced Course in KRAS Mutant NSCLC: Liquid biopsy applications Workshop. European Society of Medical Oncology.
- 2021 Oct 13 **Chair.** ESMO Virtual Advanced Course in KRAS Mutant NSCLC. European Society of Medical Oncology.
- 2021 Oct 13 **Invited Speaker.** Rare EGFR Mutations in Lung Cancer: Challenges and New Approaches. Rede D'Or (Brazil - Takeda Sponsor). Virtual.
- 2021 Oct 12 **Invited Speaker.** Precision Oncology: Highlights from ESMO Congress 2021. OncologyEducation.
- 2021 Oct 9 **Invited Speaker.** Coping with Work Overload: How to Prioritize and When to Say No. 6th Annual Young Investigators Forum in Lung Cancer-Medscape Oncology. Virtual.
- 2021 Oct 9 **Invited Speaker.** How to Effectively Advocate for Yourself. 6th Annual Young Investigators Forum in Lung Cancer-Medscape Oncology. Virtual.
- 2021 Oct 8 **Invited Speaker.** ESMO 2021: Update on EGFR Mutated Advanced NSCLC. eCancer.
- 2021 Oct 7 **Invited Speaker.** IO for NSCLC: 2021 WCLC/ESMO Updates. JCAP Virtual CTIO Post-ESMO WCLC Lung- Webcast.
- 2021 Oct 5 **Keynote Speaker.** MET Inhibitors in Lung Cancer. Novartis. Brazil. Virtual.
- 2021 Oct 4 **Invited Speaker.** Emerging Data in NSCLC in the (Neo)adjuvant Treatment Setting. Novartis Pharmaceuticals. Virtual Advisory Board Meeting- DECLINED-TIME CONFLICT.
- 2021 Sep 24 **Invited Speaker.** EGFR (Less Common Mutations, Including Exon 20 Insertions). EPICS: Global Perspectives in Lung Cancer- WCLC-ESMO 2021. Virtual.
- 2021 Sep 20 **Invited Speaker.** State of the Art in 1L Treatment: What is the current evidence? ESMO 2021 Satellite Symposium.
- 2021 Sep 18 **Invited Discussant.** Targeting VEGF and EGFR: Another Grail quest? ESMO Congress 2021 Oral Session Metastatic NSCLC.
- 2021 Sep 18 **Invited Speaker.** Testing for EGFR Exon 20 Insertions in NSCLC. Takeda Symposium-ESMO 2021-Illuminating the Path Forward in EGFR Exon20 Insertion+ mNSCLC: Unmet Needs and the Evolving Treatment Landscape. Virtual.
- 2021 Sep 16 **Invited Speaker.** Combinations including KRAS Inhibitors. European Society of Medical Oncology Annual Meeting 2021.
- 2021 Sep 14 **Invited Speaker.** Incorporating ctDNA testing into management of advanced NSCLC. International Association for the Study of Lung Cancer: 2021 World Conference on Lung Cancer.
- 2021 Sep 14 **Chair.** ctDNA in Lung Cancer Think Tank-Virtual. Inivata.
- 2021 Sep 10 **Invited Speaker.** Unmet needs for patients with advanced KRAS mutant lung cancer. International Association for the Study of Lung Cancer World Conference on Lung Cancer 2021 Satellite Symposium (Mirati). Presenter(s): **Natasha Leighl** - DECLINED DUE TO CONFLICT OF INTEREST.
- 2021 Sep **Invited Speaker.** EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects. RMEI Medical Education, LLC. DECLINED.
- 2021 Aug 28 **Invited Speaker.** PACIFIC Trial: Now and Tomorrow. VI International Symposium of Lung Cancer. Sao Paulo, Brazil. Virtual.
- 2021 Aug 27 **Invited Speaker.** For Richer, For Poorer-Targeting ALK and EGFRex20 in advanced NSCLC. Centre Hospitalier Universitaire Vaudois-Oncology Grand Rounds. Lausanne, Switzerland. WebEX.

Natasha LEIGHL

- 2021 Aug 27 **Invited Speaker.** Osimertinib as Adjuvant Treatment for Resected Lung Adenocarcinoma with EGFR Sensitizing Mutation? VI International Symposium of Lung Cancer. Sao Paulo, Brazil. Virtual.
- 2021 Aug 27 **Invited Speaker.** Financial Toxicity: How to Make New Treatments Accessible to a Larger Number of Patients? VI International Symposium of Lung Cancer. Sao Paulo, Brazil. Virtual.
- 2021 Aug **Invited Speaker.** Frontline Targeted Therapy for METex14 Skip Mutation in NSCLC: Latest Updates from 2021. Oncology Education-Novartis Webinar. DECLINED.
- 2021 Jul 3 **Invited Speaker.** 2021 LATAM Highlights: Lung Cancer. ASCO Direct. Brazil. Webinar.
- 2021 Jun 28 **Invited Speaker.** Emerging treatments for Patients with Advanced EGFR Exon 20 Insertion Mutant Lung Cancer. Takeda Oncology (Singapore). GEM Virtual Oncology Workshop.
- 2021 Jun 24 **Invited Speaker.** Imfinzi (Stage III NSCLC). AstraZeneca Canada. India. DECLINED DUE TO TIME CONSTRAINTS.
- 2021 Jun 23 **Invited Speaker.** Integrating EGFR TKIs in the management of advanced NSCLC patients with oligometastatic disease and progression in sanctuary sites. ESMO Advanced Course on EGFR+ Lung Cancer. Virtual.
- 2021 Jun 22 **Invited Speaker.** Management of CNS Metastases. ESMO Advanced Course on EGFR+ Lung Cancer. Virtual.
- 2021 Jun 22 **Invited Speaker.** Chemotherapy + TKI= Overtreatment. ESMO Advanced Course on EGFR+ Lung Cancer. Virtual.
- 2021 Jun 18 **Invited Speaker.** Evolution of Therapy in Early Stage NSCLC. Kerala Oncology Group (India). Virtual.
- 2021 Jun 15 **Invited Speaker.** Redefining Survival Expectations in NSCLC: Special Populations and First Line Therapy. MSD. Global Lung Webcast.
- 2021 Jun 11 **Invited Speaker.** Targeting EGFR exon20 insertions and rare EGFR mutations- EPICS Congress. Aptitude Health. Virtual.
- 2021 May 7 **Invited Speaker.** An Embarrassment of Riches? ALK+ Lung Cancer. SAKK Semi Annual Meeting Satellite Symposium. Switzerland.
- 2021 Apr 8 **Chair, Speaker.** PD-L1 inhibitors alone or in combination with chemotherapy first-line using real world data. European Society of Medical Oncology Virtual Plenary 2021. Switzerland.
- 2021 Mar 26 **Invited Speaker.** Hitting the target in 2020: RAS. European Lung Cancer Virtual Congress 2021.
- 2021 Mar 19 **Invited Speaker.** Revolution in Early Stage Lung Cancer Treatment. Instituto Oncoclinicas. Brazil. Virtual presentation.
- 2021 Mar 5 **Invited Speaker.** VALUE of comprehensive profiling in modern lung cancer practice. Molecular Oncology Society Conference (MOSCON) 2021. India.
- 2021 Feb 18 **Panel Lead.** Targeted Therapies - EGFR. International Association for the Study of Lung Cancer Targeted Therapies Meeting 2021. United States.
- 2021 Jan 31 **Chair.** Educational Session 22: Quality of Life. 2020 World Conference on Lung Cancer. Singapore.
- 2021 Jan 31 **Invited Speaker.** What is Quality of Life Anyway? 2020 World Conference On Lung Cancer-Virtual. Singapore. ES22.03.
- 2021 **Presenter.** Unmet needs for NSCLC patients and advances in molecular testing. Mirati Therapeutics. DECLINED.
- 2020 Dec 4 **Invited Speaker.** COVID and Lung Cancer. Virtual Perceptorship Program- Lung Cancer Patient Journey in Canada. Brazil.

Natasha LEIGHL

- 2020 Dec 2 **Invited Speaker.** Introduction to the Canadian System. Virtual Perceptorship Program- Lung Cancer Patient Journey in Canada. Brazil.
- 2020 Nov 27 **Invited Speaker.** Redefining our Expectations: Survival in Metastatic NSCLC. Merck India. India. Virtual Presentation.
- 2020 Nov 8 **Invited Speaker.** Improving Lung Cancer Management and Monitoring During Treatment with IO. MSD Israel. Israel. Virtual Presentation.
- 2020 Nov 6 **Invited Speaker.** New Directions for EGFR-Mutant NSCLC. EPICS- Lung. United States. Virtual Meeting.
- 2020 Oct 30 **Keynote Speaker.** The VALUE Study – A Canadian study to evaluate the added value of liquid biopsy in advanced NSCLC. International Society for Liquid Biopsy Annual Meeting. Presenter(s): **Natasha Leighl.**
- 2020 Oct 30 **Panelist.** Targeted Therapy for Early Stage Lung Cancer. Quantitative Imaging Workshop XV11: Leveraging CT to Accelerate Detection of Lung Cancer, COPD, and Cardiovascular Disease. Presenter(s): Panelists: **Leighl NB**, Hirsch F, Dennis PA, Herbst RS. Webcast.
- 2020 Oct 28 **Invited Speaker.** Future Developments in Lung Cancer. 2020 Current Trends in Oncology (MSD Global). Virtual Meeting.
- 2020 Oct 17 Maximising the Benefit of Immuno-Oncology. ESMO Virtual Congress 2020. Virtual Meeting.
- 2020 Oct 8 **Invited Speaker.** Treatment of Advanced NSCLC Without Actionable Genomic Aberrations. Hopital de Sion, Oncology Department Grand Rounds. Switzerland. Webinar.
- 2020 Oct 3 **Invited Speaker.** Liquid Biopsy for Tumour Monitoring. International Association for the Study of Lung Cancer Liquid Biopsy Hot Topic Meeting. Presenter(s): **Natasha Leighl.**
- 2020 Oct 2 **Invited Speaker.** Integrating Liquid Biosy into Clinical Practice: Which Patients with NSCLC? International Association for the Study of Lung Cancer Liquid Biopsy Hot Topic Meeting. Presenter(s): **Natasha Leighl.**
- 2020 Oct 2 **Chair and Speaker.** Clinical Application of Liquid Biopsy (Panel Discussion). International Association for the Study of Lung Cancer Liquid Biopsy Hot Topic Meeting. Presenter(s): **Natasha Leighl.**
- 2020 Oct 1 **Invited Speaker.** Lung Cancer and Cardiovascular Toxicity: State of the Art in 2020. Global Cardio-Oncology Summit-Canadian Cardiac Oncology Network. Toronto, Ontario, Canada. CANCELLED due to COVID-19.
- 2020 Oct **Chair.** 2020 Current Trends in Oncology. MSD Global. France. Presenter(s): Chair 14 Oct 2020 Current Trends in Patient Management; Chair/Speaker 15 Oct 2020 Meet the Expert Session1 Optimising Management in 2020; Chair/Speaker 21 Oct 2020 Management of Advanced NSCLC; Chair 22 Oct 2020 Meet the Expert Session#2 Optimizing Selection in 2020; Chair/Speaker 28 Oct 2020 Current Trends in Early stage NSCLC, SCLC and Future Developments. Virtual Meeting Oct 14-28th.
- 2020 Sep 21 **Chair.** Metastatic NSCLC Proffered Paper (Oral Abstract) Session. European Society of Medical Oncology Annual Meeting 2020. Virtual.
- 2020 Sep 21 **Invited Discussant.** New Frontiers in Immunotherapy in Lung Cancer. European Society of Medical Oncology Annual Meeting 2020. Presenter(s): **Natasha Leighl** (Mini Oral Metastatic NSCLC ESMO 2020). Virtual.
- 2020 Sep 10 **Faculty.** 5th Annual Young Investigators Forum in Lung Cancer. United States. Virtual Event.
- 2020 Aug 26 **Keynote Speaker.** The Evolution of Personalized Medicine and How it is Changing our Lives, Lung as “The Model”. DAS Genomic Summit. Brazil. Virtual Meeting.
- 2020 Aug 12 **Invited Speaker.** How to Monitor and Deal with Severe Toxicity of IO? IASLC 2020 World Conference on Lung Cancer. Singapore. Mini Symposia- CANCELLED DUE TO COVID-19.
- 2020 Aug 5 **Invited Speaker.** Immunotherapy and the COVID19 Pandemic. International Association for the Study of

Lung Cancer - MEDSCAPE Webinar.

- 2020 Jul 16 **Chair.** Neratinib in the Treatment of NSCLC. Puma Biotechnology. Meeting on-line.
- 2020 Jul 15 **Invited Speaker.** Blood vs Tissue Biopsy: How Do They Compare? Israel Oncology. Israel. Online.
- 2020 Jul 2 **Invited Speaker.** Keeping the Pace With Immunotherapy for First-Line NSCLC Treatment: Translating the Latest Evidence to Practice. Online Webinar. Recorded on July 3, 2020.
- 2020 Jun 25 **Invited Speaker.** AC CAMARGO- New Frontiers Congress. Brazil. CANCELLED DUE TO COVID-19.
- 2020 Jun 12 **Invited Speaker.** Canadian Cancer Research Achievements: CCTG BR.34. Best of ASCO 2020 Annual Meeting Oncology Education. Toronto, Ontario, Canada. Presenter(s): **Natasha Leighl**. Virtual Meeting.
- 2020 Jun 12 **Co-Chair.** Best of ASCO 2020 Annual Meeting. Oncology Education. Toronto, Ontario, Canada. Presenter(s): Co-Chair-Dr. Scott Berry. Virtual Meeting.
- 2020 Jun 10 **Invited Speaker.** ASCO Highlights-Lung. Springer Healthcare. Brazil. DECLINED due to COVID 19.
- 2020 Jun 9 **Invited Speaker.** 1L Non-Small Cell Lung Cancer, IO Update from ASCO. Bristol Myers Squibb-Post ASCO National Advisory Board. Virtual Meeting.
- 2020 Jun 9 **Speaker.** BR.34 Data Overview. AZ IO mNSCLC Global Advisory Board. Virtual presentation.
- 2020 Jun 4 **Invited Speaker.** Post-ASCO Review Podcast. The Oncology Journal Club- Episode 3. Podcast-Recorded June 2, 2020.
- 2020 May 14 **Faculty.** 2020 Young Investigators Forum in Lung Cancer. Atlanta, Georgia, United States. CANCELLED DUE TO COVID-19.
- 2020 May 7 **Invited Speaker.** IASLC Lung Cancer Hot Topic: Liquid Biopsy Meeting. Baltimore, Maryland, United States. CANCELLED DUE TO COVID-19.
- 2020 May 6 **Invited Speaker.** Annual Croatian Thoracic Society Congress. Zagreb, Croatia. CANCELLED DUE TO COVID-19.
- 2020 Apr 30 **Invited Speaker.** Breakthroughs and Challenges With Precision Medicine: Are We Ready to Take the Leap? Online. Recorded on April 30, 2020.
- 2020 Apr 18 **Invited Speaker.** Cancer Research Institute 2020 Immunotherapy Patient Summit. Roswell Park Comprehensive Cancer Center. Buffalo, New York, United States. DECLINED- due to COVID 19.
- 2020 Apr 16 **Chair.** FLAURA Speaker Panel. AstraZeneca Tagrisso Global Medical Affairs. Geneva, Switzerland. DECLINED due to COVID 19.
- 2020 Apr 15 **Invited Speaker.** KRAS. 10th European Lung Cancer Congress (ELCC). Geneva, Switzerland. CANCELLED DUE TO COVID-19.
- 2020 Apr 3 **Invited Speaker.** Multidisciplinary Forum: IO 1L Treatment in mNSCLC: Harnessing Long Term Experience Into Optimizing Patients' Outcome. MSD Israel. Tel Aviv, Israel. CANCELLED due to COVID-19.
- 2020 Apr 2 **Invited Speaker.** Improving Lung Cancer Monitoring: The Evolving Role of Patients and Care Providers. MSD Israel. Tel Aviv, Israel. CANCELLED due to COVID-19.
- 2020 Mar 31 **Keynote Speaker.** Options after IO Failure in NSCLC. Merk-7902-008 SI Investigator Meeting. Milan, Italy. CANCELLED due to COVID-19.
- 2020 Mar 21 **Invited Speaker.** Progress in EGFR +ve Lung Cancer. IASLC Best of World Lung. Bogota, Colombia. Satellite Symposium- CANCELLED DUE TO COVID-19.
- 2020 Mar 20 **Invited Speaker.** Comprehensive Plasma NGS Test for Advanced Cancer Patients. Korean Society of

Natasha LEIGHL

Laboratory Medicine. Seoul, Korea, Republic Of. CANCELLED DUE TO COVID-19.

- 2020 Mar 20 **Invited Speaker.** EGFR +ve Lung Cancer. IASLC Best of World Lung. Lima, Peru. Satellite Symposium-CANCELLED DUE TO COVID-19.
- 2020 Mar 13 **Invited Speaker.** Developing an Understanding of Biomarker Analysis and Related Treatment Decision-Making for Patients with Non-Small Cell Cancer Managed in Community-Based Practices: A Multi-Pronged CME Initiative. Miami, Florida, United States. Video-recorded Session-DECLINED due to time constraints.
- 2020 Feb 20 **Invited Speaker.** Binimetinib/ Binimetinib + Erlotinib. IASLC-2020 Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States.
- 2020 Feb 20 **Academic Faculty.** IASLC-2020 Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States. Fellows & Early Career Investigator Session.
- 2020 Jan 29 **Invited Speaker.** How to Manage Osimertinib Acquired Resistance? British Thoracic Oncology Group-18th Annual Conference. Dublin, Ireland.
- 2020 Jan 29 **Invited Speaker.** Approach to Management of Brain Metastases Following Relapse on a Next-Generation TKI. British Thoracic Oncology Group-18th Annual Conference: Takeda-Sponsored Smyposia. Dublin, Ireland.
- 2020 Jan 9 **Panelist.** Tumor Board- NSCLC. 20th Annual Meeting of the Israeli Society of Clinical and Radiotherapy. Eilat, Israel.
- 2020 Jan 9 **Invited Speaker.** Molecular Profiling in 2020: Wishes and Facts. 20th Annual Meeting of the Israeli Society of Clinical and Radiotherapy. Eilat, Israel.
- 2020 **Invited Speaker.** Changing Landscape of Therapy in 2019-2020. AstraZeneca Canada. DECLINED due to COVID 19.
- 2019 Dec 17 **Invited Speaker.** Immuno-Oncology for Lung Cancer: Clinical Updates and Future Trends. CCM International. Virtual Meeting- DECLINED due to time constraints.
- 2019 Dec 17 **Invited Speaker.** Immuno-Oncology for Lung Cancer: Clinical Updates and Future Trends. CCM International. Virtual Meeting- DECLINED due to time constraints.
- 2019 Dec 12 **Chair.** Chest Tumors: Updates. ESMO Immuno-Oncology Congress 2019. Geneva, Switzerland.
- 2019 Dec 12 **Invited Speaker.** Immunotherapy in SCLC: First and second-line approaches. ESMO Immuno-Oncology Congress 2019. Geneva, Switzerland.
- 2019 Dec 11 **Chair.** FLAURA European Panel. AstraZeneca. Geneva, Switzerland.
- 2019 Dec 11 **Invited Speaker.** Lung Cancer and the Management of Stage III and IV NSCLC With or Without Driver Mutation. AstraZeneca-GBOT and SBOC. Brazil. WEB Conference- Declined due to time constraints.
- 2019 Dec 5 **Invited Speaker.** UnMET needs in the current NSCLC treatment landscape: Live Q&A. Oncology Scientific Exchange- NSCLC Virtual Expert Forum. Zurich, Switzerland.
- 2019 Dec 4 **Invited Speaker.** UnMET needs in the current NSCLC treatment landscape: perspectives of an oncologist. Oncology Scientific Exchange- NSCLC Virtual Expert Forum. Zurich, Switzerland.
- 2019 Nov 23 **Keynote Speaker.** The Future of Liquid Biopsy in Solid Tumor Malignancies. 3rd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care. New York, New York, United States.
- 2019 Nov 8 **Invited Speaker.** Exploring New Treatment Windows for Immune Checkpoint Inhibitors in NSCLC. The Korean Academy of Tuberculosis and Respiratory Diseases. Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of.

- 2019 Nov 7 **Invited Speaker.** Basics of Immuno-Oncology. The Korean Academy of Tuberculosis and Respiratory Diseases. Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of.
- 2019 Nov 7 **Invited Speaker.** The Journey of Immuno-Oncology: Changing Landscape in Lung Cancer. The Korean Academy of Tuberculosis and Respiratory Diseases. Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of.
- 2019 Nov 7 **Invited Speaker.** New perspectives for the future treatment option in non-small cell lung cancer. Korean Society of Medical Oncology-12th Annual Meeting of the Korean Society of Medical Oncology & 1st International Conference. Seoul, Korea, Republic Of.
- 2019 Nov 2 **Invited Speaker.** Treatment of EGFR: Is there a better sequence (clinical cases)? 2nd International Symposium of Lung Cancer of Hospital Moinhos de Vento. Porto Alegre, Brazil.
- 2019 Nov 2 **Invited Speaker.** Immunotherapy and combinations in first line therapy (clinical cases). 2nd International Symposium of Lung Cancer of Hospital Moinhos de Vento. Porto Alegre, Brazil.
- 2019 Nov 1 **Invited Speaker.** Immunotherapy of Lung Cancer: Where do we go in 2020? 2nd International Symposium of Lung Cancer of Hospital Moinhos de Vento. Porto Alegre, Brazil.
- 2019 Nov 1 **Invited Speaker.** Treatment of Locally Advanced Disease (clinical cases). 2nd International Symposium of Lung Cancer of Hospital Moinhos de Vento. Porto Alegre, Brazil.
- 2019 Nov 1 **Invited Speaker.** Treatment of Initial Disease (clinical cases). 2nd International Symposium of Lung Cancer of Hospital Moinhos de Vento. Porto Alegre, Brazil.
- 2019 Nov 1 **Invited Speaker.** EPIC: Lung Cancer in 2019. Aptitude Health. New York, New York, United States. DECLINED DUE TO TIME CONFLICT.
- 2019 Oct 19 **Invited Speaker.** Management of advanced NSCLC: Checkpoint inhibitors in combination with chemotherapy. EMEAC Current Trends in Immuno-Oncology-Focus on Lung Cancer. Malaga, Spain.
- 2019 Oct 18 **Chair.** EMEAC Current Trends in Immuno-Oncology-Focus on Lung Cancer. Malaga, Spain.
- 2019 Oct 12 **Invited Speaker.** Immunotherapy in first-line NSCLC: Selecting the right regimen for the right patient. 9th Annual Oncology Congress: Hellenic Athenas Society. Hinitza, Greece.
- 2019 Oct 11 **Invited Speaker.** OncLive Global Expo. Orlando, Florida, United States. DECLINED DUE TO TIME CONFLICT.
- 2019 Oct 10 **Invited Speaker.** Emerging Oncologic Landscape and How to Advance Progress. CT Symposium 2018. Washington, District of Columbia, United States. DECLINED due to time constraints.
- 2019 Sep 28 **Invited Speaker.** Precision Medicine. Geneseeq 2018 Sino- Canada Dialogue on Lung Cancer Precision Medicine. Barcelona, Spain. DECLINED due to time constraints.
- 2019 Sep 25 **Invited Speaker.** Osimertinib: 3rd Gen TKI and CNS Activity. Simposio Beyond Evidence Redefiniendo El Tratamiento En CPNMa EGFRm. Madrid, Spain.
- 2019 Sep 8 **Invited Speaker.** What is the Role of Chemotherapy in the Era of Immunotherapy in Advanced NSCLC? IASLC 2019 World Conference on Lung Cancer. Barcelona, Spain.
- 2019 Sep 7 **Invited Speaker.** Maximizing the Impact of I-O: Timing of I-O Treatment in Early-Stage NSCLC. IASLC 2019 World Conference on Lung Cancer. Barcelona, Spain.
- 2019 Sep 7 **Chair.** Maximizing the Impact of I-O Across NSCLC. IASLC 2019 World Conference on Lung Cancer. Barcelona, Spain.
- 2019 Sep 7 **Invited Speaker.** Overview of RISE Program and Future Directions. IASLC 2019- Research and Investigator Supplemental Experience. Barcelona, Spain.

Natasha LEIGHL

- 2019 Sep **Invited Speaker.** Osimertinib in 1L. AstraZeneca. Colombia. DECLINED DUE TO TIME CONFLICT.
- 2019 Aug 7 **Invited Speaker.** New Investigator Clinical Trials Course August 799, 2019. Canadian Cancer Trials Group. Kingston, Ontario, Canada. DECLINED due to time constraints.
- 2019 Jul 23 **Invited Speaker.** Cross Trial Comparisons in Lung Cancer. Takeda Emerging Markets Web Educational Video Series.
- 2019 Jul 20 **Invited Speaker.** EGFR: Common and Uncommon Mutations: What is Next for These Patient Populations? Best of ASCO: 14th Annual New Orleans Summer Cancer Meeting. New Orleans, Louisiana, United States.
- 2019 Jul 13 **Invited Speaker.** NSCLC: The Evolving Treatment Landscape and the Role of Immuno-Oncology. Current Trends in Immuno-Oncology. Seoul, Korea, Republic Of. DECLINED DUE TO TIME CONFLICT.
- 2019 Jul 13 **Invited Speaker.** Epidural Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitors. Best of ASCO: Florida Society of Clinical Oncology. Miami, Florida, United States.
- 2019 Jul 11 **Chair.** Mesothelin-Targeting Agents. IASLC 2019 Mesothelioma Meeting. New York, New York, United States.
- 2019 Jul 11 **Invited Speaker.** Pembrolizumab + Chemotherapy in Mesothelioma. IASLC 2019 Mesothelioma Meeting. New York, New York, United States.
- 2019 Jun 20 **Speaker.** Monotherapy versus Combination. Princess Margaret Cancer Centre - MSD LATAM Clinical Observation Program. Toronto, Ontario, Canada.
- 2019 Jun 20 **Speaker.** Challenges in IO Therapy. Princess Margaret Cancer Centre - MSD LATAM Clinical Observation Program. Toronto, Ontario, Canada.
- 2019 Jun 19 **Chair.** MSD LATAM Clinical Observation Program in Lung Cancer Management. Princess Margaret Cancer Centre. Toronto, Ontario, Canada.
- 2019 Jun 19 **Speaker.** Immunotherapy in Lung Cancer Overview. Princess Margaret Cancer Centre - MSD LATAM Clinical Observation Program. Toronto, Ontario, Canada.
- 2019 Jun 1 **Keynote Speaker.** Clinical utility of comprehensive ctDNA analysis in metastatic NSCLC. Guardant Health AMEA ASCO Educational Event.
- 2019 May 31 **Invited Speaker.** Genomics for Oncologists 101- Medical Oncologist Perspective. 2019 ASCO Annual Meeting. Chicago, Illinois, United States.
- 2019 May 9 **Invited Speaker.** Interaction and Industry. prIME Oncology 2019 Young Investigators Forum in NSCLC. Atlanta, Georgia, United States.
- 2019 May 7 **Keynote Speaker.** The Treatment Landscape Post Anti-PD-1/PD-L1 Failure. MSD LEAP008 Investigator Meeting. Denver, Colorado, United States.
- 2019 May 5 **Invited Speaker.** The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons. American Association for Thoracic Surgery. Toronto, Ontario, Canada.
- 2019 Apr 24 **Invited Speaker.** Breathing New Life Into NSCLC Management: Evaluating the Expanding Role of Immunotherapy. PeerVoice. Toronto, Ontario, Canada.
- 2019 Apr 13 **Invited Speaker.** Sequencing Systemic Therapy Without Driver Mutations in CNS Metastasis from NSCLC. European Lung Cancer Conference. Geneva, Switzerland.
- 2019 Apr 12 **Invited Speaker.** Leading investigator-initiated studies. RISE Program. Geneva, Switzerland.
- 2019 Apr 12 **Chair.** Proffered Paper Session 4. European Lung Cancer Conference 2019. Geneva, Switzerland.

Natasha LEIGHL

- 2019 Apr 12 **Invited Discussant.** Updates in ALK and ROS1. European Lung Cancer Conference 2019. Geneva, Switzerland. Discussant: ALTA-1L (brigatinib v crizotinib) updated analysis; PROFILE1001 updated 4 year OS.
- 2019 Apr 11 **Chair.** Redefining Survival in NSCLC. European Lung Cancer Congress Symposium. Geneva, Unknown, Switzerland.
- 2019 Apr 11 **Invited Speaker.** Role of Monotherapy in First-Line NSCLC. European Lung Cancer Congress Symposium. Geneva, Unknown, Switzerland.
- 2019 Mar 23 **Invited Speaker.** Update in Lung Cancer. Current Trends in Immuno-Oncology. Auckland, New Zealand.
- 2019 Mar 23 **Invited Speaker.** Navigating the Treatment Pathways for NSCLC. Current Trends in Immuno-Oncology. Auckland, New Zealand.
- 2019 Mar 22 **Invited Speaker.** Monotherapy vs Combination Therapy Approaches: Where to Use Which. Current Trends in Immuno-Onocology. Auckland, New Zealand.
- 2019 Mar 22 **Invited Speaker.** Drug Reimbursement: The Canadian Perspective. Current Trends in Immuno-Oncology. Auckland, New Zealand.
- 2019 Mar 22 **Invited Speaker.** The Dynamic Landscape in NSCLC: Integrating the Latest Data into Pracice. MSD Advisory Board. Auckland, New Zealand.
- 2019 Mar 20 **Invited Speaker.** Advances in NSCLC. Auckland City Hospital Oncology Rounds. Auckland, New Zealand.
- 2019 Mar 19 **Invited Speaker.** Strategies for Keeping Established Information Fresh and Relevant. NSW Young Investigator Forum (MSD sponsored). Sydney, Australia.
- 2019 Mar 8 **Keynote Speaker.** Trials that change clinical practice: relevant comparisons and meaningful endpoints. Thoracic Oncology Munich: State of the Art 2019. Munich, Germany.
- 2019 Mar 4 **Invited Speaker.** Management of EGFRm+ Lung Cancer. St. Vincent's Hospital Noon Rounds. Melbourne, Australia.
- 2019 Mar 4 **Invited Speaker.** Moving to First-line in EGFRm+ Lung Cancer. Melbourne, Australia. Melbourne Lung Expert Roundtable.
- 2019 Mar 2 **Invited Speaker.** Lung Masterclass: Managing Lung Cancer in 2019. Sydney, Australia.
- 2019 Mar 1 **Invited Speaker.** Management of EGFRm+Lung Cancer. Westmeade Hospital Noon Rounds. Sydney, Australia.
- 2019 Mar 1 **Invited Speaker.** Moving to First-Line in EGFR+ Lung Cancer. Sydney, Australia.
- 2019 Feb 28 **Invited Speaker.** Optimal Management of EGFRm+ NSCLC. Brisbane Area Hospitals. Brisbane, Australia. Educational Dinner Meeting.
- 2019 Feb 28 **Invited Speaker.** Lung MDT. Royal Brisbane Hospital. Brisbane, Australia.
- 2019 Feb 27 **Invited Speaker.** ALK + NSCLC. Takeda. Lausanne, Switzerland. DECLINED DUE TO TIME CONFLICT.
- 2019 Feb 23 **Presenter.** Durvalumab + Tremilimumab. IASLC- 2019 Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States. Session Title: ICI Combinations (Stimulatory and Inhibitory).
- 2019 Feb 21 **Invited Speaker.** Binimetinib (MEK 1,2). IASLC- 2019 Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States. Session Title: KRAS/BRAF.
- 2018 Dec 18 **Invited Speaker.** Practical Strategies to Guideline Recommended Biomarker Testing in NSCLC. Medscape Oncology/Global. Toronto, Ontario, Canada. Web Talk.

Natasha LEIGHL

- 2018 Nov 26 **Invited Speaker.** Affording Progress in Lung Cancer. Roche- Lung Cancer Speaker Tour- Olivia Newton-John Cancer Research Institute. Melbourne, Victoria, Australia.
- 2018 Nov 24 **Invited Speaker.** Small Cell Lung Cancer Update. Olivia Newton-John Cancer Research Institute. Melbourne, Victoria, Australia.
- 2018 Nov 24 **Invited Speaker.** Changing Landscape 1L NSCLC. Olivia Newton-John Cancer Research Institute. Melbourne, Victoria, Australia.
- 2018 Nov 24 **Invited Speaker.** Future Directions of Lung Cancer Management. Olivia Newton-John Cancer Research Institute. Melbourne, Victoria, Australia.
- 2018 Nov 23 **Invited Speaker.** Update in Lung Cancer 2018. Roche- Lung Cancer Speaker Tour- Kinghorn Cancer Centre. Sydney, Australia.
- 2018 Nov 23 **Invited Speaker.** Research Progress in Lung Cancer. Roche- Lung Cancer Speaker Tour- Royal North Shore Hospital. Sydney, Australia.
- 2018 Nov 23 **Invited Speaker.** Update in Lung Cancer 2018, Kinghorn Cancer Centre. Roche- Lung Cancer Speaker Tour. Sydney, Australia.
- 2018 Nov 17 **Invited Speaker.** Managing Eligibility for, Toxicity With, and Duration of Immunotherapy. Emerging Paradigms in Care Series (EPICS)- Lung Cancer in 2018 and Beyond. New York City, New York, United States.
- 2018 Nov 16 **Invited Speaker.** The Evolving Therapeutic Landscape for ALK- Rearranged NSCLC. Emerging Paradigms in Care Series (EPICS)- Lung Cancer in 2018 and Beyond. New York City, New York, United States.
- 2018 Nov 2 **Invited Speaker.** The Role of Monotherapy in Patient Care. MSD Global NSCLC Advisory Board. Washington, District of Columbia, United States.
- 2018 Oct 16 **Invited Speaker.** Update from WCLC 2018. IASLC. Denver, Colorado, United States. Webinar.
- 2018 Sep 26 **Plenary Chair.** Take Action- Key Messages from WCLC2018. IASLC 19th World Conference on Lung Cancer. Toronto, Ontario, Canada. PL04.
- 2018 Sep 25 **Invited Discussant.** SCLC: Progress at Last? IASLC 19th World Conference on Lung Cancer. Toronto, Ontario, Canada. Plenary Presentation PL02.04.
- 2018 Sep 23 **Speaker and Moderator.** New Insights and Clinical Implications for the Treatment of ALK+ve Lung Cancer. IASLC 19th World Conference on Lung Cancer. Toronto, Ontario, Canada.
- 2018 Sep 8 **Invited Speaker.** The Utilization of Checkpoint Inhibitors in Monotherapy for NSCLC. 2018 Current Trends in Immuno-Oncology: Non-Small Cell Lung Cancer. Amsterdam, Netherlands.
- 2018 Sep 8 **Invited Speaker.** Workshop Highlights- What Have We Learned. 2018 Current Trends in Immuno-Oncology: Non-Small Cell Lung Cancer. Amsterdam, Netherlands. Co-speakers: Drs. Egbert Smit, Joop de Langen, Michel van den Heuvel.
- 2018 Sep 1 **Invited Speaker.** Osimertinib in Advanced NSCLC EGFRm 1L Treatment. III Simposio Internacional de Diagnostico em Cancer de Pulmao Oncologia D'Or- Thoracic Oncology Brazilain Group (GBOT) Meeting. Salvador, Brazil.
- 2018 Aug 31 **Invited Speaker.** Osimertinib in Advanced NSCLC EGFRm 1L Treatment. III Simposio Internacional de Diagnostico em Cancer de Pulmao Oncologia D'Or- Satellite Symposium. Rio de Janeiro, Brazil.
- 2018 Aug 30 **Invited Speaker.** FLAURA Study- Video MOC. Manual de Oncologia do Brasil (MOC). Sao Paulo, Brazil. www.mocbrasil.com.
- 2018 Aug 30 **Invited Speaker.** Osimertinib in Advanced NSCLC EGFRm 1L Treatment. III Simposio Internacional de

Diagnostico em Cancer de Pulmao Oncologia D'Or- Scientific Exchange MEeting in AC Camargo Cancer Center. Sao Paulo, Brazil.

- 2018 Aug 17 **Invited Speaker.** Evolving Treatment Landscape in 1L Metastatic NSCLC: Mono vs Combo- What Is The Optimal Approach? MSD- IASLC Latin America Conference on Lung Cancer 2018- "Pembrolizumab: The New Standard of Care in Advanced Lung Cancer". Cordoba, Argentina.
- 2018 Jun 25 **Invited Speaker.** 1st Line NSCLC AACR/ASCO review presentation. AC Camargo Hospital. Sao Paulo, Brazil. DECLINED due to time conflict.
- 2018 Jun 22 **Invited Speaker.** Metastatic NSCLC: Optimal Management of 1L Patients. MSD Oncology- Stand-Alone Scientific Symposium- "Latin America Current Trends in Immuno-oncology (CTIO)". Sao Paulo, Brazil.
- 2018 Jun 22 **Invited Speaker.** Immunotherapy for NSCLC: What's Next? MSD Oncology- Stand-Alone Scientific Symposium-"Latin America Current Trends in Immuno-oncology (CTIO)". Sao Paulo, Brazil.
- 2018 Jun 22 **Invited Speaker.** NSCLC: Clinical Cases and Discussion. MSD Oncology- Stand-Alone Scientific Symposium- "Latin America Current Trends in Immuno-oncology (CTIO)". Sao Paulo, Brazil.
- 2018 Jun 20 **Keynote Speaker.** Affording Progress in Lung Cancer. 2018 Lung Cancer SPORE. Dallas, Texas, United States.
- 2018 Jun 15 **Invited Speaker.** Beyond First Line Therapy in EGFR Positive NSCLC. Kidwai Memorial Institute of Oncology. Bengaluru, Karnataka, India.
- 2018 Jun 15 **Invited Speaker.** Beyond First Line Therapy in ALK Positive NSCLC. Kidwai Memorial Institute of Oncology. Bengaluru, Karnataka, India.
- 2018 Jun 15 **Invited Speaker.** Expert Comments. Kidwai Memorial Institute of Oncology. Bengaluru, Karnataka, India.
- 2018 Jun 15 **Invited Speaker.** Combination of Immunotherapy With Other Therapy. Kidwai Memorial Institute of Oncology. Bengaluru, Karnataka, India.
- 2018 Jun 15 **Invited Speaker.** Beyond First Line Therapy Immunotherapy in NSCLC. Kidwai Memorial Institute of Oncology. Bengaluru, Karnataka, India.
- 2018 Jun 14 **Invited Speaker.** Advanced/Metastatic Disease: Management of EGFR +ve NSCLC. Lung Cancer Updates- Meeting- Apollo Hospital. Jasola, Delhi, India.
- 2018 Jun 14 **Invited Speaker.** Locally Advanced: Management of Stage III NSCLC- Current and Future. Lung Cancer Updates- Meeting- Max Super Speciality Hospital. Saket, Delhi, India.
- 2018 Jun 14 **Moderator.** Advanced/Metastatic Disease: Management of EGFR +ve NSCLC. Lung Cancer Updates- Meeting- Max Super Specialty Hospital. Saket, Delhi, India. Panel Discussion.
- 2018 Jun 13 **Invited Speaker.** Advanced/Metastatic Disease: Management of EGFR +ve NSCLC. Lung Cancer Updates- Meeting- Tata Medial Centre. Kolkata, India.
- 2018 Jun 13 **Invited Speaker.** Locally Advanced: Management of Stage III NSCLC- Current and Future. Lung Cancer Updates- Meeting- Hotel JW Marriot. Kolkata, India.
- 2018 Jun 13 **Moderator.** Advanced/Metastatic Disease: Management of EGFR +ve NSCLC. Lung Cancer Updates- Meeting- Hotel JW Marriot. Kolkata, India. Panel Discussion.
- 2018 May 31 **Invited Speaker.** The New Standard of Care in Advanced Non-Small Cell Lung Cancer- Meet the Expert Panel Session. 2018 American Society of Clinical Oncology. Chicago, Illinois, United States.
- 2018 Apr 12 **Invited Speaker.** Practical Application of Anti-PD-1 Therapy. European Lung Cancer Conference 2018- Industry Satellite Symposium-Pembrolizumab: The New Standard of Care in Advanced Lung Cancer. Geneva, Switzerland.

Natasha LEIGHL

- 2018 Mar 17 **Invited Speaker.** Immunotherapy for Stage IV Disease. prIME- 3rd Annual Young Investigators Forum- NSCLC. Atlanta, Georgia, United States.
- 2018 Feb 21 **Session Chair.** 18th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States.
- 2017 Nov 25 **Keynote Speaker.** Immunotherapy Combination Trials. Australia Lung Cancer Trials Group Lung Cancer Symposium. Sydney, New South Wales, Australia.
- 2017 Nov 25 **Invited Speaker.** Can we Afford the Cost of New Therapies? Australia Lung Cancer Trials Group Lung Cancer Symposium. Sydney, New South Wales, Australia. Panel Debate.
- 2017 Nov 17 **Invited Speaker.** Immunotherapy in Lung Cancer. XI Annual Conference- Polish Lung Cancer Group. Warsaw, Poland.
- 2017 Nov 17 **Invited Speaker.** Future Trends in Lung Cancer. Thoracic Expert Forum. Dallas, Texas, United States. DECLINED due to time conflict.
- 2017 Nov 5 **Invited Speaker.** Recommendations on the Use of Biomarkers in Immuno-oncology Therapies in Latin America. Americas Health Foundation. Rio De Janeiro, Rio de Janeiro, Brazil.
- 2017 Nov 3 **Invited Speaker.** Progress in Biomarkers for Immunotherapy: Slow, but Steady. EPIC Lung Cancer in 2017 and Beyond. New York City, New York, United States.
- 2017 Nov 3 **Invited Speaker.** Immunotherapy Combinations: IO + IO. EPIC Lung Cancer in 2017 and Beyond. New York City, New York, United States.
- 2017 Oct 31 **Invited Speaker.** Interactive Multidisciplinary Thoracic Tumor Board. American College of Chest Physicians (CHEST 2017). Toronto, Ontario, Canada.
- 2017 Oct 18 **Invited Speaker.** The Economic Burden of Lung Cancer. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan.
- 2017 Oct 17 **Invited Speaker.** Dignity Conserving Therapy. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan.
- 2017 Oct 16 **Chair.** Joint IASLC/GLCC Session: Current Issues in Lung Cancer Advocacy. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan.
- 2017 Oct 16 **Invited Speaker.** Sustainable Care System in North America. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan.
- 2017 Sep 12 **Invited Speaker.** Immune-related Adverse Effects of Checkpoint Blockers. European Respiratory Society 2017 International Congress. Milan, Italy.
- 2017 Sep 11 **Chair.** Highlights of ESMO 2017: Oncology Opinions Round Table. Oncology Education Best of ASCO. Madrid, Spain.
- 2017 Sep 2 **Invited Speaker.** Immuno-Oncology in Frontline Treatment Setting for Advanced NSCLC. Taiwan Society of Pathology. Taipei.
- 2017 Jun 16 **Chair.** Targeted Therapies in Advanced Lung Cancer - The Next Generation. Oncology Education Best of ASCO. Toronto, Ontario, Canada.
- 2017 May 22 **Invited Speaker.** The Impact of Human Behavior and Organizational Inertia on Maximizing Personalized Lung Cancer Care. American Thoracic Society (Scientific Symposium). Washington, District of Columbia, United States.
- 2017 Mar 17 **Keynote Speaker.** Tackling the costs of lung cancer. Oncologia D'Or Neotorax. Rio de Janeiro, Brazil. II Simpósio Nacional do Diagnostico em Cancer de Pulmão.

- 2017 Mar 17 **Invited Speaker.** The importance of molecular diagnosis in EGFR mutant NSCLC patients post progression on TKI therapy. Oncologia D'Or Neotorax. Rio de Janeiro, Brazil. II Simpósio Nacional do Diagnostico em Cancer de Pulmão.
- 2017 Mar 16 **Keynote Speaker.** Experiências sobre valoração em saúde no Canadá. Oncologia D'Or Neotorax. Rio de Janeiro, Brazil. II Simpósio Nacional do Diagnostico em Cancer de Pulmão.
- 2017 Mar 9 **Faculty.** 2nd Annual Young Investigators Forum in Non-Small Cell Lung Cancer. prIME Oncology. Atlanta, Georgia, United States. Declined due to time constraints.
- 2016 Dec 6 **Invited Speaker.** ALK Targeted Therapy Update - WCLC 2016 Vienna. prIME Oncology. Vienna, Austria. DECLINED DUE TO TIME CONSTRAINTS.
- 2016 Nov 26 **Invited Speaker.** Pembrolizumab in Lung Cancer. MSD. Taipei, Taiwan, Province Of China. KEYTRUDA Launch Taiwan- DECLINED TO AVOID PHARMA CONFLICT OF INTEREST.
- 2016 Nov 18 **Invited Speaker.** Targeted Therapy in Lung Cancer. Montevideo, Uruguay. 14th Uruguay Oncology Congress- DECLINED DUE TO TIME CONFLICT.
- 2016 Nov 9 **Invited Speaker.** More Trials than Tribulations in Lung Cancer. Weill Cornell Cancer Center. New York City, New York, United States. Weill Cornell Cancer Center.
- 2016 Oct 23 **Invited Speaker.** Targeted Therapy in Lung Cancer: A New Era. Trivandrum Oncology. Trivandrum, India. Trivandrum Cancer Conference II.
- 2016 Oct 11 **Invited Speaker.** Targeted Therapy in Lung Cancer. Hospital Albert Einstein. São Paulo, Brazil. DECLINED TO TO TIME CONSTRAINTS.
- 2016 Sep 24 **Invited Discussant.** Outcomes: The Many Faces of Janus. IASLC. Chicago, Illinois, United States. Chicago Multidisciplinary Symposium in Thoracic Oncology.
- 2016 Jun 26 **Invited Speaker.** Immuno-Oncology Treatment in Lung Cancer. MSD. Taipei, Taiwan, Province Of China. Renaissance Era in Immuno-oncology of Lung Cancer.
- 2016 Jun 25 **Invited Speaker.** Immuno-Oncology Treatment in Lung Cancer. MSD. Kaohsiung, Taiwan, Province Of China. Renaissance Era in Immuno-Oncology in Lung Cancer.
- 2016 Jun 24 **Invited Speaker.** Immuno-Oncology Treatment in Lung Cancer. MSD. Taichung, Taiwan, Province Of China. Renaissance Era in Immuno-oncology of Lung Cancer.
- 2016 May 5 **Invited Speaker.** Clinical Development: Crizotinib. Pfizer. Rio de Janeiro, Brazil.
- 2016 Apr 9 **Invited Speaker.** Irish Geriatric Oncology Meeting: Lung Cancer in the Elderly. Irish Geriatric Oncology Society. Dublin, Dublin, Ireland.
- 2016 Apr 2 **Invited Speaker.** I Simposio de Diagnostico em Cancer de Pulmao Oncologia D'Or NeoTorax: Economic Impact of tissue testing and treatment in metastatic NSCLC in the era of personalized medicine. D'Or Institute of Research. Rio de Janeiro, Rio de Janeiro, Brazil.
- 2016 Apr 2 **Invited Speaker.** Quality of Life data: Planning your RCT. Oncologia D'Or. Rio de Janeiro, Brazil. Lung Cancer Diagnosis Symposium.
- 2016 Apr 1 **Keynote Speaker.** I Simposio de Diagnostico em Cancer de Pulmao Oncologia D'Or NeoTorax: Molecular Diagnosis in Lung Cancer. D'Or Institute of Research. Rio de Janeiro, Rio de Janeiro, Brazil. Lung Cancer Diagnosis Symposium.
- 2016 Apr 1 **Invited Speaker.** I Simposio de Diagnostico em Cancer de Pulmao Oncologia D'Or NeoTorax: Advances in Lung Cancer Diagnosis. D'Or Institute of Research. Rio de Janeiro, Rio de Janeiro, Brazil. Lung Cancer Diagnosis Symposium.
- 2016 Apr 1 **Invited Speaker.** I Simposio de Diagnostico em Cancer de Pulmao Oncologia D'Or NeoTorax: Cost

- Effectiveness of CT Screening. D'Or Institute of Research. Rio de Janeiro, Rio de Janeiro, Brazil.
- 2016 Mar 11 **Invited Speaker.** Beyond PDL-1: Clinical status of immune checkpoint inhibition. Thoracic Oncology Munich: TOM 2016 State of the Art. Munich, Germany. Presenter(s): DECLINED FOR CONFLICTING ENGAGEMENT.
- 2016 Mar 4 **Invited Speaker.** Treatment of Driver Mutations. PRIME Oncology. Chicago, Illinois, United States. Young Investigators Forum in NSCLC.
- 2016 Feb 25 **Invited Speaker.** Phase I/II study of tumour infiltrating lymphocytes in advanced malignant mesothelioma. IASLC Targeted Therapies Meeting. Santa Monica, California, United States.
- 2016 Feb 20 **Chair.** MEK. IASLC-16th Annual Targeted Therapies of The Treatment of Lung Cancer. Santa Monica, California, United States.
- 2016 Feb 20 **Invited Speaker.** Binimetinib + Chemotherapy. IASLC-16th Annual Targeted Therapies of The Treatment of Lung Cancer. Santa Monica, California, United States.
- 2016 Feb 20 **Invited Speaker.** IL2 + TILs. IASLC-16th Annual Targeted Therapies of The Treatment of Lung Cancer. Santa Monica, California, United States.
- 2016 Jan 30 **Keynote Speaker.** Role of Immunotherapy in Lung Cancer. Merck. Lebanon. Presenter(s): DECLINED FOR SAFETY CONCERNS.
- 2016 Jan 29 **Invited Speaker.** Practical Aspects of Immune Oncology. Peer Voice. Online. Optimizing Immunotherapy in Lung Cancer.
- 2015 Nov 12 **Invited Speaker.** Da Biologia A Terapia: Cuso-efetividade dos novo tratamentos: como incorporar as opcoes terapeuticas na rotina diaria. AC Camargo Cancer Center. Sao Paulo, São Paulo, Brazil.
- 2015 Nov 12 **Invited Speaker.** Da Biologia A Terapia: Terapia-alvo no tratamento do CPCNP: o velho e o novo. AC Camargo Cancer Center. Sao paulo, São Paulo, Brazil.
- 2015 Nov 7 **Invited Speaker.** Immune Oncology in Lung Cancer: State of the Art. AstraZeneca. Sydney, New South Wales, Australia. Sydney Lung Cancer Symposium.
- 2015 Nov 7 **Invited Speaker.** Medical Oncologists will be redundant in 25 years. Lung Cancer Symposium 2015. Sydney, New South Wales, Australia.
- 2015 Nov 6 **Chair.** Panel for Trainee case studies/projects. AstraZeneca. Sydney, New South Wales, Australia. Sydney Lung Cancer Symposium.
- 2015 Nov 6 **Invited Speaker.** Best of WCLC Denver 2015: Antiangiogenesis plus Immunotherapies in Lung Cancer. Universitat Heidelberg: Klinik Interdisziplinare Thorakale Onkologie. Dresden, Germany. Presenter(s): DECLINED (CONFLICTING ENGAGEMENT).
- 2015 Oct 8 **Invited Speaker.** Media Launch: Nintedanib in Lung Cancer. Boehringer Ingelheim. Buenos Aires, Argentina. Presenter(s): DECLINED DUE TO ACADEMIC CONFLICT.
- 2015 Oct 7 **Invited Speaker.** Nintedanib in Lung Cancer. Boehringer Ingelheim. Buenos Aires, Argentina. Presenter(s): DECLINED DUE TO ACADEMIC CONFLICT.
- 2015 Sep 7 **Invited Scientific Discussant.** Clinical Care of Lung Cancer. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States.
- 2015 Jun 18 **Speaker.** Anti-Angiogenic Agents in the Second-Line Treatment of NSCLC: Combination Therapy for Successful Outcomes. PeerVoice. Recorded CME for online delivery. (Continuing Education).
- 2015 Jun 5 **Invited Speaker.** Canadian Clinical Spotlights in Immunooncology from the 2015 ASCO Annual Meeting in Chicago (online CME). Prime Oncology. Chicago, Illinois, United States. Presenter(s): **Natasha Leighl**, Julie Brahmer.

- 2015 May 31 **Invited Discussant.** ASCO - Highlights of the Day Session. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers abstracts.
- 2015 May 31 **Invited Chair.** Clinically Meaningful Positive Trials in Lung Cancer Incorporating ASCO Benchmarks, Disparate Populations, the Real Life Setting and Community. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Session: Positive Trials in Lung Cancer: Statistical versus Real Clinical Significance.
- 2015 May 31 **Invited Speaker.** Clinically Meaningful Positive Trials in Lung Cancer Incorporating ASCO Benchmarks, Disparate Populations, the Real Life Setting and Community. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Session: Positive Trials in Lung Cancer: Statistical versus Real Clinical Significance.
- 2015 May 2 **Invited Speaker.** "Targeting DNA Repair Mechanisms in Lung Cancer". Cancer Treatment Centres of America. Scottsdale, Arizona, United States. 1st Annual New Treatments in Oncology Conference.
- 2015 Mar 14 **Invited Speaker.** Expert Practice in Lung Cancer. prIME Oncology. Amsterdam, Netherlands. Case presentation: Adenocarcinoma with ALK rearrangement: Selecting optimal approach.
- 2015 Mar 14 **Invited Speaker.** Expert Practice in Lung Cancer. prIME Oncology. Amsterdam, Netherlands. Case presentation: Squamous cell lung carcinoma: The changing treatment paradigm.
- 2015 Feb 20 **Invited Chair.** PARP/DNA Repair. IASLC-15th Annual Targeted Therapies of The Treatment of Lung Cancer. Santa Monica, California, United States. Presenter(s): **Leighl NB**. This invitation only meeting gathers the top scientists to discuss the latest advances in the treatment of lung cancer with targeted therapies, February 18-21, 2015.
- 2014 Dec 13 **Invited Speaker.** Adenocarcinoma with ALK rearrangement: Selecting the optimal approach. Expert Practice in Lung Cancer (PRIME Oncology). Prague, Czech Republic. Expert Practice in Lung Cancer Meeting.
- 2014 Dec 13 **Invited Speaker.** Squamous cell lung carcinoma: the changing treatment paradigm. Expert Practice in Lung Cancer (PRIME Oncology). Prague, Czech Republic. Expert Practice in Lung Cancer Meeting.
- 2014 Nov 28 **Invited Lecturer.** Squamous Lung Carcinoma- 2014 and beyond. Polish Lung Cancer Cooperative Group, 8th Annual Conference. Warsaw, Poland.
- 2014 Sep 14 **Chair.** Advances through Molecular Biology in Thoracic Cancer-Angiogenesis. 4th International Thoracic Oncology Congress. Dresden, Germany. Presenter(s): **Leighl NB**. September 12-14, 2014.
- 2014 Jun 20 **Keynote Speaker.** Pitfalls and Progress Targeting Lung Cancer in 2014. The Fifth Shanghai International Symposium on Respiratory Diseases. Shanghai, China.
- 2014 May 31 **Invited Speaker.** Considerations for treatment decision-making in advanced squamous cell carcinoma of the lung: Expanding Treatment Options in the Management of Advanced NSCLC. PRIME Oncology. Chicago, Illinois, United States.
- 2014 May 18 **Invited Speaker.** Therapeutic Options Now and in the Future for Early Stage Disease (Chemotherapy). 30th International Conference on Screening for Lung Cancer. New York, New York, United States.
- 2014 May 16 **Invited Speaker.** Chemotherapy for Early Disease. Prevent Cancer Foundation-Lung Cancer Workshop XI. New York, New York, United States.
- 2014 Feb 22 **Invited Speaker.** Pitfalls of clinical research-panel discussion. All Ireland Cooperative Oncology Research Group (ICORG). Dublin, Ireland.
- 2014 Feb 22 **Invited Speaker.** What is a phase II study? Different phase II designs. All Ireland Co-operative Oncology Research Group (ICORG). Dublin, Ireland.
- 2013 Nov 30 **Invited Speaker.** What is the appropriate use of extended therapy in NSCLC. II Simposio GBOT: Pos-

- Mundial de Pulmao. Salvador, Brazil.
- 2013 Nov 30 **Invited Speaker.** Optimal chemotherapy for stage III NSCLC. II Simposio GBOT: Pos-Mundial de Pulmao. Salvador, Brazil.
- 2013 Nov 29 **Invited Speaker.** Role of angiokinase inhibition in second-line lung cancer therapy. II Simposio GBOT: Pos-Mundial de Pulmao. Salvador, Brazil.
- 2013 Nov 9 **Invited Speaker.** Is there an optimal TKI in EGFR-mutant Lung Cancer? 8th Annual New York Lung Cancer Meeting. New York, New York, United States.
- 2013 Oct 30 **Invited Speaker.** Translating Research into Practice- Cost Effectiveness of Modern Therapies. 15th IASLC World Lung Conference on Lung Cancer. Sydney, Australia.
- 2013 Oct 27 **Invited Speaker.** Targeting Angiogenesis. 15th IASLC World Lung Conference on Lung Cancer - Symposium. Sydney, Australia.
- 2013 Oct 27 **Invited Speaker.** Planning an Academic Career in Lung Cancer. 15th IASLC World Lung Conference on Lung Cancer. Sydney, Australia.
- 2013 Oct 25 **Invited Speaker.** ASCO 2013 Update: Lung Cancer. 51st Annual Meeting of Japan Society of Clinical Oncology. Kyoto, Japan.
- 2013 Oct 25 **Invited Speaker.** Meet the Professor Session: Clinical trial design and biomarkers in lung cancer. 51st Annual Meeting of Japan Society of Clinical Oncology. Kyoto, Japan.
- 2013 Sep 28 **Invited Speaker.** Improvements in the Management of Non-small Cell Lung Cancer...Seriously! Fred Hutchinson Cancer Research Center/University of Washington School of Medicine Comprehensive Oncology Review Course. Seattle, Washington, United States.
- 2013 Sep 13 **Invited Speaker.** Best practices for breast cancer follow up (Seguimiento). American Society of Clinical Oncology Multidisciplinary Cancer Management Course. Montevideo, Uruguay.
- 2013 Sep 12 **Invited Speaker.** Tratamiento del adenocarcinoma de pulmon estadio IV. American Society of Clinical Oncology Multidisciplinary Cancer Management Course. Montevideo, Uruguay.
- 2013 Aug 17 **Invited Speaker.** Lung Cancer – Non-small Cell Local-regional/Small cell/Other Thoracic Cancers. Best of ASCO 2013 Los Angeles. Los Angeles, California, United States.
- 2013 Jun 13 **Invited Speaker.** How to evaluate the real impact in global survival based on recent advances in non-small cell lung cancer. Next Frontiers to Cure Cancer – Integrating Science and Patient Care. A.C. Camargo Cancer Center. Sao Paulo, Brazil.
- 2013 Jun 13 **Invited Speaker.** The influence of patient age in treatment decisions for non-small cell lung cancer. Next Frontiers to Cure Cancer – Integrating Science and Patient Care. A.C. Camargo Cancer Center. Sao Paulo, Brazil.
- 2013 Jun 3 **Invited Speaker.** Oral Abstract Discussant, Lung Cancer – Non-small Cell Metastatic: A Universe of New Agents for Metastatic NSCLC. 2013 ASCO Annual Meeting. Chicago, Illinois, United States.
- 2013 May 31 **Invited Speaker.** Canadian Oncology Resident Education at ASCO 2013: Lung Cancer. ASCO 2013. Chicago, Illinois, United States.
- 2013 Apr 14 **Invited Speaker.** Role of angiogenesis in the treatment of solid tumours. Scientific Exchange Meeting, Targeting Angiogenesis: New Developments and Future Options. Sydney, Australia.
- 2013 Apr 13 **Invited Speaker.** Where VEGF/VEGFR targeted therapies and trials can fit in the future. Scientific Exchange Meeting, Targeting Angiogenesis: New Developments and Future Options. Sydney, Australia.
- 2013 Apr 13 **Invited Speaker.** Biomarker testing in practice (Meet-the-Professor Session). Scientific Exchange Meeting, Targeting Angiogenesis: New Developments and Future Options. Sydney, Australia.

Natasha LEIGHL

- 2013 Apr 13 **Invited Speaker.** Overview of clinical development of VEGF/VEGFR inhibitors in lung cancer to date. Scientific Exchange Meeting, Targeting Angiogenesis: New Developments and Future Options. Sydney, Australia.
- 2013 Feb 22 **Chair.** HDAC inhibitors. 13th Annual Targeted Therapies of the Treatment of Lung Cancer. Santa Monica, California, United States.
- 2013 Feb 22 **Invited Speaker.** Debate on Maintenance Therapy Nonsquamous: Erlotinib. 13th Annual Targeted Therapies of the Treatment of Lung Cancer. Santa Monica, California, United States.
- 2013 Jan 17 **Invited Speaker.** Highlights in Lung Cancer from 2012. GRACE.org and LUNGEVITY. United States.
- 2012 Oct 20 **Invited Speaker.** Treatment of the PS2 Advanced NSCLC Patient. Oncology CME. Tokyo, Japan.
- 2012 Sep 7 **Invited Speaker.** Cost of Routine Genotyping - Can We Afford It? Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, United States.
- 2012 Jun 1 **Invited Chair.** Moving towards Personalized Medicine in Non-Small Cell Lung Cancer: The Cost of Targeting Therapy, including Diagnostics, Patient Selection, and Targeted Therapies. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. The Cost of Lung Cancer: Screening, Personalized Medicine, and Palliative Care-Education Session.
- 2012 Jun 1 **Invited Speaker.** Moving towards Personalized Medicine in Non-Small Cell Lung Cancer: The Cost of Targeting Therapy, including Diagnostics, Patient Selection, and Targeted Therapies. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. The Cost of Lung Cancer: Screening, Personalized Medicine, and Palliative Care-Education Session.
- 2012 Jun 1 **Invited Speaker.** ASCO Lung Update. CORE Meeting 2012 ASCO Annual Meeting. Chicago, Illinois, United States.
- 2012 Feb 3 **Invited Speaker.** Angiogenesis inhibitors in lung cancer – beyond VEGF. 2nd Lung Cancer Network “From the Bench to the Bedside”. Athens, Greece.
- 2011 Nov 26 **Invited Speaker.** Incorporating new drugs and cost effectiveness in an era of personalized medicine – the Canadian experience. Primeiro Simposio Anual, Nucleo de Oncologia Toracica, NCI Brasil. Rio de Janeiro, Brazil.
- 2011 Nov 26 **Invited Speaker.** Management of the metastatic lung cancer patient. Primeiro Simposio Anual, Nucleo de Oncologia Toracica, NCI Brasil. Rio de Janeiro, Brazil.
- 2011 Nov 12 **Invited Speaker.** Management of Lung Cancer with EGFR mutation after failure of TKI. 21st Asia Pacific Cancer Conference. Kuala Lumpur, Malaysia.
- 2011 Nov 12 **Invited Speaker.** Lung Cancer – Biomarkers and Beyond. 21st Asia Pacific Cancer Conference. Kuala Lumpur, Malaysia.
- 2011 Nov 11 **Invited Speaker.** Angiogenesis inhibition in NSCLC. 21st Asia Pacific Cancer Conference. Kuala Lumpur, Malaysia.
- 2011 Oct **Invited Speaker.** Systemic Therapy for Lung Cancer. Kuwait Cancer Centre. Kuwait, Saudi Arabia. Presented at 3 hospitals in Kuwait October 14-27, 2011.
- 2011 Aug 15 **Invited Speaker.** Managing advanced NSCLC in 2011: State of the Art versus State of the Union. Cancer Council Western Australia. Perth, Australia.
- 2011 Aug 13 **Invited Speaker.** Best of ASCO 2011: Breast Cancer. Medical Oncology Group of Australia/ASCO. Adelaide, Australia.
- 2011 Aug 11 **Invited Speaker.** Update in Maintenance Therapy in Advanced NSCLC and Can We Afford Advances in Lung Cancer Care? Medical Oncology Group of Australia Annual Meeting. Adelaide, Australia.

Natasha LEIGHL

- 2011 Aug 11 **Invited Speaker.** Meet the Professor Session: Advances in Breast Cancer. Medical Oncology Group of Australia Annual Meeting. Adelaide, Australia.
- 2011 Aug 10 **Invited Speaker.** Managing advanced NSCLC outside of Utopia (or What should I do?). Medical Oncology Group of Australia Annual Meeting. Adelaide, Australia.
- 2011 Jul 28 **Invited Speaker.** Reviewing anti-VEGF therapy in NSCLC. IV Latin American Summit. Buenos Aires, Argentina.
- 2011 Jul 6 **Invited Speaker.** Directions in anti-angiogenesis: are we making progress? Maintaining Momentum in NSCLC Research Symposium, 14th World Conference on Lung Cancer. Amsterdam, Netherlands.
- 2011 Jul 4 **Invited Discussant Oral presentations.** EGFR and ALK testing. 14th World Conference on Lung Cancer (International Association for the Study of Lung Cancer): Mini Oral Biomarkers VI. Amsterdam, Netherlands.
- 2011 May 3 **Invited Speaker.** Personalizing Early Lung Cancer Clinical Trials. Lung Cancer Workshop VIII: Application of High Resolution CT Imaging Data to Lung Cancer Drug Development - Measuring Progress. Bethesda, United States.
- 2011 Mar 23 **Visiting Professor.** Evolution of Lung Cancer Therapy: At What Cost? NCI Italy (Istituto Nazionale Tumori): Grand Rounds. Napoli, Italy.
- 2011 Feb 25 **Chair.** mTOR/PI3Kinase Inhibitors. International Association for the Study of Lung Cancer (IASLC): 11th Annual Targeted Therapies meeting. Santa Monica, United States.
- 2010 Nov 6 **Invited Speaker.** OPTIMAL and Beyond 1st line Therapy in Advanced NSCLC. European Society of Medical Oncology Personalized Medicine in Oncology. Chiangmai, Thailand.
- 2010 Nov 5 **Invited Speaker.** Role of Anti-angiogenesis in NSCLC. European Society of Medical Oncology Personalized Medicine in Oncology. Chiangmai, Thailand.
- 2010 Nov 4 **Invited Lecturer.** Biomarker Summit. Copenhagen. DECLINED due to conflict.
- 2010 Apr 23 **Invited Speaker.** Non-small cell lung cancer – a model for personalized treatment in clinical practice. Anti-VEGF therapies in NSCLC. 2nd Contemporary Oncology Congress. Poznan, Poland.
- 2010 Mar 12 **Invited Speaker.** New treatment perspectives in cancer. COI Brasil. Rio de Janeiro, Brazil. Lung Cancer Case Discussion.
- 2010 Mar 12 **Invited Speaker.** Evolution of Targeted Therapies and New perspectives in Advanced Non-small cell lung cancer. New treatment perspectives in Cancer. COI Brasil. Rio de Janeiro, Brazil.
- 2010 Feb 24 **Chair.** VEGF Inhibitors. 10th Annual Targeted Therapies of the Treatment of Lung Cance. Santa Monica, California, United States.
- 2009 Nov 25 Treatment Decision-making in advanced NSCLC. Lung Multidisciplinary Team Meeting, Sydney Cancer Centre. Sydney, Australia. (Continuing Education).
- 2009 Nov 25 Optimal Treatment in 1st Line Maintenance and 2nd Line NSCLC. Oncology Department Meeting, Calvary Mater Hospital. Newcastle, Australia. (Continuing Education).
- 2009 Nov 24 1st line Maintenance and 2nd line Therapy in Advanced NSCLC. Medical Oncology Noon Rounds, St. George Hospital. (Continuing Education).
- 2009 Nov 24 1st line Maintenance therapy in advanced NSCLC. Lung Multidisciplinary Tumour Discussion, Thoracic Oncology Service, Westmead Hospital. Sydney, Australia. (Continuing Education).
- 2009 Nov 23 Advanced NSCLC: Educational Update, The evolving treatment paradigm. Clinical Oncology Society of Australia. Melbourne, Australia. (Continuing Education).

Natasha LEIGHL

- 2009 Nov 18 Meet the Expert - Case studies. Clinical Oncology Society of Australia Annual Scientific Meeting. Gold Coast, Australia. (Continuing Education).
- 2009 Nov 18 Development of brain metastases in the era of targeted agents. Cerebral metastases from lung and other cancers. Clinical Oncology Society of Australia Annual Scientific Meeting. Gold Coast, Australia. (Continuing Education).
- 2009 Nov 17 Treatment Decision Making in Lung Cancer – Lung Cancer in the Year 2010. Clinical Oncology Society of Australia Annual Scientific Meeting. Gold Coast, Australia. (Continuing Education).
- 2009 Nov 17 Improving patient outcomes in advanced NSCLC – the evolving treatment paradigm. Optimal therapy for 1st line maintenance and 2nd line treatment of NSCLC. Satellite Meeting, COSA ASM. Gold Coast, Australia. (Continuing Education).
- 2009 Oct 2 Anti-EGFR Monoclonal Antibody Cetuximab with chemotherapy in first-line treatment of advanced NSCLC. Novel Agents in the Treatment of Lung Cancer. New Approaches to First-Line Therapy, 7th Cambridge Conference. Cambridge, Massachusetts, United States. (Continuing Education).
- 2009 Aug 28 Use of Targeted Agents in Adjuvant NSCLC Treatment. II Simposio Internacional Pos Mundial Cancer de Pulmao. Salvador, Bahia, Brazil. Aug 28-29/09. (Continuing Education).
- 2009 Aug 28 Treatment of the Elderly and Patients with Poor Performance Status. II Simposio Internacional Pos Mundial Cancer de Pulmao. Salvador, Bahia, Brazil. Aug 28-29/09. (Continuing Education).
- 2009 Aug 28 Targeted Therapy in SCLC. II Simposio Internacional Pos Mundial Cancer de Pulmao. Salvador, Bahia, Brazil. Aug 28-29/09. (Continuing Education).
- 2009 Aug 28 Adjuvant Therapy in NSCLC Update 2009. II Simposio Internacional Pos Mundial Cancer de Pulmao. Salvador, Bahia, Brazil. Aug 28-29/09. (Continuing Education).
- 2009 Aug 2 **Chair.** Bringing Quality of Life Assessment into the Mainstream of Lung Cancer Management. Minisymposium. San Francisco, United States. (Continuing Education).
- 2009 Jul 24 A Blueprint for excellence in NSCLC patient care. 3rd Chinese Conference on Medical Oncology. Beijing, China. (Continuing Education).
- 2009 Apr 29 Therapeutic Landscape in NSCLC. Avastin in Kidney and Lung Cancer Meeting. San Jose, Costa Rica. (Continuing Education).
- 2009 Apr 29 Safety Profile of Avastin in NSCLC. Avastin in Kidney and Lung Cancer Meeting. San Jose, Costa Rica. (Continuing Education).
- 2009 Mar 8 Treatment of Non-small cell lung cancer: Focus on Anti-angiogenesis. GI & Lung Expert Forum. Sao Paulo, Brazil. (Continuing Education).
- 2009 Mar 6 Inhibition of Signaling Pathways in Lung Cancer – Latest Evidence Applied to Clinical Practice. 3rd Caribbean Association of Oncology and Haematology Conference. Nassau, Bahamas. (Continuing Education).
- 2009 Feb 20 VEGF Trap. 9th Annual Targeted Therapies of the Treatment of Lung Cancer (IASLC). Santa Monica, California. (Continuing Education).
- 2009 Feb 7 Treatment of Locally Advanced (Stage III) Non-small Cell Lung Cancer. III Simposio do Centro Oncologico de Florianopolis - CEOF. Florianopolis, Brazil.
- 2009 Feb 6 Adjuvant Treatment for NSCLC. III Simposio do Centro Oncologico de Florianopolis - CEOF. Florianopolis, Brazil. (Continuing Education).
- 2009 Jan 9 From Phase III to Phase IV trials – Focus on Efficacy. Key Considerations in Oncology Trials. China Center for Pharmaceutical Int'l Exchange. Beijing, China. (Continuing Education).

- 2008 Nov 14 **Invited Speaker.** First-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous, non-small cell lung cancer: AVAiL (BO17704), a phase III randomised study. Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, Illinois, United States. Plenary presentation.
- 2008 Oct 18 Treatment of lung cancer. 9th Meeting of the International Society of Geriatric Oncology. Montreal, Quebec, Canada. (Continuing Education).
- 2008 Oct 4 **Chair.** Molecular biomarkers: are they ready for clinical applications? 7th Scientific and Educational Conference Lung Cancer 2008. Gdansk, Poland. (Continuing Education).
- 2008 Oct 3 Second-line treatment of advanced NSCLC: chemotherapy. 7th Scientific and Educational Conference Lung Cancer 2008. Gdansk, Poland. (Continuing Education).
- 2008 Oct 3 Targeting EGFR and VEGF. 7th Scientific and Educational Conference Lung Cancer 2008. Gdansk, Poland. (Continuing Education).
- 2008 Jun 20 Integrating antiangiogenesis therapy in the management of advanced non small cell lung cancer. NCI/ASCO Lung Cancer in Croatia Workshop. Zagreb, Croatia. (Continuing Education).
- 2008 May 21 Patient management: Additional Benefits through Tailored Treatment. Avastin Launch. Tel Aviv, Israel.
- 2008 May 9 Anti-angiogenic treatment and Lung Cancer: Defining new therapeutic approaches for lung cancer patients. Satellite Symposium, 14th PanHellenic Congress of Clinical Oncology. Athens, Greece. (Continuing Education).
- 2007 Dec 8 Angiogenesis Inhibitors in Advanced Non-small Cell Lung Cancer. 2007 Annual Meeting of Taiwan Society of Pulmonary and Critical Care Medicine. Kaohsiung, Taiwan, Province Of China. (Continuing Education).
- 2007 Dec 1 Combinations of Targeted Agents with Chemotherapy: Maximizing Synergy while Minimizing Antagonism. 4th Annual Symposium on the Future of Lung Cancer. Washington, District of Columbia. (Continuing Education).
- 2007 Sep 23 Lung cancer – historical and current perspectives. Media Briefing on Avastin in Lung Cancer. Barcelona, Spain. (Continuing Education).
- 2007 Sep 22 Exploring lung cancer care: learning from the past. Lung Cancer Expert Meeting. Barcelona, Spain. (Continuing Education).
- 2007 Sep 22 Masterclass: AVAiL and E4599: what do the data mean to my patients? Lung Cancer Expert meeting. Barcelona, Spain. (Continuing Education).
- 2007 Jul 2 AVAiL – putting the results in context. Italian SAIL investigator meeting. Naples, Italy. (Continuing Education).
- 2007 Jun 4 Avastin in Lung Cancer – Extending benefits of therapy. Satellite Symposium, ASCO (Roche). Chicago, Illinois. (Continuing Education).
- 2007 Jun 1 Avastin in Lung Cancer (AVAiL). Case Presentations, ASCO Investigator Meeting. Chicago, Illinois.
- 2006 Jun 30 Non-small Cell Lung Cancer Overview. TIME Meeting. Barcelona, Spain. (Continuing Education).
- 2006 Jun 3 **Chair.** Lung Cancer 1 Oral Session. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta, Georgia. Jun 1-3/06. (Continuing Education).
- 2006 Apr 2 **Session Co-Chair, Introductory speaker.** Enhancing Molecular Therapy. AACR Mini symposium. Washington, District of Columbia. (Continuing Education).
- 2005 Dec 9 Clinical Crossfire: Non-taxanes for metastatic breast cancer after adjuvant taxane therapy. San Antonio Breast Cancer Symposium. San Antonio, Texas, United States. (Continuing Education).

Natasha LEIGHL

- 2004 Oct **Invited Speaker.** Quality of Life Methodology in Lung Cancer - Aventis Advisory Board. Aventis. Vienna, Austria. (Continuing Education).
- 2004 Jun 3 Quality of Life in Advanced NSCLC: Quality of Life International Advisory Board. ASCO. New Orleans, Louisiana. (Continuing Education).
- 2003 Dec 4 Rencontres Marseillaises Sure le Cancer Bronchique – Coûts et coût-efficacité: Existe-t-il des divergences? Influence des systèmes de soins: Avis Canadien. CHU Marseilles, France. (Continuing Education).
- 2003 Dec 4 Rencontres Marseillaises Sure le Cancer Bronchique – Information des patients: Retard Européen ou différences de mentalité? Avis Canadien. CHU Marseilles, France. (Continuing Education).
- 2003 Feb 28 **Invited Speaker.** The Cost of Lung Cancer Chemotherapy: Can we afford not to treat? Danish Lung Cancer Group Meeting. Copenhagen, Denmark.
- 2003 Jan 11 **Invited Speaker.** Patient Education in Advanced NSCLC: The impact of treatment. New Strategies in the Treatment of Advanced Non-small Cell Lung Cancer. Berlin, Germany.
- 2002 Aug 9 **Invited Speaker.** "What to do? Decision Analysis Tools in Advanced Cancer Settings". 12th Annual Hematology/Oncology Reviews – State of the Art Treatment of Hematology/Oncology Disorders (Mayo Clinic). Amelia Island, Florida, United States.

Presented Abstracts

- 2020 Apr 24 **Presenter.** Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial. AACR Virtual Annual Meeting 2020. San Diego, California, United States. Presenter(s): **Natasha Leighl**. Virtual Poster Session; Abstract #10434.
- 2020 Jan 14 Defining VALUE: Routine Liquid Biopsy in NSCLC diagnosis- a Canadian Trial in Progress. AACR Special Conference on Advances in Liquid Biopsies. Miami, Florida, United States. Presenter(s): Jennifer Law. Poster/ Abstract Presentation.
- 2017 Jun 22 3-Year Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Pembrolizumab in KEYNOTE-001. 24th Asia Pacific Conference. Seoul, Korea, Republic Of. Oral Presentation.
- 2009 Aug 3 Bone and Brain Metastasis in NSCLC. 13th World Conference on Lung Cancer. San Francisco. **Leighl NB**. Oral poster discussion.
- 2009 Jul 31 Derivation of utility values from EORTC QLQ-C30 values in lung cancer. 13th World Conference on Lung Cancer. San Francisco. Jang R, Isogai PK, Mittmann N, Bradbury PA, Shepherd F, Feld R, **Leighl NB**. Poster Discussion. July 31-August 4, 2009.
- 2009 Jul 31 Prognostic impact of patterns of nodal subcategories and pleural or pericardial effusions in Small Cell Lung Cancer (SCLC). 13th World Conference on Lung Cancer. San Francisco. Lwin Z, Patsios D, Ma C, **Leighl N**. Poster Presentation. July 31-August 4, 2009. (Trainee Presentation).
- 2009 Jul 31 Chemoradiation in older patients with stage III non-small cell lung cancer (NSCLC). 13th World Conference on Lung Cancer. San Francisco. Ng DM, Sun A, Coate L, Ma C, Beznak A, Brade A, Burkes RL, Cho J, Feld R, Liu G, Shepherd F, **Leighl NB**. Poster Presentation. July 31-August 4, 2009. (Trainee Presentation).
- 2009 Jul 31 Known Brain Metastases: A valid exclusion criterion in non-small cell lung cancer (NSCLC) clinical trials?: an audit of the eligibility criteria in NSCLC trials, and an evaluation of treatment delivery, toxicity and survival experienced by patients with brain metastases. 13th World Conference on Lung Cancer. San Francisco. Bradbury PA, Twumasi-Ankrah P, Ding K, Shepherd FA, Goss G, **Leighl NB**, Laurie S, Seymour L. Oral Presentation. July 31- August 4, 2009.

- 2009 Jul 31 The Panc-Canadian Early Detection of Lung cancer Study. 13th World Conference on Lung Cancer. San Francisco. Lam S, Tsao MS, Tammemagi M, May J, Roberts H, McWilliams A, Tremblay A, Puksa S, Martel S, Johnston M, Nicholas G, Peacock S, Sin D, Liu G, Goffin J, Evans B, Borrowes P, Stewart L, Yasfuku K, Soghrati K, Seely J, Manos D, Gingras M, Amjadi K, **Leighl N**, Gazdar A, Shepherd F. Oral Presentation. July 31-August 4, 2009.
- 2009 Jul 31 Positron Emission Tomography in Small Cell Lung Cancer: A Systematic Review and Practice Guideline in Ontario, Canada. 13th World Conference on Lung Cancer. San Francisco. Ung YC, Ellis P, **Leighl N**, Sun A, Walker-Dilks C, Evans WK. Poster Discussion. July 31-August 4, 2009.
- 2009 Jul 31 Impact of age on outcome and toxicity in patients treated aggressively with curative intent trimodality treatment for locally advanced non-small cell lung cancer (NSCLC). 13th World Conference on Lung Cancer. San Francisco. Coate LE, Ma C, Hope AJ, Pierre AF, Bezjak A, Brade A, Darling G, Feld R, **Leighl N**, Sun A, Keshavjee S, Shepherd FA. Poster Discussion. July 31-August 4, 2009.
- 2009 Jul 31 Management Change As A Result Of Positron Emission Tomography (PET) In A Prospective Randomized Clinical Trial. 13th World Conference on Lung Cancer. San Francisco. Ung YC, Sun A, MacRae R, Gu CS, Wright J, Yu E, Darling G, **Leighl N**, Evans WK, Levine M. Poster Presentation. July 31-August 4, 2009.
- 2008 Nov 14 A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous, non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, United States. **Leighl NB**, Reck M, Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Mezger J, Archer V. Plenary presentation. (Continuing Education).
- 2008 May 5 A cost utility analysis of erlotinib in patients with previously treated advanced non-small cell lung cancer. ISPOR 13th Annual International Meeting. Toronto, Ontario. Bradbury PA, Jang R, Isogai P, Ng R, Mittmann N, Evans W, Shepherd FA, **Leighl NB**. Poster presentation (PCN58). Values in Health 11(3):A72, 2008. (Trainee Presentation).
- 2007 Sep 23 Safety of bevacizumab in non-small cell lung cancer subjects receiving full-dose anti-coagulation treated on protocol BO17704. ECCO 14. Barcelona, Spain. **Leighl N**, Bennouna J, Kuo HP, Szima B, Gottfried M, Kunitsyn A, Trigo JM, Chang GC, Cosaert J, Manegold C. Poster presentation. September 23-27, 2007.
- 2007 Sep 23 Efficacy and safety results from BO17704, a randomized, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer. ECCO 14. Barcelona, Spain. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, **Leighl N**, Mezger J, Moore N, Reck M. Oral presentation. September 23-27, 2007.
- 2007 Sep 23 Management of hypertension in patients with advanced or recurrent non-squamous non-small cell lung cancer receiving first-line cisplatin and gemcitabine with bevacizumab or placebo-results from randomized phase III trial BO17704. ECCO 14. Barcelona, Spain. Bennouna J, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, **Leighl N**, Mezger J, Moore N, Manegold C. Oral presentation. September 23-27, 2007.
- 2007 Sep 23 Subgroup results from a randomized, double-blind, multicentre phase III study of bevacizumab in combination with cisplatin-gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer: study BO 17704. ECCO 14. Barcelona, Spain. Eberhardt W, Reck M, von Pawel J, Zatloukal, Ramlau R, Gorbounova V, **Leighl N**, Mezger J, Moore N, Manegold C. Oral presentation. September 23-27, 2007.
- 2007 Sep 15 Induction chemo-radiation therapy followed by surgical resection for non-small cell lung cancer invading the chest wall. European Association of CardioThoracic Surgery 21st Annual meeting. Geneva, Switzerland. Fischer S, Yeung J, Tomaszek S, Darling G, Pierre AF, Sun A, **Leighl N**, Lara-Guerra H, Anraku M, Waddell TK, Keshavjee S, de Perrot M. September 15-19, 2007.
- 2007 Jun 27 Safety of Bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anti-coagulation (FDAC) treated on protocol BO17704 (AVAiL). 8th International Lung Congress. Maui,

- Hawaii. **Leighl N**, Bennouna J, Kuo HP, Szima B, Gottfried M, Kunitsyn A, Trigo J, Chang G, Cosaert J, Manegold C. Poster presentation. June 27 – 30, 2007.
- 2006 Jun 22 Impact of an electronic quality of life assessment tool on resource utilization in advanced non-small cell lung cancer. MASCC 18th International Symposium. Toronto. **Leighl NB**, Meharchand JM, Hollen PJ, Stewart J, Gralla RJ. Poster Presentation. June 22-24, 2006.
- 2006 Jun 2 A cost effectiveness analysis of the NCIC JBR.10 trial of adjuvant chemotherapy with vinorelbine/cisplatin after complete resection of early stage non-small cell lung cancer. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta. Ng R, Mittmann N, Florescu M, Shepherd F, Salvarrey A, Seymour L, Evans W, **Leighl N**. For poster presentation. June 2-6 2006. (Trainee Presentation).
- 2006 Jun 2 The potential for lost productivity in lung cancer patients. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta. Zawisza D, Pepe C, Mittmann N, Feld R, Shepherd F, **Leighl N**. For poster presentation. 2-6 June 2006. (Trainee Presentation).
- 2006 Jun 2 A prospective evaluation of the attitudes of patients, physicians and nurses using a computer-assisted quality of life instrument in a multicenter clinical trial in non-small cell lung cancer. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta. Gralla RJ, Hollen P, **Leighl N**, Meharchand J, Krieger H, Solow H. For poster presentation. June 2-6 2006.
- 2006 Jun 2 Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized NCIC CTG trials. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta. Asmis TR, Ding K, Whitehead M, Seymour L, Shepherd FA, **Leighl N**, Goss G. For poster presentation. June 2-6 2006.
- 2006 Jun 2 Compliance of adjuvant chemotherapy in NSCLC: no longer an issue. American Society of Clinical Oncology 2006 Annual Meeting. Atlanta. Aljubran A, **Leighl N**, Pintilie M, Feld R, Burkes R, Shepherd F. For poster presentation. June 2-6 2006.
- 2005 Sep 12 Phase 1/2 study of GTI-2040 plus docetaxel in advanced NSCLC. National Cancer Institute CTEP Early Drug Development Meeting. Bethesda, Massachusetts. **Leighl NB**, Laurie SA, Knox JJ, Shepherd FA, Burkes RL, Tannock IF, Pond GR, Zweibel J, Moore MJ. September 12-13, 2005.
- 2005 Jul 3 For richer, for poorer: A willingness to pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. 11th World Conference on Lung Cancer. Barcelona, Spain. **Leighl N**, Tsao S, Zawisza D, Nematollahi M, Shepherd F. Poster presentation. July 3-6, 2005. Abstract 972.
- 2005 Jul 3 Phase 1/2 study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer. Barcelona, Spain. **Leighl N**, Laurie S, Knox J, Ellis P, Shepherd F, Burkes R, Pond G, Zwiebel J, Moore M. Poster presentation. July 3-6, 2005. Abstract 1692.
- 2005 Jul 3 Review of practice patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. 11th World Conference on Lung Cancer. Barcelona, Spain. Visbal A, Kassam F, Johnston M, Feld R, Shepherd F, Darling G, Keshavjee S, Pierre A, Waddell T, **Leighl N**. Poster discussion. July 3-6, 2005. (Trainee Presentation).
- 2005 Jul 3 Randomized trial to investigate the impact of a computer-generated quality of life assessment program on treatment patterns for advanced non-small cell lung cancer patients. 11th World Conference on Lung Cancer. Barcelona, Spain. Kassam F, Salvarrey A, Shepherd F, Feld R, Gralla R, **Leighl N**. Poster presentation. July 3-6, 2005. Abstract 1658. (Trainee Presentation).
- 2005 Jul 3 Are age and co-morbidity independent prognostic factors in the treatment of metastatic NSCLC : A Review of NCIC randomized trial BR18. 11th World Conference on Lung Cancer. Barcelona, Spain. Asmis T, Ding K, Shepherd F, **Leighl N**, Seymour L, Goss G. Poster presentation. July 3-6, 2005.
- 2005 Jul 3 Can performance status be determined accurately by patients? results of a prospective trial evaluating ECOG and Karnofsky PS as well as patient-rated PS in non-small cell lung cancer (NSCLC). 11th World

- Conference on Lung Cancer. Barcelona, Spain. Gralla R, Hollen P, Kuruvilla P, Meharchand J, Solow H, **Leighl N**, Chin C, Stewart J. Poster presentation. July 3-6, 2005. Abstract 1447.
- 2005 Jun Pilot study of a decision aid for patients with metastatic colorectal cancer. 3rd International Shared Decision-Making Conference. Ottawa. **Leighl N**, Butow PN, Tattersall MHN, McJannett M, Clarke S, Boyer MJ, Barratt A, Glare P, Princess Margaret Hospital GI Medical Oncology Site Group. Oral presentation. (abstract 6C3).
- 2005 Jun A decision aid or patients with metastatic colorectal cancer deciding between supportive care and supportive care plus chemotherapy. 3rd International Shared Decision-Making Conference. Ottawa. Butow P, **Leighl N**, Shepherd H, Tattersall MHN. Oral presentation (abstract 6C4).
- 2005 Jun Development and pilot evaluation of a decision aid for advanced breast cancer patients considering chemotherapy. 3rd International Shared Decision-Making Conference. Ottawa. **Leighl N**, Butow P, Tattersall MHN, Shepherd H, Vardy J, Chiew K, Sullivan A, Hamilton A. Oral presentation (abstract 5D3). (Trainee Presentation).
- 2005 Jun Pilot Study of a Decision Aid for Patients with Metastatic Colorectal Cancer. 3rd International Shared Decision-Making Conference. Ottawa. **Leighl N**, Butow PN, Tattersall MHN, McJannett M, Clarke S, Boyer MJ, Barratt A, Glare P, Princess Margaret Hospital GI Medical Oncology Site Group. Oral presentation. (abstract 6C3).
- 2005 May 16 Phase 1/2 study of GTI-2040 plus docetaxel in advanced NSCLC. CTEP/Lorus Investigators' Meeting. Orlando, Florida. **Leighl NB**, Laurie SA, Knox JJ, Shepherd FA, Burkes RL, Tannock IF, Pond GR, Zweibel J, Moore MJ.
- 2005 Results of induction chemotherapy followed by extrapleural pneumonectomy and high-dose hemithoracic radiation for malignant pleural mesothelioma. AATS. de Perrot M, Uy K, Keshavjee S, Darling G, Waddell T, Pierre A, Roberts H, Cho J, Visbal A, **Leighl N**, Johnston M. (Trainee Presentation).
- 2004 Jun 24 Can quality of life and patient reported outcomes be assessed efficiently in clinical practice and clinical trials? A COMET group study using a hand-held computer-assisted form of the validated LCSS instrument in patients with non-small cell lung cancer. 16th International Symposium Supportive Care in Cancer. Miami Beach, Florida. Meharchand J, Kuruvilla P, Solow H, **Leighl N**, Hollen PJ, Gralla RJ. Poster presentation. June 24-27, 2004.
- 2003 Sep Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting. ECCO 12. Copenhagen. Bushill-Matthews L, Jackson D, Aristides M, von Pawel J, De Marinis F, Gervais R, Shepherd FA, **Leighl N**, Liepa AM. Poster Presentation.
- 2003 Sep An economic analysis of the TAX 326 trial. ECCO 12. Copenhagen. **Leighl NB**, Shepherd FA, Tsao WS, Lindgren P, Belani C, Fossella FV, Goodwin PG. Poster presentation.
- 2003 Needs assessment of advanced lung cancer patients. American Society of Clinical Oncology Annual Meeting. **Leighl NB**, Patel M, Nematollahi M, Feld R, Shepherd F. Poster presentation (Abst #2631). (Trainee Presentation).
- NCIC CTG IND.196: Phase I study of foretinib (GSK1363089) and erlotinib in patients with advanced pretreated NSCLC. 5th Asia Pacific Lung Cancer Conference. Fukuoka, Japan. **Leighl N**, Tsao M, Ho C, Shepherd F, Murray N, Goffin J, Nicholas G, Seymour L, Goss G, Bradbury P. Oral presentation at the 5th Asia Pacific Lung Cancer Conference, November 25-28, 2012, Fukuoka, Japan. J Thorac Oncol 2012; 7(11 Suppl 5): S453 (abstr O-022).

Presented and Published Abstracts

- 2023 Dec 6 **Presenter.** Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO Immuno-Oncology Congress December 6-8, 2023. Genève (fr), Switzerland.

Presenter(s): **N. Leighl**.

Publication Details:

Leighl N, Paz-Ares L, Rodriguez Abreu D, Hui R, Baka S, Bigot F, Nishio M, Smolin A, Ahmed S, Schoenfeld A, Daher S, Cortinovis DL, Di Noia VP, Linardou H, Gainor J, Okpara CE, Deng X, Kush DA, Song A, Cho BC. Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. *Immuno-Oncology & Technology*. 2023 Dec;20(Supplement). Presentation #650. **Principal Author**.

2023 Dec LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study. ESMO Immuno-Oncology Congress December 6-8, 2023. Genève (fr), Switzerland.

Publication Details:

Reinmuthh N, Özgüroğlu M, **Leighl NB**, Galetta D, Hacibekiroglu I, Roubec J, Sendur MAN, Bria E, Cicin I, Grohé C, Harputluoglu H, Kilickap S, Novello S, Opalka P, Riccardi F, Ruseva RK, Lang S, Hodari M, Donner N, de Marinis F. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study. *Immuno-Oncology & Technology*. 2023 Dec;20(Supplement). **Coauthor or Collaborator**.

2023 Oct Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies. ESMO Congress 2023. Madrid, Spain.

Publication Details:

Schmid S, UI Haq S, Zhan LJ, Brown MC, Patel D, Shepherd FA, **Leighl N**, Sacher A, de Perrot M, Cho J, Zaeimi F, Lok B, Bratman S, Tsao M-S, Frueh M, Bradbury P, Liu G. Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies. *Ann Oncol*. 2023 Oct;34(Suppl 2):S1137. Abst #2201P. **Coauthor or Collaborator**.

2023 Oct Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting. ESMO Congress 2023. Madrid, Spain. Presenter(s): A. Mittal.

Publication Details:

Mittal A, Everest L, Patel D, Zhan LJ, Brown C, Zaeimi F, Schmid S, Khan K, Dietrich K, Balaratnam K, Garcia Pardo de Santayana M, Eng L, Sacher A, Shepherd FA, **Leighl N**, Cho J, de Perrot M, Liu G, Bradbury P. Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting. *Ann Oncol*. 2023 Oct;34(Suppl 2):S1134. Abst #2192P. **Coauthor or Collaborator**.

2023 Oct Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations. ESMO Congress 2023. Madrid, Spain.

Publication Details:

Feng F, Hueniken K, Fan Z, Faour E, Corke L, Leigh N, Liu G, Bradbury P, Sacher A, Eng L, Stockley T, Tsao M-S, Shepherd FA. Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations. *Ann Oncol*. 2023 Oct;34(Suppl 2):S778. Abst #1353P. **Coauthor or Collaborator**.

2023 Oct Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A. ESMO Congress 2023. Madrid, Spain. Available from: <https://doi.org/10.1016/j.annonc.2023.09.2394>.

Publication Details:

Gadgeel SM, Mok TSK, Peters S, Nadal E, Han J-Y, Alatorre Alexander JA, **Leighl N**, Sriuranpong V, Pérol M, Castro GD, de Marinis F, Tan DSW, Paul S, Assaf ZJ, MacLennan M, Lohmann TO, Slade M, Mathisen MS, Bhagawati-Prasad V, Dziadziuszko R. Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A. *Ann Oncol*. 2023 Oct;34(Suppl 2):S782-S783. Abst #1361P.

Coauthor or Collaborator.

- 2023 Oct Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). ESMO Congress 2023. Madrid, Spain. Available from: <https://doi.org/10.1016/j.annonc.2023.10.673>.
- Publication Details:*
Kim D-W, Goto K, Schram A, Hollebecque A, Rha SY, Nishino K, Duruisseaux M, Umemoto K, Part JO, **Leighl N**, Macarulla Mercade T, Liu SV, Al-Hallak MN, Cleary J, Neuzillet C, Goto Y, Joe AK, Adeyemi S, Jauhari S, Drilon A. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023 Oct;34(Suppl 4):S1702-S1703. Abst #595P. **Coauthor or Collaborator.**
- 2023 Oct Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). ESMO Congress 2023. Madrid, Spain. Available from: <https://doi.org/10.1016/j.annonc.2023.09.2567>.
- Publication Details:*
Schram A, Macarulla T, Cleary J, Neuzillet C, Arnold D, Reiss KA, Bekaii-Saab T, Rodon J, Goto K, Rha SY, Duruisseaux M, **Leighl N**, Weinberg BA, Al-Hallak MN, Joe AK, Adeyemi S, Wasserman E, Koeman K-J, Drilon A, O'Reilly EM. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). Ann Oncol. 2023 Oct;34(Suppl 2):S895-S896. Abst #1618P. **Coauthor or Collaborator.**
- 2023 Oct Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) non small cell lung cancer (NSCLC). ESMO Congress 2023. Madrid, Spain. Available from: <https://doi.org/10.1016/j.annonc.2023.09.2349>.
- Publication Details:*
Schram A, Goto K, Kim D-W, Hollebecque A, Rha SY, Nishino K, Duruisseaux M, Umemoto K, Park JO, **Leighl N**, Macarulla T, Liu SV, Al-Hallak MN, Cleary J, Neuzillet C, Goto Y, Joe AK, Adeyemi S, Jauhari S, Drilon A. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) non small cell lung cancer (NSCLC). Ann Oncol. 2023 Oct;34(Suppl 2):S756-S757. Abst #1315MO. **Coauthor or Collaborator.**
- 2023 Oct Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies. ESMO Congress 2023. Madrid, Spain. Available from: <https://doi.org/10.1016/j.annonc.2023.09.983>.
- Publication Details:*
Schmid S, UI Haq S, Zhan LJ, Brown MC, Patel D, Shepherd FA, **Leighl N**, Sacher A, de Perrot M, Cho J, Zaeimi F, Lok B, Bratman S, Tsao M-S, Frueh M, Bradbury P, Liu G. Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies. Ann Oncol. 2023 Oct;34(Suppl 2):S1137. Abst #2201P. **Coauthor or Collaborator.**
- 2023 Sep 12 **Presenter.** Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): **Natasha Leighl**. Oral presentation.
- Publication Details:*
Leighl N, Cho BC, Hiret S, Han J-Y, Lee KH, Llacer Perez C, Krebs MG, De Braud F, Haura E, Sanborn RE, Yang J C-H, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ou S-HI, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Roshak A, Schnepp RW, Kim P, Mertz J, Thayu M, Shreeve SM, Knoblauch RE, Spira AI. Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology. 2023 Nov;18(11):S93-S94. Abstr #OA21.04. **Principal Author.**
- 2023 Sep 11 Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC). IASLC 2023 World

Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): Jamie Feng. Poster presentation.

Publication Details:

Feng J, Hueniken K, Fan AJ, Corke L, **Leighl NB**, Liu G, Bradbury PA, Sacher A, Eng L, Stockley T, Tsao MS, Shepherd F. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2023 Sep. Abstr #P2.09-28. **Coauthor or Collaborator.**

2023 Sep 10 FURVENT, Phase 3 trial testing Furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): A.I. Spira. Poster presentation.

Publication Details:

Spira AI, Cho BC, Felip E, Garon EB, Goto K, Johnson ML, **Leighl NB**, Passaro A, Plancharad D, Popat S, Yang J, Lu X, Jiang Y, Huang J, Lam M, Kowanzet M, Wang S, Le J, Hsu JY, Zhou C. FURVENT, Phase 3 trial testing Furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. Journal of Thoracic Oncology. 2023 Sep. Abstr #P2.09-18. **Principal Author.**

2023 Sep 10 **Presenter.** Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study. IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): **Natasha Leighl**. Poster presentation.

Publication Details:

Garcia Pardo M, Czarnecka K, Law JH, Fan ZJ, Waddell TK, Yasufuku K, Liu G, Donahoe LL, Pierre A, Le LW, Gunasegaran T, Ghumman N, Bradbury PA, Shepherd F, Sacher A, Corke L, Feng J, Stockley T, Pal P, Rogalla P, Pipinikas C, Howarth KD, Tsao M, **Leighl NB**. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study. Journal of Thoracic Oncology. 2023 Sep. Abstr #P1.22-04. **Principal Author.**

2023 Sep Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers. IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): Jamie Feng. Poster presentation.

Publication Details:

Feng J, Waddell T, Yasufuku K, Kelly D, Meti N, Pierre A, Keshavjee S, Yeung J, Cypel M, Donahoe L, Wakeam E, de Perrot M, Law J, Salvarrey A, Le LW, Lister J, Cabanero M, Tsao MS, Pipinikas C, Howarth K, **Leighl N**. Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers. Journal of Thoracic Oncology. 2023 Sep. Abstr #EP07.02. **Coauthor or Collaborator.**

2023 Sep Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort. IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): Heather Halperin. Poster presentation.

Publication Details:

Halperin H, Gibson AJW, Sung M, Tomasini P, Dean M, Law J, Cheung WY, **Leighl NB**, Hao D. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort. Journal of Thoracic Oncology. 2023 Nov;18(11):S657. Abstr #EP12.01-42. **Coauthor or Collaborator.**

2023 Sep Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). IASLC 2023 World Congress on Lung Cancer Sep 9-12, 2023. Singapore. Presenter(s): Luna Jia Zhan. Poster presentation.

Publication Details:

Zhan LJ, Barghout S, Raptis S, Al-Agha F, Popovacki A, Esfahanian N, Kasymjanova G, Proulx-Rocray F, Chan S, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Cleary-Gosine J, Gibson AJ, Hublely L, Balaratnam LK, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd F, **Leighl N**, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA). Journal of Thoracic Oncology. 2023 Sep.

Abstr #EP12.03-02. **Coauthor or Collaborator.**

2023 Jun 30 **Faculty.** LatAm Oncology Summit 2023. Mexico City, Mexico. DECLINED.

2023 Jun 16 **Roundtable Discussion.** EPIC Conference Coverage: ASCO 2023-Focus on Lung Cancer- Virtual. APTITUDE Health. DECLINED.

Publication Details:

EPIC Conference Coverage: ASCO 2023-Focus on Lung Cancer- Virtual.

2023 Apr 18 A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). American Association for Cancer Research - Apr 14-19, 2023. Orlando, Florida, United States. Presenter(s): Christopher Theriau. Available from: <https://doi.org/10.1158/1538-7445.AM2023-CT206>.

Publication Details:

Theriau CF, Feng J, Eng L, Shepherd FA, DeCarolis M, Glenns V, Kulkarni S, VanderMeer R, Zurawska-Fortin U, Hao D, Le L, Wozniczka I, Al-Kindy A, Xie D, Zhang T, Subramanian V, Stockley T, Bradbury PA, Liu G, **Leighl NB.** A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). Cancer Res. 2023 Apr 14;83(Suppl 8). Abst #CT206. **Coauthor or Collaborator.**

2023 Apr 17 **Supervisor.** ctDNA dynamics in early stage node negative lung cancers. American Association for Cancer Research - Apr 14-19, 2023. Orlando, Florida, United States. Presenter(s): Jamie Feng. Available from: <https://doi.org/10.1158/1538-7445.AM2023-3387>. (Trainee Presentation)

Publication Details:

Feng J, Waddell T, Yasufuku K, Pierre A, Keshavjee S, Yeung J, Cypel M, Donahoe L, Wakeam E, de Perrot M, Law J, Salvarrey A, Le LW, Lister J, Cabanero M, Tsao M, Pipinikas C, Howarth K, **Leighl NB.** ctDNA dynamics in early stage node negative lung cancers. Cancer Res. 2023 Apr 4;83(Suppl 7). Abst #3387. **Coauthor or Collaborator.**

2023 Mar 31 Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis. European Lung Cancer Congress (ELCC) 2023. Denmark. Presenter(s): N. Girard. Poster presentation. Available from: [https://doi.org/10.1016/S1556-0864\(23\)00273-3](https://doi.org/10.1016/S1556-0864(23)00273-3).

Publication Details:

Girard N, **Leighl N,** Ohe Y, Kim TM, Demirdjian L, Bourla AB, Abdul Sultan A, Mahadevia P, Bauml JM, Sabari J. Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis. Journal of Thoracic Oncology. 2023 Apr;18(4):S51-S52. Abstr #19P. **Coauthor or Collaborator.**

2023 Mar 31 Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe. European Lung Cancer Congress (ELCC) 2023. Denmark. Presenter(s): N. Girard. poster presentation. Available from: [https://doi.org/10.1016/S1556-0864\(23\)00281-2](https://doi.org/10.1016/S1556-0864(23)00281-2).

Publication Details:

Girard N, Wolf J, Kim TM, Leigh L, Knott C, Li T, Cabrieto J, Diels J, Sermon J, Mahadevia P, Schioppa CA, Sabari J. Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe. Journal of Thoracic Oncology. 2023 Apr;18(4):S56. Abstr #27P. **Coauthor or Collaborator.**

2023 Mar 31 Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC). European Lung Cancer Congress (ELCC) 2023. Denmark. Presenter(s): N Reinmuth. poster presentation. Available from: [https://doi.org/10.1016/S1556-0864\(23\)00424-0](https://doi.org/10.1016/S1556-0864(23)00424-0).

Publication Details:

Reinmuth N, de Marinis F, **Leighl N**, Sadow S, Davey K, Ozguroglu M. Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC). Journal of Thoracic Oncology. 2023 Apr;18(4):S134. Abstr #170P. **Coauthor or Collaborator**.

2023 Mar 29 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC. European Lung Cancer Congress (ELCC) 2023. Denmark. Presenter(s): P Garrido Lopez. oral presentation. Available from: [https://doi.org/10.1016/S1556-0864\(23\)00257-5](https://doi.org/10.1016/S1556-0864(23)00257-5).

Publication Details:

Garrido Lopez P, Girard N, Cho BC, Sabari J, Spira A, Sanborn RE, Goto K, Yang JC-H, Curtin J, Lyu X, He A, Penton J, Edwards J, Low Massin G, Xia K, Chioda M, Thayu M, Knoblauch RE, Mahadevia P, **Leighl N**. Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC. Journal of Thoracic Oncology. 2023 Apr;18(4):S36-S37. Abstr #30. **Coauthor or Collaborator**.

2022 Oct 14 Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients- A Canadian Trial through the Exactis Network (NCT04564079). Molecular Analysis for Precision Oncology Congress. Amsterdam, Netherlands. Presenter(s): Karen Gambaro. Poster.

Publication Details:

Gambaro K, Marques M, Hebert-Losier A, McNamara S, Batist G, Crapoulet N, Finn N, Awan A, The Exactis Network, **Leighl N**, Agulnik J. Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients- A Canadian Trial through the Exactis Network (NCT04564079). Anals of Oncology. 2022 Oct 16;33(S8):S1429-S1430. **Coauthor or Collaborator**.

2022 Sep 10 **Presenter**. Real-World Treatment Patterns and Outcomes Based on PD-1 Status in Tx-Naive Patients with METex14 Advanced Non-Small Cell Lung Cancer (aNSCLC). ESMO Congress 2022. Paris, France. Presenter(s): **N. Leighl**. Poster Presentation-1112P.

Publication Details:

Leighl N, Hampe M, Wu W, Kim J, Pretre V, Ye F. Real-World Treatment Patterns and Outcomes Based on PD-1 Status in Tx-Naive Patients with METex14 Advanced Non-Small Cell Lung Cancer (aNSCLC). Anals of Oncology, Abstract Book of the ESMO Congress 2022. 2022 Sep;33(Supplement 7):S1059-1060. **Principal Author**.

2022 Sep 9 Evolution of Biomarker Testing Among Non-Squamous/Non-Small Cell Lung Cancer (NSCLC) Patients and Impact on Turnaround Times (TAT). ESMO Congress 2022. Paris, France. Presenter(s): R Tudor. Poster Presentation, Abstract #4572.

Publication Details:

Fan Z, Tudor R, Le L, Tsao MS, **Leighl N**, Cabanero M. Evolution of Biomarker Testing Among Non-Squamous/Non-Small Cell Lung Cancer (NSCLC) Patients and Impact on Turnaround Times (TAT). Anals of Oncology, Abstract Book of the ESMO Congress 2022. 2022 Sep;33(Supplement 7):S1076. **Coauthor or Collaborator**.

2022 Sep 9 Nivolumab-Ipilimumab with ctDNA-guided Treatment Intensification as a Chemotherapy-sparing Strategy in Metastatic Non-Small Cell Lung Cancer (ATLAS). ESMO Congress 2022. Paris, France. Presenter(s): L. Corke. Poster Presentation-1191TIP.

Publication Details:

Corke L, Garcia Pardo de Santayana M, Meteleva K, Shepherd FA, Bradbury P, Eng L, Kuang S, Cabanero M, Rogalla P, Liu G, Tsao MS, Pugh TJ, Wang B, Ohashi P, **Leighl N**, Sacher A. Nivolumab-Ipilimumab with ctDNA-guided Treatment Intensification as a Chemotherapy-sparing Strategy in Metastatic Non-Small Cell Lung Cancer (ATLAS). Anals of Oncology, Abstract Book of the ESMO Congress 2022. 2022 Sep;33(Supplement 7):S1093. **Coauthor or Collaborator**.

- 2022 Sep 9 Evolution of the Tumor Immune Microenvironment in Hepatocellular Carcinoma (HCC) and Non-Squamous Non-Small Lung Cancer (NSCLC) with Liver Metastases Treated with Atezolizumab and Bevacizumab (INTEGRATE). ESMO Congress 2022. Paris, France. Presenter(s): A. Sacher. Poster Presentation 1202TiP.
- Publication Details:*
Sacher A, Lau S, Allen M, Corke L, Makarem M, Chen E, Jang RWJ, Elimova E, Grant R, Shepherd FA, Bradbury P, Eng L, Rogalla P, Liu G, Tsao MS, **Leighl N**, Garonce-Hediger R, Wang B, Ohashi P, Knox J. Evolution of the Tumor Immune Microenvironment in Hepatocellular Carcinoma (HCC) and Non-Squamous Non-Small Lung Cancer (NSCLC) with Liver Metastases Treated with Atezolizumab and Bevacizumab (INTEGRATE). Annals of Oncology, Abstract Book of the ESMO Congress 2022. 2022 Sep;33(Supplement 7):S1098. **Coauthor or Collaborator**.
- 2022 Aug 12 **Presenter**. Intracranial Activity of Tepotonib in Patients with MET EXON 14 (METEX14) Skipping NSCLC Enrolled in Vision. Second Annual Conference on CNS Clinical Trials and Brain Metastases. Toronto, Ontario, Canada. Presenter(s): **N. Leighl**. Poster Presentation.
- Publication Details:*
Leighl N, Bestvina C, Patel J, Le X, Veillon R, Anderson I, Demedts I, Garassino MC, Mazieres J, Morise M, Smit E, Eggleton SP, O'Brate A, Otto G, Bruns R, Schumacher KM, Paik P. Intracranial Activity of Tepotonib in Patients with MET EXON 14 (METEX14) Skipping NSCLC Enrolled in Vision. Journal of Neuro-Oncology Advances. 2022 Aug 5;4(Issue Supplement 1):i22. **Principal Author**.
- 2022 Aug 9 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): M. Garcia. Oral Abstract 13.04.
- Publication Details:*
Garcia M, Garcia De Herreros M, Auclin E, Caravaca G, Sart J, Riudavets M, Vasseur D, Albarran-Artahona V, Laguna JC, Gorria T, Lopez Castros R, Teixido C, Castellano G, Bedmar Martinez A, Arcocha A, Vinolas N, Reyes R, Prat A, Reguart N, Elio J, **Leighl N**, Besse B, Mezquita L. Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study. Journal of Thoracic Oncology. 2022 Sep;17(9):S34-S35. **Coauthor or Collaborator**.
- 2022 Aug 6 LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC). IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): N. Reinmuth. EPoster14.05-009.
- Publication Details:*
Reinmuth N, De Marinis F, **Leighl N**, Sadow S, Davey K, Ozguroglu M. LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC). Journal of Thoracic Oncology. 2022 Sep;17(9):S547. **Coauthor or Collaborator**.
- 2022 Aug 6 Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving RD-1 Inhibitors for Metastatic NSCLC. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): C. Poletes. MA14.08.
- Publication Details:*
Poletes C, Cheng SC, Zhan LJ, Lee J, Patel D, Bradbury PA, Shepherd FA, **Leighl NB**, Sacher AG, Liu G, Lau SC. Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving RD-1 Inhibitors for Metastatic NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S95-S96. **Coauthor or Collaborator**.
- 2022 Aug 6 Prevalence and Outcomes of EGFR Exon 20 Insertion Mutation in NSCLC: Princess Margaret Cancer Centre Experience. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): Abhenil Mittal. EPoster04.01-001.
- Publication Details:*

Mittal A, Hueniken K, Cheng S, Zhan LJ, Brown C, Mai V, Lee J, Adewole OO, Herman J, Sabouhanian A, Storm E, Chowdhury MT, Moore A, Walia P, Hoxha T, Parker J, Patel D, Balantaram K, Khan K, Marcia M, Schmid S, Sacher AG, Bradbury PA, Shepherd FA, **Leighl NB**, Liu G. Prevalence and Outcomes of EGFR Exon 20 Insertion Mutation in NSCLC: Princess Margaret Cancer Centre Experience. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S245. **Coauthor or Collaborator**.

2022 Aug 6 Co-Occurring Mutations, Smoking Status, and Prognosis of Early Stage Resected NSCLCs with EGFR Mutations. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): A. Moore. EPoster03.01-002.

Publication Details:

Moore A, Pianarosa E, Khan K, Balaratnam K, Chowdhury MT, Walia P, Sabouhanian A, Herman J, Strom E, Corke L, Mai V, Zhan LJ, Brown MC, Cheng S, Hueniken K, **Leighl N**, Shepherd FA, Bradbury P, Sacher A, Liu G, Garcia M. Co-Occurring Mutations, Smoking Status, and Prognosis of Early Stage Resected NSCLCs with EGFR Mutations. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S237. **Coauthor or Collaborator**.

2022 Aug 6 Treatment Patterns and Outcomes of First-Line Osimertinib treated Advanced EGFR Mutated NSCLC Patients: A Real-World Study. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): J.Y.Lee. EPoster08.02-082.

Publication Details:

Lee JY, Mai V, Garcia M, Cheng S, Khan K, Balaratnam K, Thakral A, Brown MC, Zhan L, Corke L, **Leighl N**, Shepherd FA, Bradbury P, Sacher A, Liu G. Treatment Patterns and Outcomes of First-Line Osimertinib treated Advanced EGFR Mutated NSCLC Patients: A Real-World Study. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S440. **Coauthor or Collaborator**.

2022 Aug 6 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): T. Hoxha. EPoster02.04-009.

Publication Details:

Hoxha T, Pienkowski M, Khan K, Moore A, Balaratnam K, Chowdhury MT, Walia P, Sabouhanian A, Herman J, Strom E, Hueniken K, Corke L, **Leighl N**, Shepherd FA, Bradbury P, Sacher A, Cheng S, Brown MC, Mai V, Garcia M, Zhan LJ, Xu W, Liu G. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S236. **Coauthor or Collaborator**.

2022 Aug 6 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): T. Hoang. EPoster08.01-067.

Publication Details:

HoangT, Elliot MJ, Poletes C, Makarem M, Corke L, Weiss J, Tsao MS, Bradbury P, Shepherd FA, Liu G, **Leighl N**, Sacher A, Lau SCM. Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S372. **Coauthor or Collaborator**.

2022 Aug 6 Treatment Patterns and Outcomes Among Patients with EGFR Mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): J. Sabri. EPoster08.02-173.

Publication Details:

Sabri J, Pisano S, Gemmler K, Mueller J, Bernabe-Caro R, Girard N, Goto K, **Leighl N**, Ohe Y, Kim TM, Lee S-H, Demirdjian L, Harvey R, Rudolph S, Mahadevia P, Baum J, Besse B. Treatment Patterns and Outcomes Among Patients with EGFR Mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings. *Journal of Thoracic Oncology*. 2022 Sep;17(9):S488-S548. **Coauthor or Collaborator**.

- 2022 Aug 6 Frontline and Post-Osimertinib Therapy for EGFR-Mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): N. Girard. EPoster08.02-016.
- Publication Details:*
Girard N, Besse B, Bernabe-Caro R, Goto K, **Leighl N**, Ohe Y, Sabari J, Lee S-H, Lin X, Schaeffer M, Nair S, Li T, Di Scala L, Potluri R, Mahadevia P, Thayu M, Kim TM. Frontline and Post-Osimertinib Therapy for EGFR-Mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs. Journal of Thoracic Oncology. 2022 Sep;17(9):S404-S405. **Coauthor or Collaborator**.
- 2022 Aug 6 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting. IASLC 2022 World Congress on Lung Cancer. Vienna, Austria. Presenter(s): J. Subramanian. EPoster08.02.080.
- Publication Details:*
Subramanian J, Gregg J, Berktaş M, Jiang Z, Li J, Taylor A, **Leighl N**. EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting. Journal of Thoracic Oncology. 2022 Sep;17(9):S438-S439. **Senior Responsible Author**.
- 2022 Aug 6 The Patient Impact of Liquid Biopsy-Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. IASLC 2022 World Conference on Lung Cancer. Vienna, Austria. Presenter(s): L. Corke. EPoster04.02-004.
- Publication Details:*
Corke L, Laskin J, Agulnik J, Laurie S, Hao D, Juergens R, Fernandes R, Le L, Law J, Ezeife D, Shookoohi A, Kasymjanova G, Kelly S, Nadon T, Lanman R, Kiedrowski L, **Leighl N**. The Patient Impact of Liquid Biopsy-Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2022 Sep;17(9):S261-S262. **Senior Responsible Author**.
- 2022 Jun 5 Plasma First: Accelerating Lung Cancer Diagnosis Through Liquid Biopsy. American Society of Clinical Oncology (ASCO). Chicago, Illinois, United States. Presenter(s): Miguel Garcia Pardo. Poster.
- Publication Details:*
Garcia Pardo M, Czarnecka K, Law JL, Salvarrey AM, Fernandes R, Fan J, Corke L, Le LW, Waddell TK, Yasufuku K, Liu G, Shepherd FA, Bradbury PA, Sacher AG, Stockley T, Pal P, Tsao MS, **Leighl NB**. Plasma First: Accelerating Lung Cancer Diagnosis Through Liquid Biopsy. Journal of Clinical Oncology. 40(16). **Senior Responsible Author**.
- 2022 Feb 24 Plasma First: Accelerating Lung Cancer Diagnosis and Molecular Profiling Through Liquid Biopsy. IASLC-Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, United States. Presenter(s): Miguel Garcia Pardo. Poster.
- Publication Details:*
Garcia Pardo M, Czarnecka K, Law JL, Salvarrey AM, Fernandes R, Fan J, Corke L, Le LW, Waddell TK, Yasufuku K, Liu G, Shepherd FA, Bradbury PA, Sacher AG, Stockley T, Pal P, Tsao MS, **Leighl NB**. Plasma First: Accelerating Lung Cancer Diagnosis and Molecular Profiling Through Liquid Biopsy. **Senior Responsible Author**.
- 2021 Oct Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage 1B-111A NSCLC. 2021 World Conference on Lung Cancer- virtual event. Presenter(s): Sabine Schmid-. #488; Poster Presentation.
- Publication Details:*
Schmid S, Garcia M, Hueniken K, Balaratnam K, Patel D, Zhan L, Brown MC, Sacher AG, Bradbury P, **Leighl N**, Shepherd FA, Liu G. Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage 1B-111A NSCLC. Journal of Thoracic Oncology. 2021 Oct;16(10S):S945. **Coauthor or Collaborator**.

- 2021 Sep 19 **Presenter.** Amivantamab Monotherapy and in Combination with Lazertinib in Post-Osimertinib EGFR-Mutant NSCLC: Analysis from the CHRYSALIS Study. ESMO Congress 2021 Mini Oral Metastatic NSCLC. Presenter(s): **N.B. Leighl**. 1192MO.
- Publication Details:*
Leighl NB, Shu CA, Minchom A, Felipe E, Cousins S, Cho BC, Park K, Hans J-Y, Boyer M, Lee Ck, Moreno Garcia V, Tomasini P, Viteri S, Xie J, Mertz J, Artis E, Schnepf RW, Knoblauch RE, Thayu M, Trigo Perez JM. Amivantamab Monotherapy and in Combination with Lazertinib in Post-Osimertinib EGFR-Mutant NSCLC: Analysis from the CHRYSALIS Study. *Anal of Oncology*. 2021 Sep;32(Supplement 5):S951-952. **Principal Author**.
- 2021 Sep 12 The economic VALUE of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Doreen Ezeife-. Abstract # 830; Oral Presentation.
- Publication Details:*
Ezeife D, Spackman R, Juergens R, Laskin J, Agulnik J, Hao D, Laurie S, Law J, Le L, Kiedrowski L, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, Li J, Fernandes R, Shokoohi A, Lanman R, **Leighl N**. The economic VALUE of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. *Journal of Thoracic Oncology*. 16(10S):S876. OA16.02. **Senior Responsible Author**.
- 2021 Sep 9 Validation of scalable, automated data extraction in an advanced lung cancer patient. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Marie-Pier Gauthier-. Abstract #482-Oral Presentation.
- Publication Details:*
Gauthier M-P, Law J, Le L, Li JJN, zahir S, Sung M, Pettengell C, Darwish L, Aviv S, Chu R, Sacher AG, Liu G, Bradbury P, Shepherd FA, **Leighl N**. Validation of scalable, automated data extraction in an advanced lung cancer patient. *Journal of Thoracic Oncology*. 2021 Oct;16(10S):S861-S862. AO08.04. **Senior Responsible Author**.
- 2021 Sep 9 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Sabine Schmid-. Abstract # 289; Mini Oral Presentation.
- Publication Details:*
Schmid S, Chotai S, Cheng S, Zhan L, Balaratnam K, Khan K, Patel D, Brown MC, Xu W, Moriarty PM, Kaidanovich-Beilin O, Shepherd FA, Sacher AG, **Leighl N**, Bradbury P, Liu G. Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort. *Journal of Thoracic Oncology*. 2021 Oct;16(10S):S908-S909. MA08.02. **Coauthor or Collaborator**.
- 2021 Sep 8 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Simren Chotai. #474-ePoster Presentation.
- Publication Details:*
Chotai S, Schmid S, Cheng S, Zhan L, Balaratnam K, Khan K, Patel D, Brown MC, Xu W, Moriarty P, Kaidanovich-Beilin O, Shepherd FA, Sacher AG, **Leighl N**, Bradbury P, Liu G. Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada. *Journal of Thoracic Oncology*. 2021 Oct;16(10S):S1089. P45.07. **Coauthor or Collaborator**.
- 2021 Sep 8 Sequencing of PD-1 inhibitors and TKIs in metastatic NSCLC with MET exon 14 skipping mutation may influence survival. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Sally Lau-. #506; Poster Presentation.
- Publication Details:*
Lau S, Perdrizet K, Giffoni D, Mata MM, Fung A, Liu G, Bradbury P, Shepherd FA, Sacher AG, Sheffield B, Hwang D, Tsao M, Cheng S, Cheema P, **Leighl N**. Sequencing of PD-1 inhibitors and TKIs in metastatic NSCLC with MET exon 14 skipping mutation may influence survival. *Journal of Thoracic*

Oncology. 2021 Oct;16(10S):S1086-S1087. P45.05. **Senior Responsible Author.**

2021 Sep 8 Is Relapse-Free Survival at 2 Yrs an appropriate surrogate for Overall Survival at 5-Yrs in EGFR-mutated resected NSCLC. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Miguel-Garcia-. Poster Presentation.

Publication Details:

Garcia M, Schmid S, Hueniken K, Zhan L, Balaratnam K, Khan K, Fares AF, Sze WS, Smith EC, Aggarwal R, Brown MC, Patel D, Sacher AG, Bradbury PA, Shepherd FA, **Leighl NB**, Liu G. Is Relapse-Free Survival at 2 Yrs an appropriate surrogate for Overall Survival at 5-Yrs in EGFR-mutated resected NSCLC. Journal of Thoracic Oncology. 2021 Oct;16(10S):S1107-S1108. P48.05. **Coauthor or Collaborator.**

2021 Sep 8 Clinical-demographics Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Joshua Herman-. Abstract # 209; Poster Presentation.

Publication Details:

Herman J, Schmid S, Zhan L, Garcia M, Brown MC, Khan K, Chowdhury M, Sabouhanian A, Walia P, Strom E, Sacher AG, Bradbury P, Shepherd FA, **Leighl N**, Cheng S, Patel D, Shultz D, Liu G. Clinical-demographics Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients. Journal of Thoracic Oncology. 2021 Oct;16(10S):S967-S968. FP12.07. **Coauthor or Collaborator.**

2021 Sep 8 PD-L1 assessment in cytology is comparable to histology in predicting treatment response to checkpoint inhibitors in NSCLC. 2021 World Conference on Lung Cancer- virtual event. Presenter(s): Sally Lau-. #238; Poster Presentation.

Publication Details:

Lau S, Rabindranath J, Weiss J, Li J, Nirmalakumar S, Ruff H, Boerner S, Tong LC, Tsao M, Pal P, Cabanero M, Hsu YH, Fung A, Sacher AG, Shepherd FA, Liu G, Bradbury P, Yasufuku K, Czarnecka-Kujawa K, Ko HM, **Leighl N**, Schwock J. PD-L1 assessment in cytology is comparable to histology in predicting treatment response to checkpoint inhibitors in NSCLC. Journal of Thoracic Oncology. 2021 Oct;16(10S):S963. FP12.01. **Co-Principal Author.**

2021 Sep 8 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients with Advanced/Metastatic ALK+ NSCLC. 2021 World Conference on Lung Cancer- Virtual Event. Presenter(s): Sabine Schmid-. #484, Poster Presentation.

Publication Details:

Schmid S, Chotai S, Cheng S, Zhan L, Balaratnam K, Khan K, Patel D, Brown MC, Xu W, Moriarty P, Kaidanovich-Belin I, Shepherd FA, Sacher A, **Leighl N**. Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients with Advanced/Metastatic ALK+ NSCLC. Journal of Thoracic Oncology. 2021 Oct;16(10S):S1088. P45.07. **Coauthor or Collaborator.**

2021 Sep 8 **Presenter.** Amivantamab, an EGFR-MET bispecific antibody, in EGFR Exon 20. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Keunchil Park/ Joshua Sabari-. E-Poster-Featured Poster Presentation.

Publication Details:

Park K, Haura EB, **Leighl NB**, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Lee Ck, Sabari JK, Spira JK, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab, an EGFR-MET bispecific antibody, in EGFR Exon 20. **Coauthor or Collaborator.**

2021 Sep **Presenter.** Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907. 2021 World Conference on Lung Cancer-Virtual Event.

Presenter(s): **Natasha Leighl**. Poster Presentation.

Publication Details:

Leighl N, Alexandru A, Ohe Y, Ruff P, Hida T, Nishio M, Rothenstein J, Tomiak A, Lowry P, Kumagai T, Gore I, Ntambwe I, Marimuthu S, Schenker M. Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907. Journal of Thoracic Oncology. 2021 Oct;16(10S):S949-S950. FP04.01. **Principal Author**.

2021 Jun 4 The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system. ASCO 2021 Annual Meeting Online. Presenter(s): Carly C. Barron. Abstract ID 337823. (Trainee Presentation)

Publication Details:

Barron CC, Stockley T, Law JH, Shabir M, Fernandes R, Zhang T, Le LW, Tsao MS, Kamel-Reid S, Pal P, Cabanero M, Schwock J, Ko H, Liu G, Bradbury PA, Sacher AG, Shepherd FA, **Leighl NB**, Perdrizet K. The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system. Journal of Clinical Oncology. 2021 May 28;39(15):S3126-3126. **Senior Responsible Author**.

2021 Mar 25 From Liquid Biopsy to Cure: Using CtDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Non-Small Cell Lung Cancer (NSCLC) Resection. European Lung Cancer Congress-Scientific Committee-Virtual. Presenter(s): D. Kelly. e-Poster- 77TiP.

Publication Details:

Kelly D, Le LW, Law J, Waddell T, Bratman S, **Leighl N**. From Liquid Biopsy to Cure: Using CtDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Non-Small Cell Lung Cancer (NSCLC) Resection. Journal of Thoracic Oncology. 2021 Apr 1;16(4- Supplement):S736. **Senior Responsible Author**.

2021 Mar 25 Accelerating Lung Cancer Diagnosis through Liquid Biopsy. European Lung Cancer Virtual Congress. Presenter(s): Miguel Garcia Pardo de Santayana. Abstract #199. (Trainee Presentation)

Publication Details:

Garcia Pardo de Santayana M, Czarnecka K, Waddell T, Stockley T, Law J, Le JW, Pal P, Rogalla P, Kelly DC, **Leighl N**. Accelerating Lung Cancer Diagnosis through Liquid Biopsy. Journal of Thoracic Oncology. 2021 Mar;16(4):S748-S802. **Senior Responsible Author**.

2021 Jan 28 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-Small Cell Lung Cancer. 2020 World Conference on Lung Cancer- Virtual. Singapore. Presenter(s): J.K. Sabari. Oral Abstract-OA04.04.

Publication Details:

Sabari JK, Shu CA, Park K, **Leighl N**, Mitchell P, Kim S, Lee J, Kim D, Viteri S, Spira A, Han J, Trigo J, Lee CK, Lee KH, Girard N, Yang T, Goto K, Sanborn RE, Yang JC, Xie J, Roshak A, Thayu M, Knoblauch RE, Cho BC. Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2021 Mar;16(35):S108-109. **Coauthor or Collaborator**.

2021 Jan 28 Clinical Activity of BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. 2020 World Conference on Lung Cancer- Virtual. Singapore. Presenter(s): Q. Chu. Featured Poster- FP03.03.

Publication Details:

Chu Q, **Leighl N**, Surmont V, Van Herpen C, Sibille A, Markman B, Clarke S, Juergens R, Acosta Rivera M, Andelkovic V, Rudin C, Snow S, Kim D, Sanatani M, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, Dipiero A, Ready N. Clinical Activity of BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. Journal of Thoracic Oncology. 2021 Mar 1;16(3-Supplement):S195. **Coauthor or Collaborator**.

2021 Jan 28 **Senior Responsible Author**. Demonstrating VALUE of Liquid Biopsy for Lung Cancer in Lung Cancer in

a Public Healthcare System. IASLC 2020 World Conference on Lung Cancer. Singapore. Presenter(s): D. Hao. Poster Presentation;Virtual Worldwide Meeting.

Publication Details:

Hao D, Laskin J, Laurie S, Agulnik J, Juergens R, Ezeife D, Law J, Le L, Kiedrowski K, Melowsky B, Shepherd F, Cohen V, Vandermeer R, Shokoohi A, Li J, Fernandes R, Lanman R, **Leighl N**. Demonstrating VALUE of Liquid Biopsy for Lung Cancer in Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. 16(Suppl 2). In Press. **Senior Responsible Author**.

2020 Nov 14 **Presenter**. Health and budget impact of liquid-based comprehensive genomic profile testing (LBx-CGP) in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients. ISPOR Europe 2020 Annual Meeting. Italy. Presenter(s): Patel YP (ePoster).

Publication Details:

Patel YP, Husereau D, **Leighl NB**, Melosky B, Nam J. Health and budget impact of liquid-based comprehensive genomic profile testing (LBx-CGP) in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients. Value in Health. 2020 May;23(Suppl 1):S1-S398. abstract 106365. **Coauthor or Collaborator**.

2020 Oct 10 Barriers and Facilitators to Implementation of Serial Point-of-Care Hearing Tests Using a Novel iPad-Based Audiometry in Platinum Chemotherapy-Treated Cancer Patients (pts). ASCO Quality of Care Symposium. Presenter(s): S. Soberano. Poster Presentation, Virtual.

Publication Details:

Soberano S, Khan K, Hueniken K, Famoriyo ED, Sorano J, Gill S, Zhan LJ, Shepherd FA, Sacher AG, Bradbury PA, **Leighl NB**, Bedard PL, Hansen Ar, SpreaficoA, Xu W, Brown C, Liu G. Barriers and Facilitators to Implementation of Serial Point-of-Care Hearing Tests Using a Novel iPad-Based Audiometry in Platinum Chemotherapy-Treated Cancer Patients (pts). Journal of Clinical Oncology. 38, 2020. (suppl 29; abstr 223). **Coauthor or Collaborator**.

2020 Oct 2 **Presenter**. The VALUE of routine Liquid Biopsy for NSCLC patients in a Public Healthcare System. IASLC Hot Topic meeting: Liquid Biopsy 2020. Virtual Meeting, United States. Presenter(s): **Leighl, NB**. Poster Presentation
Abstract P01.22.

Publication Details:

Laskin J, Law J, Agulnik J, Hao D, Juergens R, Laurie S, Ezeife D, Le L, Kiedrowski K, Lanman R, **Leighl N**. The VALUE of routine Liquid Biopsy for NSCLC patients in a Public Healthcare System. Journal of Thoracic Oncology. 16(Suppl 2). Abstract VP01.22
In Press. **Senior Responsible Author**.

2020 Sep 19 **Presenter**. The VALUE of Detecting Resistance Through Liquid Biopsy. ESMO Virtual Congress. Presenter(s): S. Laurie. Poster Presentation: 1195P.

Publication Details:

Laurie S, Agulnik J, Hao D, Juergens R, Ezeife D, Law J, Le L. Kiedrowski K, Shepherd FA, Cohen V, Melosky B, VanderMeer R, Wheatley-Price P, Lanman R, **Leighl N**, Laskin J. The VALUE of Detecting Resistance Through Liquid Biopsy. Annals of Oncology 2020. 2020 Sep 1;31(S4):S786-87.
DOI:<https://doi.org/10.1016/j.annonc.2020.08.089>. **Senior Responsible Author**.

2020 Sep 19 **Presenter**. Automating Access to Real World Evidence. European Society of Medical Oncology Annual Meeting 2020. Germany. Presenter(s): Gauthier MP. Poster at ESMO Virtual Congress 2020 Science Weekend abstract 4593. (Trainee Presentation)

Publication Details:

Gauthier MP, Law J, Le L, Li JJN, Zahir S, Sung M, Chu R, **Leighl NB**. Automating Access to Real World Evidence. Ann Oncol. 2020 Sep;31(Suppl 4):S245-S1216. Abstract 4593. **Senior Responsible Author**.

- 2020 May 29 Improved Prognostication for Lung Cancer Patients From Computed Tomography Imaging Using Deep Learning. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Felipe Torres. Poster; Abstract #2044.
- Publication Details:*
Torres F, Akbar S, Baldauf-Lenschen F, **Leighl NB**. Improved Prognostication for Lung Cancer Patients From Computed Tomography Imaging Using Deep Learning. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):2044-2044. DOI: 10.1200/JCO.2020.38.15_suppl.2044
Published on-line May 25, 2020. **Senior Responsible Author**.
- 2020 May 29 Rapid Expansion of M-MDSCs and Association With High Levels of Plasma TSLP and Primary Resistance to PD-1 Inhibitors in Metastatic NSCL. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Sally CM Lau. Poster; Abstract #3084.
- Publication Details:*
Lau S CM, Wong S, Wang B, Patel D, Fares A, Tsao MS, Bradbury PA, Liu G, **Leighl NB**, Shepherd FA, Ohashi PS, Sacher AG. Rapid Expansion of M-MDSCs and Association With High Levels of Plasma TSLP and Primary Resistance to PD-1 Inhibitors in Metastatic NSCL. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):3084-3084. DOI: 10.1200/JCO.2020.38.15_suppl.3084
Published on-line May 25, 2020. **Coauthor or Collaborator**.
- 2020 May 29 The Impact of Tobacco Retail Density on Overall Survival (OS) in Lung Cancer Survivors. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Lawson Eng. Poster; Abstract #12058.
- Publication Details:*
Eng L, Hueniken K, Norwood TA, Romme Gj, Brown MC, Hope AJ, Bezjak A, Sacher AG, Bradbury PA, Shepherd FA, **Leighl NB**, Pierre A, Selby P, Goldstein DP, Xu W, Giuliani ME, Evans WK, Chaiton M, Liu G. The Impact of Tobacco Retail Density on Overall Survival (OS) in Lung Cancer Survivors. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):12058-12058. DOI: 10.1200/JCO.2020.38.15_suppl.12058
Published on-line May 25, 2020. **Coauthor or Collaborator**.
- 2020 May 29 Demonstrating the Value of Liquid Biopsy for Lung Cancer in a Public Health Care System. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Juergens, Rosalyn A. Poster; Abstract #3546.
- Publication Details:*
Juergens RA, Ezeife DA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Shepherd FA, Cohen V, Shokoohi A, Vandermeer R, Li JJ, Hanson I, Fernandes R, Salvarrey AM, Lanman RB, **Leighl NB**. Demonstrating the Value of Liquid Biopsy for Lung Cancer in a Public Health Care System. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):3456-3546. DOI: 10.1200/JCO.2020.38.15_suppl.3546
Published on-line May 25, 2020. **Senior Responsible Author**.
- 2020 May 29 Genomic Analysis of Driver-Negative Lung Adenocarcinoma (LA) in Lifetime Never Smokers. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Fares, Aline Fusco. Poster; Abstract #3571.
- Publication Details:*
Fares AF, Martins-Filho SN, Li Q, Seto A, Stewart EL, Zhang T, Lau S, Ravi D, Weiss J, Patel D, Phan N, Sacher AG, Bradbury PA, Stockley T, **Leighl NB**, Shepherd FA, Tsao MS, Liu G. Genomic Analysis of Driver-Negative Lung Adenocarcinoma (LA) in Lifetime Never Smokers. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):3571. DOI: 10.1200/JCO.2020.38.15_suppl.3571
Published on-line May 25, 2020. **Coauthor or Collaborator**.
- 2020 May 29 TCR Clonality and Treg Frequency as Predictors of Outcome in Stage III NSCLC Treated with Durvalumab. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Sally CM Lau. Poster; Abstract #3050.
- Publication Details:*
Lau SCM, Soleimani S, Wong SWY, Pedersen S, Wang BX, Elkrief A, Patel D, Fares AF, Jao K, Daaboul

N, Hakozaiki T, Bradbury PA, Liu G, **Leighl NB**, Tsao MS, Ohashi PS, Pugh TJ, Routy B, Shepherd FA, Sacher AG. TCR Clonality and Treg Frequency as Predictors of Outcome in Stage III NSCLC Treated with Durvalumab. *Journal of Clinical Oncology*. 2020 May 20;38(15_Suppl):3050-3050. DOI: 10.1200/JCO.2020.38.15_suppl.3050
Published on-line May 25, 2020. **Coauthor or Collaborator**.

2020 May 29 Lung-MAP (SWOG S1400): Design, Implementation, and Lessons Learned From a Biomarker-Driven Master Protocol (PDMP) for Previously-treated Squamous Lung Cancer (sqNSCLC). 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Mary Weber Redman. Poster; Abstract #9576.

Publication Details:

Redman MW, Papadimitrakopoulou V, Minichiello K, Gandara DR, Hirsch FR, Mack PC, Schwartz LH, Vokes EE, Ramalingam SS, **Leighl NB**, Bradley J, LeBlanc ML, Malik S, Miller VZ, Sigal EV, Adam S, Blanke CD, Kelly K, Herbst RS, Hutchinson F. Lung-MAP (SWOG S1400): Design, Implementation, and Lessons Learned From a Biomarker-Driven Master Protocol (PDMP) for Previously-treated Squamous Lung Cancer (sqNSCLC). *Journal of Clinical Oncology*. 2020 May 20;38(15_Suppl):9576. DOI: 10.1200/JCO.2020.38.15_suppl.9576
Published on-line May 25, 2020. **Coauthor or Collaborator**.

2020 May 29 Nazartinib (EGF816) in Patients with Treatment-naive EGFR-mutant Non-Small Cell Lung Cancer (NSCLC): Updated Phase II results. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Daniel Shao-Weng Tan. Poster; Abstract #9574.

Publication Details:

Tan DS, **Leighl NB**, Yang J, Riely G, Sequist LV, Toyozawa R, Wolf J, Felip E, Kim SW, Aix SP, Smit EF, Hida T, Grohe C, Ghebremariam S, O'Sullivan-Djentuh, Belli R, Giovannini M, Kim D. Nazartinib (EGF816) in Patients with Treatment-naive EGFR-mutant Non-Small Cell Lung Cancer (NSCLC): Updated Phase II results. *Journal of Clinical Oncology*. 2020 May 20;38(15_Suppl):9574. DOI: 10.1200/JCO.2020.38.15_suppl.9574
Published on-line May 25, 2020. **Coauthor or Collaborator**.

2020 May 29 **Presenter**. SWOG S1400F (NCT03373760): A Phase II Study of Durvalumab Plus Tremelimumab for Previously Treated Patients with Acquired Resistance to PD-1 Checkpoint Inhibitor Therapy and Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 2020 ASCO Virtual Scientific Program. United States. Presenter(s): **Natasha Leighl**. Poster, Abstract #9623.

Publication Details:

Leighl NB, Redman MQ, Rizvi NA, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy S, Crawford J, Bradley JD, Stinchcombe T, Ramalingam SS, Miao J, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou V, Kelly K. SWOG S1400F (NCT03373760): A Phase II Study of Durvalumab Plus Tremelimumab for Previously Treated Patients with Acquired Resistance to PD-1 Checkpoint Inhibitor Therapy and Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). *Journal of Clinical Oncology*. 2020 May 20;38(15_Suppl):9623. DOI: 10.1200/JCO.2020.38.15_suppl.9623
Published on-line May 25, 2020. **Principal Author**.

2020 May 29 **Presenter (Oral Metastatic NSCLC Session)**. CCTG BR34 A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC). 2020 ASCO Virtual Scientific Program. United States. Presenter(s): **Natasha Leighl**. Oral Abstract #9502.

Publication Details:

Leighl NB, Laurie SA, Goss GD, Hughes BGM, Stockler MR, Tsao MS, Kulkarni S, Blais N, Joy AA, Mates M, Rana P, Yadav S, Underhill C, Lee CW, Bradbury PA, Hiltz A, Dancey J, Ding K, Vera Badillo FE. CCTG BR34 A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC). *Journal of Clinical Oncology*. 2020 May 20;38(15_Suppl):9502-9502. DOI: 10.1200/JCO.2020.38.15_suppl.9502
Published on-line May 25, 2020. **Principal Author**.

- 2020 May 29 CNS Outcomes in EGFR/ALK Wild-Type NSCLC Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors (ICI). 2020 ASCO Virtual Scientific Program. United States. Presenter(s): David Benjamin Schulz. eAbstract #14505.
- Publication Details:*
Shultz DB, Lau SCM, Poletes C, Le LW, MacKay K, Shepherd FA, Bradbury PA, **Leighl NB**, Liu G, Sacher AG. CNS Outcomes in EGFR/ALK Wild-Type NSCLC Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors (ICI). Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):14505-14505. DOI: 10.1200/JCO.2020.38.15_suppl.14505
Published on-line May 25, 2020. **Coauthor or Collaborator.**
- 2020 May 29 Predictors of and Longitudinal Assessment of Health Utility Scores in Patients with Small Cell Lung Cancer Using Real-World Data. 2020 ASCO Virtual Scientific Program. United States. Presenter(s): Nathan Kuehne. eAbstract #19306.
- Publication Details:*
Kuehne N, Hueniken K, Xu W, Shakik S, Vedadi A, Pinto D, Brown C, Bradbury PA, Shepherd FA, Sacher AG, **Leighl NB**, Lok BH, Liu G, O’Kane G. Predictors of and Longitudinal Assessment of Health Utility Scores in Patients with Small Cell Lung Cancer Using Real-World Data. Journal of Clinical Oncology. 2020 May 20;38(15_Suppl):19306-19306. DOI: 10.1200/JCO.2020.38.15_suppl.19306
Published on-line May 25, 2020. **Coauthor or Collaborator.**
- 2020 Apr 27 Methylation Signatures Associated with T790M Status in Progressive NSCLC. AACR Annual Meeting 2020. San Diego, California, United States. Presenter(s): G. O’Kane. Abstract 1869.
- Publication Details:*
O’Kane GM, Leon AJ, Shabir M, Law JH, Bradbury PA, Liu G, Sacher A, Shepherd FA, Torti D, Stockley TL, Tsao M, Pugh TJ, **Leighl NB**. Methylation Signatures Associated with T790M Status in Progressive NSCLC. Cancer Research. 2020 Aug;80(16):Supplement. DOI: 10.1158/1538-7445. AM2020-1869. **Senior Responsible Author.**
- 2020 Jan 14 Defining VALUE: Routine Liquid Biopsy in NSCLC Diagnosis- A Canadian Trial in Progress. AACR Special Conference on Advances in Liquid Biopsies. Miami, Florida, United States. Presenter(s): J. Law. Poster Presentation A26.
- Publication Details:*
Agulnik J, Law JH, Juergens R, Laskin J, Laurie S, Hao D, Ezeife D, Le lw, Kiedrowski LA, Lanman RB, **Leighl NB**. Defining VALUE: Routine Liquid Biopsy in NSCLC Diagnosis- A Canadian Trial in Progress. Clinical Cancer Research 2020. 2020 Jun;26(11_Suppl). Abstract nr A26
DOI: <https://doi.org/10.1158/1557-3265.LiqBiop20-A26>. **Senior Responsible Author.**
- 2019 Oct 26 Routine Edmonton Symptom Assessment System (ESAS) scores in Epithelioid Malignant Pleural Mesothelioma (eMPM) Patients Undergoing Palliative Systemic Therapy. 2019 Supportive Care in Oncology Symposium. San Francisco, California, United States. Presenter(s): Kietrick K. Poster Presentation, Abstr #96.
- Publication Details:*
Dietrich K, Zhan L, Herman M, Nagaratnam S, Corbett K, Patel D, Hueniken K, Xu W, Brown M, de PerrotM, Cho J, **Leighl N**, Bradbury P, Liu G. Routine Edmonton Symptom Assessment System (ESAS) scores in Epithelioid Malignant Pleural Mesothelioma (eMPM) Patients Undergoing Palliative Systemic Therapy. Journal of Clinical Oncology. 2019;37(2019 (suppl 31; abstr 96)). **Coauthor or Collaborator.**
- 2019 Sep 27 Brigantinib (BRG) in Asian vs non-Asian Patients (pts) with crizotinib (CRZ)- refractory ALK+NSCLC in the Phase II ALTA Trial. ESMO Congress 2019. Barcelona, Spain. Presenter(s): DH Lee. Poster Presentation: 1543P.
- Publication Details:*
Lee DH, Kim DW, Camidge DR, Langer CJ, Huber RM, Tiseo M, West HL, Groen HJM, Reckamp KL,

Hochmair MJ, **Leighl NB**, Hansen KH, Gettinger SN, Paz-Ares L, Kim ES, Smit EF, Kim Sw, Ni Q, Zhang P, Ahn MJ. Brigantini (BRG) in Asian vs non-Asian Patients (pts) with crizotinib (CRZ)- refractory ALK+NSCLC in the Phase II ALTA Trial. Annals of Oncology. 2019 Oct 1;30(Issue Supplement 5):V634. **Coauthor or Collaborator.**

2019 Sep 27 Phase II/III Blood First Assay Screening trial (BFAST) in Patients (pts) with treatment -naive NSCLC: Initial Results from the ALK+ Cohort. ESMO Congress 2019. Barcelona, Spain. Presenter(s): SM Gadgeel. LBA81_PR.

Publication Details:

Gadgeel SM, Mok TSK, Peters S, Alexander JAA, **Leighl NB**, Sriuranpong V, Perol M, De Castro Jr, G, Nadal E, DeMarinis F. Phase II/III Blood First Assay Screening trial (BFAST) in Patients (pts) with treatment -naive NSCLC: Initial Results from the ALK+ Cohort. Anals of Oncology. 2019 Oct 1;30(Supplement_5):V918. **Coauthor or Collaborator.**

2019 Sep 10 Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors after Tyrosine Kinase Inhibitors. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): P. Pal. Mini Oral Abstract: MA18.07.

Publication Details:

Pal P, Fares, A, Patel D, Stewart E, Perera-Low N, Grindley A, Allison F, Pham NA, Shi R, **Leighl N**, Shepherd F, Bradbury P, Sacher A, Rogalla P, Yasufuku K, Cabanero M, Tsao M, Liu G, Martins-Filho S, Nguyen L. Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors after Tyrosine Kinase Inhibitors. 2019. 2019:344. **Coauthor or Collaborator.**

2019 Sep 8 E1505:Adjuvant Chemotherapy +/- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): Wakelee H. Mini Oral Abstract: MA06.07.

Publication Details:

Wakelee H, Dahlberg S, Keller S, Tester W, Aisner S, Rothman J, Patel J, Delaune R, McDermott S, Shafqat A, Perez-Soler R, Chapman A, Kasbari S, Traynor A, Evans T, Horn L, Graziano S, Gandara D, Adjel A, Butts C, **Leighl N**, Ramalingam S, Schiller J. E1505:Adjuvant Chemotherapy +/- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:286. **Coauthor or Collaborator.**

2019 Sep 8 Chemotherapy Enhances The Efficacy of Immunotherapy. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): **N. Leighl**. Educational Session: ES01.02.

Publication Details:

Leighl N. Chemotherapy Enhances The Efficacy of Immunotherapy. Journal of Thoracic Oncology. 2019 Oct;14(10, Supplement):S13-S14. **Principal Author.**

2019 Sep 7 Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): M. Makarem. Poster P2.16-05. (Trainee Presentation)

Publication Details:

Makarem M, Ezeife D, Smith A, Law J, Tsao M, **Leighl NB**. Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:905. **Senior Responsible Author.**

2019 Sep 7 A Phase III Randomized Study of Nivolumab/Ipilimumab Vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): L. Bazhenova. Oral Presentation : OA04.01.

Publication Details:

Bazhenova L, Redman M, Gettinger S, Hirsch FR, Mack P, Schwartz L, Dandara D, Bradley J,

Stinchcomber T, **Leighl N**, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakoupoulou V, Herbst R. A Phase III Randomized Study of Nivolumab/Ipilimumab Vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer. 2019 World Conference on Lung Cancer Book of Abstracts. 2019;(223).

2019 Sep 7 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detecting Through Cell-Free DNA. 2109 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): E. Stewart. Poster Presentation: P2.14-62. (Trainee Presentation)

Publication Details:

Stewart E, Martins-Filho S, Cabanero M, Wang A, Huang J, Bao H, Wu X, Patel D, Chen Z, Law J, Bradbury P, Shepherd F, **Leighl N**, Tsao M, Pugh T, Bratman S, Liu G, Sacher A. Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detecting Through Cell-Free DNA. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:893. **Coauthor or Collaborator.**

2019 Sep 7 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial -Mesenchymal-Transition. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): A. Fares. Poster Presentation: P2.03-37. (Trainee Presentation)

Publication Details:

Fares A, Martins-Filho S, Raghavan V, Stewart E, Ravi D, Seiss J, Hueniken K, Patel D, Pham NA, Sacher A, Bradbury P, **Leighl N**, Shepherd F, Tsao M, Liu G. Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial -Mesenchymal-Transition. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:732.

2019 Sep 7 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): S. Martins-Filho. Poster Presentation: P2.03-11. (Trainee Presentation)

Publication Details:

Martins-Filho S, Fares A, Raghavan V, Stewart E, Ravi D, Perdrizet K, Weiss J, Hueniken K, Patel D, Pham NA, Sacher A, Bradbury P, **Leighl N**, Shepherd F, Tsao M, Liu G. Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:719.

2019 Sep 7 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): E. Stewart. Poster Presentation: P1-14-07.

Publication Details:

Stewart E, Wang A, Huang J, Bao H, Wu X, Ptel D, Chen Z, Law J, Bradbury P, Shepherd F, Sacher A, Tsao M, Bratman S, **Leighl N**, Pugh T, Liu G. Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:582. **Coauthor or Collaborator.**

2019 Sep 7 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): L. Eng. Poster Presentation: P1.10-05.

Publication Details:

Eng L, Su J, Hueniken K, Brown MC, Hope A, Bezjak A, Sacher A, Bradbury P, Shepherd F, **Leighl N**, Pierre A, Selby P, Godstein D, Xu W, Giuliani M, Evans W, Liu G, Chaiton M. Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:539. **Coauthor or Collaborator.**

2019 Sep 7 Clinico-Pathological Profile of Adenocarcinoma of the Lung- A Prospective Study in a Nepalese Population. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): S. Dulal. ePoster: EP1.01-30. (Trainee Presentation)

Publication Details:

Dulal S, Paudel B, Shah A, Neupane P, Acharya B, Chapagain S, Rayamajhi A, Thapa R, Brustugun OT, **Leighl N**. Clinico-Pathological Profile of Adenocarcinoma of the Lung- A Prospective Study in a Nepalese Population. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:967. **Senior Responsible Author**.

2019 Sep 7 Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer. 2019 World Conference on Lung Cancer. Barceloan, Spain. Presenter(s): C. Pettengell. Poster Presentation: P1.16-07.

Publication Details:

Pettengell C, Law J, Le L, Sung M, Lau S, Sacher A, Merritt D, Demarco P, **Leighl N**. Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer. 2019 World Conference on Lung Cancer Book of Abstract. 2019:616. **Senior Responsible Author**.

2019 Sep 7 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): J. Law. ePoster: EP1.16-05.

Publication Details:

Law J, Pettengell C, Chen L, Le L, Sung M, Aviv S, Lau S, Sacher A, Merritt D, Demarco P, **Leighl N**. Real World Outcomes of Advanced NSCLC Patients with Liver Metastases. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:1106. **Principal Author**.

2019 Sep 6 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): K. Perdrizet. Poster Presentation: P1.01-30. (Trainee Presentation)

Publication Details:

Perdrizet K, Stockley T, Law J, Shabir M, Zhang T, Le L, Lau A, Tsao M, Kamel-Reid S, Pal P, Cabanero M, Schwock J, Ko H, Liu G, Bradbury P, Sacher A, Shepherd F, **Leighl N**. Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:389-390. **Senior Responsible Author**.

2019 Sep 6 Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. 2019 ASCO Quality Care Symposium. San Diego, California, United States. Presenter(s): Lorin Dodbiba. Poster Abst #102.

Publication Details:

Dodbiba L, Hueniken K, Jiang SX, Chan SWS, Smith EC, Eng L, Patel D, Razooqi M, Brown MC, Shepherd FA, **Leighl NB**, Bradbury PA, Xu W, Sacher AG, Liu G. Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. Journal of Clinical Oncology. 2019;37(2019 (suppl 27; abst 102)). **Coauthor or Collaborator**.

2019 Sep 6 Dominant Circulating Myeloid Populations are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): S. Lau. Poster Presentation: P1.01-70. (Trainee Presentation)

Publication Details:

Lau S, Le L, Chan SWS, Smtih E, Ryan M, Brown MC, Hueniken K, Eng L, Patel D, Chen RQ, Sung M, Zer A, Bradbury P, Ohashi P, Shepherd F, Tsao M, **Leighl N**, Liu G, Sacher. Dominant Circulating Myeloid Populations are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:409. **Coauthor or Collaborator**.

2019 Sep Smoking History May Help Predict Immunotherapy Response in PDL1+ Lung Cancer Patients. 2019

World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): K.Karim. ePoster: EP1.04-24. (Trainee Presentation)

Publication Details:

Karim K, Sung M, Le L, Lau S, Sacher A, **Leighl N**. Smoking History May Help Predict Immunotherapy Response in PDL1+ Lung Cancer Patients. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:1015. **Senior Responsible Author.**

2019 Sep Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy- A Nepalese Cohort. 2019 World Conference on Lung Cancer. Barcelona, Spain. Presenter(s): S. Dulal. ePoster: EP1.01-40. (Trainee Presentation)

Publication Details:

Dulal S, Paudel B, Shah A, Neupane P, Acharya B, Chapagain S, Karn A, Shilpakar R, Thapa R, Gautam B, Brustugun OT, **Leighl N**. Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy- A Nepalese Cohort. 2019 World Conference on Lung Cancer Book of Abstracts. 2019:970-971. **Senior Responsible Author.**

2019 Jun 3 Tobacco retail availability and tobacco cessation in lung cancer and head and neck (HN) cancer survivors. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Lawson Eng. Poster Presentation, Abstr #11559.

Publication Details:

Eng L, Su J, Habbous S, Hueniken K, Brown MC, Saunders D, de Almeida, JR, Hope A, Bejzak A, Shepherd FA, **Leighl NB**, Pierre A, Selby P, Goldstein DP, Xu W, Giuliani ME, Evans WK, Liu G, Chaiton M. Tobacco retail availability and tobacco cessation in lung cancer and head and neck (HN) cancer survivors. Journal of Clinical Oncology 37, 2019 (suppl; abstr 11559). **Coauthor or Collaborator.**

2019 Jun 2 Generating real-world evidence: Using automated data extraction to replace manual chart review. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Jennifer Law. Abstract e18096.

Publication Details:

Law J, Pettengell C, Le LW, Aviv S, DeMarco P, Merritt DC, Lau SCM, Sacher AG, **Leighl NB**. Generating real-world evidence: Using automated data extraction to replace manual chart review. Journal of Clinical Oncology. 2019;37(2019 (suppl; abstr e18096)). **Senior Responsible Author.**

2019 Jun 2 A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (LUNG-MAP Sub-Study S14001, NCT02785952). 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Lyudmila Bazhenova. Poster Presentation; Abstr #9014.

Publication Details:

Bazhenova L, Redman MW, Gettinger SN, Hirsch FR, Mack PC, Schwartz LH, Gardara DR, Bradley JD, Stinchcombe T, **Leighl NB**, Ramalingam SS, Tavernier SS, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst RS. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (LUNG-MAP Sub-Study S14001, NCT02785952). Journal of Clinical Oncology 37, 2019 (suppl; abstr 9014). **Coauthor or Collaborator.**

2019 Jun 2 Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Edward B. Garon. Poster presentation; Abstr #LBA9015.

Publication Details:

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, **Leighl NB**, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. Journal of Clinical Oncology. 2019 Oct 1;37(28):2518-

2527. **Coauthor or Collaborator.**

2019 Jun 2 A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (LUNG-MAP Sub-Study, S1400G). 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Taofeek Kunie Owonikoko. Poster Presentation; Abstr #9022. (Trainee Presentation)

Publication Details:

Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe T, **Leighl NB**, Al Baghdadi T; Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (LUNG-MAP Sub-Study, S1400G). Journal of Clinical Oncology 37, 2019 (suppl;abstr 9022). 2019. **Coauthor or Collaborator.**

2019 Jun 1 Quantifying EpCAM heterogeneity of circulating-tumor cells (CTCs) from small cell lung cancer (SCLC) patients. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Hadas Sorotsky. Abstract # e90091.

Publication Details:

Sorotsky H, Aparanthi M, Wang DZ, McFadden F, Popescu SN, Mohamad RM, Pereira M, Weiss J, Patel D, Majeed S, Cabanero M, Sacher AG, Bradbury PA, **Leighl NB**, Shepherd FA, Tsao MS, Liu G, O'Kelly S, Lok BH. Quantifying EpCAM heterogeneity of circulating-tumor cells (CTCs) from small cell lung cancer (SCLC) patients. Journal of Clinical Oncology 37, 2019 (suppl; abstr e20091). **Coauthor or Collaborator.**

2019 Jun 1 Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) V 3: integrating expanded genomic sequencing into the Canadian publicly funded health care model. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Kirstin Perdrizet. Poster Presentation; Abstr #2620. (Trainee Presentation)

Publication Details:

Perdrizet K, Stockly T, Law JH, Shabir M, Zhang T, Le LW, Lau A, Tsao MS, Pal P, Cabanero M, Ko H, Schwock J, Kamel-Reid S, Liu G, Sacher AG, Bradbury PA, Shepherd FA, **Leighl NB**. Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) V 3: integrating expanded genomic sequencing into the Canadian publicly funded health care model. Journal of Clinical Oncology 37, 2019 (suppl; abstr 2620). **Senior Responsible Author.**

2019 Jun 1 Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung cancer adenocarcinoma (LUAD). 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Sebastiao N. Martins-Filho. Poster Presentation; Abstr #3110.

Publication Details:

Martins-Filho SN, Weiss J, Pham NA, Cabanero M, Fares AF, Stewart EL, Patel D, McConnell J, Bradbury PA, Sacher AG, **Leighl NB**, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G. Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung cancer adenocarcinoma (LUAD). Journal of Clinical Oncology 37, 2019 (suppl; abstr 3110). **Coauthor or Collaborator.**

2019 Jun Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI). 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Sally Lau. Abstr #e20667. (Trainee Presentation)

Publication Details:

Lau SCM, Le LW, Smith EC, Chan SWS, Ryan M, Brown MC, Hueniken K, Eng L, Patel D, Chen RQ, Sung MRU, Zer A, Bradbury PA, Ohashi PS, Shepherd FA, Tsao MS, Liu G, **Leighl NB**, Sacher AG. Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI). Journal of Clinical Oncology 37, 2019 (suppl: abstr e20667). **Coauthor or Collaborator.**

- 2019 Jun Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. 2019 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Sally Lau. Abstr #e20597. (Trainee Presentation)
- Publication Details:*
Lau SCM, Le LW, Chan SWS, Smith EC, Ryan M, Brown MC, Hueniken K, Eng L, Patel D, Chen PQ, Zer A, Sung MR, Bradbury PA, Ohashi PS, Shepherd FA, Tsao MS, **Leigh NB**, Liu G, Sacher AG. Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. Journal of Clinical Oncology 37, 2019 (suppl; abstr e20594). **Coauthor or Collaborator**.
- 2019 Mar 29 Clinical utility of comprehensive cell-free DNA (cfNDA) analysis to identify genomic biomarkers in new diagnosed metastatic non-small cell lung cancer (mNSCLC). 2019 AACR Annual Conference. Atlanta, Georgia, United States. Oral Presentation.
- Publication Details:*
Leigh NB, Page RD, Raymond VM, Dainel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA. Clinical utility of comprehensive cell-free DNA (cfNDA) analysis to identify genomic biomarkers in new diagnosed metastatic non-small cell lung cancer (mNSCLC). Clinical Cancer Research. 2019 Aug 1;25(15):4691-4700. doi: 10.1158/1078-0432.CCR-19-0624. Epub 2019 April 15. **Principal Author**.
- 2019 Mar 17 Characterizing ERBB2 Mutations in Non-Small Cell Lung Carcinoma: University Health Network Experience. USCAP 2019 Annual Meeting. Presenter(s): Nina Chang, Kirstin Perdrizet, Tracy Stockley, Ming Tsao, Laura Ranich, Geoffrey Liu, Adrian Sacher, Frances Shepherd, David Hwang, Joerg Schwock, Hyang Mi Ko, Scott Boerner, Jennifer Law, **Natasha Leighl**, Prodipto Pal. Poster presentation. (Trainee Presentation)
- Publication Details:*
Characterizing ERBB2 Mutations in Non-Small Cell Lung Carcinoma: University Health Network Experience. **Coauthor or Collaborator**.
- 2018 Sep 29 Financial Toxicity Among Patients with Lung Cancer in a Publicly Funded Health System. ASCO Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Dr. Doreen Ezeife. Poster Presentation, Abstr 192; Merit Award.
- Publication Details:*
Ezeife D, Morganstein J, Le LW, Bradbury PA, Liu G, Shepherd F, **Leighl N**. Financial Toxicity Among Patients with Lung Cancer in a Publicly Funded Health System. Journal of Clinical Oncology. 2018 May;36(2018 (suppl 30)). 192-192. **Senior Responsible Author**.
- 2018 Sep 29 The Influence of Patient-reported Adverse Events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) Patients. ASCO Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Sharara Shakik. Poster Presentation, Abstr 185.
- Publication Details:*
Shakik S, Vedadi A, Brown MC, Xu W, O'Kane GM, Liu G, Shepherd FA, **Leighl NB**, Bradbury PA, Lok BH, Sacher AG. The Influence of Patient-reported Adverse Events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Clinical Oncology. 2018 May;36(2018 (supple 30)). Abstr 185. **Coauthor or Collaborator**.
- 2018 Sep 29 Developing a Standard Approach to Immune Checkpoint Inhibitor Toxicity Management in Ontario. ASCO Quality Care Symposium. Phoenix, Arizona, United States. Presenter(s): Andrea Crespo. Poster Presentation, Abstr 255.

Publication Details:

Crespo A, Abella L, Baetz TD, Gallo-Hershberg D, Lakhani Ni, **Leighl NB**, Pasetka M, Seymour L, Vu K, Forbes LM. Developing a Standard Approach to Immune Checkpoint Inhibitor Toxicity Management in Ontario. *Journal of Clinical Oncology*. 2018 May;36(2018 (supple 30)). Abstr 255. **Coauthor or Collaborator**.

2018 Sep 25 Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Michael Herman. Poster Presentation: P2.01-46. (Trainee Presentation)

Publication Details:

Herman M, **Leighl N**, Shepherd F, Liu G, Bradbury P. Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility. *Journal of Thoracic Oncology*. 2018 Oct;13(10). S682. **Coauthor or Collaborator**.

2018 Sep 25 Quality of Life Outcomes for FDA-approved Agents in Advanced Non-Small Cell Lung Cancer. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Hamzeh Albaba. Poster Presentation: P2.01-03. (Trainee Presentation)

Publication Details:

Albaba H, Bezzak A, **Leighl,N**. Quality of Life Outcomes for FDA-approved Agents in Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*. 2018 Oct;13(10). S666. **Senior Responsible Author**.

2018 Sep 25 The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Hadas Sorotsky. Poster Presentation: P3.03-29. (Trainee Presentation)

Publication Details:

Sorotsky H, Cabanero M, Moskovitz M, Weiss J, Pintilie M, **Leighl N**, Bradbury P, Liu G, Kia A, Pugh T, Torti D, Torchia J, Tsao M, Shepherd F. The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*. 2018 Oct;13(10). S921. **Coauthor or Collaborator**.

2018 Sep 25 Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Doreen Ezeife. Mini- Oral Session: MA14.06. (Trainee Presentation)

Publication Details:

Ezeife D, Morganstein J, Lau S, Law J, Le L, Bradbury P, Liu G, Shepherd F, **Leighl N**. Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome. *Journal of Thoracic Oncology*. 2018 Oct;13(10). S405. **Senior Responsible Author**.

2018 Sep 25 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. E. Stewart. Mini Oral Abstract MA27.03. (Trainee Presentation)

Publication Details:

Stewart E, Cabanero M, Raghavan J, Bruce J, Guilhamon P, Sinhgania R, Pham N, Shen SY, Li M, **Leighl N**, Shepherd F, Pugh T, DeCarvalho D, Lupien M, Liu G, Tsao M. Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft. *Journal of Thoracic Oncology*. 2018 Oct;13(10). S455. **Coauthor or Collaborator**.

2018 Sep 25 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. F. Moraes. Mini Oral Abstract MA25.11. (Trainee Presentation)

Publication Details:

Moraes F, Weiss J, Moskovitz M, Sorotsky H, Pintilie M, **Leighl N**, Bradbury P, Liu G, Zadeh G, Doherty

Natasha LEIGHL

M, Kia A, So J, Cabanero M, Pugh T, Sugumar V, Torit D, Tsao M, Torchia J, Shultz D, Shepherd F, Lok B. Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT. Journal of Thoracic Oncology. 2018 Oct;13(10). S449-S450. **Coauthor or Collaborator.**

2018 Sep 25 Lung Patient Derived Xenograft and Organoid. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. N. Moghal. Meet the Expert Session, MTE01.02. (Trainee Presentation)

Publication Details:

Moghal N, Pham N, Shi R, Radulovich N, Li M, Raghavan V, Li Q, Wang D, Tong J, Zhu C, Li L, Stewart E, Tamblyn L, Weiss J, Martins-Filho S, Ravi D, Pintilie M, Moran M, Liu G, **Leighl N**, Shepherd F. Lung Patient Derived Xenograft and Organoid. Journal of Thoracic Oncology. 2018 Oct;13(10S). S206-229. **Coauthor or Collaborator.**

2018 Sep 25 Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. M.J. Lee. Poster Presentation P2.06-23. (Trainee Presentation)

Publication Details:

Lee MJ, Kuehne N, Hueniken K, Sorotsky H, Liang M, Patel D, Cheng D, Chen Z; Eng L, Brown MC, Cho J, **Leighl N**, De Perrot M, Reisman D, Xu W, Bradbury P, Liu G. Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival. Journal of Thoracic Oncology. 2018 Oct;13(10). S751. **Coauthor or Collaborator.**

2018 Sep 25 Defining the Roll of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. E. Wakeam. Mini Oral Abstract MA23.07. (Trainee Presentation)

Publication Details:

Wakeam E, Stokes S, Adibfar A, **Leighl N**, Giuliani M, Varghese T, Darling G. Defining the Roll of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer. Journal of Thoracic Oncology. 2018 Oct;13(10). S 440. **Coauthor or Collaborator.**

2018 Sep 25 Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. B. Id Said. Poster Presentation p2.15-10. (Trainee Presentation)

Publication Details:

Id Said B, Hueniken K, Brown MC, Patel D, Liange M, Labbe C, Eng L, Naik H, Bradbury P, Shepherd F, **Leighl N**, Liu G, O'Kane G. Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2018 Oct;13(10). S820-821. **Coauthor or Collaborator.**

2018 Sep 25 Awareness of the Harms of Continued Smoking Among Lung Carcer (LC) Survivors. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. L. Eng. Mini Oral Abstract MA18.07. (Trainee Presentation)

Publication Details:

Eng L, Liu S, Farzanfar D, Alton D, Smith E, McCartney A, Yeung S, Basgaran A, Balaratnam K, Mattina K, Harper C, Mhan R, Brown MC, Hope A, Bradbury P, Sacher A, **Leighl N**, Shepherd F, Bezjak A, Howell D, Jones J, Xu W, Goldstein D, Evans W, Selby P, Giuliani M, Liu G. Awareness of the Harms of Continued Smoking Among Lung Carcer (LC) Survivors. Journal of Thoracic Oncology. 2018 Oct;13(10S). S420. **Coauthor or Collaborator.**

2018 Sep 25 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A REAL WORLD ASSESSMENT. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. K. Hueniken. Poster Presentation P1.13-11. (Trainee Presentation)

Publication Details:

Hueniken K, Hurry M, Jiang S, Labbe C, Brown MC, Eng L, Naik H, Liang M, Patel D, Bradbury P, **Leighl N**, Shepherd F, Xu W, O'Kane G, Walton R, Liu G. PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A REAL WORLD ASSESSMENT. Journal of Thoracic Oncology. 2018 Oct;13(10S). S586. **Coauthor or Collaborator**.

2018 Sep 25 Real-World Evaluations of Tolerability in Older Adult Patients (equal or greater than 75 years old) with EGFR-mutated NSCLC. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. S. Jiang. Poster Presentation P1.01-42. (Trainee Presentation)

Publication Details:

Jiang S, Hurry M, Hueniken K, Labbe C, Brown MC, Eng L, Naik H, Liang M, Patel D, Bradbury P, **Leighl N**, Shepherd F, Xu W, Liu G, Walton R, O'Kane G. Real-World Evaluations of Tolerability in Older Adult Patients (equal or greater than 75 years old) with EGFR-mutated NSCLC. Journal of Thoracic Oncology. 2018 Oct;13(10S). P1.01-42. **Coauthor or Collaborator**.

2018 Sep 25 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Doreen Ezeife. Poster Presentation: P2.01-29. (Trainee Presentation)

Publication Details:

Ezeife D, Kirk V, Coyte P, Nixon N, Hancock-Howard R, **Leighl N**. Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2018 Oct;13(10). S675. **Senior Responsible Author**.

2018 Sep 25 Next Generation Sequencing in Lung Cancer Using the Outcomine Comprehensive Assay: The Canadian Publicly Funded Experience. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Kirstin Perdrizet. Poster Presentation: P2.03-04. (Trainee Presentation)

Publication Details:

Perdrizet K, Stockley T, Law J, Shabir M, Le L, Tsao M, Kamel-Reid S, Zhang T, Sawczak M, Hwang D, Pal P, Liu G, Bradbury P, Shepherd F, Sacher A, **Leighl N**. Next Generation Sequencing in Lung Cancer Using the Outcomine Comprehensive Assay: The Canadian Publicly Funded Experience. Journal of Thoracic Oncology. 2018 Oct;13(10). S717. **Senior Responsible Author**.

2018 Sep 25 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Kirstin Perdrizet. Poster Presentation: P2.03-03. (Trainee Presentation)

Publication Details:

Perdrizet K, Stockley T, Tsao M, Morganstein J, Kamel-Reid S, Ranich L, Shepherd F, Bradbury P, Liu G, Hwang D, Pal P, Schwock J, Boerner S, Sacher A, Law J, **Leighl N**. Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. Journal of Thoracic Oncology. 2018 Oct;13(10). S717. **Senior Responsible Author**.

2018 Sep 25 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. K. Kulkarni. Poster Presentation P1.01.-52. (Trainee Presentation)

Publication Details:

Kulkarni S, Laurie S, Goss G, Perrone F, Hughes B, Pavlakakis N, Stockler M, Blais A, Zibdawi L, Vera-Badillo F, **Leighl N**. BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC. Journal of Thoracic Oncology. 2018 Oct;13(10S). S480-481. **Senior Responsible Author**.

2018 Sep 25 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. S. Jiang. Mini Oral Abstract MA18.09. (Trainee Presentation)

Publication Details:

Jiang S, Hurry M, Hueniken K, Brown MC, Liang M, Patel D, Labbe C, Eng L, Naik H, Bradbury P, **Leighl N**, Shepherd F, Xu W, Liu G, Walton R, O'Kane G. Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2018 Oct;13(10). S420-421. **Coauthor or Collaborator.**

2018 Sep 25 Detection of EGFR Mutations in cfDNA and Development of Resistance. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. G. O'Kane. Poster Presentation P1.13-15. (Trainee Presentation)

Publication Details:

O'Kane G, Liu G, Stockley T, Shabir M, Zhang T, Le L, Shepherd F, Bradbury P, **Leighl N**. Detection of EGFR Mutations in cfDNA and Development of Resistance. Journal of Thoracic Oncology. 2018 Oct;13(10). S587. **Senior Responsible Author.**

2018 Sep 25 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Michael Sung. Poster Presentation P3.04-20. (Trainee Presentation)

Publication Details:

Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd F, Bradbury P, Liu G, **Leighl N**. Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 2018 Oct;13(10). S929. **Senior Responsible Author.**

2018 Sep 25 Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Michael Sung. Poster Presentation P2.01-94. (Trainee Presentation)

Publication Details:

Sung M, Nadjafti M, Santos G, Le L, Hwang D, TSao M, **Leighl N**. Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre. Journal of Thoracic Oncology. 2018 Oct;13(10). S701. **Senior Responsible Author.**

2018 Sep 25 A Phase 1/1b Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. D. Graham. Poster Presentation P1.01-54. (Trainee Presentation)

Publication Details:

Graham D, Chen E, Pisters K, Bradbury P, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendie S, Sawczak M, **Leighl N**. A Phase 1/1b Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC. Journal of Thoracic Oncology. 2018 Oct;13(10). S481-482. **Senior Responsible Author.**

2018 Sep 25 The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases. 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. M. Moskovitz. Poster Presentation P3.16-07. (Trainee Presentation)

Publication Details:

Moskovitz M, Cabanero M, Torchia J, Sorotsky H, Weiss J, Pintilie M, **Leighl N**, Bradbury P, Liu G, Zadeh G, Doherty M, Kia A, Torti D, Tsao M, Pugh T, Shepherd F. The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases. Journal of Thoracic Oncology. 2018 Oct;13(10). S1005-1006. **Coauthor or Collaborator.**

2018 Sep 24 Achieving Value in Cancer Diagnostics: Blood vs Tissue Molecular Profiling- A Prospective Canadian Study (VALUE). 19th World Lung Cancer Conference. Toronto, Ontario, Canada. Presenter(s): Dr. Doreen Ezeife. Mini- Oral Session: MA02.11. (Trainee Presentation)

Publication Details:

Ezeife D, Agulnik J, Juergens R, Laskin J, Le L, Hao D, Bebb G, Law, J, Skrzypczak S, Juri D, Lanman R, **Leighl N**. Achieving Value in Cancer Diagnostics: Blood vs Tissue Molecular Profiling- A Prospective Canadian Study (VALUE). Journal of Thoracic Oncology. 2018 Oct;13(10). S362. **Senior Responsible Author.**

2018 Jun 4 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Dr. Kirstin Perdrizet. Poster Presentation Abstr #12062.

Publication Details:

Perdrizet K, Stockley T, Tsao MS, Morganstein J, Kamel-Reid S, Ranich L, Shepherd F, Liu G, Bradbury P, Hwang D, Pal P, Schwock J, Boerner S, Law J, **Leighl NB**. Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. Journal of Clinical Oncology. 2018 May;36(15_suppl (May 2018)):12062-12062. **Senior Responsible Author.**

2018 Jun 4 Hyperprogressive Disease (HPD) in Early-Phase Immunotherapy (IO) Trials. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Yada Kanjanapan. Poster Presentation, Abstract 3063.

Publication Details:

Kanjanapan Y, Day D, Wang L, Hansen AR, Razak A, Spreafico A, **Leighl NB**, Joshua A, Butler M, Hogg, D, Liu L, Bedard P. Hyperprogressive Disease (HPD) in Early-Phase Immunotherapy (IO) Trials. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 3063-3063. **Coauthor or Collaborator.**

2018 Jun 3 4-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab: Results from KEYNOTE-001. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Enriqueta Felip. Poster Presentation, Abstr #9030.

Publication Details:

Felip E, Hellmann, MD, Hui R, Carcereny E, **Leighl NB**, Ahn M-J, Eder, JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Jensen E, Kush DA, Garon EB. 4-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab: Results from KEYNOTE-001. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 9030-9030. **Coauthor or Collaborator.**

2018 Jun 3 First Comprehensive Report of Impact of Genomic Alterations, Chemotherapy, Targeted Therapy and Immunotherapy on Outcomes in the Genomics Driven Squamous Master Protocol LungMAP. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Vassiliki Papadimitrakopoulou. Poster Discussion, Abstr #9019.

Publication Details:

Papadimitrakopoulou V, Weber Redman M, Gandara DR, Hirsch FR, Mack PC, Langer CJ, Edelman MJ, Aggarwal C, Socinski MA, Gettinger SN, Waqar SN, Griffin K, Leigh NB, Owonikoko TK, Bradley JD, Ramalingam SS, Stinchcombe T, David C. First Comprehensive Report of Impact of Genomic Alterations, Chemotherapy, Targeted Therapy and Immunotherapy on Outcomes in the Genomics Driven Squamous Master Protocol LungMAP. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 9019-9019. **Coauthor or Collaborator.**

2018 Jun 3 Association Between Progression-Free Survival (PFS) rate (PFSR) and Overall Survival (OS) in LUME_Meso, A Study of nintedanib (N) vs. Placebo (P) in Combination with First-Line Pemetrexed/Cisplatin (PEM/CIS) in Patients (pts) with Malignant Pleural Mesothelioma (MPM). 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Nick Pavlakakis. Poster Presentation, Abstr #8568.

Publication Details:

Pavlakis N, Grosso F, Steele NL, Nowak AK, Novello S, Popat S, Greillier L, Reck M, John T, Taylor P, **Leighl NB**, Ceresoli GL, Sorensen JB, Planchard D, Hughes BGM, Mazieres J, Socinski MA, von

Wangenheik U, Barrueco J, Scagliotti G. Association Between Progression-Free Survival (PFS) rate (PFSR) and Overall Survival (OS) in LUME_Meso, A Study of nintedanib (N) vs. Placebo (P) in Combination with First-Line Pemetrexed/Cisplatin (PEM/CIS) in Patients (pts) with Malignant Pleural Mesothelioma (MPM). Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 8568-8568. **Coauthor or Collaborator.**

2018 Jun 3 Tumor Burden (TB) and Treatment Exposure (TE) in Patients (pts) with Malignant Pleural Mesothelioma (MPM) Receiving Nintedanib (N)/Placebo (P) in Combination with First-Line Pemetrexed/Cisplatin (PEM/CIS) in Phase II of the LUME-Meso Study. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Sanjay Popat. Poster Presentation, Abstr #8566.

Publication Details:

Popat S, Grosso F, Steele Ni, Nowak AK, Novello S, Greillier L, Reck M, John T, Taylor P, **Leighl NB**, Ceresoli GL, Sorensen JB, Pavlakis N, Planchard D, Hughes BGM, Mazieres J, Socinski MA, Buchner H, Barrueco J, Scagliotti G. Tumor Burden (TB) and Treatment Exposure (TE) in Patients (pts) with Malignant Pleural Mesothelioma (MPM) Receiving Nintedanib (N)/Placebo (P) in Combination with First-Line Pemetrexed/Cisplatin (PEM/CIS) in Phase II of the LUME-Meso Study. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 8566-8566. **Coauthor or Collaborator.**

2018 Jun 3 Brigantinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non-Small Cell Lung Cancer (NSCLC): Efficacy Updates and Exploratory Analysis of CN ORR and Overall ORR by Baseline (BL) Brain Lesion Status. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Rudolf M. Huber. Poster Presentation, Abstr #9061.

Publication Details:

Huber Rm, Kim D-W, Ahn M-J, Langer CJ, Tiseo M, West H, Groen HJM, Reckamp KL, Hochmair MJ, **Leighl NB**, Holmskov Hansen K, Gettinger SN, Paz-Ares LG, Kim Es, Smit EF, Kim S-W, Reichmann W, Kerstein D, Camidge DR. Brigantinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non-Small Cell Lung Cancer (NSCLC): Efficacy Updates and Exploratory Analysis of CN ORR and Overall ORR by Baseline (BL) Brain Lesion Status. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). 9061-9061. **Coauthor or Collaborator.**

2018 Jun 3 The Effect of Prior Smoking History on the Molecular Profile of EGFR Mutant (EGFRm) Non-Small Cell Lung Cancer. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Dr. Hadas Sorotsky. Poster Presentation Abstr #8533. (Trainee Presentation)

Publication Details:

Sorotsky H, Moskovitz M, Weiss J, Pintillie M, **Leighl NB**, Bradbury P, Liu G, Kia A, Cabanero M, Pugh TJ, Torti D, Tsao MS, Torchia J, Shepherd FA. The Effect of Prior Smoking History on the Molecular Profile of EGFR Mutant (EGFRm) Non-Small Cell Lung Cancer. Journal of Clinical Oncology. 2018 Oct;36(15_suppl (May 2018)). 8533-8533. **Coauthor or Collaborator.**

2018 Jun 1 Detection of EGFR Mutations in cfDNA and Development of Resistance. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Dr. Grainne M. O'Kane. Abstract e21072.

Publication Details:

O'Kane GM, Liu G, Stockley T, Shabir M, Zhang T, Le L, Shepherd F, Bradbury P, **Leighl NB**. Detection of EGFR Mutations in cfDNA and Development of Resistance. Journal of Clinical Oncology. 2018 May;36(15_suppl -published on line June 01, 2018 before print.). **Senior Responsible Author.**

2018 Jun 1 Financial Toxicity Among Patients with Lung Cancer in a Publicly Funded Health System. 2018 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Dr. Doreen Ezeife. Poster Presentation, Abstr #192.

Publication Details:

Ezeife D, Morganstein J, Le LW, Bradbury PA, Liu G, Shepherd F, **Leighl N**. Financial Toxicity Among Patients with Lung Cancer in a Publicly Funded Health System. Journal of Clinical Oncology. 2018

May;30(15_suppl (October 2018)). 192-192. **Senior Responsible Author.**

2018 Apr 12 **Presenter.** The Influence of Comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) Compared to Non-Small Cell Lung Cancer (NSCLC). 8th European Lung Cancer Congress. Geneva, Switzerland. Presenter(s): Dr. A. Vidad. Poster Presentation 81P.

Publication Details:

Vedadi A, ShakikS, Brown MC, Xu W, Shepherd F, **Leighl N**, Bradbury P, Liu G, O'Kane G. The Influence of Comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) Compared to Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2018 Apr;13(4S):S44-45. **Coauthor or Collaborator.**

2018 Apr 12 **Presenter.** Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer. 8th European Lung Cancer Congress. Geneva, Switzerland. Poster Presentation: 139PD.

Publication Details:

Leighl N, Karaseva N, Nakagawa K, Cho B-C, Gray JE, Hovey T, Walding A, Ryden A, Novello S. Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2018 Apr;13(4S):S81-S82. **Principal Author.**

2018 Jan 26 **Presenter.** Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost. ASCO-SITC Clinical Immune-Oncology Symposium. San Francisco, California, United States. Presenter(s): Mor Moskowitz. Poster. (Trainee Presentation)

Publication Details:

Moskovitz MT, Matthews PM, Pavel AM, Xu W, Bradbury PA, Liu G, Shepherd FA, **Leighl NB**. Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost. J Clin Oncol. **Senior Responsible Author.**

2017 Oct 18 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Anna Nowak. Mini Oral Abstract 19.03 -.

Publication Details:

Nowak A.,Grosso F, Steele N, Novello S., Popat S., Greillier L., John, T., **Leighl, N. B.**, Reck, M, Pavlakis, N, Sørensen, J.B., Planchard D., Ceresoli G.L., Hughes B., Mazieres, J., Socinski M., Salnikov A., Kitzing T., Braunger J., Pietzko K., Scagliotti, G.V. Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S1884. <https://doi.org/10.1016/j.jthor.2017.09.636>. **Coauthor or Collaborator.**

2017 Oct 18 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Stephen Lam. Oral Abstract 15.01.

Publication Details:

Tammemägi M., Schmidt H.C., Martel S., McWilliams A., Goffin J.R., Johnston M., Goss G., Tremblay A., Bhatia R., Liu G., Soghrati K., Yasufuku K., Hwang D.M., Laberge F., Gingras M., Pasian S., Couture C., Mayo J.R., Nasute Fauerbach P.V., S. Atkar-Khattra, Peacock S.J., Cressman S., Ionescu D., English J.C., Finley R.J., Yee J., Puksa S., Stewart L., Tsai S., Haider E., Boylan C., Cutz J., Manos D., Xu Z., Nicholas G., Seely J.M., Amjadi K., Sekhon H.S., Burrowes P., Maceachern P., Urbanski S., Sin D., Tan W.C., **Leighl N.B.**, Shepherd F.A., Evans W.K., Tsao M.S., Lam S. Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S1784. **Coauthor or Collaborator.**

- 2017 Oct 18 Canadian Multicentre Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Ming Sound Tsao. Poster Session 3.01-019 -.

Publication Details:

Tsao, M., Zhang T., Cheema P.K., Laskin J., Karsan A., Barnes T., Liu G., Owen S., Rothenstein J., Burkes R., Iqbal M., Spatz A., Izevbaye I., Kempen L.V., Kamel-Reid S., **Leighl N.B.** Canadian Multicentre Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S2207. **Senior Responsible Author.**

- 2017 Oct 18 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Tristan Alexandra Barnes. Poster Session 3.01-062. (Trainee Presentation)

Publication Details:

Barnes, T.A., Laskin J., Cheema P.K., Liu G., Iqbal M., Rothenstein J., Burkes R., Owen S., Laurence D., Carvalhana I., Markin L., Wong L., Perera-Low N. Sawczak M., Tsao M.S., **Leighl N.B.** The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S2225. **Senior Responsible Author.**

- 2017 Oct 18 Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): John Cho. Poster Session. Available from: <https://doi.org/10.1016/j.jtho.2017.09.1717>.

Publication Details:

Cho J, Bradbury P, Patsios D, Keshavjee S, **Leighl NB**, Hope AJ, De Perrot M. Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 Nov;12(11, Suppl 2):S2308. Abstr #P3.09-007. **Coauthor or Collaborator.**

- 2017 Oct 18 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Anna Nowak. Mini Oral Abstract 19.03 -.

Publication Details:

Nowak A.,Grosso F, Steele N, Novello S., Popat S., Greillier L., John, T., **Leighl, N. B.**, Reck, M, Pavlakis, N, Sørensen, J.B., Planchard D., Ceresoli G.L., Hughes B., Mazieres, J., Socinski M., Salnikov A., Kitzing T., Braunger J., Pietzko K., Scagliotti, G.V. Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S1884. <https://doi.org/10.1016/j.jthor.2017.09.636>. **Coauthor or Collaborator.**

- 2017 Oct 17 A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author(s): Barbara Melosky. Poster Session 2.01-032.

Publication Details:

Bradbury P., Melosky B., Tu D., Nicholas G., Wheatley-Price P., Laurie S.A., Goss G., Florescu M., Basappa N., Reiman A., Tan A., Hao D., Rothenstein J., **Leighl N.B.**, Goffin J.R., Kollmannsberger C., Kaurah P., Brown-Walker P., Seymour L. A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S2081. **Coauthor or Collaborator.**

- 2017 Oct 17 Examining Metabolomics as a Prognostic Marker in Metastatic Non-Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Desiree Hao. Poster Session 2.01-055.

Publication Details:

Hao, D., Sengupta A., Ding K., **Leighl N.B.**, Shepherd F.A., Seymour L., A. Weljie A. Examining Metabolomics as a Prognostic Marker in Metastatic Non-Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S2090. **Coauthor or Collaborator.**

2017 Oct 17 **Presenter.** Dignity Conserving Therapy. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Education Session 06.06.

Publication Details:

Leighl, N.B. Dignity Conserving Therapy. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S1625. <https://doi.org/10.1016/j.jthor.2017.09.130>. **Principal Author.**

2017 Oct 16 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author(s): D. Ross Camidge. Poster Session 1.01-001.

Publication Details:

Camidge, D.R., Tiseo M., Ahn M., Reckamp K.L., Hansen K.H., Kim S., Huber R.M., West H.L., Groen H.J., Hochmair M.J., **Leighl N.B.**, Gettinger S.N., Langer C.J., Paz-Ares L., Smit E.F., Kim E.S., Reichmann W., Kerstein D., Kim D. Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial. Journal of Thoracic Oncology. 2017 Dec;12(11, Suppl 2):S1892. **Coauthor or Collaborator.**

2017 Oct 16 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: D. Ross Camidge. Poster Session 1.01-004.

Publication Details:

Camidge D.R., Ahn M., Reckamp K.L., West H.L., Huber R.M., Langer C.J., Bazhenova L.A., **Leighl N.B.**, Reichmann W., Kerstein D., Kim D. Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S1893. **Coauthor or Collaborator.**

2017 Oct 16 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial. IASLC 18th World Conference on Lung Cancer. Yokohama, Japan. Presenter(s): Presenting Author: Myung-Ju Ahn. Oral Abstract 05.05.

Publication Details:

Ahn M., Camidge D.R., Tiseo M., Reckamp K.L., Hansen K.H., Kim S., Huber R., West H.L., Groen H.J., Hochmair M.J., **Leighl N.B.**, Gettinger S.N., Langer C.J., Paz-Ares L., Smit E.F., Kim E.S., Reichmann W., Kerstein D., Kim D. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial. Journal of Thoracic Oncology. 2017 Nov;12(11, Suppl 2):S 1755. <https://doi.org/10.1016/j.jtho.2017.09.350>. **Coauthor or Collaborator.**

2017 Sep 16 Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) 1 pemetrexed/cisplatin (PEM/ CIS) vs placebo (P) 1 PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). IASLC 2017 Chicago. Chicago, Illinois, United States. Oral Presentation.

Publication Details:

Novello S., Nowak A.K., Grosso F., Steele N., Popat S., L. Greillier L., John T., Leigh N.B., Reck M., Pavlakis N., Sorensen J.B., Planchard D., Ceresoli G.L., Hughes B., Mazieres J., Socinski M.A., U. von Wangenheim U., Barrueco J., Morsli N., Scagliotti G. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) 1 pemetrexed/cisplatin (PEM/ CIS) vs placebo (P) 1 PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Journal of Thoracic Oncology. 2017 Sep 18;12(11, Suppl 1):S1555. <http://doi.org/10.1016/j.tho.2017.09.018>. **Coauthor or Collaborator.**

- 2017 Sep 11 EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients. ESMO 2017 Congress. Madrid, Spain. Presenter(s): Grainne O’Kane. 127Poster Presentation. (Trainee Presentation)
- Publication Details:*
O’Kane G.M., Li T., Tsao M, Liu G., Pugh T.J., **Leighl N.B.** EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients. Annals of Oncology. 2017 Sep 18;28(Suppl 5). v22-v42. 10.1093/annonc/mdx363. **Senior Responsible Author.**
- 2017 Sep 8 Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination. ESMO 2017 Congress. Madrid, Spain. 397Poster Presentation.
- Publication Details:*
Kanjanapan Y., Day D., Butler M., Wang L., Joshua A.M., Hogg D., **Leighl N.B.**, Razak A.R.A., Hansen A.R., Boujos S., Chappell M.A., Chow K., Paolo M., Sherwin B., Stayner L-A., Soultani L., Zambrana A., Siu L.L., Bedard P.L., Spreafico A. Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination. Annals of Oncology. 2017 Sep 18;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx367.303>. **Coauthor or Collaborator.**
- 2017 Sep 8 Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. ESMO 2017 Congress. Madrid, Spain. 1121Poster Presentation.
- Publication Details:*
Karim S., Ding K., Bradbury P., Ellis P., Mittman N.,Xiaoqun Sun X., Millward M., Liu G., Sun S., Stockler M.R., Cohen V., Blais N., Sangha R., Boyer M., Sasidharan R., Lee C., Shepherd F.A., Goss G., Seymour L., **Leighl N.B.** Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. Annals of Oncology. 2017 Sep 18;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx375.009>. **Senior Responsible Author.**
- 2017 Sep 8 Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). ESMO 2017 Congress. Madrid, Spain. 1297Oral Presentation.
- Publication Details:*
Spigel D.R., McLeod M., Hussein M.A.,Waterhouse D.M., Einhorn L., Horn L., Creelan B, Babu S., **Leighl N.B.**, Couture F., Chandler J., Goss G., Keogh G., Garon E.B., Blankstein K.B.,Daniel D.B., Mohamed M., Li A., Aanur N. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 2017 Sep 18;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx380.002>. **Coauthor or Collaborator.**
- 2017 Sep 8 Treatment beyond disease progression: ALK inhibitors in ALKrearranged advanced NSCLC. ESMO 2017 Congress. Madrid, Spain. 1347Poster Presentation.
- Publication Details:*
Leighl N.B., Kuo J., Pavel A., Prescilla M., Shepherd F.A., G. Liu, Bradbury P., Moskovits M. Treatment beyond disease progression: ALK inhibitors in ALKrearranged advanced NSCLC. Annals of Oncology. 2017 Sep 18;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx380.049>. **Principal Author.**
- 2017 Sep 8 Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ ref) small-cell lung cancer (SCLC). ESMO 2017 Congress. Madrid, Spain. 1528Poster Discussion.
- Publication Details:*
Chu Q.S-C., van Herpen C., **Leighl N.B.**, Markman B., Clarke S., Juergens R.A., Basciano P., Lathers D., Tannenbaum-Dvir S., Urbanska K., G. Kollia G., Darby C.,Williams D., Kolaitis G., Ready N. Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with

relapsed/refractory (rel/ ref) small-cell lung cancer (SCLC). Annals of Oncology. 2017 Sep;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx386.002>. **Coauthor or Collaborator**.

2017 Sep 8 Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) 1 pemetrexed/cisplatin (PEM/ CIS) vs placebo (P) 1 PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). ESMO 2017 Congress. Madrid, Spain. 1618Poster Discussion.

Publication Details:

Novello S., Nowak A.K., Grosso F., Steele N., Popat S., L. Greillier L., John T., Leigh N.B., Reck M.,Pavlakis N., Sorensen J.B., Planchard D., Ceresoli G.L.,Hughes B., Mazieres J.,Socinski M.A., U. von Wangenheim U., Barrueco J., Morsli N., Scagliotti G. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) 1 pemetrexed/cisplatin (PEM/ CIS) vs placebo (P) 1 PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Annals of Oncology. 2017 Sep 18;28(Suppl 5). <https://doi.org/10.1093/annonc/mdx389.003>. **Coauthor or Collaborator**.

2017 Jun 22 **Presenter**. 3-Year Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Pembrolizumab in KEYNOTE-001. 2017 ASCO Annual Meeting. Chicago, Illinois, United States. Poster Discussion.

Publication Details:

Leighl, N.; Hellmann, M.D. ;Hui R.; Carcereny E.; Felip E.; Ahn, M-J., Eder, J.P., Balmanoukian A.S.; Aggarwal C.; Horn L.; Patnaik A.; Gubens M.; Ramalingam S.S.; Lubiniecki G.M.; Zhang J.; Piperdi B.; Garon E.B. 3-Year Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Pembrolizumab in KEYNOTE-001. Journal of Clinical Oncology. 2017 May;35(15):Suppl 9011-9011. DOI: 10.1200/JCO.2017.35.15. **Principal Author**.

2017 Jun 3 Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit? 2017 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Sierra Cheng. Oral Presentation.

Publication Details:

Cheng, S., McDonald, E.J., Cheung, M.C., Arciero, V.S., Qureshi, M., Jiang, D., Ezeife, D., Sabharwal, M., Chambers, A., Han, D., **Leighl, N.**, Sabarre, K-A., Chan, K. Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit? Journal of Clinical Oncology. 2017 Aug 20;35(24):2764-2771. **Coauthor or Collaborator**.

2016 Dec Stage 11 NSCLC Treated with Non-Surgical Approaches: A Multi-Institutional Report of Outcomes. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): S Dudani. P1.05-069 - Poster Presentation.

Publication Details:

Dudani S, Zhu X, Yoko,DW, Yamada A, Ho C, Pantarotto J, **Leighl NB**, Zhang T, Wheatley-Price P. Stage 11 NSCLC Treated with Non-Surgical Approaches: A Multi-Institutional Report of Outcomes. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S657-658. **Coauthor or Collaborator**.

2016 Dec Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Kelvin Young. P1.06-039-Poster Presentation.

Publication Details:

Young K, Marquez M, Yeung J, Shepherd F, Keshavjee S, Renner E, Kim J, Ross H, Aliev T, Liu G, **Leighl NB**, Feld R, Bradbury. Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1). **Coauthor or Collaborator**.

- 2016 Dec Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Elliot Wakeam. P1.07-016- Poster Presentation. Available from: <https://doi.org/10.1016/j.jtho.2016.11.927>.
- Publication Details:*
Wakeam E, Varghese Jr T, **Leighl NB**, Giuliani M, Finlayson SR, Darling G. Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer. J Thorac Oncol. 2017 Jan;12(1):S705. Abstr #P1.07-016. **Coauthor or Collaborator**.
- 2016 Dec Giving a Voice to Patients and Caregivers Through The Lung Cancer Canada 'Faces of Lung Cancer' Survey: Topic: Patient's Voice, Patient's Information. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Mark Doherty. P2.08-001- Poster Presentation.
- Publication Details:*
Doherty M, Sit C, **Leighl N**, Wheatley-Price P. Giving a Voice to Patients and Caregivers Through The Lung Cancer Canada 'Faces of Lung Cancer' Survey: Topic: Patient's Voice, Patient's Information. J Thorac Oncol. 2017 Jan;12(1):S1109. Abstr #P2.08-001. **Coauthor or Collaborator**.
- 2016 Dec ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Alona Zer. OA221/02-Oral Presentation.
- Publication Details:*
Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, **Leighl N**, Liu G, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd F. ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S326-327. **Coauthor or Collaborator**.
- 2016 Dec The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Grainne O'Kane. P2.03b-008 - Poster Presentation.
- Publication Details:*
O'Kane GM, Labbe C, Su S, Tse B, Tam V, Tse T, Doherty MK, Stewart E, Brown C, Perez Cosio A, Patel, Liang M, Gill G, Rett A, Leugn Y, Naik H, Eng L, Mittmann N, **Leighl NB**, Feld R, Bradbury P, Shepherd F, Xu W, Howell, D, Liu G. The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S937. **Coauthor or Collaborator**.
- 2016 Dec Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM:Phase 11 Findings from the Placebo-Controlled LUME-Meso Trial. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): F. Grosso. OA22.02-Oral Presentation.
- Publication Details:*
Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, **Leighl NB**, Reck M, Taylor P, Pavlakis N, Sorensen JB, Planchard D, Ceresoli GL, Hughes B, Mazieres J, Socinski MA, Mueller M, Von Wangenheim U, Loembe AB, Morsli N, Barrueco J, Scagliotti GV. Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM:Phase 11 Findings from the Placebo-Controlled LUME-Meso Trial. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S329-S330. **Coauthor or Collaborator**.
- 2016 Dec Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): D. R. Camidge. P3.02a-013-Poster Presentation.
- Publication Details:*
Camidge D.R, Tiseo M, Ahn K, Reckamp K, Hansen KH, Kim S, Huber R, West H, Groen H, Hochmair MJ, **Leighl N**, Gettinger SN, Langer C, Paz-Ares L, Smit E, KimES, Reichmann W, Clackson T, Kerstein D, Haluska F, Kim D. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates

from ALTA, a Pivotal Randomized Phase 2 Trial. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S1167-S1169. **Coauthor or Collaborator.**

2016 Dec Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): E L Stewart. P3.02b-028- Poster Presentation.

Publication Details:

Stewart EL, Cabanero M, Pham N, Shen SY, Li T, Bruce JP, Li M, **Leighl N**, Shepherd F, Pugh TJ, DeCarvalho D, Lupien M, Liu G, Tsao MS. Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S1203. **Coauthor or Collaborator.**

2016 Dec Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer. 17th IASLC World Conference on Lung Cancer. Vienna, Austria. Presenter(s): Alona Zer. P3.02c-076- Poster Presentation.

Publication Details:

Stewart EL, Cabanero M, Pham N, Shen SY, Li T, Bruce JP, Li M, **Leighl N**, Shepherd F, Pugh TJ, DeCarvalho D, Lupien M, Liu G, Tsao MS. Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer. Journal of Thoracic Oncology, Supplement. 2017 Jan;12(1):S1323. **Coauthor or Collaborator.**

2016 Oct Unsung Heroes of Lung Cancer: Perspectives from Caregivers in the Lung Cancer Canada Survey. ESMO 2016 Congress. Copenhagen, Denmark. Presenter(s): Mark Doherty. Abstract #3356- Poster Discussion Presentation.

Publication Details:

Doherty M, Sit C, **Leighl N**, Wheatley-Price P. Unsung Heroes of Lung Cancer: Perspectives from Caregivers in the Lung Cancer Canada Survey. ESMO 2016 Congress Abstract Book- Supplement to Anal of Oncology. **Coauthor or Collaborator.**

2016 Aug 25 P2:39: Long-Term OS for Patients with Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pemetrexed: Track: Immunotherapy. IASCL 7th Latin American Conference on Lung Cancer. Panama City, Panama. Presenter(s): Ramalingam S.

Publication Details:

Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, **Leighl N**, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. P2:39: Long-Term OS for Patients with Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pemetrexed: Track: Immunotherapy. Journal of Thoracic Oncology. 2016 Oct 1;11(10S):S241-S242. **Coauthor or Collaborator.**

2016 Apr 13 176P: ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. European Lung Cancer Conference. Geneva, Switzerland. Presenter(s): Alona Zer.

Publication Details:

Zer A, Hershko-Klement A, Hwang D, Korpany G, **Leighl N**, Liu G, Fied R, Burkes R, Tsao M, Shepherd F. 176P: ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology, Supplement. 2016 Apr;1(11(4Suppl)):S134. **Coauthor or Collaborator.**

2016 Jan 15 **Co-author.** Elimination of second-hand smoke exposure after a lung or head and neck cancer diagnosis and subsequent patient smoking cessation. ASCO 2016 Cancer survivorship symposium. San Francisco, California, United States. Presenter(s): L Eng. (Trainee Presentation)

Publication Details:

Eng L, Laton D, Song Y, Farzanfar D, Krysz L, Yoannidis T, milne R, Habbous S, Brown C, Vennettili A,

Shepherd FA, **Leighl N**, Hope A, Howell Dr, Jones J, Selby P, Xu W, Goldstein D, Giuliani M, Liu G. Elimination of second-hand smoke exposure after a lung or head and neck cancer diagnosis and subsequent patient smoking cessation. **Coauthor or Collaborator**.

2016 Jan 15 **Co-author**. What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, oncologists and family physician? ASCO 2016 Cancer survivorship symposium. San Francisco, California, United States. Presenter(s): Martine Puts.

Publication Details:

Puts M, Krzyzanowka M, Fitch M, Warde P, Tourangeau A, Sattar S, **Leighl N**, Amir, Alibhai S. What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, oncologists and family physician? **Coauthor or Collaborator**.

2015 Nov 13 **Co-author**. Oral Presentation: What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, oncologists and family physician? International Society of Geriatric Oncology (SIOG) 2015 Annual Conference. Prague, Czech Republic. Presenter(s): Martine Puts.

Publication Details:

Puts M, Krzyzanowka M, Fitch M, Warde P, Tourangeau A, Sattar S, **Leighl N**, Amir, Alibhai S. Oral Presentation: What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, oncologists and family physician? **Coauthor or Collaborator**.

2015 Sep 25 **Co-author**. Efficacy and Safety of Pembrolizumab for Patients with Previously Treated Advanced NSCLC Enrolled in KEYNOTE-001. European Cancer Conference 2015 (ECCO-ESMO). Vienna, Austria. Presenter(s): JC Soria.

Publication Details:

Soria JC, Flotten O, Horn L, Felip E, Gandhi L, Hui R, Hellmann M, **Leighl N**, Zhang J, Kondic A, Rangwala R, Lubiniecki GM, Garon EB. Efficacy and Safety of Pembrolizumab for Patients with Previously Treated Advanced NSCLC Enrolled in KEYNOTE-001.

2015 Sep **Presenter**. Oral 31.02: Pembrolizumab for NSCLC: Immune-Mediated Adverse Events and Corticosteroid Use. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): **Leighl N**.

Publication Details:

Leighl N, Gandhi L, Hellmann MD, Horn L, Ahn MJ, Garon EB, Hui R, Ramalingam SS, Zhang J, Lubiniecki G, Raftopoulos H, Hamid O. Oral 31.02: Pembrolizumab for NSCLC: Immune-Mediated Adverse Events and Corticosteroid Use. J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S223. **Principal Author**.

2015 Sep **Co-author**. Plenary 04.03 Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): Wakelee H.

Publication Details:

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei A, **Leighl N**, Aisner S, Rothman JM, Patel JM, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Horn L, Ramalingam SS, Schiller J. Plenary 04.03 Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505. J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S66. **Coauthor or Collaborator**.

2015 Sep **Presenter**. Mini Oral 05.13: Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC) Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on Outcome. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): Doherty M. (Trainee Presentation)

Publication Details:

Doherty MK, Korpanty G, Tomasini P, Alizadeh M, Jao K, Labbe C, Mascaux C, Martin P, Kamel-Reid S, Pintilie M, Liu G, Bradbury P, Feld R, **Leighl N**, Chung C, Shepherd F. Mini Oral 05.13: Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC) Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on Outcome. J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S279. **Coauthor or Collaborator.**

2015 Sep **Presenter.** MiniOral 25.01: A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): SA Laurie.

Publication Details:

Laurie SA, Hao D, **Leighl N**, Goffin J, Khomani A, Filion M, Pond GR, Levine MN. MiniOral 25.01: A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial. J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S352. **Coauthor or Collaborator.**

2015 Sep **Presenter.** MiniOral 29.12: Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): Lim C. (Trainee Presentation)

Publication Details:

Lim C, Sung M Mouriany N, Sawczak M, Paul T, Perera-Low N, Foster A, Zawisza A, Feld R, Liu G, Shepherd F, **Leighl N**. MiniOral 29.12: Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S371. **Senior Responsible Author.**

2015 Sep **Presenter.** Poster 3.04-044: Pembrolizumab for NSCLC: EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer. 16th IASLC World Conference on Lung Cancer. Denver, Colorado, United States. Presenter(s): Labbe C. (Trainee Presentation)

Publication Details:

Labbe C, Stewart E, Brown C, Perez Cosio A, Bennettilli A, Patel D, Cheng N, Liang M, Gill G, Leung Y, Haik H, Mittmann N, **leighl N**, Feld R, Bradbury P, Shepherd F, Howell D, Liu G. Poster 3.04-044: Pembrolizumab for NSCLC: EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer. J Thorac Oncol. 2015 Sep;10(9 (Suppl 2)):S704. **Coauthor or Collaborator.**

2015 Jun 25 **Co-author/collaborator.** Quality of Life and Satisfaction with Care in Caregivers of Patients with Advanced Cancer: Results from a Trial of Early Palliative Care. Multinational Association of Supportive Care in Cancer (MASCC/ISOO). Copenhagen, Denmark. Poster Presentation.

Publication Details:

McDonald J, Swami N, Hannon B, Pope A, Oza A, **Leighl N**, Tannock I, Kryzanowska M, Rodin G, Le L, Zimmermann C. Quality of Life and Satisfaction with Care in Caregivers of Patients with Advanced Cancer: Results from a Trial of Early Palliative Care. Supportive Cancer in Care. 2015;23:S206. (Suppl 1): S1-S388. **Coauthor or Collaborator.**

2015 Jun 14 **Co-author/collaborator.** The influence of gene expression profiling on decisional conflict in chemotherapy treatment decision-making for early-stage breast cancer. Health Technology Assessment International. Oslo, Norway. Poster Presentation.

Publication Details:

MacDonald KV, Bombard Y, Deal K, Trudeau M, **Leighl N**, Marshall DA. The influence of gene expression profiling on decisional conflict in chemotherapy treatment decision-making for early-stage breast cancer. Proceedings of HTAi 12th Annual Meeting. 2015 Jun 14.

2015 May 29 **Senior Responsible Author.** EGFR mutations in NSCLC: Does ethnicity influence outcomes? American

Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation; abstr e17633. (Trainee Presentation)

Publication Details:

Tomasini P, Sung M, Kamel-Reid S, Tsao MS, Liu G, Bradbury PA, Shepherd FA, Feld R, **Leighl NB**. EGFR mutations in NSCLC: Does ethnicity influence outcomes? Journal of Clinical Oncology. 2015 Jun;33. (suppl; abstr 3 17633). **Senior Responsible Author**.

2015 May 29 **Co-author/collaborator**. First-in-human phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 8013. (Trainee Presentation)

Publication Details:

Tan DS, Seto T, **Leighl NB**, Riely GJ, Sequist LV, Felip E, Wolf J, Yang JC, Matushansky I, Yu X, Schmitz SH, Chi X, Kim D. First-in-human phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. Journal of Clinical Oncology. 2015;33. (suppl; abstr 8013). **Co-Principal Author**.

2015 May 29 **Senior Responsible Author**. Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 6534. (Trainee Presentation)

Publication Details:

Lim CH, Sung M, Nouriany NZ, Sawczak M, Paul T, Perera-Low N, Feld R, Liu G, Shepherd FS, **Leighl NB**. Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? Journal of Clinical Oncology. 2015;33. (suppl; abstr 6534). **Senior Responsible Author**.

2015 May 29 **Co-author/collaborator**. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr e 19006. (Trainee Presentation)

Publication Details:

Korpanty G, Kamel-Reid S, Tsao MS, Hwang DM, Zer AI, Liu G, **Leighl NB**, Feld R, Gill B, Pintilie M, Shepherd FS. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. Journal of Clinical Oncology. 2015;33. (suppl; abstr e 19006). **Coauthor or Collaborator**.

2015 May 29 **Co-author/collaborator**. Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM). American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr TPS7586. (Trainee Presentation)

Publication Details:

Doherty M, **Leighl NB**, Feld R, Bradbury P, Wang L, Nie J, Yen P, Pniak M, Nguyen LT, Butler MO, de Perrot M. Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 2015;33. (suppl; abstr TPS7586). **Coauthor or Collaborator**.

2015 May 29 **Co-author/collaborator**. Predictive value of co-existing KRAS and PT53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 11060. (Trainee Presentation)

Publication Details:

Tomasini P, Jao K, Kamel-Reid S, Stockley T, Tsao MS, Liu G, **Leighl NB**, Feld R, Bradbury PA, Pintilie M, Mascaux C, Shepherd FS. Predictive value of co-existing KRAS and PT53 mutations on response to

chemotherapy in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015;33. (supple; abstr 11060). **Coauthor or Collaborator.**

2015 May 29 **Co-author/collaborator.** Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 7521. (Trainee Presentation)

Publication Details:

Jao K, Tomasini P, Kamel-Reid S, Tsao MS, Korpanty G, Mascaux C, Liu G, **Leighl NB**, Feld R, Bradbury PA, Ennis M. Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015;33. (suppl; abstr 7521). **Coauthor or Collaborator.**

2015 May 29 **Co-author/collaborator.** Quality of life and satisfaction with care in caregivers of patients with advanced cancer: Results from a trial of early palliative care. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 9513.

Publication Details:

McDonald JC, Swami N, Hannon B, Pope A, Le LW, Oza A, Leighl NL, Tannock I, Kryzanowska MK, Rodin G, Zimmermann C. Quality of life and satisfaction with care in caregivers of patients with advanced cancer: Results from a trial of early palliative care. Journal of Clinical Oncology. 2015;33. (suppl; abstr 9513). **Coauthor or Collaborator.**

2015 May 29 **Co-author/collaborator.** Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 9556.

Publication Details:

Eng L, Alton D, Yoannidis T, Song Y, Milne R, Sarabia S, Merali Z, Habbous S, Brown MC, Vennettilli A, Shepherd FA, **Leighl N**, Hope AJ, Howell D, Jones JM, Selby P, Xu W, Goldstein DP, Giuliani ME, Liu G. Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation. Journal of Clinical Oncology. 2015;33. (supple; abstr 9556). **Coauthor or Collaborator.**

2015 May 29 **Co-Author/Collaborator.** Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro;MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 8026.

Publication Details:

Rizvi NA, Garon EB, **Leighl NB**, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Rangwala RA, Lubiniecki G, Zhang J, Emancipator K, Roach CM, Rutledge R, Hui R, Ahn MA, Horn L, Felip E, Costa EC. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro;MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. Journal of Clinical Oncology. 2015;33. (supple; abstr 8026). **Coauthor or Collaborator.**

2015 Apr 18 **Co-author/collaborator.** Efficacy of pembrolizumab (MK-347) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001. American Association for Cancer Research 2015 Annual Meeting. Philadelphia, Pennsylvania, United States. Poster Presentation, Abstr CT104.

Publication Details:

Garon EB, Rizvi N, Hui R, **Leighl NB**, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens MA, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Zhang J, Rangwala RA, Lubiniecki GM, Roach CM, Emancipator K, Gandhi L. Efficacy of pembrolizumab (MK-347) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001. Proceedings of AACR 2015 Annual Meeting. 2016 Apr. Abstract # CT104. **Coauthor or Collaborator.**

2014 Nov 28 **Invited Lecturer.** Squamous Lung Cancer- 2014 and beyond. Polish Lung Cancer Co-operative Group,

8th Annual Conference. Warsaw, Poland.

Publication Details:

Leighl N. Squamous Lung Cancer- 2014 and beyond. *Onkologia W Praktyce Klinicznej*. 2014 Nov 28;2014(10, suppl):E9-E10. Presented at 8th Annual Conference-Polish Lung Cancer Group, Warsaw, Poland, Nov 28-29, 2014. **Principal Author.**

2014 Nov 18 **Co-author/collaborator.** Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in $\geq 50\%$ of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Barcelona, Spain. Poster Presentation.

Publication Details:

Garon EG, Rizvi NA, **Leighl NB**, Hui R, Eder JP, Patnaik A, Aggarwal C, Horn L, Balmanoukian AS, Gubens MA, Felip-Font E, Carceny Costa E, Soria JC, Ahn MJ, Arkenau Ht, Lee Js, Robinet G, Lubiniecki GM, Zhang J, Emancipator K, Rutledge R, Dolled-Filhart M, Gandhi L. Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in $\geq 50\%$ of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population. *European Journal of Cancer*. 2014 Nov;50(Suppl 6):44-45. **Coauthor or Collaborator.**

2014 Nov 11 **Collaborator.** The influence of gene expression profiling on decisional conflict in chemotherapy treatment decision-making for early-stage breast cancer. ISPOR 17th Annual European Congress. Amsterdam, Netherlands. Poster presentation at ISPOR November 2014.

Publication Details:

Marshall D, MacDonald K, Deal K, Trudeau M, **Leighl N**, Bombard Y. The influence of gene expression profiling on decisional conflict in chemotherapy treatment decision-making for early-stage breast cancer. *Value in Health*. 2014 Nov;17(7):A569. **Coauthor or Collaborator.**

2014 Nov 8 **Senior Responsible Author.** The Cost-effectiveness of second-line crizotinib in EML4-ALK rearranged NSCLC. ISPOR 17th Annual European Congress. Amsterdam, Netherlands. Poster presentation at ISPOR November 2014. (Trainee Presentation)

Publication Details:

Djalalov S, Graham DM, Beca J, Hoch JS, Tsao MS, **Leighl N**. The Cost-effectiveness of second-line crizotinib in EML4-ALK rearranged NSCLC. *Value in Health*. 2014 Nov;17(7):A642. **Senior Responsible Author.**

2014 Sep 26 **Collaborator.** Prophylactic Treatment for Rash Induced by EGFR Inhibitor Improves Rash Without Compromising on Efficacy The PanCanadian Rash Trial: A Randomized Phase III Trial In NSCLC. ESMO 2014. Madrid, Spain. Poster Presentation at ESMO 2014.

Publication Details:

Melosky B, Burkes R, Chu QS, Hao D, Ho C, Anderson H, Lee C, **Leighl NB**, Murray N, Sun S, Winston R, Lam W, Laskin J. Prophylactic Treatment for Rash Induced by EGFR Inhibitor Improves Rash Without Compromising on Efficacy The PanCanadian Rash Trial: A Randomized Phase III Trial In NSCLC. *Annals of Oncology*. 2014;25((suppl 4)):iv449. **Coauthor or Collaborator.**

2014 Sep 14 **Co-Author/Collaborator.** Genetic Polymorphisms Associated with Toxicity are Associated with Overall Survival Following Curative Radiation for Non-Small Cell Lung Cancer. ASTRO 56th Annual Meeting. San Francisco, California, United States. Poster Presentation.

Publication Details:

Barrett K, Xu J, Kim S, Boyd K, Cheng D, ChenZ, Bezjak A, Sun A, Cho J, Brade A, **Leighl N**, Shepherd F, Xu W, Liu G, Hope A. Genetic Polymorphisms Associated with Toxicity are Associated with Overall Survival Following Curative Radiation for Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology, Physics*. 2014 Sep 1;90(1):S811. Supplement. **Coauthor or Collaborator.**

- 2014 Sep 14 **Co-Author/Collaborator.** Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). ASTRO 56th Annual Meeting. San Francisco, California, United States. Poster Presentation.
- Publication Details:*
Balmanoukian AS, Rizvi NA, Garon EB, Patnaik A, Gandhi L, **Leighl NB**, Goldman JW, Eder JP, Johnson EA, Blumenschein GR, Gubens MA, Papadoupoulso KP, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson ME, Hui R. Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 2015 Nov 15;90(5):S1-S2. Supplement. **Coauthor or Collaborator.**
- 2014 Jun 1 **Collaborator.** Lung cancer in never-smokers from the Princess Margaret Cancer Centre. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Korpanty G, Kamel-Reid S, Tsao MS, Zer A Liu G, **Leighl NB**, Feld R, Pintilie M, Shepherd FA. Lung cancer in never-smokers from the Princess Margaret Cancer Centre. J Clin Oncol. 2014;32(5s):(suppl; abstr 8099). **Coauthor or Collaborator.**
- 2014 Jun 1 **Senior Responsible Author.** Estimation of drug cost avoidance (DCA) and pathology drug cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Tang PA, Hay, AE, O'Callaghan CJ, Mittmann N, Chambers C, Pater JL, **Leighl NB**. Estimation of drug cost avoidance (DCA) and pathology drug cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada. J Clin Oncol. 2014;32(5s):(suppl: abstr 6560). **Senior Responsible Author.**
- 2014 Jun 1 **Senior Responsible Author.** Biomarker testing and time-to-treat decision in patients with advanced non-small cell lung cancer. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)
- Publication Details:*
Lim CH, Le L, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Tsao MS, **Leighl NB**. Biomarker testing and time-to-treat decision in patients with advanced non-small cell lung cancer. J Clin Oncol. 2014;32(5s):(suppl; abstr 6595). **Senior Responsible Author.**
- 2014 Jun 1 **Collaborator.** Modified isolated lung perfusion technique for allowance of prolonged perfusion without acute lung injury: A preclinical study of doxorubicin. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Reck dos Santos PA, Sakamoto J, Chen M, Linacre V, Arce C, Hwang D, de Perrot M, Liu M, **Leighl NB**, Keshavjee S, Waddell TK, Cypel M. Modified isolated lung perfusion technique for allowance of prolonged perfusion without acute lung injury: A preclinical study of doxorubicin. J Clin Oncol. 2014;32(5s):(suppl; abstr 10597). **Coauthor or Collaborator.**
- 2014 Jun 1 **Collaborator.** Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Scagliotti GV, **Leighl NB**, Nowak AK, Pavlakis N, Popat S, Sorensen JB, Barrueco J, Kaiser R, Loembe A, Mueller M, von Wangenheim U, Reck M. Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study. J Clin Oncol. 2014;32(5s).

(suppl; abstr TPS7612). **Coauthor or Collaborator.**

2014 Jun 1 **Collaborator.** Prophylactic treatment for rash induced by EGFR inhibitor improves rash without compromising on efficacy. The Pan-Canadian Rash Trial: A randomized Phase III trial in NSCLC. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster presentation 2014 ASCO Annual Meeting.

Publication Details:

Melosky BL, Anderson H, Burkes RL, Chu QS, Hao D, Ho V, Ho C, Lee CW, Murray N, **Leighl NB**, Sun S, Winston RD, Laskin JJ. Prophylactic treatment for rash induced by EGFR inhibitor improves rash without compromising on efficacy. The Pan-Canadian Rash Trial: A randomized Phase III trial in NSCLC. J Clin Oncol. 2014;32(5s):(suppl; abstr 8013). Poster presentation 2014 ASCO Annual Meeting. **Coauthor or Collaborator.**

2014 Jun 1 **Collaborator.** Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Garon EB, **Leighl NB**, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, Goldman JW, Hui R, Soria JC, Tara C, Gangadhar TC, Sun JM, Patnaik A, Gubens MA, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson ME, Gandhi L. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(5s):(suppl; abstr 8020). Poster Presentation. **Co-Principal Author.**

2014 Jun 1 **Senior Responsible Author.** A targeted intervention to improve awareness to molecular testing in NSCLC. ASCO Annual Meeting 2014. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Zer A, Cutz JC, Sekhon HS, Hwang DM, Sit C, Binnie M, Brade AM, Chung TB, Kamel-Reid S, Narinder P, Tsao MS, Waddell TK, da Cunha Santos G, Patel M, Carter RF, **Leighl NB**. A targeted intervention to improve awareness to molecular testing in NSCLC. J Clin Oncol. 2014;32(5s):(suppl; abstr 6547). **Senior Responsible Author.**

2014 May 31 **Collaborator.** First two years of health system resources and costs following a stage defined breast cancer diagnosis: A population based approach. ISPOR 19th Annual International Meeting. Montreal, Quebec, Canada. Poster Presentation.

Publication Details:

Mittmann N, Porter J, Rangrej J, Seung SJ, Saskin R, Cheung M, **Leighl NB**, Hoch J, Trudeau M, Evans W, Dainty KN, DeAngelis C, Earle CC. First two years of health system resources and costs following a stage defined breast cancer diagnosis: A population based approach. Value in Health. 2014 May;17(3):A97. **Coauthor or Collaborator.**

2014 May 31 **Collaborator.** Cost-Utility analysis of newer HER2- testing technologies to target trastuzumab in the adjuvant breast cancer setting. ISPOR 19th Annual International Meeting. Montreal, Quebec, Canada. Poster Presentation.

Publication Details:

Ferrusi IL, Kulin NA, Goeree R, **Leighl NB**, Pullenayegum EM, Phillips K, Marshall D. Cost-Utility analysis of newer HER2- testing technologies to target trastuzumab in the adjuvant breast cancer setting. Value in Health. 2014 May;17(3):A90. **Coauthor or Collaborator.**

2014 May 31 **Senior Responsible Author.** The cost-effectiveness of 2nd line crizotinib in EML4-Alk rearranged advanced NSCLC in Ontario. ISPOR 19th Annual International Meeting. Montreal, Quebec, Canada. Poster Presentation.

Publication Details:

Djalalov S, Graham DM, BEca J, Hoch JS, Tsao MS, Cutz JC, **Leighl NB**. The cost-effectiveness of 2nd

line crizotinib in EML4-ALK rearranged advanced NSCLC in Ontario. Value in Health. 2014 May;17(3):A90. **Senior Responsible Author.**

2014 May 31 **Collaborator.** Cost-utility analysis of practice deviations from guidelines in HER-2 targeted testing and treatment for breast cancer. ISPOR 19th Annual International Meeting. Montreal, Quebec, Canada. Poster Presentation.

Publication Details:

Ferrusi IL, Kulin NA, Goeree R, **Leighi NB**, Pullenayegum EM, Phillips K, Marshall D. Cost-utility analysis of practice deviations from guidelines in HER-2 targeted testing and treatment for breast cancer. Value in Health. 2014 May;17(3):A91. **Coauthor or Collaborator.**

2014 Jan 16 **Collaborator.** A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer. 2014 Gastrointestinal Cancers Symposium. San Francisco, California, United States. Poster presentation at 2014 Gastrointestinal Cancers Symposium January 16-18, 2014 in San Francisco, California.

Publication Details:

Chan KK, Tu D, O'Callaghan CJ, Au HJ, **Leighi NB**, Brundage MD, Jonker DJ, Karapetis CS, Ringash J, Zalcborg JR, Hoch JS, Tebbutt NC, Shapiro J, Price TJ, Pavlakis N, Van Hazel GA, Mittmann N. A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer. J Clin Oncol. 2014 Jan;32:(suppl 3; abstr 547). **Coauthor or Collaborator.**

2013 Nov 2 **Senior Responsible Author.** Cost effectiveness of EML-4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK positive non-small cell lung cancer in a publicly funded system (Ontario, Canada). ISPOR 16th Annual European Congress. Dublin, Ireland. Poster Presentation.

Publication Details:

Djalalov S, Beca J, Hoch JS, Drahn MD, Tsao MS, Cutz JC, **Leighi NB**. Cost effectiveness of EML-4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK positive non-small cell lung cancer in a publicly funded system (Ontario, Canada). Value in Health. 2013 Nov;16(7):A410. **Senior Responsible Author.**

2013 Nov 2 **Co-author/collaborator.** Population Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. ISPOR 16th Annual European Meeting. Dublin, Ireland. Poster Presentation.

Publication Details:

Mittmann N, Sueng SJ, Liu N, Porter J, Saskin R, Hoch JS, Evans W, **Leighi N**, Trudeau M, Earle CC. Population Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. Value in Health. 2013;16(7):A430. **Coauthor or Collaborator.**

2013 Nov 2 **Collaborator.** Stage-Based Utilization of Chemotherapy Agents in a Canadian Breast Cancer Population. ISPOR 16th Annual European Meeting. Dublin, Ireland. Poster Presentation.

Publication Details:

Mittmann N, Seung SJ, Porter J, Rangrej J, Liu N, Trudeau M, DeAngelis C, Hoch JS, **Leighi N**, Earle C.C. Stage-Based Utilization of Chemotherapy Agents in a Canadian Breast Cancer Population. Value in Health. 2013;16(7):A426. **Coauthor or Collaborator.**

2013 Nov 1 **Co-Author/Collaborator.** Patients' perceptions of early palliative oncology care: A qualitative analysis. ASCO Quality Symposium Annual Meeting November 1-2, 2013. San Diego, California, United States. Poster presentation at ASCO Quality Care Symposium November 1-2, 2013.

Publication Details:

Hannon B, Swami N, Krzyzanowska MK, **Leighi NB**, Amit M, Oza AM, Moore MJ, Rodin G, Tannock I, Zimmermann C. Patients' perceptions of early palliative oncology care: A qualitative analysis. J Clin Oncol. 2013 Nov;31. (suppl 31; abstr 138). **Coauthor or Collaborator.**

2013 Nov 1 **Co-Author/Collaborator.** Access to personalized medicine: Factors influencing the use and value of

gene expression profiling in treatment decision making. 2013 ASCO Quality Care Symposium. San Diego, California, United States. Poster Presentation.

Publication Details:

Bombard Y, Rozmovits L, Trudeau ME, **Leighl NB**, Deal K, Marshall D. Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision making. Journal of Clinical Oncology. 2013;31. (suppl 31; abstr 10). **Coauthor or Collaborator**.

2013 Nov 1 **Co-Author/ Collaborator**. Patients' and caregivers' views on the timing and benefits of early palliative care: A qualitative study. 2013 ASCO Quality Care Symposium. San Diego, California, United States. Poster Presentation.

Publication Details:

Patients' and caregivers' views on the timing and benefits of early palliative care: A qualitative study. 31. 2013. (supple 31; abstr 157). **Coauthor or Collaborator**.

2013 Nov **Co-author/collaborator**. The effect of two BRM promoter polymorphisms on the risk of advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in smokers. 15th World Conference on Lung Cancer. Sydney, Australia. Poster presentation. MO05.11.

Publication Details:

Cuffe S, Qiu X, Patel D, Azad AK, Cheng D, Chen Z, Boyd K, **Leighl NB**, Xu W, Shepherd FA, TSao MS, Reisman DN, Liu G. The effect of two BRM promoter polymorphisms on the risk of advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in smokers. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S285-S286. MO05.11 Poster presentation 15th World Conference on Lung Cancer. **Coauthor or Collaborator**.

2013 Nov **Senior Responsible Author**. Needs assessment of advanced lung cancer patients-evolution over a decade? 15th World Conference on Lung Cancer. Sydney, Australia. MO27.08 Poster presentation.

Publication Details:

Zawisza D, Ali V, Djalalov S, Patel M, Lin S, Tudor R, Le L, **Leighl NB**. Needs assessment of advanced lung cancer patients-evolution over a decade? Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S424. **Senior Responsible Author**.

2013 Oct 31 **Collaborator**. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving Kras-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results. 15th World Conference on Lung Cancer. Sydney, Australia. MO18.10 Poster presentation.

Publication Details:

Mazieres J, Gandara DR, **Leighl NB**, Wheler JJ, Farlesi F, Zalzman G, Kelly K, Reckamp KL, Gordon MS, Hirt S, Shepherd FA, Janku F, Cho BC, Park K, Infante JR, Richards DA, Wu Y, Schramek DJ, Cox DS, Piepszak AM, Liu Y, Gardner OS, Reddareddigari VGR, Blumenschein GR. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving Kras-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S369-S370. **Coauthor or Collaborator**.

2013 Oct 30 **Presenter**. Approach to biomarker testing: perspectives from various specialities. 15th World Conference on Lung Cancer. Sydney, Australia. Presenter(s): **N. Leighl**. Poster Presentation.

Publication Details:

Leighl NB, Ellis P, Verma S. Approach to biomarker testing: perspectives from various specialities. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2- S1086. **Principal Author**.

2013 Oct 30 **Senior Responsible Author**. Afatinib in advanced pretreated NSCLC- A Canadian experience. 15th World Conference on Lung Cancer. Sydney, Australia. P3.11-049 Poster presentation.

Publication Details:

Melosky B, Kan M, Tudor R, Lin S, Lau A, Panzarella T, **Leighl NB**. Afatinib in advanced pretreated NSCLC- A Canadian experience. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S1212. **Senior Responsible Author.**

2013 Oct 28 **Senior Responsible Author.** A cost-effectiveness analysis of the 15-gene expression signature in guiding adjuvant chemotherapy in early stage non-small cell lung cancer based on the JBR.10 trial. 15th World Conference on Lung Cancer. Sydney, Australia. MO08.08 Oral Presentation. (Trainee Presentation)

Publication Details:

Wong KM, Li S, Ding K, Bradbury P, Tsao MS, Shepherd FA, Chung C, Ng R, Seymour L, **Leighl NB**. A cost-effectiveness analysis of the 15-gene expression signature in guiding adjuvant chemotherapy in early stage non-small cell lung cancer based on the JBR.10 trial. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S304. **Senior Responsible Author.**

2013 Oct 27 **Presenter.** Biomarker analysis of NCIC Clinical Trials Group IND. 196 - A Phase I study of Erlotinib plus Foretinib in advanced pretreated non-small cell lung cancer patients. 15th World Conference on Lung Cancer. Sydney, Australia. MO12.04 Oral Presentation.

Publication Details:

Leighl NB, Tsao MS, Sakashita S, Tu D, Ho C, Shepherd FA, Murray N, Nicholas G, Goffin JR, Kim L, Kamel-Reid S, Ho J, Zhang T, Sukhai M, Seymour L, Goss G, Bradbury, P. Biomarker analysis of NCIC Clinical Trials Group IND. 196 - A Phase I study of Erlotinib plus Foretinib in advanced pretreated non-small cell lung cancer patients. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S330-S331. **Principal Author.**

2013 Oct 27 **Collaborator.** Oral MEK1/MEK 2 inhibitor trametinib (GSK1120212) in combination with docetaxel in a Phase 1/1B trial involving Kras-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC) efficacy and biomarker results. 15th World Conference on Lung Cancer. Sydney, Australia.

Publication Details:

Bennouna J, **Leighl NB**, Kelly K, Blumenschein GR, Zalcman G, Audebert C, Gomez-Roca C, Reckamp KL, Infante JR, Lara P, Shepherd FA, Janku F, Cho BC, Park K, Braiteh FS, Jotte RM, Wu Y, Schramek Daniel J, Cox DS, Piepszak AM, Liu Y, Garnder OS, Peddareddigari VGR, Gandara DR. Oral MEK1/MEK 2 inhibitor trametinib (GSK1120212) in combination with docetaxel in a Phase 1/1B trial involving Kras-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC) efficacy and biomarker results. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S370-S371. MO18.11 Poster presentation 15 World Conference on Lung Cancer. **Coauthor or Collaborator.**

2013 Oct 27 **Senior Responsible Author.** Economic Analysis of TORCH: Erlotinib vs. Cisplatin and Gemcitabine as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). 15th World Conference on Lung Cancer. Sydney, Australia. P1-11-020 Poster presentation.

Publication Details:

Chung C, Jiang H, Isaranuwatthai W, Di Maio M, Lau A, Hoch J, Feld, R, Tsao MS, Gridelli C, Gallo C, Ciardiello F, Butts CA, Perrone F, **Leighl, N**. Economic Analysis of TORCH: Erlotinib vs. Cisplatin and Gemcitabine as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S602-S603. **Senior Responsible Author.**

2013 Oct 27 **Collaborator.** BRM promoter variants and survival outcomes of advanced non-small cell lung cancer (NSCLC) patients: A validation study in The NCIC Clinical Trials Group (NCIC-CTG) BR24 clinical Trial. 15th World Conference on Lung Cancer. Sydney, Australia. O01.03 Poster presentation.

Publication Details:

Cuffe S, Cheg L, Azad AK, Brhane Y, Cheng D, Chen Z, Qiu X, Boyd K, **Leighl NB**, Xu W, Chen BE, Bradbury P, Shepherd FA, Seymour L, Tsao MS, Reisman DN, Liu G. BRM promoter variants and survival outcomes of advanced non-small cell lung cancer (NSCLC) patients: A validation study in The

NCIC Clinical Trials Group (NCIC-CTG) BR24 clinical Trial. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S132-S133. **Coauthor or Collaborator**.

2013 Oct 27 **Collaborator**. Patient-derived primary non-small cell lung carcinoma (NSCLC) xenograft models for mechanistic studies of resistance to EGFR tyrosine kinase inhibitor therapy. 15th World Conference on Lung Cancer. Sydney, Australia.

Publication Details:

Mascaux C, Martin P, Stewart E, Panchal D, Kim L, Sakashita S, Wang D, Li M, Pham NA, **Leigh NB**, Liu G, Shepherd FA, Tsao MS. Patient-derived primary non-small cell lung carcinoma (NSCLC) xenograft models for mechanistic studies of resistance to EGFR tyrosine kinase inhibitor therapy. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S163-S164. O08.07 Poster presentation 15th World Conference on Lung Cancer. **Coauthor or Collaborator**.

2013 Oct 27 **Coauthor**. The impact of body mass index on survival in stage 3 and 4 lung cancer. 15th World Conference on Lung Cancer. Sydney, Australia.

Publication Details:

Wong KM, Cuffe S, Coate L, Espin-Garcia O, Boyd K, Feld R, **Leigh N**, Shepherd FA, Xu W, Liu G. The impact of body mass index on survival in stage 3 and 4 lung cancer. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S234. O24.05 Poster presentation 15th World Conference on Lung Cancer. **Coauthor or Collaborator**.

2013 Oct 27 **Co-author/collaborator**. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). 15th World Conference on Lung Cancer. Sydney, Australia. Poster presentation. MO18.02. (Trainee Presentation)

Publication Details:

Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, **Leigh NB**, Gubens MA, Goldman J, Lubiniecki GM, Lunceford J, Gergich K, Rizvi N. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S364-S365. MO18.02 Poster presentation 15th World Conference on Lung Cancer. **Coauthor or Collaborator**.

2013 Oct 27 **Senior Responsible Author**. Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. 15th World Conference on Lung Cancer. Sydney, Australia. Poster presentation; P3. 12-015. (Trainee Presentation)

Publication Details:

Sacher A, Lara-Guerra H, Waddell T, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling GE, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, **Leigh NB**. Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. Journal of Thoracic Oncology. 2013 Nov;(8):Suppl 2, S1222. **Senior Responsible Author**.

2013 Oct 27 **Senior Responsible Author**. The cost-effectiveness of second-line crizotinib in EML4-ALK rearranged advanced non-small cell lung cancer. 15th World Conference on Lung Cancer. Sydney, Australia. Poster presentation. P3. 24-037. (Trainee Presentation)

Publication Details:

Graham DM, Djalalov S, Beca J, Hoch J, Tsao MS, Cutz JC, **Leigh NB**. The cost-effectiveness of second-line crizotinib in EML4-ALK rearranged advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S1317-S1318. P3.24-037 Poster presentation 15th World Conference on Lung Cancer. **Senior Responsible Author**.

2013 Oct 27 **Co-Author/Collaborator**. Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet. 15th World Conference on Lung Cancer. Sydney, Australia. P3.07-038 Poster presentation.

Publication Details:

Collaud S, Machuca T, Mercier O, Waddell T, Yasufuku K, Pierre A, Darling GE, Cypel M, Rampersaud Y, Lewis S, Shepherd FA, **Leighl NB**, Cho J, Bezzak A, Keshavjee S, de Perrot M. Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet. Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S1122. **Coauthor or Collaborator**.

2013 Oct 27 **Co-Principle Author**. A randomized, open-label Phase II trial of volasertib as monotherapy and in combination with standard dose pemetrexed compared with pemetrexed monotherapy in second-line non-small cell lung cancer (NSCLC). 15th World Conference on Lung Cancer. Sydney, Australia. P3.11-027 Poster presentation.

Publication Details:

Ellis PM, **Leighl NB**, Hirsh V, Reaume MN, Blais N, Wierzbiicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. A randomized, open-label Phase II trial of volasertib as monotherapy and in combination with standard dose pemetrexed compared with pemetrexed monotherapy in second-line non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2013 Nov;8:Suppl 2, S1200. **Co-Principal Author**.

2013 Oct 27 **Senior Responsible Author**. Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. 15th World Conference on Lung Cancer. Sydney, Australia. Poster presentation. P1. 11-020.

Publication Details:

Martin P, Shiau CJ, Pasic MD, Tsao MS, Kamel-Reid S, Le L, Higgins BP, Cheng SY, Burkes RL, Ng M, Arif S, Turdor R, Ling SCX, Ellis PM, Hubay S, Kuruvilla S, Laurie SA, Jing Li, Shepherd FA, **Leighl NB**. Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. J Clin Oncol. 2013;31:(suppl; abstr e19077. **Senior Responsible Author**.

2013 Oct 24 **Collaborator**. 5-Year experience with accelerated induction hyperfractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). 15th World Conference on Lung Cancer. Sydney, Australia. MO14.09 Poster presentation.

Publication Details:

De Perrot M, Mercier O, Feld R, **Leighl NB**, Waddell T, Hope A, Yasufuku K, Keshavjee S, Cho BCJ. 5-Year experience with accelerated induction hyperfractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). Journal of Thoracic Oncology. 2013 Nov;8:Suppl 8, S345-346. MO14.09 Poster presentation. **Coauthor or Collaborator**.

2013 Sep 27 **Collaborator**. Homecare utilization and costs in stage IV lung cancer: A Canadian public payer experience. European Cancer Congress. Amsterdam, Netherlands. Poster Presentation.

Publication Details:

Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, **Leighl NB**, Hoch JS, Trudeau M, Evans WK, Earle CC. Homecare utilization and costs in stage IV lung cancer: A Canadian public payer experience. European Journal of Cancer. 2013 Sep;49. Suppl 2, Abstr 1501. **Coauthor or Collaborator**.

2013 May 31 **Senior Responsible Author**. Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. ASCO Annual Meeting 2013. Chicago, Indiana, United States. Poster Presentation.

Publication Details:

Sacher AG, Lara-Guerra H, Waddell TK, Kim L, Chen Z, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, **Leighl NB**. Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. J Clin Oncol. 2013;31:(suppl; abstr 7516). **Senior Responsible Author**.

2013 May 31 **Collaborator**. Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster

Presentation.

Publication Details:

Cuffe S, Cheng L, Azad AKBrhane Y, Cheng D, Chen Z, Qiu X, Boyd K, Emami M, **Leighl NB**, Der S, Xu W, Shepherd FA, Tsao MSReisman Liu G. Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31:(suppl; abstr 11057). **Coauthor or Collaborator.**

2013 May 31 **Collaborator.** Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). ASCO Annual Meeting 2013. Chicago, Illinois, United States. Oral Presentation.

Publication Details:

Bedard PL, Oza AM, Tsao MS, **Leighl NB**, Krzyzanowska MK, Dhan NC, Clarke B, Berman HK, Serra S, Craddock KJ, Chadwick D, Zhang T, Sukhai MA, Yu C, Hansen AR, Kamel-Reid S, Siu LL. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J Clin Oncol. 2013 Jun;31:(suppl; abstr 11002). **Coauthor or Collaborator.**

2013 May 31 **Senior Responsible Author.** Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Gandara DR, Hirt S, Blumenschein GR, Barlesi F, Delord JP, Madelaine J, Infant JR, Reckamp KL, Lara P, Audebert C, Cho BC, Park K, Braithe FS, Jotte RM, Wu Y, Schramek DJ, Piepszak AM, Gardner OS, Peddareddigari VGR, **Leighl NB**. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. J Clin Oncol. 2013;31:(suppl; abstr 8028). **Senior Responsible Author.**

2013 May 31 **Collaborator.** The impact of body mass index on survival in stage 3 and 4 lung cancer. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Wong KM, Cuffe C, Coate LE, Espin-Garcia O, Boyd K, Feld R, **Leighl NB**, Shepherd FA, Xu W, Liu G. The impact of body mass index on survival in stage 3 and 4 lung cancer. J Clin Oncol. 2013;31:(suppl; abstr 1579). **Coauthor or Collaborator.**

2013 May 31 **Co-Author/Collaborator.** Willingness of patients to provide biologic samples for pharmacogenomic testing. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Loo TT, Cuffe S, Hon H, Martin P, Brown MC, Alibhai SMH, **Leighl NB**, Mascaux C, Tsao MS, Shepherd FA, Qiu X, Xu W, Liu G. Willingness of patients to provide biologic samples for pharmacogenomic testing. J Clin Oncol. 2013;31:(suppl; abstr 6543). **Coauthor or Collaborator.**

2013 May 31 **Collaborator.** Accelerated hypofractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Results of a phase I/II study. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

de Perrot M, Feld F, **Leighl NB**, Opitz I, Anraku M, Cho J. Accelerated hypofractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Results of a phase I/II study. J Clin Oncol. 2013;31:(suppl; abstr 7526). **Coauthor or Collaborator.**

2013 May 31 **Senior Responsible Author.** Clinical Impact of EGFR Mutation Fraction and Tumor Cellularity in EGFR Mutation Positive NSCLC. American Society of Clinical Oncology 2013 Annual Meeting. Chicago, Illinois,

United States. Not presented, but published in conjunction with the meeting.

Publication Details:

Martin P, Shiau CJ, Pasic MD, Tsao MS, Kamel-Reid S, Le L, Higgins BP, Cheng SY, Burkes RL, Ng M, Arif S, Tudor R, Lin S, Ellis PM, Hubay S, Kuruvilla S, Laurie SA, Li J, Shepherd FA, **Leighl NB**. Clinical Impact of EGFR Mutation Fraction and Tumor Cellularity in EGFR Mutation Positive NSCLC. Journal of Clinical Oncology. 2013;31. (suppl; abstr e 19077). **Coauthor or Collaborator**.

2013 May 31 **Senior Responsible Author**. Economic Analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2013 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Chung C, Isaranuwatchai W, Di Maio M, Jiang H, Lau A, HOch JS, Feld R, Tsao MS, Gridelli C, Ciardiello F, Butss CA, Gallo C, Perrone F, **Leighl NB**. Economic Analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2013;31. (suppl; abstr e 19031). **Senior Responsible Author**.

2013 May 31 **Co-Author/ Collaborator**. Patients' Perceptions of Early Palliative Oncology Care: A Qualitative Analysis. American Society of Clinical Oncology 2013 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Hannon B, Swami N, Krzyzanowska M, **Leighl NB**, Oza AM, Moore MJ, Rodin G, Tannock I, Zimmermann C. Patients' Perceptions of Early Palliative Oncology Care: A Qualitative Analysis. Journal of Clinical Oncology. 2013;31. (suppl; abstr e20639). **Coauthor or Collaborator**.

2013 May 30 **Collaborator**. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. ASCO Annual Meeting 2013. Chicago, Illinois, United States. Poster Presentation. Available from: 18.038.

Publication Details:

Kelly K, Mazieres J, **Leighl NB**, Barlesi F, Gomez-Roca GA, Bennouna J, Cho BC, Park K, Infante JR, Richards DA, Wu Y, Schramek DJ, Cox DS, Gardner OS, Peddareddigari VGR, Blumenschein GR. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. J Clin Oncol. 2013;31:(suppl; abstr 8027). **Coauthor or Collaborator**.

2013 May 18 **Collaborator**. Patient Preferences: Understanding Risk-Benefit Trade-Offs of Genomic Testing in Chemotherapy Decisions for Breast Cancer Patients. ISPOR 18th Annual International Meeting. New Orleans, Louisiana, United States. Poster Presentation.

Publication Details:

Marshall D, Bombard Y, Trudeau M, **Leighl N**, Pykerman K., Dela K. Patient Preferences: Understanding Risk-Benefit Trade-Offs of Genomic Testing in Chemotherapy Decisions for Breast Cancer Patients. Value in Health. 2013 May;16(3):A147-A148. Abstract PCN110. **Coauthor or Collaborator**.

2013 May 18 **Senior Responsible Author**. Cost-effectiveness of EML4-ALK fusion testing in combination with crizotinib treatment for patients with advanced non-small cell lung cancer living in Ontario. ISPOR 18th Annual International Meeting. New Orleans, Louisiana, United States. Poster presentation.

Publication Details:

Djalalov S, Hoch JS, Beca J, Krahn M, Tsao MS, Cutz JC, **Leighl NB**. Cost-effectiveness of EML4-ALK fusion testing in combination with crizotinib treatment for patients with advanced non-small cell lung cancer living in Ontario. Value in Health. 2013 May;16(3):A142. **Senior Responsible Author**.

2012 Dec 4 **Senior Responsible Author**. Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer. 2012 CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, Texas, United States. Poster

Presentation. (Trainee Presentation)

Publication Details:

Ng D, Ferrusi I, Khong H, Trudeau M, Earle C, Marshall D, **Leighl N**. Poster presentation at 2012 CTRC-AACR San Antonio Breast Cancer Symposium, Dec 4-8, 2012, San Antonio TX. Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer. Cancer Res. 2012 Dec 15;72(24 Suppl). P5-18-14; doi:10.1158/0008-5472. **Senior Responsible Author**.

2012 Nov 30 **Co-author/collaborator**. Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario. 2012 ASCO Quality Care Symposium. San Diego, California, United States. Poster Presentation.

Publication Details:

Earle C, Ferrusi IL, Trudeau ME, **Leighl NB**, Pullenayegum E, Khong H, Hoch J, Marshall D. Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario. J Clin Oncol. 2012;30:(suppl 34; abstr 166. Poster presentation 2012 ASCO Quality Care Symposium November 30- December 1, 2012 in San Diego, California. **Coauthor or Collaborator**.

2012 Nov 30 **Co-author/collaborator**. Cancer patients' and physicians' preferences for decision making regarding pharmacogenomic testing (PGT). 2012 ASCO Quality Care Symposium. San Diego, California, United States. Poster presentation.

Publication Details:

Cuffe S, Hon H, Qiu X, Masroor S, De Souza B, McFarlane G, Wong CKA, Tobros K, Azad AK, Hasani E, Rozanec N, **Leighl NB**, Atehortua NA, Alibhai SMH, Xu W, Issa AM, Liu G. Cancer patients' and physicians' preferences for decision making regarding pharmacogenomic testing (PGT). J Clin Oncol. 2012;30:(suppl 34; abstr 13). Poster presentation at 2012 ASCO Quality Care Symposium November 30- December 1, 2012 in San Diego, California. **Coauthor or Collaborator**.

2012 Nov 25 **Presenter**. NCIC CTG IND.196: Phase 1 study of foretinib (GSK 1363089) and erlotinib in patients with advanced pretreated NSCLC. 5th Asia Pacific Lung Cancer Conference. Fukuoka, Japan. Oral Presentation.

Publication Details:

Leighl N, Tsao M, Ho C, Shepherd F, Murray N, Goffin J, Nicholas G, Seymour L, Goss G, Bradbury P. NCIC CTG IND.196: Phase 1 study of foretinib (GSK 1363089) and erlotinib in patients with advanced pretreated NSCLC. Journal of Thoracic Oncology. 2012 Nov;7(11 Suppl 5):S453. Oral presentation 5th Asia Pacific Lung Cancer Conference November 25-28, 2012, Fukuoka, Japan, (abst O-022). **Principal Author**.

2012 Nov 6 **Co-Author/Collaborator**. A pooled analysis to evaluate the incidence of proteinuria, hypoalbuminemia, and edema secondary to MET and VEGFR inhibition. 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Dublin, Ireland. Poster presentation; abstr 313.

Publication Details:

Bradbury P, Eisenhauer E, Rayson D, Lupichuk S, Chia S, **Leighl N**, Ho C, Seymour L. A pooled analysis to evaluate the incidence of proteinuria, hypoalbuminemia, and edema secondary to MET and VEGFR inhibition. Eur J Cancer. 2012 Nov;48(Suppl 6):96. **Coauthor or Collaborator**.

2012 Nov 6 **Presenter**. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Dublin, Ireland. Poster presentation.

Publication Details:

Leighl NB, Tsao MS, Ho C, Shepherd FA, Murray N, Goffin J, Nicholas G, Seymour L, Goss GD, Bradbury P. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. European Journal of Cancer. 2012 Nov;48(Suppl 6):Page 187. Abstr 607.

Principal Author.

- 2012 Nov **Co-author/collaborator.** Adherence to human epidermal growth factor receptor-2 (HER2) testing and adjuvant trastuzumab treatment guidelines in a Canadian province. ISPOR 15th Annual European Meeting. Berlin, Germany. Poster presentation. PCN158.
- Publication Details:*
Ferrusi IL, Trudeau M, Earle CC, **Leighl NB**, Pullenayagum H, Khong H, Hoch J, Marsahl D. Adherence to human epidermal growth factor receptor-2 (HER2) testing and adjuvant trastuzumab treatment guidelines in a Canadian province. Value in Health. 2012 Nov;15(7):A438. PCN158 Poster presentation ISPOR 2012. **Coauthor or Collaborator.**
- 2012 Oct 30 **Co-author/collaborator.** Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments. 2012 ASCO Quality Care Symposium. San Diego, California, United States. Poster Presentation.
- Publication Details:*
Eng L, Su J, Qiu X, Palepu PR, Hon H, Fadhel E, Harland L, Delfa A, Habbous S, Kashigar A, Cuffe S, **Leighl NB**, Pierre A, Selby P, Goldstein DP, Liu G, Xu W. Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments. J Clin Oncol. 2012 Nov;30:(suppl 34; abstr 75). Poster presentation at 2012 ASCO Quality Care Symposium November 30- December 1, 2012 in San Diego, California. **Coauthor or Collaborator.**
- 2012 Jun 2 **Co-author/collaborator.** The value of personalizing medicine: medical oncologists' and patients' perspectives on genomic testing of breast tumours in chemotherapy treatment decisions. ISPOR 17th Annual International Meeting. Washington, District of Columbia, United States. Poster presentation, PCN101. (Trainee Presentation)
- Publication Details:*
Trudeau M, Bombard Y, Rozmovitz L, **Leighl N**, Deal K, Marshall D. The value of personalizing medicine: medical oncologists' and patients' perspectives on genomic testing of breast tumours in chemotherapy treatment decisions. Value in Health. 2012 Nov;15(7s):A429.
- 2012 Jun 2 **Co-Author/Collaborator.** Guidelines for health technologies: Specific guidance for oncology products in Canada. ISPOR 15th Annual International Meeting. Washington, District of Columbia, United States. Poster presentation.
- Publication Details:*
Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, **Leighl NB**, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Guidelines for health technologies: Specific guidance for oncology products in Canada. Value in Health. 2012 May;15(3):580-585. **Coauthor or Collaborator.**
- 2012 Jun 1 **Co-author/collaborator.** Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Cuffe S, Qiu X, Azad AK, Xin Qiu, Boyd K, Kuang Q, Marsh S, Savas S, Emami M, Perera N, Palepu PR, Chen Z, Patel D, Cheng D, Feld R, **Leighl NB**, Shepherd FA, Tsao MS, Xu W, Liu G. Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2012 Jun;30:(suppl; abstr 7586). Poster presentation at 2012 ASCO Annual Meeting. **Coauthor or Collaborator.**
- 2012 Jun 1 **Co-author/collaborator.** Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC). American Society of Clinical

Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Presenter(s): Poster Presentation.

Publication Details:

Azad AK, Qiu X, Cuffe S, Qiu X, Boyd K, Kuang Q, Emami M, Perera N, Palepu PR, Patel D, Chen Z, Cheng D, Feld R, **Leighl NB**, Shepherd FA, Tsao MS, Wei Xu, Liu G. Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2012 Jun;30:(suppl; abstr 1535). Poster presentation at 2012 ASCO Annual Meeting. **Coauthor or Collaborator**.

2012 Jun 1 **Co-author/collaborator**. The value of personalizing medicine: Medical oncologists' and patients' perspectives on genomic testing of breast tumors in chemotherapy treatment decisions. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Trudeau ME, Bombard Y, Rozmovits L, **Leighl NB**, Deal K, Marshall D. The value of personalizing medicine: Medical oncologists' and patients' perspectives on genomic testing of breast tumors in chemotherapy treatment decisions. J Clin Oncol. 2012;30:(suppl; abstr e1100). 2012 ASCO Annual Meeting. **Coauthor or Collaborator**.

2012 Jun 1 **Co-author/collaborator**. Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Eng L, Su J, Palepu PR, Hon H, Fadhel E, Harland L, La Delfa A, Habbous S, Kashigar A, Cuffe S, **Leighl NB**, Pierre A, Goldstein DP, Liu G, Xu W. Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors. J Clin Oncol. 2012;30:(suppl; abstr 9032). Poster presentation at 2012 ASCO Annual Meeting. **Coauthor or Collaborator**.

2012 Jun 1 **Co-author/collaborator**. Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Oral presentation.

Publication Details:

Hon H, Qiu XTobros K, Wong CKA, Bradley De Souza B, McFarlane G, Masroor S, Azad AK, Hasani E, Rozanec N, **Leighl NB**, Alibhai SMH, Xu W, Issa AM, Liu G, Cuffe S. Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). J Clin Oncol. 2012 Jun 1;30:(suppl; abstr 6005). Oral presentation 2012 ASCO Annual Meeting. **Coauthor or Collaborator**.

2012 Jun 1 **Co-author/collaborator**. Cluster-randomized trial of early palliative care for patients with metastatic cancer. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Oral presentation.

Publication Details:

Zimmermann C, Swami N, Rodin G, Tannock I, Krzyzanowska MK, **Leighl NB**, Oza AM, Moore MJ, Rydall A, Donner A. Cluster-randomized trial of early palliative care for patients with metastatic cancer. J Clin Oncol. 2012 Jun;30:(suppl; abstr 9003). Oral presentation 2012 ASCO Meeting. **Coauthor or Collaborator**.

2012 Jun 1 **Senior Responsible Author**. Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Sacher AG, Le LW, Lau A, Earle C, **Leighl NB**. Metastatic NSCLC: Treatment patterns, outcomes, and costs of newer agents. J Clin Oncol. 2012 Jun;30:(suppl; abstr 7606). Poster presentation at 2012 ASCO Annual Meeting. **Senior Responsible Author**.

- 2012 Jun 1 **Co-author/collaborator.** Global survey on barriers to clinical cancer research. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Cufer T, Cazap EL, Delgado LB, Digumarti R, **Leighl NB**, Meshref MM, Minami H, Robinson E, Yamaguchi NH, Sadikov A, Seruga B, Pyle D. Global survey on barriers to clinical cancer research. J Clin Oncol. 2012 Jun;30:(suppl;abstr e16505). Poster presentation at 2012 ASCO Annual Meeting. **Coauthor or Collaborator.**
- 2012 Jun 1 **Co-author/collaborator.** Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Presenter(s): Poster Presentation.
- Publication Details:*
Cuffe S, Cheng L, Azad AK, Brhane Y, Cheng D, Chen Z, Qiu X, Boyd K, Emami M, **Leighl NB**, Der S, Xu W, Shepherd FA, Tsao MS, Reisman D, Liu G. Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2012 Jun;31:(suppl; abstr 11057). Poster presentation at 2012 ASCO Annual Meeting. **Coauthor or Collaborator.**
- 2012 Jun 1 **Co-author/collaborator.** The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. American Society of Clinical Oncology 2012 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.
- Publication Details:*
Wong KM, Qiu X, Cheng D, Azad AK, Prakruthi R, Roberts H Knox JJ, Wong, Darling GE, Waldron JN, Goldstein DP, **Leighl NB**, Shepherd FA, Tsao MS, Der S, Reisman D, Liu G. The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. J Clin Oncol. 2012;30:(suppl; abstr 10522). Poster presentation 2012 ASCO Annual Meeting. **Coauthor or Collaborator.**
- 2012 May 23 **Co-author/collaborator.** The Value of Personalizing Medicine: Medical Oncologists' and Patients' Perspectives on Genomic Testing of Breast Tumors in Chemotherapy Treatment Decisions. Health Technology Assessment International Annual Scientific Congress. Bilbao, Spain. Oral Presentation.
- Publication Details:*
Bombard Y, Rozmovits L, Trudeau L, **Leighl N**, Deal K, Marshall, D. The Value of Personalizing Medicine: Medical Oncologists' and Patients' Perspectives on Genomic Testing of Breast Tumors in Chemotherapy Treatment Decisions. Gaceta Sanitaria. 2012 Jun;26(Espec Cong):41. **Coauthor or Collaborator.**
- 2011 Dec 10 **Co-author/collaborator.** Population-based health care cost estimates related to Non-Hodgkins Lymphoma. 2011 Annual Meeting of American Society of Hematology. San Diego, United States. Poster Presentation.
- Publication Details:*
Mittman N, Cheung M, Isogai PK, Saskin R, Liu N, Hoch JS, **Leighl NB**, Trudeau ME, Evans WK, Kainty KN, Earle CC. Population-based health care cost estimates related to Non-Hodgkins Lymphoma. Blood. 2011 Dec 10;118:abstr 2068. Poster, 2011 Annual Meeting of the American Society of Hematology, San Diego CA. **Coauthor or Collaborator.**
- 2011 Oct 2 **Co-Author/Collaborator.** Phase I Trial of Radiation with Concurrent and Consolidation Pemetrexed and Cisplatin in Patients with Unresectable Stage IIIA/B Non-Small Cell Lung Cancer. ASTRO 53rd Annual Meeting. Miami, Florida, United States. Poster Presentation.
- Publication Details:*
Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, **Leighl N**, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd F. Phase I Trial of Radiation with Concurrent and Consolidation Pemetrexed and Cisplatin in Patients with Unresectable Stage IIIA/B Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology, Physics. 2012 Apr 1;79(5):1395-1401. **Coauthor or Collaborator.**

- 2011 Sep 23 **Co-Author/Collaborator.** 1414 POSTER single nucleotide polymorphism analysis and outcome in advanced-stage cancer patients treated with Bevacizumab. 2011 European Multidisciplinary Cancer Congress. Stockholm, Sweden. Poster Presentation.
- Publication Details:*
Lambrechts D, Delmar P, Miles DW, **Leighl NB**, Saltz L, Escudier B, Van Cutsem E, Scherer SJ, Carmeliet P, de Haas S. 1414 POSTER single nucleotide polymorphism analysis and outcome in advanced-stage cancer patients treated with Bevacizumab. European Journal of Cancer. 2011 Sep;47(Suppl 1):S173. **Coauthor or Collaborator.**
- 2011 Sep 23 **Co-Author/Collaborator.** 1412 POSTER Genetic markers in relation to bevacizumab-induced hypertension. 2011 European Multidisciplinary Cancer Congress. Stockholm, Sweden. Poster Presentation.
- Publication Details:*
Lambrechts D, Miles DW, **Leighl N**, Saltz L, Escudier B, Van Cutsem E, Bansal AT, Scherer SJ, Carmeliet P, de Haas S. 1412 POSTER Genetic markers in relation to bevacizumab-induced hypertension. European Journal of Cancer. 2011 Sep;47(Suppl 1):S172-S173. **Coauthor or Collaborator.**
- 2011 Jul 7 **Senior Responsible Author.** Evolving patterns in the interpretation of phase III trial outcomes in the treatment of advanced NSCLC. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O44.01 Oral presentation in NSCLC – Advanced Stage and Statistics Session, 14th World Conference on Lung Cancer, Amsterdam, Netherlands.
- Publication Details:*
Sacher A, Le L, **Leighl N**. Evolving patterns in the interpretation of phase III trial outcomes in the treatment of advanced NSCLC. Journal of Thoracic Oncology. 2011 Jul 7;6(6):Suppl 2, S472. **Senior Responsible Author.**
- 2011 Jul 7 **Senior Responsible Author.** Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P4.210. Poster Presentation. (Trainee Presentation)
- Publication Details:*
Nadjafi M, Santos GDC, Le L, Hwang DM, Tsao MS, **Leighl NB**. Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S1520-1521. **Senior Responsible Author.**
- 2011 Jul 7 **Co-author/collaborator.** An Ontario Clinical Oncology Group (COG) randomized trial (PET START) of FDG PET/CT in patients with stage 3 non-small cell lung cancer (NSCLC): Impact of PET on radiation treatment volumes. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O35.01 Poster presentation 14th World Conference on Lung Cancer.
- Publication Details:*
Ung YC, Giu CS, Cline K, Sun A, Macrae R, Wright J, Yu E, Ehrlich L, Gulenchyn K, Shulman H, Dayes I, Dhesy-Thind B, Darling G, **Leighl N**, Evans W, Julian J, Levine M. An Ontario Clinical Oncology Group (COG) randomized trial (PET START) of FDG PET/CT in patients with stage 3 non-small cell lung cancer (NSCLC): Impact of PET on radiation treatment volumes. Journal of Thoracic Oncology. 2011 Jun 3;6(6):Suppl 2, S428. O35.01 Poster presentation 14th World Conference on Lung Cancer. **Coauthor or Collaborator.**
- 2011 Jul 6 **Co-author/collaborator.** Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O32.05 Oral Presentation at Medical Oncology VI Session. (Trainee Presentation)
- Publication Details:*
Yu JL, Simmons C, Victor C, Han D, Hogeveen S, **Leighl N**, Verma S. Impact of new chemotherapeutic

and targeted agents on survival in stage IV non-small cell lung cancer. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S416-S417. **Coauthor or Collaborator.**

2011 Jul 6 **Co-author/collaborator.** Improvement in survival but not skeletal morbidity in stage IV NSCLC patients with bone metastases: time to consider bone targeted therapy? 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3.004 Poster Presentation.

Publication Details:

Yu JL, Verma S, Victor C, Han D, Hogeveen, **Leighi NB**, Simmons C. Improvement in survival but not skeletal morbidity in stage IV NSCLC patients with bone metastases: time to consider bone targeted therapy? Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2. **Coauthor or Collaborator.**

2011 Jul 6 **Co-author/collaborator.** Correlation of dosimetric factors in the development of esophagitis and radiation pneumonitis in patients with limited stage small cell lung carcinoma. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3.269 Poster presentation.

Publication Details:

Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le L, Brade A, Cho J, **Leighi NB**, Shepherd FA, Hope A. Correlation of dosimetric factors in the development of esophagitis and radiation pneumonitis in patients with limited stage small cell lung carcinoma. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S1348. **Coauthor or Collaborator.**

2011 Jul 6 **Co-author/collaborator.** Acute toxicities observed with neoadjuvant short accelerated hemithoracic radiotherapy (RT) followed by extra-pleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Preliminary results. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3. 292 Poster presentation 14th World Conference on Lung Cancer.

Publication Details:

Cho J, Feld R, **Leighi NB**, de Perrot M. Acute toxicities observed with neoadjuvant short accelerated hemithoracic radiotherapy (RT) followed by extra-pleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): Preliminary results. Journal of Thoracic Oncology. 2011 Jun 3;6(6):Suppl 2, S1364. **Coauthor or Collaborator.**

2011 Jul 6 **Presenter.** Preliminary report of a randomized trial of computer-assisted quality of life assessment in advanced NSCLC patients. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3.088 Poster presentation.

Publication Details:

Leighi NB, Salvarrey A, Kassam F, Shepherd FA, Feld R, Tang F, Hollen P, Gralla RJ. Preliminary report of a randomized trial of computer-assisted quality of life assessment in advanced NSCLC patients. Journal of Thoracic Oncology. 2011 Jul 6;6(6):Suppl 2, s1220-s1221. **Principal Author.**

2011 Jul 5 **Presenter.** Assessing survival and time to treatment for patients diagnosed with malignant pleural mesothelioma in Ontario, Canada. Amsterdam, Netherlands. MO07.07 Mini oral presentation at Biomarkers, Chemotherapy and Radiotherapy in Mesothelioma Session. (Trainee Presentation)

Publication Details:

Hasani A, Sun B, Liu G, Xu W, Feld R, **Leighi NB**. Assessing survival and time to treatment for patients diagnosed with malignant pleural mesothelioma in Ontario, Canada. Journal of Thoracic Oncology. 2011 Jul 5;6(6):Suppl 2, S536-S537. **Senior Responsible Author.**

2011 Jul 5 **Co-author/collaborator.** Final Results of a University of Chicago Phase II Consortium trial of cediranib (C) in patients (PTS) with malignant mesothelioma (MM). 14th World Conference on Lung Cancer. Amsterdam, Netherlands. MO07.08 Mini Oral Presentation at Biomarkers, Chemotherapy and Radiotherapy in Mesothelioma Session.

Publication Details:

Campbell NP, Kunnavakkam R, **Leighi N**, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E,

Thomas SP, Stadler WM, Vokes E, Kindler HL. Final Results of a University of Chicago Phase II Consortium trial of cediranib (C) in patients (PTS) with malignant mesothelioma (MM). Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S537. **Coauthor or Collaborator**.

2011 Jul 4 **Collaborator**. Chemoradiotherapy for recurrent NSCLC: retrospective database analysis of two large cancer centers. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O13.03 Poster presentation at Clinical Cases and Clinical Decisions 1 Session. (Trainee Presentation)

Publication Details:

Ng D, Moretto P, Goss GD, Nicholas G, Laurie S, Sun A, **Leighl N**, Macrae R, Bar J. Chemoradiotherapy for recurrent NSCLC: retrospective database analysis of two large cancer centers. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S332. **Coauthor or Collaborator**.

2011 Jul 3 **Senior Responsible Author**. AZD0530, an inhibitor of SRC kinases, in platinum-pretreated advanced non-small cell lung cancer (NSCLC): A trial of the PMH Phase II Consortium. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3.147 Poster presentation.

Publication Details:

Laurie SA, Goss GD, Shepherd FA, Reaume N, Nicholas G, Philip L, Wang L, Oza A, Hirsh V, Wright J, **Leighl N**. AZD0530, an inhibitor of SRC kinases, in platinum-pretreated advanced non-small cell lung cancer (NSCLC): A trial of the PMH Phase II Consortium. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S1262. **Senior Responsible Author**.

2011 Jun 7 **Senior Responsible Author**. Implementation of a national EGFR testing strategy in a publicly funded health system. Amsterdam, Netherlands. P4.199 Poster Presentation.

Publication Details:

Ellis PM, Verma S, Sehdev S, Younas J, **Leighl N**. Implementation of a national EGFR testing strategy in a publicly funded health system. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S1513. **Senior Responsible Author**.

2011 Jun 7 **Co-author/collaborator**. Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E 1505, A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC). 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O42.03 Oral Presentation.

Publication Details:

Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano S, **Leighl NB**, Adjei AA, Schiller J. Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E 1505, A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S464. **Coauthor or Collaborator**.

2011 Jun 6 **Senior Responsible Author**. Elderly patients with advanced NSCLC in Phase III clinical trials: Are the elderly excluded from practice-changing trials in advanced NSCLC? 14th World Conference on Lung Cancer. Amsterdam, Netherlands. P3.086 Poster presentation. (Trainee Presentation)

Publication Details:

Sacher A, Le L, **Leighl N**, Coate L. Elderly patients with advanced NSCLC in Phase III clinical trials: Are the elderly excluded from practice-changing trials in advanced NSCLC? Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S1219. **Senior Responsible Author**.

2011 Jun 3 **Co-author/collaborator**. An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Ung Y, Gu Cline K, Sun A, MacRae RM, Wright E, Yu L, Ehrlich L, Gulenchyn KY, Shulman H, Dayes IS, Dhesy-Thind SK, Darling GE, **Leighl NB**, Evans K, Julian JA, Levine MN. An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. J Clin Oncol. 2011;29:(suppl; abstr 7018). **Coauthor or Collaborator.**

2011 Jun 3 **Senior Responsible Author.** Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)

Publication Details:

Hasani A, Sun B, Liu G, Xu W, Feld R, **Leighl NB**. Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada. J Clin Oncol. 2011;29:(suppl; abstr 7085). **Senior Responsible Author.**

2011 Jun 3 **Co-Author/Collaborator.** Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States.

Publication Details:

Yu JL, Simmons C, Victor EC, Han D, Hogeveen S, **Leighl NB**, Verma S. Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. J Clin Oncol. 2011;29. (suppl; abstr e18015) 2011 ASCO Annual Meeting. **Coauthor or Collaborator.**

2011 Jun 3 **Co-author/collaborator.** Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, **Leighl NB**, Adjei AA, Schiller JH. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29:(suppl; abstr 7013). Poster presentation at 2011 ASCO Annual Meeting. **Coauthor or Collaborator.**

2011 Jun 3 **Co-Author/Collaborator.** Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Campbell NP, Kunnavakkam R, **Leighl NB**, Vincent MD, D. R. mas, W. Stadler M, Vokes EE, Kindler HL. Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium. J Clin Oncol. 2011;29:(suppl; abstr 7027). **Coauthor or Collaborator.**

2011 Jun 3 **Co-author/collaborator.** Population based health care cost estimate related to breast cancer by staging. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster presentation, abstract 6108.

Publication Details:

Mittmann N, Isogai PK, Saskin R, Liu N, Hoch J, **Leighl NB**, Cheung MC, Trudeau ME, Evans WK, Dainty K, Earle C. Population based health care cost estimate related to breast cancer by staging. Journal of Clinical Oncology. 2011;29(15s). **Coauthor or Collaborator.**

2011 Jun 3 **Senior Responsible Author.** Shifting patterns in the interpretation of phase III clinical trial outcomes in the treatment of advanced NSCLC. American Society of Clinical Oncology 2011 Annual Meeting. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)

Publication Details:

Sacher AG, **Leighl NB**. Shifting patterns in the interpretation of phase III clinical trial outcomes in the treatment of advanced NSCLC. J Clin Oncol. 2011;29:(suppl; abstr 6105). **Senior Responsible Author**.

2011 Jun 3 **Senior Responsible Author**. Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital. 2011 ASCO Annual Meeting. Chicago, Illinois, United States. Presenter(s): Nadjafi M, Santos GDC, Le LW, Hwang, Tsao MS, **Leighl NB**. Poster Presentation. (Trainee Presentation)

Publication Details:

Nadjafi M, Santos GDC, Le LW, Hwang, Tsao MS, **Leighl NB**. Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital. Journal of Clinical Oncology. 2011;29. suppl; abstr e 18027. **Senior Responsible Author**.

2011 Jun **Co-author/collaborator**. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage 1 non-small cell lung cancer. 14th World Conference on Lung Cancer. Amsterdam, Netherlands. O02.06 Oral Presentation at Radiation Oncology 1 Session.

Publication Details:

Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, **Leighl N**, Warde P, Gutierrez E, Dobrow M, Coyte P, Yung T, Bezjak A, Hope A. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage 1 non-small cell lung cancer. Journal of Thoracic Oncology. 2011 Jun;6(6):Suppl 2, S280-281. **Coauthor or Collaborator**.

2010 Dec 9 **Co-author/collaborator**. Improvement in Survival but no Skeletal Morbidity in Stage IV Non-small Cell Lung Cancer Patients with Bone Metastases: Is it Time to Consider Bone Targeted Therapy in Metastatic Lung Cancer? 2010 Chicago Multidisciplinary Thoracic Oncology Symposium (ASTRO/IASCL). Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Yu JL, Verma J, Victor C, Han D, Hogeveen S, Leighl C, Simmons C. Improvement in Survival but no Skeletal Morbidity in Stage IV Non-small Cell Lung Cancer Patients with Bone Metastases: Is it Time to Consider Bone Targeted Therapy in Metastatic Lung Cancer? Journal of Thoracic Oncology. 2010 Dec;5(12)(Suppl 7):S535-S536. **Coauthor or Collaborator**.

2010 Dec 8 **Co-author/collaborator**. Access to and utilization of HER2 testing in early stage breast cancer in Ontario, Canada. 33rd Annual San Antonio Breast Cancer Symposium, Dec 8-12, 2010. San Antonio, Texas, United States. Poster presentation (P-1-10-09). (Trainee Presentation)

Publication Details:

Ferrusi IL, Trudeau M, Earle C, **Leighl NB**, Pullenayegum E, Cascagnette P, Marshall DA. Access to and utilization of HER2 testing in early stage breast cancer in Ontario, Canada. Cancer Research. 2010 Dec;70(24). Supple, P-1-10-09.

2010 Oct 31 **Co-Author/Collaborator**. Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC). ASTRO 52nd Annual Meeting. San Diego, California, United States. Poster Presentation.

Publication Details:

Hope A, Coate LE, Massey M, Sacher A, Barrett K, Keshavjee S, Darling G, **Leighl NB**, Bezjak A, Shepherd FA. Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology, Physics. 2010 Nov 1;78(3):S505. Supplement. **Coauthor or Collaborator**.

2010 Oct 31 **Co-Author/Collaborator**. Patterns of Failure in Patients with Limited-Stage Small cell Lung Carcinoma. ASTRO 52nd Annual Meeting. San Diego, California, United States. Poster Presentation.

Publication Details:

Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LE, Brade A, Cho J, **Leighl NB**, Shepherd FA, Hope AJ. Patterns of Failure in Patients with Limited-Stage Small cell Lung Carcinoma. International Journal of Radiation Oncology Biology Physics. 2010 Nov 1;78(3):S495. Supplement. **Coauthor or Collaborator**.

2010 Oct 8 **Co-author/collaborator**. Everolimus plus erlotinib vs. everolimus alone in previously treated patients with advanced non-small cell lung cancer. 35th Annual European Society of Medical Oncology (ESMO) Congress, Oct 8-12, 2010. Milan, Italy. Poster Presentation.

Publication Details:

Bennouna J, Besse B, **Leighl NB**, Blais N, Traynor AM, Papadimitrakopoulos V, Klimovsky J, Jappe A, Jehl V, Johnson BE. Everolimus plus erlotinib vs. everolimus alone in previously treated patients with advanced non-small cell lung cancer. Ann Oncol. 2010 Oct;Suppl 8(viii140). **Coauthor or Collaborator**.

2010 Oct **Senior Responsible Author**. A systemic review and consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 35th Annual European Society of Medical Oncology (ESMO) Congress, Oct 8-12, 2010. Milan, Italy. Poster Presentation.

Publication Details:

Ellis PM, Blais N, Soulieres D, Ionescu DN, Liu G, Melosky B, Reiman T, Shepherd FA, Tsao M, **Leighl NB**. A systemic review and consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Ann Oncol. 2010 Oct;21(Suppl 8):viii 39. **Senior Responsible Author**.

2010 Jun 8 **Co-author/collaborator**. Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2010 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Coate LE, Massey C, Hope AJ, Pierre A, Bezjak A, **Leighl NB**, Darling GE, Sun A, Keshavjee S, Shepherd FA. Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2010;28(15s):(suppl; abstr 7014). **Coauthor or Collaborator**.

2010 Jun 7 **Presenter**. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer. American Society of Clinical Oncology 2010 Annual Meeting. Chicago, Illinois, United States. Poster Discussion Presentation.

Publication Details:

Leighl NB, Soria J, Bennouna J, Blais N, Traynor, AM. Papadimitrakopoulos V, Klimovsky J, Jappe A, Jehl V, Johnson BE. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 2010;28(15s):(suppl; abstr 7524). **Principal Author**.

2010 Jun 7 Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer. American Society of Clinical Oncology 2010 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Karapetis CS, Clingan PR, **Leighl NB**, Durbin-Johnson B, O'Neill V, Spigel DR. Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer. Journal of Clinical Oncology. 2010;28(15s). (suppl; abstr 7535). **Coauthor or Collaborator**.

2010 Jun 7 **Co-author/collaborator**. Randomized trial of concurrent versus sequential docetaxel plus bortezomib in platinum pretreated non-small cell lung cancer. American Society of Clinical Oncology 2010 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Lara P, Longmate J, Argiris A, Gitlitz BJ, Mack PC, Lau DH, Koczywas M, **Leighl NB**, Gandara DR. Randomized trial of concurrent versus sequential docetaxel plus bortezomib in platinum pretreated non-

small cell lung cancer. Journal of Clinical Oncology. 2010;28(15s). (suppl; abstr 7533). **Coauthor or Collaborator.**

2010 Jun 4 **Co-author/collaborator.** A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer. American Society of Clinical Oncology 2010 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Feld R, Woo MM, Shepherd FA, **Leighl NB**, Elshtein R, Hengelage T, Hirawat S. A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer. Journal of clinical oncology. 2010;28. suppl; abstr e 13089. **Coauthor or Collaborator.**

2010 Jan **Co-author/collaborator.** Comprehensive geriatric assessment (CGA) in treatment decisions in elderly patients (pts) with gastrointestinal (GI) cancer. 2010 Gastrointestinal Cancers Symposium. Orlando, Florida, United States. Abstract #120, Poster Presentation at 2010 Gastrointestinal Cancers Symposium January 22-24, 2010 in Orlando Florida.

Publication Details:

Horgan AM, Knox JJ, Palepu P, Liu G, **Leighl NB**, Alibhai SM. Comprehensive geriatric assessment (CGA) in treatment decisions in elderly patients (pts) with gastrointestinal (GI) cancer. J Clin Oncol. 2010 Jan;January. Abstract #120, Poster Presentation at 2010 Gastrointestinal Cancers Symposium January 22-24, 2010 in Orlando Florida. **Coauthor or Collaborator.**

2010 **Senior Responsible Author.** Analysis of biomarkers in the AVAiL phase III randomised study of first-line bevacizumab with cisplatin-gemcitabine in patients with non-small cell lung cancer. European Lung Cancer Conference/ESMO/IASLC 2010. Lugano, Switzerland. Poster Presentation.

Publication Details:

Reck M, De Haas SL, Evers S, Delmar PR, Manegold C, Scherer SJ, **Leighl NB**. Analysis of biomarkers in the AVAiL phase III randomised study of first-line bevacizumab with cisplatin-gemcitabine in patients with non-small cell lung cancer. Journal of Thoracic Oncology. 2010 May;5(5). Supplement 1. **Senior Responsible Author.**

2009 Nov **Co-author/collaborator.** Dosimetric and clinical parameters contributing to esophagitis and radiation pneumonitis following treatment for small cell carcinoma. American Society of Therapeutic Radiation Oncology 2009 Annual Meeting. Chicago, Illinois, United States. Poster Presentation, abstr 1081.

Publication Details:

Hope AJ, Guiliani MK, MaC, Bezjak A, Sun A, Brade A, Cho BJ, **Leighl NB**, Shepherd FA, Lindsay PE. Dosimetric and clinical parameters contributing to esophagitis and radiation pneumonitis following treatment for small cell carcinoma. I.J. Radiation Oncology*Biophysics. 2009 Nov;75(3):S162. Suppl 1, abstr 1081. **Coauthor or Collaborator.**

2009 May 30 **Co-author/collaborator.** The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Bradbury PA, Twumasi-Ankrah P, Ding K, **Leighl NB**, Goss GD, Laurie S, Shepherd FA, Seymour L. The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2009;27(15s). (suppl; abstr 8075). **Coauthor or Collaborator.**

2009 May 30 **Co-author/collaborator.** Final safety results of BO17704 (AVAIL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small lung cancer (NSCLC). American Society of Clinical Oncology 2009 Annual

Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Hirsh V, Ramlau R, von Pawel J, Zatloukal P, Vera G, **Leighl N**, Mezger J, Archer V, Reck M. Final safety results of BO17704 (AVAIL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small lung cancer (NSCLC). Journal of Clinical Oncology. 2009;27(15s). (suppl; abstr 8039). **Coauthor or Collaborator.**

2009 May 30 **Co-author/collaborator.** Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Ung Y, Sun A, MacRae R, Gu C, Wright J, Uy E, Darling G, **Leighl N**, Evans W, Levine M. Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). Journal of Clinical Oncology. 2009;27(15s). (suppl; abstr 7548). **Coauthor or Collaborator.**

2009 May 30 **Co-author/collaborator.** Mesothelin as a marker of response in malignant pleural mesothelioma. American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, **Leighl N**, Feld R, Cho B, DEPerrot M, Liu G. Mesothelin as a marker of response in malignant pleural mesothelioma. Journal of Clinical Oncology. 2009;27(15s). (suppl; abstr 7581). **Coauthor or Collaborator.**

2009 May 30 **Principle Author.** Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAIL). American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Leighl NB, Zatloukal J, Mezger PJ, Ramlau R, Archer V, Moore N, Reck M. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAIL). J Clin Oncol. 2009 May 30;27(15s). (suppl; abstr 8050). **Principal Author.**

2009 May 30 **Senior Responsible Author.** A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer. American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Goldberg RJ, Jang RW, **Leighl NB**. A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer. A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer. J Clin Oncol. 2009;27(15s). (suppl; abstr 6581). **Senior Responsible Author.**

2009 May **Senior Responsible Author.** A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma. Results after completion of stage 1. A trial of the Princess Margaret Hospital Phase II Consortium. American Society of Clinical Oncology 2009 Annual Meeting. Orlando, Florida, United States. Poster Presentation.

Publication Details:

Taylor SK, Chia S, Dent S, Clemons M, Greci P, Wang L, Oza AM, Ivy P, Pritchard KI, **Leighl N**. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma. Results after completion of stage 1. A trial of the Princess Margaret Hospital Phase II

Consortium. J Clin Oncol. 2009;27:15s. (suppl; abstr 1133). **Senior Responsible Author.**

2008 May 30 **Senior Responsible Author.** A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer in the NCIC CTG JBR.10 trial. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)

Publication Details:

Jang RW, Le Maitre A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, **Leighl NB.** A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer in the NCIC CTG JBR.10 trial. J Clin Oncol. 2008 May;20(26). (suppl; abstr 6535). **Senior Responsible Author.**

2008 May 30 **Co-author/collaborator.** A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Ellis PM, Chu QS, **Leighl NB,** Laurie SA, Trommeshauser D, Hanft G, Munzert G, Gyorffy S. A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2008 May;20(26). (suppl; abstr 8115). **Coauthor or Collaborator.**

2008 May 30 **Co-author/collaborator.** The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Wheatley-Price P, Le Maitre A, Ding K, **Leighl NB,** Hirsh V, Seymour L, Shepherd FA. The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials. J Clin Oncol. 2008 May 20;20(26). (suppl; abstr 8054). **Coauthor or Collaborator.**

2008 May 30 **Co-author/collaborator.** Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Le Maitre A, Ding K, Shepherd FA, **Leighl NB,** Arnold A, Seymour L. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2008 May;20(26). (abstr 8065). **Coauthor or Collaborator.**

2008 May 30 **Co-author/collaborator.** A phase 1/2 study investigating the combination of RAD001 and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: Phase 1 results. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Papadimitrakopoulou V, Bluemenschein G, **Leighl N,** Bennouna J, Soria JC, Burris H, Dimitrijevic S, Kunz T, Di Scala L, Johnson BE. A phase 1/2 study investigating the combination of RAD001 and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: Phase 1 results. J Clin Oncol. 2008 May;26. (May 20 suppl; abstr 8051). **Coauthor or Collaborator.**

2008 May 5 **Senior Responsible Author.** Preliminary cost-consequence analysis of epirubicin/Cisplatin/5FU (ECF) compared to epirubicin/cisplatin/capecitabine (ECS) in patients with advanced esophagogastric cancer. ISPOR 13th Annual International Meeting. Toronto, Ontario, Canada. Poster presentation (PCN37). (Trainee Presentation)

Publication Details:

Horgan AM, Knox J, Liu G, Bradbury PA, Sahi C, **Leighl NB**. Preliminary cost-consequence analysis of epirubicin/Cisplatin/5FU (ECF) compared to epirubicin/cisplatin/capecitabine (ECS) in patients with advanced esophagogastric cancer. *Values in Health*. 2008;11(3):A65. **Senior Responsible Author**.

2008 May 5 **Senior Responsible Author**. Derivation of utility values from EORTC QLQC30 in lung cancer. ISPOR 13th Annual International Meeting. Toronto, Ontario, Canada. Poster presentation (PCN78. (Trainee Presentation)

Publication Details:

Jang RW, Mittmann N, Isogai P, Bradbury PA, **Leighl NB**. Derivation of utility values from EORTC QLQC30 in lung cancer. *Values in Health*. 2008;11(3):A77-8. **Senior Responsible Author**.

2007 Sep 6 **Co-author/collaborator**. Preoperative gefitinib in clinical stage 1 NSCLC: PD3-2-5. 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Poster Presentation.

Publication Details:

Lara-Guerra H, **Leighl N**, Salvarrey A, Sakurada A, Paul, NS, Boerner S, Pond GR, Shepherd FA, Tsao MS, Waddell TK. Preoperative gefitinib in clinical stage 1 NSCLC: PD3-2-5. *J Thorac Oncol* 2. 2007;8(Suppl 4):PD3-2-5, S464. **Co-Principal Author**.

2007 Sep 5 **Senior Responsible Author**. An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer. 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Poster Presentation. (Trainee Presentation)

Publication Details:

Bradbury P, Seymour L, Ng R, Mittmann N, Cote I, Shepherd FA, **Leighl NB**. An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol* 2. 2007;8(Suppl 4):P3-068, S707. **Senior Responsible Author**.

2007 Sep 5 **Senior Responsible Author**. Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice. 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Presenter(s): Poster Presentation. (Trainee Presentation)

Publication Details:

Ng R, Loreto M, Lee R, **Leighl NB**. Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice. *J Thorac Oncol* 2. 2007;8(Suppl 4):P3-120, S730. **Senior Responsible Author**.

2007 Sep 3 A phase II study of UCN-01 in combination with topotecan in patients with chemosensitive relapsed small cell lung cancer (SCLC): a study of the PMH phase II Consortium. 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Poster Presentation.

Publication Details:

Leighl N, Laurie S, Gauthier I, Ellis P, Duguay Y, Pond G, Bhagwat M, Dancey J, Moore M, Goss G. A phase II study of UCN-01 in combination with topotecan in patients with chemosensitive relapsed small cell lung cancer (SCLC): a study of the PMH phase II Consortium. *J Thorac Oncol* 2. 2007;8(Suppl 4):PD6-1-7, S427. **Principal Author**.

2007 Sep 2 **Co-author/collaborator**. Randomized phase III trial of cisplatin/gemcitabine with placebo or with bevacizumab as first-line therapy for non-squamous non-small cell lung cancer (AVAiL). 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Oral Presentation.

Publication Details:

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, **Leighl N**, Mezger J, Archer V,

Moore N, Manegold C, the BO17704 study group. Randomized phase III trial of cisplatin/gemcitabine with placebo or with bevacizumab as first-line therapy for non-squamous non-small cell lung cancer (AVAiL). J Thorac Oncol 2. 2007;8(Suppl 4):C1-06, S360. **Coauthor or Collaborator**.

2007 Jun 4 **Co-author/collaborator**. When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. American Society of Clinical Oncology 2007 Annual Meeting. Chicago, Illinois, United States. Oral Presentation.

Publication Details:

Leighl NB, Shepherd H, Butow P, Clarke SJ, McJannett M, Beale P, Wilcken N, Moore MJ, Chen EX, Goldstein D, Tattersall MHN. When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20;25(18S):6509. (Supplement). **Principal Author**.

2007 Jun 2 **Co-author/collaborator**. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. American Society of Clinical Oncology 2007 Annual Meeting. Chicago, Illinois, United States. Presenter(s): Oral Presentation.

Publication Details:

Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, **Leighl N**, Mezger J, Archer V, Reck M, the BO17704 study group. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20;25(18S):LBA7514/388s. (June 20 Supplement). **Coauthor or Collaborator**.

2007 Jun 1 **Co-author/collaborator**. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). American Society of Clinical Oncology 2007 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Massarelli E, Miller VA, **Leighl NB**, Rosen PJ, Albain KS, Hart LL, Melnyk O, Sternas L, Ackerman J, Herbst RS. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20;25(18S):7627. (Supplement). **Coauthor or Collaborator**.

2007 Jun 1 **Co-author/collaborator**. Impact of induction chemotherapy and adjuvant radiation therapy on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. American Society of Clinical Oncology 2007 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

de Perrot M, Feld R, Anraku M, Bezjak A, Burkes R, Roberts H, Cho J, Visbal A, **Leighl N**, Keshavjee S, Johnston M. Impact of induction chemotherapy and adjuvant radiation therapy on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20;20(25):18S. June 20 Supplement:7708. **Coauthor or Collaborator**.

2007 Jun 1 IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSLC): A study of the NCIC Clinical Trials Group. American Society of Clinical Oncology 2007 Annual Meeting. Chicago, Illinois, United States. Poster Presentation.

Publication Details:

Goss GD, Laurie S, Shepherd F, **Leighl N**, Chen E, Gauthier I, Reaume N, Feld R, Powers J, Seymour L. IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor

(VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20;25(18S):7649. **Coauthor or Collaborator.**

2005 Nov 6 **Senior Responsible Author.** Quality of life and resource utilization of patients with advanced non-small cell lung cancer: A Canadian perspective. ISPOR 8th Annual European Meeting. Florence, Italy. PCN48 Poster presentation.

Publication Details:

Mittmann N, Wang M, Cote I, **Leighl NB.** Quality of life and resource utilization of patients with advanced non-small cell lung cancer: A Canadian perspective. Value in Health. 2005 Nov;8(6):A48. **Senior Responsible Author.**

2005 Jun Performance status revisited: are there differences between the Karnofsky and ECOG performance status scales which can be important in clinical decision making. 17th MASCC International Symposium. Geneva, Switzerland. Poster Presentation, Abstr 25-185.

Publication Details:

Gralla R, Hollen P, Meharchand J, **Leighl N,** Chin C, Stewart J. Performance status revisited: are there differences between the Karnofsky and ECOG performance status scales which can be important in clinical decision making. Supp Care Cancer. 2005;13(6):475-6. Abstr 25-185. **Coauthor or Collaborator.**

2005 Jun **Co-author/collaborator.** Should patients rate their own performance status (PS)? Results of a prospective study comparing patient-generated PS or observer-rated PS using both the ECOG and Karnofsky scales. 17th MASCC International Symposium. Geneva, Switzerland. Poster presentation, Abstr 25-186.

Publication Details:

Gralla R, Hollen P, Kuruvilla P, **Leighl N,** Chin C, Stewart J. Should patients rate their own performance status (PS)? Results of a prospective study comparing patient-generated PS or observer-rated PS using both the ECOG and Karnofsky scales. Supp Care Cancer. 2005;13(6):476. Abstr 25-186. **Coauthor or Collaborator.**

2005 May 13 **Co-author/collaborator.** Paclitaxel Poliglumex (XYOTAX™) in combination with Carboplatin for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary Data. American Society of Clinical Oncology 5th Annual Meeting. Orlando, Florida, United States. Poster Presentation, abstract 7230.

Publication Details:

Nemunaitis JJ, **Leighl N,** Miller W, Cormier Y, Bernareggi A, Oldham F. Paclitaxel Poliglumex (XYOTAX™) in combination with Carboplatin for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary Data. Journal of Clinical Oncology. 2005;23(16S). June 1 Supplement, Abstr 7230. **Coauthor or Collaborator.**

2005 May 13 **Senior Responsible Author.** Referral patterns for adjuvant therapy in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2005 Annual Meeting. Orlando, Florida, United States. Abstract 7217 Poster presentation. (Trainee Presentation)

Publication Details:

Kassam F, Johnston M, Feld R, Shepherd FA, Darling G, Keshavjee S, Pierre A, Waddell T, Hornby J, **Leighl NB.** Referral patterns for adjuvant therapy in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2005;23(16S). June 1 Supplement. **Senior Responsible Author.**

2005 May 13 **Co-author/collaborator.** Phase 1 study of GTI-2040 in combination with docetaxel in advanced NSCLC. American Society of Clinical Oncology 2005 Annual Meeting. Orlando, Florida, United States. Poster Presentation. Abstract 7253.

Publication Details:

Leighl NB, Laurie SA, Knox JJ, Shepherd FA, Burkes RL, Tannock IF, Pond GR, Zweibel J, Moore MJ. Phase 1 study of GTI-2040 in combination with docetaxel in advanced NSCLC. 2005 Proc ASCO. 2005. American Society of Clinical Oncology Annual Meeting, Orlando, June 2005. Abstract 7253. **Senior Responsible Author.**

2005 May 13 **Co-author/collaborator.** Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients with non-small cell lung cancer (NSCLC). American Society of Clinical Oncology 2005 Annual Meeting. Orlando, Florida, United States. Poster presentation, Abstract 8067.

Publication Details:

Kuruvilla PG, Krieger H, Zibdawi L, Meharchand J, Solow H, **Leighl N**, Chin C, Stewart JA, Hollen PJ, Gralla RJ. Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients with non-small cell lung cancer (NSCLC). 2005 Proc ASCO. 2005. **Senior Responsible Author.**

2004 Dec 8 **Co-author/collaborator.** Phase II study of perifosine in metastatic or advanced breast cancer. 27th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, United States. Poster Presentation. (abstr 1077).

Publication Details:

Leighl NB, Warr DG, Vandenberg T, Dent S, Tannock IF, Crump M, Tozer R, Clemons M, Dancey JE, Moore MJ. Phase II study of perifosine in metastatic or advanced breast cancer. Breast Cancer Res and Treatment. 2004;88(Suppl 1):S67. (abstr 1077). **Principal Author.**

2003 Nov **Principle Author.** Costs of managing toxicities in advanced non-small cell lung cancer with pemetrexed compared with docetaxel as second-line chemotherapy. ISPOR 6th Annual European Meeting. Barcelona, Spain. PCN10 Poster Presentation.

Publication Details:

Aristides M, Jackson D, Liepa AM, **Leighl NB**. Costs of managing toxicities in advanced non-small cell lung cancer with pemetrexed compared with docetaxel as second-line chemotherapy. Value in Health. 2003 Nov;6(6):734-735. **Senior Responsible Author.**

P2.01-032 - A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219 (Now Available) (ID 9083)

09:00 - 09:00 | Presenting Author(s): Barbara Melosky | Author(s): Penelope Bradbury, D. Tu, G. Nicholas, P. Wheatley-Price, S.A. Laurie, Glenwood Goss, M. Florescu, N. Basappa, A. Reiman, A. Tan, Desiree Hao, J. Rotherstein, **Natasha B Leighl**, John R Goffin, C. Kollmannsberger, P. Kaurah, P. Brown-Walker, L. Seymour.

P2.01-032 - A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219 (Now Available) (ID 9083)

09:00 - 09:00 | Presenting Author(s): Barbara Melosky | Author(s): Penelope Bradbury, D. Tu, G. Nicholas, P. Wheatley-Price, S.A. Laurie, Glenwood Goss, M. Florescu, N. Basappa, A. Reiman, A. Tan, Desiree Hao, J. Rotherstein, **Natasha B Leighl**, John R Goffin, C. Kollmannsberger, P. Kaurah, P. Brown-Walker, L. Seymour.

P2.01-032 - A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219 (Now Available) (ID 9083)

09:00 - 09:00 | Presenting Author(s): Barbara Melosky | Author(s): Penelope Bradbury, D. Tu, G. Nicholas, P. Wheatley-Price, S.A. Laurie, Glenwood Goss, M. Florescu, N. Basappa, A. Reiman, A. Tan, Desiree Hao, J. Rotherstein, **Natasha B Leighl**, John R Goffin, C. Kollmannsberger, P. Kaurah, P. Brown-Walker, L. Seymour.

Presenter. PD-L1 assessmetn in cytology is comparable to histology in predicting treatment response to checkpoint inhibitors in NSCLC. 2021 World Lung Cancer on Lung Cancer- Virtual Event. Presenter(s): Sally Lau-. Abstract #238; Featured Poster.

Publication Details:

Lau S, Rabindranath M, Weiss J, Li J, Nirmalakumar S, Ruff H, Boerner S, Tong LC, Tsao M, Pal P, Cabanero M, Hsu YH, Fung A, Sacher AG, Shepherd FA, Liu G, Bradbury P, Yasufuku K, Czarnecka-Kujawa K, Ko HM, **Leighl N**, Schwock J. PD-L1 assessmetn in cytology is comparable to histology in predicting treatment response to checkpoint inhibitors in NSCLC. **Coauthor or Collaborator.**

Presenter. Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage 1B-IIIa NSCLC. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Sabine Schmid-. Abstract #488; Poster Presentation.

Publication Details:

Schmid S, Garcia M, Hueniken K, Balaratnam K, Patel D, Zhan L, Brown MC, Sacher AG, Bradbury P, **Leighl N**, Shepherd FA, Liu G. Prevalence, treatment patterns and long-term clinical outcomes of patients with EGFR positive resected stage 1B-IIIa NSCLC. **Coauthor or Collaborator.**

Presenter. Real-world clinically-relevant toxicities of ALK TKIs in a cohort of patients with advanced/metastatic ALK+ NSCLC. 2021 World Conference on Lung Cancer-Virtual Event. Presenter(s): Sabine Schmid-. Abstract #484; Poster Presentation.

Publication Details:

Schmid S, Chotai S, Cheng S, Zhan L, Balaratnam K, Khan K, Patel D, Brown MC, Xu W, Moriarty PM, Kaidanovich-Beilin O, Shepherd FA, Sacher AG, **Leighl N**, Bradbury P, Liu G. Real-world clinically-relevant toxicities of ALK TKIs in a cohort of patients with advanced/metastatic ALK+ NSCLC. **Coauthor or Collaborator.**

Prognostic effects of TP53 variants co-occurring in patients with HER2-mutated non-small cell lung cancer (NSCLC). American Society of Oncology.

Publication Details:

Feng J, Hueniken K, Zhen F, Corke L, **Leighl N**, Liu G, Bradbury PA, Sacher AG, Eng L, Stockley T, Tsao MS, Shepherd FA. Prognostic effects of TP53 variants co-occurring in patients with HER2-mutated non-small cell lung cancer (NSCLC). J Clin Oncol. 41(Suppl 16; abstr e21065).

Media Appearances

- 2021 Dec **Moderator.** ALK-positive NSCLC. The ASCO Post. Virtual roundtable discussion-filmed- DECLINED.
- 2021 Mar **Invited Speaker.** Comment on KRYSTAL-1 (MRTX849 in patients with KRAS G12C mutant NSCLC). European Lung Cancer Virtual Congress 2021 Press Programme. Presenter(s): **Natasha Leighl** - DECLINED DUE TO CONFLICT OF INTEREST.
- 2020 Nov **Invited Speaker.** 2020 Lung Ca Quantatative Imaging Session: F. Hirsch and N Leighl-"Targeted Therapy Trial for Aggressive Early Stage Lung Cancer". The ASCO Post. United States. DECLINED due to time constraints.
- 2020 Mar **Interviewee.** Updates in RAS. Interviewer: Video Journal of Oncology. On-line Interview- DECLINED due to time constraints.
- 2019 Oct 25 **Invited Speaker.** Practice Changing Updates on First-Line Treatment of Lung Cancer. PeerVoice. Toronto, Ontario, Canada. Recorded on October 25, 2019 for CME for online delivery.
- 2019 Jun 4 **Invited Speaker.** Immunotherapy and Novel Publications presented at ASCO. Interviewer: Rottterdam Chicago. Chicago, Illinois, United States. In Studio Interview- DECLINED due to time constraints.
- 2019 Apr 24 **Invited Speaker.** Breathing New Life into NSCLC Management: Evaluating the Expanding Role of

Natasha LEIGHL

Immunotherapy. PeerVoice. Online. Recorded on April 24, 2019 for CME.

2015 Aug 10 **Invited Speaker.** A Look at New and Future Options. Peer Voice. Online. Second-line Treatment of Adenocarcinoma.

Chair

2022 Jul 6 **Chair.** Hawaiian Lung Cancer Summit July 6 - 9. Dava Oncology. Kona, Hawaii, United States.

Invited Chair

2022 Oct 22 **Invited Speaker.** Expanding Clinical Applications of Liquid Biopsy. International Society for Liquid Biopsy 2022 Annual Meeting. Miami, Florida, United States.

Invited Discussant

2022 Sep 12 **Invited Speaker.** Presidential Session III: Beyond Chemotherapy: Every Step Counts. ESMO 2022 Annual Meeting. Paris, France.

Meeting Chair

2023 Mar 3 The right treatment for the right patient at the right time: a MDT endeavour to optimise patient selection in lung cancer. Astra Zeneca Global Diagnostics (non promotional). San Jose, Costa Rica.

Published abstract (of presentation)

2013 Oct 25 **Invited Speaker.** Educational Topics of ASCO: Lung Cancer in 2013. 51st Annual Meeting of Japan Society of Clinical Oncology. Kyoto, Japan. Proceedings of 51st Annual Meeting of Japan Society of Clinical Oncology.

Published Abstract (to accompany invited lecture)

2013 Oct 27 **Principle Author.** Cost-effectiveness of modern therapies. 15th World Conference on Lung Cancer. Sydney, Australia. MS25.3 Poster presentation.

Workshop Lead

2023 Mar 4 MDT Case Discussion. Astra Zeneca Global Diagnostics (non promotional). San Jose, Costa Rica.

2023 Mar 3 Biomarker Testing algorithms in NSCLC. Astra Zeneca Global Diagnostics (non promotional). San Jose, Costa Rica.

Other Presentations

2023 Dec 20 **Invited Speaker.** Real World Evidence - where are we now? Exactis Podcast series. Canada.

2020 Mar 19 **Invited Speaker.** Revolution in Systemic Therapy of Early Stage Lung Cancer. Oncoclinicas Institute: Multidisciplinary Meeting of Thoracic Oncology. Brazil. Presenter(s): **Natasha Leighl.**

2008 Sep 12 Exploring New Pathways in Drug Development: Rational Targets for Antitumour Therapy. ESMO Stockholm 2008 Satellite Symposium. Stockholm, Sweden. (Continuing Education).

2008 Sep 11 Goals of Therapy: Patient and Physician Perspectives. Horizons III Lung Cancer Expert Forum. Stockholm, Sweden. (Continuing Education).

2008 Mar 8 Treatment of Non-small cell lung cancer: Focus on Anti-angiogenesis. GI & Lung Expert Forum. Brazil.

Natasha LEIGHL

(Continuing Education).

- 2007 Jun 30 Tarceva: Robust Evidence for its Use in Advanced Non-small Cell Lung Cancer. Tarceva Integrated Meeting of Excellence. Barcelona, Spain. (Continuing Education).
- 2005 May 16 A phase ½ study of GTI-2040 in combination with high-dose cytarabine in refractory or relapsed AML. GTI-2040 Investigator Meeting. Orlando, Florida. (Continuing Education).
- 2004 Sep 13 Phase I study of GTI-2040 plus taxotere in patients with NSCLC. National Cancer Institute CTEP Early Drug Development. Bethesda, Maryland. (Continuing Education).
- 2003 Aug 13 **Chair.** Practice Guidelines Oral Presentations. IASLC 10th WCLC. Vancouver. (Continuing Education).

2. NATIONAL

Invited Lectures and Presentations

- 2024 Mar 14 **Invited Speaker.** Think Tank on Antibody Drug Conjugates. DAVA Oncology-2024 Lung Summit. Victoria, British Columbia, Canada. DECLINED.
- 2023 Dec 1 **Invited Speaker.** ctDNA Assessment: __Technical aspects and __clinical implementation. Saskatchewan Precision Medicine Symposium 2023. Saskatoon, Saskatchewan, Canada.
- 2023 Nov 14 **Speaker.** Leveraging Liquid Biopsy for Early Cancer Prediction and Assessment. Frontline Genomics-Liquid Biopsy ONLINE- Virtual Series. DECLINED.
- 2023 Nov 12 **Invited Speaker.** Pleanary Session- Liquid Biopsies. 2023 Canadian Cancer Research Conference. Halifax, Nova Scotia, Canada. DECLINED.
- 2023 Nov 7 **Invited Speaker.** Liquid Biopsy in Lung Cancer. MSD National MSL Team. Montreal, Canada.
- 2023 Sep 29 **Invited Speaker.** Precision Oncology in Lung Cancer. Best of Precision Oncology 2023 (Oncology Education). Toronto, Ontario, Canada.
- 2023 Sep 7 **Invited Speaker.** Narrowing the Care Gap in NSCLC With Rare EGFR Alterations: The Next Frontier in Precision Medicine. Peervoice Canada. Canada. Recorded presentation and discussion for CME.
- 2023 Jun 22 **Invited Speaker.** National Lung Cancer Consultation Meeting-Virtual. Merck Canada. DECLINED.
- 2023 Jun 16 **Invited Speaker.** Is there a path forward for chemo-free periadjuvant therapy? Early-Stage Lung Cancer International Expert Retreat. Montreal, Quebec, Canada.
- 2023 Jun 16 **Section chair.** Emerging predictive and prognostic technologies for early stage NSCLC. Early-Stage Lung Cancer International Expert Retreat. Montreal, Quebec, Canada.
- 2023 Jun **Panelist.** Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting. PeerVoice. DECLINED.
- 2023 May 12 **Invited Speaker.** Lung Cancer Voices: Overcoming treatment resistance. Lung Cancer Canada. Ottawa, Canada.
- 2023 Apr 28 **Invited Speaker.** CCTG BRC.2E: Lessons Learned. Canadian Cancer Trials Group Spring Meeting. Toronto, Canada.
- 2022 Nov 23 **Invited Speaker.** KRAS G12C, CodeBreak200 and beyond. Amgen. Canada.
- 2022 Nov 18 **Invited Speaker.** What Medical Oncologists need to know about circulating tumor DNA. Best of Oncology East 2022. Canada.

Natasha LEIGHL

- 2022 Oct 12 **Invited Speaker.** Moving Beyond Osimertinib. Janssen National Advisory Board. Canada.
- 2022 Sep 30 **Invited Speaker.** Canadian Immuno-Oncology Conference 2022: Best of Lung Cancer. Oncology Education.CA. Canada.
- 2022 Sep 16 **Invited Speaker.** Targeted Therapy in Early Stage NSCLC. Canadian Association of Thoracic Surgeons. Toronto, Canada.
- 2022 Aug 30 **Invited Speaker.** Lung Cancer: A Learning Session with Dr. Natasha Leighl. Ipsen Canada. Canada.
- 2022 Aug 12 **Invited Speaker.** CAMP PODS: Emerging Targets in NSCLC. Canadian Association of Molecular Oncologists. Vancouver, British Columbia, Canada.
- 2022 Jun 17 **Speaker.** National Lung Cancer Advisory Board Meeting. Merck Canada. Virtual. DECLINED.
- 2022 Jun 17 **Chair.** Best of ASCO Toronto. Oncology Education.
- 2022 May 25 **Invited Speaker and Chair.** Novel Strategies for Managing EGFR exon20 insertion mutant NSCLC (Central, Eastern Canada). Janssen Inc. Canada.
- 2022 May 25 **Invited Speaker and Chair.** Novel Strategies for Managing EGFR exon20 insertion mutant NSCLC (Western Canada). Janssen Inc. Canada.
- 2022 Apr 29 **Invited Speaker.** CCTG BR34: Randomized trial of durvalumab plus tremelimumab with or without chemotherapy in patients with advanced NSCLC. Canadian Cancer Trials Group 2022 Spring Meeting Plenary Session. Canada.
- 2022 Apr 6 **Invited Speaker.** VALUE of liquid biopsy - a Canadian Study. Guardant Liquid Biopsy National Consultants Meeting. Canada.
- 2022 Mar 3 **Chair.** Treatment Landscape of ALK+ NSCLC. Takeda Oncology.
- 2022 Mar 2 **Chair and Speaker.** Amivantamab in EGFR Ex20ins NSCLC. Janssen Canadian National Advisory Board Meeting.
- 2022 Jan 14 **Invited Speaker.** Immunotherapy Combinations for First-Line Advanced NSCLC Treatment: Clinical insights on current and emerging options. Peer Voice (online). Canada.
- 2022 Jan 11 **Speaker.** TRK fusion cancer. Bayer. Toronto, Ontario, Canada. DECLINED.
- 2021 Dec 9 **Invited Speaker.** HER2 and EGFR Exon 20 Mutations. GEOQ Lung Cancer Conference.
- 2021 Dec 3 **Chair and Speaker.** NSCLC in Canada and Immunotherapy Advances. BeiGene National Medical NSCLC Advisory Board.
- 2021 Nov 3 **Invited Speaker.** Genomics 101. Oncology Rounds- CHUM-Virtual.
- 2021 Nov 3 **Roundtable Discussion.** Latest Advances in EGFR-mutated NSCLC and the Targeting of Exon 20 Insertion Mutations-What this means in Clinical Practice. VJOncology. Virtual.
- 2021 Oct 19 **Invited Speaker.** Driver Mutations in NSCLC: What's New? WCLC/ESMO Highlights (Amgen sponsored). Virtual.
- 2021 Oct 6 **Invited Speaker.** Update in KRAS: Phase I/II Data for Sotorasib and other KRAS inhibitors. Amgen National Oncology Advisory Board.
- 2021 Sep 29 **Invited Speaker.** Targeting EGFR Exon20ins mutations in NSCLC. Janssen Canadian National Advisory Board Meeting.
- 2021 Sep 17 **Invited Speaker.** Current Management of EGFRex20 Insertion NSCLC. Canadian National Advisory Board Meeting-Janssen. Virtual.

Natasha LEIGHL

- 2021 Sep 16 **Invited Speaker.** New and Emerging Targets in Lung Cancer. Precision Rx Dx.
- 2021 Sep 14 **Invited Speaker.** Navigating the Evolving Treatment Landscape in NSCLC: EGFR and ALK. MedPlan TARGET Train the Trainer.
- 2021 Jul 16 **Invited Speaker.** The Rising Cost of Cancer Drugs and Impact on Access. Best of ASCO 2021 Annual Meeting - Vancouver. Vancouver, British Columbia, Canada.
- 2021 Jun 25 **Co-Chair.** Best of ASCO 2021 Annual Meeting. Virtual.
- 2021 Jun 18 **Invited Speaker.** Recent advances in Lung Cancer Immunotherapy: ASCO 2021 Update. MSD National Advisory Board Meeting. Virtual.
- 2021 Jun 15 **Invited Speaker.** ASCO 2021 Update 1L Therapy. BMS National Advisory Board. Virtual.
- 2021 Jun 11 **Invited Speaker.** Who's on First? Systemic Therapy of Advanced NSCLC. Atlantic Canada Oncology Group 2021 Virtual Symposium. Canada. Presenter(s): **Natasha Leighl.**
- 2021 Jun 8 **Invited Speaker.** MET inhibitors in Lung Cancer. Health Canada pre-NDS Meeting (Capmatinib). Ottawa, Ontario, Canada.
- 2021 May 18 **Invited Speaker.** The Lung Cancer Patient Journey- "Getting to Treatment". Merck eSeries: Illuminating the Lung Cancer Patient Journey. Virtual.
- 2021 May 6 **Invited Speaker.** Targeting EGFR in Canada. Health Canada pre-NDS Meeting (Amivantamab). Ottawa, Canada.
- 2021 Apr 6 **Invited Speaker.** Lung Cancer Update. Novartis Canada.
- 2021 Mar 4 **Invited Speaker.** Tepotinib and other MET inhibitors: the Canadian Landscape. Canadian Agency for Drugs and Technologies in Health (presubmission meeting Tepotinib).
- 2021 Feb 16 **Chair and Speaker.** Updates in KRAS Post WCLC. Post-WCLC Review (Sponsor Amgen Canada). Virtual Program.
- 2021 Feb 2 **Invited Speaker.** Immunotherapy for NSCLC Today and Tomorrow: Mining the Evidence to Refine Care. Canada.
- 2021 Jan 20 **Invited Speaker.** Lung Cancer in 2021-Right Treatment, Right Person, Right Time. Lung Health Foundation. Canada. Virtual Presentation.
- 2020 Dec 7 **Invited Speaker.** Adjuvant EGFR TKIs in Lung Cancer. AstraZeneca Canada-Early-Stage NSCLC Advisory Board. Virtual Meeting.
- 2020 Dec 3 **Speaker.** Lung Cancer in Canada - Focus on Master Protocol Designs. Health Canada. Canada. Virtual Meeting.
- 2020 Nov 4 **Chair and Speaker.** RET +ve Lung Cancer. Eli Lilly Canada-National Selpercatinib Advisory Meeting. Virtual Meeting.
- 2020 Oct 29 **Moderator.** "Examining an Evolving Treatment Landscape: Contextualizing the Role of Immunotherapy as a First Line Option in Thoracic Cancer". Fusion MD/BMS. Virtual Speaker Tour-Dr. Hossein Borghaei.
- 2020 Oct 23 **Host and Moderator.** What's it ALK About. Fusion MD. Canada. Presenter(s): Ross Camidge, MD, PhD. Virtual Webcast.
- 2020 Oct 14 **Speaker.** Lung Cancer in Canada - Focus on SCLC. Health Canada. Canada. Virtual Meeting.
- 2020 Jun 23 **Invited Speaker.** The Changing Treatment Landscape in First Line Metastatic Non-Small Cell Lung Cancer. Merck Colloque. Virtual, On-Line Seminar.
- 2020 Jun 19 **Invited Speaker.** 24th Annual ACOG Symposium. Halifax, Nova Scotia, Canada. CANCELLED DUE TO

COVID-19.

- 2020 Jun 12 **Invited Speaker.** Checkpoint Inhibitors in the Treatment of Lung Cancer in Canada. Merck Canada-National Lung Cancer Advisory Board. Canada. Virtual Meeting.
- 2020 Jun 11 **Speaker.** Lung Cancer in Canada - Focus on RET. Health Canada. Canada. Virtual Meeting.
- 2020 Apr 22 **Speaker.** Lung Cancer in Canada - Focus on MET. Health Canada. Canada. Virtual Meeting.
- 2020 Feb 14 **Chair; Invited Speaker.** Canadian Landscape of ALK Inhibitors. Brigatinib National Consultants Meeting. Toronto, Ontario, Canada.
- 2020 Feb 7 **Invited Speaker.** ROS 1. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2019 Nov 7 **Invited Speaker.** Canadian Immuno-Oncology Summit 2019. Toronto, Ontario, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 Nov **Invited Speaker.** Lung Cancer 2019. Hoffman-LaRoche. Toronto, Ontario, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 Jul 18 **Invited Speaker.** An Introduction to Basket Trials. PanCanadian Oncology Drug Review pERC Meeting. Toronto, Ontario, Canada.
- 2019 Jun 24 **Invited Speaker.** ROS1 Testing in Lung Cancer: An Oncologist's Perspective. Canadian Association of Pathologists. Niagara-on-the-Lake, Ontario, Canada.
- 2019 Jun 21 **Invited Speaker.** Evolving ALK Landscape and Patterns of Resistance in ALK positive NSCLC. Canadian Summer Oncology Update 2019. Whistler, British Columbia, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 Jun 14 **Invited Speaker.** SCLC Immunotherapy Trial Updates. Merck Canada: National Lung Advisory Board. Mississauga, Ontario, Canada.
- 2019 May 30 **Invited Speaker.** Benefits and Challenges of Tissue-Agnostic Oncology Treatments. Canadian Association for Healthcare Reimbursement. Toronto, Ontario, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 May 28 **Invited Speaker.** TARGET: Update on Targeted Therapies in Lung Cancer. MedPlan. Toronto, Ontario, Canada.
- 2019 May 4 **Invited Speaker.** BR.34: A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous NSCLC. Canadian Cancer Trials Group. Toronto, Ontario, Canada.
- 2019 Apr 4 Takeda Canada Brigatinib Advisory Board. Toronto, Ontario, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 Feb 7 **Chair.** Comprehensive Liquid Biopsy Testing in Metastatic Lung Cancer. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2019 Feb 7 **Invited Speaker.** Canadian VALUE Study- Finding Value in Cancer Diagnostics. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2018 Oct 26 **Invited Speaker.** Pharmacoeconomic Evaluation of ROS-1 Testing and Reimbursement. Pfizer- ROS-1 and cMET Ad Board Meeting. Montreal, Quebec, Canada.
- 2018 Jun 20 **Invited Speaker.** Respirology Rounds. Jewish General Hospital. Montreal, Quebec, Canada. DECLINED due to time conflict.
- 2018 Jun 19 **Invited Speaker.** Best of ASCO-Lung Cancer. OncologyEducation.com. Montreal, Quebec, Canada.
- 2017 Aug 10 **Invited Speaker.** Economic Evaluation in Phase III Trials. Canadian Cancer Trials Group New

Investigator Clinical Trials Course. Kingston, Ontario, Canada.

- 2017 Aug 10 **Invited Speaker.** Economic Evaluation Workshop. Canadian Cancer Trials Group New Investigator Clinical Trials Course. Kingston, Ontario, Canada.
- 2017 Jun 24 **Invited Speaker.** What I-O Really Means for your NSCLC Patients. Canadian Summer Oncology Update-Lunch Symposium. Whistler, British Columbia, Canada.
- 2017 Jun 23 **Invited Speaker.** Update on Lung Cancer. Canadian Conference on Community Oncology. Whistler, British Columbia, Canada.
- 2017 Jun 23 **Invited Speaker.** Case Studies on Lung Cancer. Canadian Summer Oncology Update. Whistler, British Columbia, Canada. Case Studies in Lung Cancer.
- 2017 Jun 16 **Chair.** Best of ASCO. Oncology Education. Toronto, Ontario, Canada.
- 2017 Apr 24 **Invited Speaker.** Reimbursement Perspectives on Precision Medicine - the Clinician's view. 2017 CADTH Symposium. Ottawa, Ontario, Canada.
- 2017 Mar 23 **Keynote Speaker.** Advances in Immunotherapy in Lung Cancer in 2017 - Morning Rounds. Leguaudeur Hospital Oncology Department. Montreal, Quebec, Canada.
- 2017 Mar 23 **Invited Speaker.** Pulmonary Noon Rounds: What does the future look like in lung cancer? Jewish General Hospital Pulmonary Division. Montreal, Quebec, Canada.
- 2017 Mar 22 **Invited Speaker.** Immunotherapy in NSCLC in 2017: Where are we at? Pulmonary rounds. University of Sherbrooke. Sherbrooke, Quebec, Canada.
- 2017 Mar 22 **Keynote Speaker.** Immunotherapy in Lung Cancer 2017. CME sponsored by Bristol Myers Squibb. Montreal, Quebec, Canada.
- 2017 Mar 21 **Invited Speaker.** IO therapy and biomarkers in NSCLC - when, why and how? Pulmonary rounds. Department of Respiratory Medicine, IUCPQ. Laval, Quebec, Canada.
- 2017 Feb 10 **Invited Speaker.** Canadian Perspective: Lung Cancer. University of British Columbia. Vancouver, British Columbia, Canada. Canadian Lung Cancer Conference.
- 2016 Nov 18 **Invited Speaker.** Navigating Treatment Access and Cost. Lung Cancer Canada. Toronto, Ontario, Canada. Lung Cancer Patient Summit 2016.
- 2016 Nov 4 **Invited Speaker.** Immunotherapy in Lung Cancer. CHUM/Jewish General Hospital. Montreal, Quebec, Canada.
- 2016 Nov 3 **Invited Speaker.** Advances in Lung Cancer. Hospital Maisonneuve Rosemont. Montreal, Quebec, Canada. Pulmonary Noon Rounds.
- 2016 Oct 21 **Invited Speaker.** Updates in Cancer Treatment. ATOG. Halifax, Nova Scotia, Canada. 6th Atlantic Canada Thoracic Oncology Conference- DECLINED DUE TO TIME CONFLICT.
- 2016 Sep 14 **Invited Speaker.** Companion Diagnostics. Innomar. TBA. Innomar Live 2016- DECLINED DUE TO TIME CONFLICT.
- 2016 Jun 17 **Chair.** Best of ASCO-2016 Annual Meeting- Welcome Address by Chairs. Oncology Education. Toronto, Ontario, Canada. Presenter(s): Co-Chair- Dr. Scott Berry.
- 2016 Jun 17 **Chair.** Best of ASCO-2016 Annual Meeting- Summary and Closing Remarks by Chairs. Oncology Education. Toronto, Ontario, Canada. Presenter(s): Co-Chair- Dr. Scott Berry.
- 2016 Apr 27 **Invited Panelist.** Cancer Care in 2025. CAMO. Toronto, Ontario, Canada. 2016 CAMO Evening Symposium- DECLINED DUE TO TIME CONSTRAINTS.
- 2016 Feb 4 **Invited Speaker.** Lung Cancer in 2016. Astellas Pharma National Training Meeting. Markham, Ontario,

Canada. Presenter(s): **Leighl N.**

- 2016 Jan 20 **Invited Speaker.** Management of ROS1+ Lung Cancer. Pfizer/CROS Consortium. Montreal, Quebec, Canada. CROS Molecular Testing Meeting.
- 2015 Nov 3 **Invited Panelist.** Immuno-Oncology Treatment in Lung Cancer. CAPT. Toronto, Ontario, Canada. 2015 CAPT Annual Meeting-DECLINED DUE TO TIME CONFLICT.
- 2015 Oct 30 **Co-Chair.** Best of Lung & Immuno Summit in 2015. Immuno-Oncology. Toronto, Ontario, Canada. Immunotherapy in Lung Cancer: Personalized medicine or one size fits all?.
- 2015 Oct 30 **Co-Chair.** Best of Lung & Immuno Summit in 2015. Immuno-Oncology. Toronto, Ontario, Canada. Welcome Address & Introduction.
- 2015 Oct 29 **Invited Speaker.** Checkpoint: Exploring New Frontiers in Cancer Therapy: Efficacy and Safety of Immuno-Oncology in Lung Cancer. Bristol Myers Squibb. Toronto, Ontario, Canada.
- 2015 Sep 22 **Keynote Speaker.** Immune RECIST Criteria in Lung Cancer. Oncology Education. Canada. webinar.
- 2015 Aug 13 **Invited Speaker.** NCIC Clinical Trials Group New Investigator Clinical Trials Course. NCIC Clinical Trials Group. Kingston, Ontario, Canada. Plenary Session 4: Correlative Science Studies in Phase III Trials-Economic Evaluation.
- 2015 Aug 13 **Invited Speaker.** NCIC Clinical Trials Group New Investigator Clinical Trials Course. NCIC Clinical Trials Group. Kingston, Ontario, Canada. Workshop 6: Economic Evaluation.
- 2015 Jul 10 **Speaker.** CHECKPOINT: Efficacy and Safety of Immuno-Oncology in Lung Cancer. MedPlan Communications Inc. Videorecorded CME for online delivery. (Continuing Education).
- 2015 Jun 16 **Invited Speaker.** Lung cancer in men and women, funding, and stigma. House of Commons' Standing Committee on Health. Ottawa, Ontario, Canada. Presenter(s): Dr. **Natasha Leighl**, Dr. Paul Wheatley-Price, Dr. Stephen Lam, Dr. Diana Ionescu. Invitation to appear before the Committee to contribute to its study of lung cancers.
- 2015 Jun 12 **Invited Speaker.** Best of ASCO Canada 2015: Lung Cancer. American Society of Clinical Oncology. Toronto, Ontario, Canada.
- 2015 Apr 30 **Invited Speaker.** Optimizing Patient Care in the Era of Precision Medicine: A partnership between medical oncologists and pathologists. Canadian Association of Medical Oncologists. Toronto, Ontario, Canada. Presenter(s): Dr. **Natasha Leighl**, Dr. Ming S. Tsao.
- 2015 Apr 30 **Invited Speaker.** "Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada". Pan-Canadian Lung Cancer Screening Network. Toronto, Ontario, Canada. Presentation of publication.
- 2015 Apr 25 **Invited Speaker.** Lung Cancer Care, Current Challenges and Opportunities: Key Findings from the Ontario Lung Cancer Summit. Canadian Respiratory Conference 2015. Ottawa, Ontario, Canada. Presenter(s): Dr. **Natasha Leighl**.
- 2015 Feb 6 **Invited Speaker.** Third Generation EGFR TKI. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2015 Feb 5 **Invited Speaker.** Advocacy- What Can You Do To Make A Difference. Canadian Oncology Resident Education Program @ Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2014 Nov 20 **Invited Speaker.** Sequencing and Beyond in Lung Cancer. Jewish General Hospital. Montreal, Quebec, Canada. Thoracic Group Noon Rounds.
- 2014 Nov 19 **Invited Speaker.** Advances in Profiling and Targeted Therapy for Lung Cancer. Jewish General Hospital. Montreal, Quebec, Canada. The Mona Zavalkoff Annual Lecture Series on "Innovations and Advances in Lung Cancer".

- 2014 Nov 6 **Invited Speaker.** Lung Cancer: Today and Tomorrow. Bristol-Myers Squibb Canada. Montreal, Quebec, Canada.
- 2014 Oct 1 **Invited Speaker.** Optimal Strategy in EGFR Inhibition: 2014- A Canadian Perspective. CARE Faculty. Toronto, Ontario, Canada.
- 2014 Sep 11 **Invited Speaker.** Lung Cancer. Health Canada Preceptorship. Toronto, Ontario, Canada.
- 2014 Jul 13 **Invited Speaker.** Impact of molecular testing for NSCLC: An oncologist's perspective. Canadian Association of Pathologists Annual Meeting. Toronto, Ontario, Canada.
- 2014 Jun 20 **Invited Speaker.** Best of ASCO- Lung. Best of ASCO Canada. Toronto, Ontario, Canada.
- 2014 May 29 **Invited Speaker.** Patient Perspective: Stigma of Lung Cancer. Pan-Canadian Lung Cancer Screening Meeting. Montreal, Quebec, Canada.
- 2014 May 8 **Invited Speaker.** Lung Cancer Advocacy: Lung Cancer Canada. Alberta Health Services-Alberta Provincial Lung Tumor Team Meeting. Edmonton, Alberta, Canada.
- 2014 Apr 5 **Invited Speaker.** Immuno-Oncology and Lung Cancer. BMS Symposium at ISOPP XIV. Montreal, Quebec, Canada.
- 2014 Feb 6 **Invited Speaker.** Current Challenges in the Canadian Landscape of Lung Cancer Treatment. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2014 Feb 6 **Invited Chair.** PD-1 vs PD-L1. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada. Debate.
- 2014 Feb 6 **Invited Speaker.** How to Advocate For Your Patient. Vancouver, British Columbia, Canada.
- 2013 Sep 21 **Invited Speaker.** Finding the target – molecular testing and personalized medicine within NSCLC. Canadian Association of Radiation Oncology –COMP Joint Scientific Meeting. Montreal, Quebec, Canada. Workshop.
- 2013 Aug 22 **Invited Speaker.** Workshop on how to integrate economic evaluation into trials. NCIC Clinical Trials Group New Investigator Clinical Trials Course. Kingston, Ontario, Canada.
- 2013 Aug 22 **Invited Speaker.** Economic Evaluation in Phase III Trials. NCIC Clinical Trials Group New Investigator Clinical Trials Course. Kingston, Ontario, Canada.
- 2013 Jul 10 **Invited Speaker.** Biomarker Testing in Lung Cancer. Boehringer Ingelheim Oncology Training. Toronto, Ontario, Canada.
- 2013 Jun 14 **Invited Speaker.** Best of Lung Cancer at ASCO 2013. Best of ASCO Canada 2013. Toronto, Ontario, Canada.
- 2013 Feb 8 **Invited Speaker.** Standard treatment for Stage III Unresectable NSCLC. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2013 Feb 7 **Invited Speaker.** The Future in Lung Cancer. Canadian Oncology Resident Education Program. Vancouver, British Columbia, Canada.
- 2012 May 4 **Invited Speaker.** State of the Art Treatment in Advanced NSCLC: ça existe au Canada? XXXVIIth Annual Meeting of the Association des medecins hematologues et oncologues du Quebec. Montreal, Quebec, Canada.
- 2012 Jan 26 **Invited Speaker.** State of the Art Lung Cancer Treatment: On sale in a province near you. Canadian Lung Cancer Conference. Vancouver, British Columbia, Canada.
- 2012 Jan 12 **Invited Speaker.** How to Estimate Physician and Patient Responses to Personal Information. Health Economics Methodology Research Challenge. Health Canada/CIHR Personalised Medicine in Canada

Workshop. Ottawa, Ontario, Canada.

- 2010 Sep 18 **Invited Speaker.** The role of maintenance therapy in metastatic NSCLC. Atlantic Thoracic Oncology Conference. Halifax, Nova Scotia, Canada.
- 2010 Mar 26 **Invited Speaker.** Vascular Endothelial Growth Factor. Canadian National Consensus Meeting Integrating Biomarkers into the Diagnosis and Treatment of NSCLC. Toronto, Ontario, Canada.
- 2010 Jan 29 **Invited Speaker.** Monoclonal antibodies are the only maintenance therapy for Stage IV NSCLC. Western Canadian Lung Cancer Conference 2010. Vancouver, British Columbia, Canada. Debate.
- 2010 Jan 28 **Invited Speaker.** The evolution of NSCLC therapy: at what cost? Western Canadian Lung Cancer Conference 2010. Vancouver, British Columbia, Canada.
- 2010 Jan 22 **Invited Speaker.** ASA404 in NSCLC – Preclinical and Clinical Experience. ATTRACT-2 Investigator Meeting. Montreal, Quebec, Canada.
- 2009 Oct 23 **Invited Speaker.** Moving Towards Personalized Medicine: Lung Cancer Therapy in 2009. National Oncology Pharmacy Symposium. Ottawa, Ontario.
- 2009 Oct 1 **Invited Speaker.** Economic Evaluation. Special Topics in Clinical Trials. New Investigators Clinical Trials Course, NCIC Clinical Trials Group. Kingston, Ontario. (Continuing Education).
- 2009 Sep 30 The Key Elements of a Successful Phase III Trial. Plenary Session 3: Phases of Clinical Development of Therapeutics – Phase III, New Investigators Clinical Trials Course, NCIC Clinical Trials Group. Kingston, Ontario. (Continuing Education).
- 2008 Feb 22 Abraxane in NSCLC. Regional Consultants Meeting in NSCLC. Vancouver, British Columbia. (Continuing Education).
- 2007 Aug 7 Current Landscape of the Management of advanced NSCLC in Canada in the year 2007. Health Canada. Ottawa, Ontario. (Continuing Education).
- 2006 Nov 3 Second-line therapy in NSCLC. Thoracic Cancer Advisory Board (Lilly). Montreal, Quebec. (Continuing Education).
- 2006 Jun 16 Targeted Therapy in Lung Cancer. Annual Atlantic Canada Oncology Group Mtg. Charlottetown, Prince Edward Island. (Continuing Education).
- 2006 Mar 6 Role of erlotinib in 2nd line NSCLC therapy. Ontario Consultants Meeting at Canadian Oncology Winter Conference. Kamloops. (Continuing Education).
- 2005 Nov 22 EGFR TKIs in advanced NSCLC: the magic bullet? H. Murphy Bliss Cancer Centre, Memorial University. St. John's. (Continuing Education).
- 2004 Dec 2 Management of NSCLC in the Elderly. Univ of Montreal Continuing Medical Education CD ROM-based Program. (Continuing Education).
- 2004 Jul 22 **Invited Speaker.** Quality of Life and the Impact of Systemic Therapy. Bliss Murphy Cancer Centre. St. John's, Newfoundland and Labrador, Canada.
- 2004 May 27 Quality of Life and Systemic Therapy in Advanced NSCLC. Nova Scotia Cancer Centre Grand Rounds. Halifax, Nova Scotia. (Continuing Education).
- 2003 Oct 5 Symptom Control in Advanced NSCLC – is chemotherapy as good as it gets? CANO Symposium (2003 Annual CANO Meeting). Ottawa, Ontario. (Continuing Education).
- 2001 Nov 2 **Invited Speaker.** "Review of Nonsmall Cell Lung Cancer and rationale for BR.21". National Cancer Institute of Canada BR.21 Participants Meeting. Bermuda.

Presented Abstracts

- 2009 May 11 Economic Evaluations of Targeted Therapy – do they meet the needs of decision-makers? Canadian Association for Health Services and Policy Research (CHSPR) Conference. Calgary, Alberta. Ferrusi IL, Marshall DA, Kulin NA, **Leighl NB**, Phillips KA. Oral Presentation. May 11-14, 2009. (Trainee Presentation).
- 2009 Apr 30 A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma. Results after completion of stage 1. A trial of the Princess Margaret Hospital Phase II Consortium. 2009 CAMO Annual Meeting. Toronto, Ontario. Taylor SK, Chia S, Dent S, Clemons M, Greci P, Wang L, Oza AM, Ivy P, Pritchard KI, **Leighl N**. Poster presentation. (Trainee Presentation).
- 2008 May 7 Socio-demographic determinants of health-related quality of life in patients with metastatic cancer. 2008 Canadian Association of Psychosocial Oncology Conference. Halifax, Nova Scotia. Zimmermann C, Burman D, Rodin G, Swami N, Krzyzanowska M, **Leighl N**, Bryson J, Seccareccia D, Banerjee S, Kaya E, Moore M, Tannock I. Oral presentation (ref 183) May 7-9, 2008.
- 2008 May 1 A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer in the NCIC CTG JBR.10 trial. 2008 CAMO Annual Meeting. Toronto, Ontario. Jang RW, Le maitre A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, **Leighl NB**. Poster presentation. (Trainee Presentation).
- 2008 May 1 The impact of surgery, systemic therapy and surveillance on outcomes for multifocal bronchioloalveolar carcinoma. 2008 CAMO Annual Meeting. Toronto, Ontario. Cheung WY, Hwang D, Chung T, Johnston M, **Leighl NB**. Poster presentation. (Trainee Presentation).
- 2008 May Economic Evaluations of Targeted Therapy – do they meet the needs of decision-makers? CAHSPR Conference. Calgary, Alberta. Ferrusi IL, Marshall DA, Kulin NA, **Leighl NB**, Phillips KA. Oral Presentation.
- 2006 May 10 Quality of Life and Utility in advanced non-small cell lung cancer patients. 3rd Joint Therapeutics Congress, Canadian Association of Population Therapeutics. Toronto. Mittmann N, **Leighl N**, Wang M, Cote I. 10-12 May 2006.
- 2006 Apr 27 An economic analysis of the NCIC JBR.10 trial, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer. 2006 CAMO Annual Meeting. R Ng, N Mittmann, M Florescu, F Shepherd, A Salvarrey, L Seymour, W Evans, **N Leighl**. For oral presentation. (Trainee Presentation).
- 2005 Feb Feasibility, Reliability, and Validity Testing of a computer-generated quality of life assessment and scoring program for patients with lung cancer (LCSS-QL). 8th National Conference on Cancer Nursing Research. Ft. Lauderdale, Florida. Hollen PJ, Gralla RJ, **Leighl N**, Landen B, Kimber H, Butta V.

Presented and Published Abstracts

- 2023 Jun 22 **Invited Speaker**. Barriers & Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays Across Canada. Colorectal Cancer Resource & Action Network. Canada. Virtual. DECLINED.
- Publication Details:*
Barriers & Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays Across Canada.
- 2015 Apr 30 **Senior Responsible Author**. Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)- Are Research Biopsies a Barrier to Participation in Clinical Trials? Canadian Association of Medical Oncologists. Toronto, Ontario, Canada. Oral Presentation 2015 CAMO Annual Scientific Meeting. (Trainee Presentation)
- Publication Details:*
Lim C, Sung M, Nouriany N, Sawczak M, Paul T, Perera-Low N, Feld R, Liu G, Shepherd F, **Leighl N**.

Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)- Are Research Biopsies a Barrier to Participation in Clinical Trials? 2015 CAMO Annual Scientific Meeting-Book of Abstracts. 2015 Apr 30;(April 30, 2015):6. **Senior Responsible Author.**

2014 May 12 **Co-author/collaborator.** The Value of Personalizing Medicine: Medical Oncologists' Views on Gene Expression Profiling in Breast Cancer Treatment. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Yvonne Bombard. Poster Presentation.

Publication Details:

Bombard Y, Rozmovits, Trudeau M, **Leighl NB**, Deal K, Marshall DA. The Value of Personalizing Medicine: Medical Oncologists' Views on Gene Expression Profiling in Breast Cancer Treatment. Proceedings of 2014 ARCC Conference. 2014 May 12:21. **Coauthor or Collaborator.**

2014 May 12 **Co-author/collaborator.** The Influence of Gene Expression Profiling (GEP) on Decisional Conflict in Chemotherapy Treatment Decision-Making for Early-Stage Breast Cancer (BrCa). Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Karen MacDonald. Poster Presentation.

Publication Details:

MacDonald K, Bombard Y, **Leighl N**, Deal K. The Influence of Gene Expression Profiling (GEP) on Decisional Conflict in Chemotherapy Treatment Decision-Making for Early-Stage Breast Cancer (BrCa). Proceedings of 2014 ARCC Conference. 2014 May 12:21. **Coauthor or Collaborator.**

2014 May 12 **Co-author/collaborator.** First Two Years of Health System Resources and Costs Following a Stage Defined Breast Cancer Diagnosis: A Population-Based Approach. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Nicle Mittmann. Poster Presentation.

Publication Details:

Porter J, Rangrej J, Seung SJ, Saskin R, Chung M, **Leighl N**, Hoch J, Trudeau M, Evans W, Kainty K, DeAngelis C, Earle C. First Two Years of Health System Resources and Costs Following a Stage Defined Breast Cancer Diagnosis: A Population-Based Approach. Proceedings of 2014 ARCC Conference. 2014 May 12:22. **Coauthor or Collaborator.**

2014 May 12 **Co-author/collaborator.** A Systemic Review of Factors Influencing Older Adults' Decisin to Accept or Decline The Proposed Cancer Treatment. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Martine Puts. Poster Presentation.

Publication Details:

Puts M, Tapscott B, Howell D, Krzyzanowska M, **Leighl N**, Monette J, Springall E, Wan-Chow-Wah D. A Systemic Review of Factors Influencing Older Adults' Decisin to Accept or Decline The Proposed Cancer Treatment. Proceedings of 2014 ARCC Conference. 2014 May 12:27. **Coauthor or Collaborator.**

2014 May 12 **Co-author/collaborator.** Homecare Utilization and Costs in Stage IV Lung Cancer: A Canadian Public Payer Experience. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Nicole Mittmann. Poster Presentation.

Publication Details:

Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, **Leighl N**, Hoch JS, Trudeau M, Evans W. Homecare Utilization and Costs in Stage IV Lung Cancer: A Canadian Public Payer Experience. Proceedings of 2014 ARCC Conference. 2014 May 12:36. **Coauthor or Collaborator.**

2014 May 12 **Co-author/collaborator.** Stage-Based Utilization of Chemotherapy Agents in a Breast Cancer Population. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Nicole Mittmann. Poster Presentation.

Publication Details:

Mittmann N, Seung SJ, Porter J, Rangrej J, Liu N, Trudeau M, DeAngelis C, Hoch J, **Leighl N**, Earle C. Stage-Based Utilization of Chemotherapy Agents in a Breast Cancer Population. Proceedings of 2014 ARCC Conference. 2014 May 12:42. **Coauthor or Collaborator**.

2014 May 12 **Senior Responsible Author**. The Cost-Effectiveness of 2nd Line Crizotinib in EML4-ALK Rearranged Advanced NSCLC in Ontario. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Sandjar Djalalov. Poster Presentation.

Publication Details:

Djalalov S, Graham D, Beca J, Hoch J, Tsao MS, Cutz JC, **Leighl N**. The Cost-Effectiveness of 2nd Line Crizotinib in EML4-ALK Rearranged Advanced NSCLC in Ontario. Proceedings of 2014 ARCC Conference. 2014 May 12:43. **Senior Responsible Author**.

2014 May 12 **Co-author/collaborator**. Population-Based Trends in Radiation Therapy for a Canadian Breast Cancer Cohort. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2014. Toronto, Ontario, Canada. Presenter(s): Nicole Mittmann. Poster Presentation.

Publication Details:

Seung SJ, Liu N, Porter J, Saskin R, Hoch J, Evans W, **Leighl N**, Trudeau M, Earle C. Population-Based Trends in Radiation Therapy for a Canadian Breast Cancer Cohort. Proceedings of 2014 ARCC Conference. 2014 May 12:53. **Coauthor or Collaborator**.

2013 Sep 21 **Co-Author/Collaborator**. Long term outcome after an-bloc resection of non-small cell lung cancer invading the pulmonary sulcus and spine. CATS Paper Session. Ottawa, Ontario, Canada. Oral Presentation at the CATS Paper Session.

Publication Details:

Collaud, S., Waddell, T.K., Yasufuku, K., Pierre, A.F., Darling, G.E., Cypel M., Rampersaud, Y.R., Lewis, S.J., Shepherd, F.A., **Leighl, N.B.**, Cho, J., Bezjak A., Tsao, M., Keshavjee S., de Perrot, M. Long term outcome after an-bloc resection of non-small cell lung cancer invading the pulmonary sulcus and spine. Proceedings of the CATS Annual Meeting of September 2013. **Coauthor or Collaborator**.

2013 May 28 **Co-author/collaborator**. Patient preferences: Understanding Risk-Benefit Trade-offs of Genomic Testing in Chemotherapy Treatment Decisions for Breast Cancer Patients. Canadian Association for Health Services and Policy Research (CAHSPR) Conference. Vancouver, British Columbia, Canada. Presenter(s): Karen Pykerman. Poster Presentation.

Publication Details:

Pykerman K, Bombard Y, Trudeau M, **Leighl N**, Marshall DA, Child AJE. Patient preferences: Understanding Risk-Benefit Trade-offs of Genomic Testing in Chemotherapy Treatment Decisions for Breast Cancer Patients. Proceedings of Canadian Assoc for Health Services and Policy Research (CAHSPR) Annual Meeting 2013. 2013 May 28:70.

2013 May 28 **Co-author/collaborator**. Access to personalized medicine: The case of gene expression profiling breast cancer. Canadian Association for Health Services and Policy Research (CAHSPR). Vancouver, British Columbia, Canada. Presenter(s): Yvonne Bombard. Poster Presentation.

Publication Details:

Bombard Y, Roxmovits L, Trudeau M, **Leighl N**, Deal K, Marshall D. Access to personalized medicine: The case of gene expression profiling breast cancer. Proceedings of Canadian Assoc for Health Services and Policy Research (CAHSPR) Annual Meeting 2013. 2013 May 28:31. **Coauthor or Collaborator**.

2013 May 27 **Co-author/collaborator**. Access to personalized medicine: The case of gene expression profiling in breast cancer. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2013. Vancouver, British Columbia, Canada. Presenter(s): Dr. Yvonne Bombard. Poster Presentation.

Publication Details:

Bombard, Y., Rozmovits, L., Trudeau, M., **Leighl, N.**, Deal, K., Marshall, DA. Access to personalized

medicine: The case of gene expression providing in breast cancer. Proceedings of 2013 ARCC Conference. 2013 May 27:19. **Coauthor or Collaborator.**

2013 May 27 **Co-author/collaborator.** Patient preferences: Understanding risk-benefit trade-offs of genomic testing in chemotherapy treatment decisions for breast cancer patients. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference. Vancouver, British Columbia, Canada. Presenter(s): Dr. Deborah Marshall. Poster Presentation.

Publication Details:

Marshall, D., Bombard, Y., Trudeau, M., **Leighl, N.**, Pykerman, K. Patient preferences: Understanding risk-benefit trade-offs of genomic testing in chemotherapy treatment decisions for breast cancer patients. Proceedings of 2013 ARCC Conference. 2013 May 27:20. **Coauthor or Collaborator.**

2013 May 27 **Co-author/collaborator.** Cost-Effectiveness of EML-4-ALK Fusion Testing in Combination with Crizotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer. Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2013. Vancouver, British Columbia, Canada. Presenter(s): Jaclyn Beca. Poster Presentation.

Publication Details:

Hoch J, Beca J, Krahn M, Tsao MS, **Leighl N**, Djalalov S. Cost-Effectiveness of EML-4-ALK Fusion Testing in Combination with Crizotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer. Proceedings of 2013 ARCC Conference. 2013 May 27:27. **Coauthor or Collaborator.**

2013 May 27 **Co-author/collaborator.** Systematic Collection of Ethnicity Data Across Multiple Disease Sites at Princess Margaret Cancer Centre (PMCC). Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2013. Vancouver, British Columbia, Canada. Presenter(s): Oleksandr Halytskyy. Poster Presentation.

Publication Details:

Halytskyy, O, Borgida A, Kuang Q, Chen DD, **Leighl N**, Cleary S, Knox J, Gallinger S, Cotterchio M, Liu G. Systematic Collection of Ethnicity Data Across Multiple Disease Sites at Princess Margaret Cancer Centre (PMCC). Proceedings of 2013 ARCC Conference. 2013 May 27:39. **Coauthor or Collaborator.**

2012 May 28 **Co-author/collaborator.** Adherence to Human Epidermal Growth Factor Receptor-2 (HER2) Testing & Adjuvant Trastuzumab Treatment Guidelines in Ontario. ARCC Conference 2012. Montreal, Quebec, Canada. Presenter(s): Dr. Craig Earle. Poster Presentation.

Publication Details:

Ferrusi I, Marshall DA, Trudeau M, **Leighl NB**, Pullenayegum E, Khong H, Hoch JS, Earle CC. Adherence to Human Epidermal Growth Factor Receptor-2 (HER2) Testing & Adjuvant Trastuzumab Treatment Guidelines in Ontario. Proceedings of 2012 ARCC Conference. 2012 May 28:22. **Coauthor or Collaborator.**

2012 May 28 **Co-author/collaborator.** Closing the Personalized Medicine Information Gap in Breast Cancer: Central HER2 Test Documentation Practice in Ontario. ARCC Conference 2012. Montreal, Quebec, Canada. Presenter(s): Ilia Ferrusi. Poster Presentation.

Publication Details:

Ferrusi I, Earle C, Trudeau M, **Leighl N**, Pullenayegm E, Hoch JS, Marshall D. Closing the Personalized Medicine Information Gap in Breast Cancer: Central HER2 Test Documentation Practice in Ontario. Proceedings of 2012 ARCC Conference. 2012 May 28:27.

2012 May 28 **Co-author/collaborator.** The value of personalizing medicine: Medical Oncologists' and Patients' Perspectives On Genomic Testing of Breast Tumors in Chemotherapy Treatment Decisions. Canadian Centre for Applied Research in Cancer Control (ARCC) conference. Montreal, Quebec, Canada. Presenter(s): Dr. Yvonne Bombard. Poster Presentation.

Publication Details:

Ferrusi IL, Trudeau M, Earle C, **Leighl NB**, Pullenayegum E, Cascagnette P, Marshall DA. The value of personalizing medicine: Medical Oncologists' and Patients' Perspectives On Genomic Testing of Breast Tumors in Chemotherapy Treatment Decisions. Proceedings of 2012 ARCC Conference. 2012 May:14.

2011 Apr 17 **Co-Author/Collaborator**. Providing evidence to inform decision making – do economic evaluations of targeted therapy follow economic evaluation guidelines? The Canadian Association for Population Therapeutics (CAPT) Annual Conference, Ottawa, Apr 17-19, 2011. Ottawa, Ontario, Canada. Poster presentation. (Trainee Presentation)

Publication Details:

Ferrusi IL, **Leighl NB**, Kulin NA, Marshall DA. Providing evidence to inform decision making – do economic evaluations of targeted therapy follow economic evaluation guidelines? J Popul Ther Clin Pharmacol. 2011;18(2):e207-e208. **Coauthor or Collaborator**.

2011 Apr **Co-author/collaborator**. Documentation of human epidermal growth factor receptor-2 testing and trastuzumab treatment in Ontario breast cancer patients: a retrospective analysis. The Canadian Association for Population therapeutics (CAPT) Annual Conference, Ottawa, Apr 17-19, 2011. Ottawa, Ontario, Canada. Poster presentation. (Trainee Presentation)

Publication Details:

Ferrusi IL, Trudeau M, Earle C, **Leighl N**, Cascagnette P, Pullenayegum E, Hoch J, Marshall DA. Documentation of human epidermal growth factor receptor-2 testing and trastuzumab treatment in Ontario breast cancer patients: a retrospective analysis. J Popul The Clin Pharmacol. 2011 Apr 8;18(2):e176-e218.

2010 Oct 8 **Senior Responsible Author**. A Systematic Review and Consensus Recommendations on the use of Biomarkers in the treatment of non-small cell lung carcinoma. 35th Annual European Society of Medical Oncology (ESMO) Congress, Oct 8-12, 2010. Milan, Italy. Poster presentation. .

Publication Details:

Ellis PM, Blais N, Soulieres D, Ionescu DN, Liu G, Melosky B, Reiman T, Shepherd FA, Tsao M, **Leighl NB**. A Systematic Review and Consensus Recommendations on the use of Biomarkers in the treatment of non-small cell lung carcinoma. Ann Oncol. 2010 Oct;21:392P. (Suppl 8): viii139. **Senior Responsible Author**.

2010 Mar 28 **Co-author/collaborator**. How are breast cancer testing practices for personalised medicine documented in Ontario? A retrospective review of coded surgical pathology reports. CAPT Annual Conference, March 28-30, 2010. Toronto, Ontario, Canada. Poster Presentation.

Publication Details:

Ferrusi IL, Marshall DA, Earle C, Trudeau M, **Leighl NB**, Pullenayegum E. How are breast cancer testing practices for personalised medicine documented in Ontario? A retrospective review of coded surgical pathology reports. Canadian Journal of Clinical Pathology. 2010 Mar;Winter 2010(17 (1)):e102. **Coauthor or Collaborator**.

Media Appearances

2023 May 11 **Panelist**. Second Opinion for Health Concerns. Zoomer, Vision TV. Toronto, Ontario, Canada. DECLINED.

Invited Speaker. RefiningThe Roll of Immunotherapy-Based Combinations in NSCLC: Expert Insights on the Latest Evidence. PeerVoice Canada. Canada. DECLINED.

On-Camera Expert. Lung Cancer. Interviewer: Dr. Marla Shairo. Canadian Health & Family Series-Fall/Winter 2021, CTV. Canada. DECLINED.

Other Presentations

- 2021 Aug Canadian Cancer Society-Challenge Grants. Reviewer for Immunotherapy applications-DECLINED.
- 2021 May **Judge.** HOSA Canada. Competitive Event- DECLINED.
- 2003 Aug 9 The psychosocial impact of advanced lung cancer. Meeting of the Minds. Vancouver. (Continuing Education).

3. PROVINCIAL / REGIONAL

Invited Lectures and Presentations

- 2024 Apr 16 **Invited Speaker.** IO Resistance- New Therapies and Clinical Trials. Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada. DECLINED.
- 2024 Mar 26 **Invited Speaker.** "Liquid Biopsies: A new era of earlier cancer detection, diagnosis, and treatment". Ontario Institute for Cancer Research FACIT biennial Translational Research Conference. King City, Ontario, Canada. DECLINED- TIME CONFLICT.
- 2023 Sep 29 **Chair and Invited Speaker.** Treatment Advances in Early Stage. Ontario Forum for Management of Early Stage Lung cancer. Toronto, Ontario, Canada.
- 2023 Apr 15 **Invited Speaker.** Uncommon Genomic Alterations in NSCLC - What to do and when? Ontario Thoracic Cancer Conference. Niagara-on-the-lake, Ontario, Canada.
- 2021 May 12 **Invited Speaker.** Update on EGFR including Adjuvant Therapy. Grand River Regional Oncology Rounds. Kitchener, Ontario, Canada.
- 2021 Jan 22 **Invited Speaker.** ALK+ Lung Cancer-An Embarrassment of Riches? Windsor Regional Hospital-Cancer Program. Ontario, Canada. Oncology Rounds- Virtual.
- 2021 Jan 20 **Invited Speaker.** The Changing Face of Lung Cancer. Stronach Regional Cancer Centre. Ontario, Canada. Oncology Rounds- Virtual.
- 2021 **Moderator.** Management of patients with ALK+NSCLC. Pfizer Canada. Ontario, Canada. Moderate Case Discussion Webinars-DECLINED.
- 2020 Apr 3 **Invited Speaker.** 15th Annual Ontario Thoracic Cancer Conference. McMaster University - Continuing Health Sciences Education. Niagara-on-the-Lake, Ontario, Canada. CANCELLED due to COVID-19.
- 2019 Apr 6 **Invited Speaker.** Alezolizumab in SCLC. McMaster University- 14th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2019 Jan 31 **Invited Speaker.** Getting to ROS-1. Pfizer Learning Program. Montreal, Quebec, Canada.
- 2018 Nov 1 **Invited Speaker.** The Role of Real World Evidence in Immunotherapy. Canadian Immuno-Oncology Summit 2018. Toronto, Ontario, Canada.
- 2018 Oct 26 **Invited Speaker.** Designing Basket Trials. pCODR Provincial Advisory Group. Toronto, Ontario, Canada.
- 2018 Feb 8 **Invited Speaker.** I-O: Who Benefits. Canadian Lung Cancer Conference- Breathing Life into a Possible Cure: A Canadian Impact. Vancouver, British Columbia, Canada.
- 2017 Oct 27 **Invited Speaker.** Should an EGFR TKI be the Standard of Care in the Adjuvant Treatment of EGFR Mutated NSCLC- Yes. Best of Lung Cancer Summit (Oncology Education). Toronto, Ontario, Canada.
- 2017 May 12 **Invited Speaker.** Funding Issues for Continuing TKI beyond RECIST Progression. Oligoprogressive,Pseudoprogressive and Oligometastatic NSCLC 2017. Ottawa, Ontario, Canada.

Economics and Funding Issues for Continuing TKI beyond RECIST Progression.

- 2017 May 3 **Invited Speaker.** Progress in Lung Cancer. Southlake Regional Health Centre. Newmarket, Ontario, Canada. Oncology Grand Rounds.
- 2017 Apr 9 **Invited Speaker.** Highlights of Research Activities in NSCLC. 12th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2016 Jul 7 **Invited Speaker.** Lung Cancer Screening. Grand River Regional Cancer Centre. Kitchener, Ontario, Canada. Grand River Grand Oncology Rounds- DECLINED DUE TO TIME CONFLICT.
- 2016 Apr 9 **Invited Speaker.** New Drugs in Medical Oncology? What is it worth? McMaster University Health Sciences- 11th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2016 Jan 29 **Keynote Speaker.** Better Breathing Conference: Canada's Silent Cancer - a Tidal Wave of Progress. Ontario Thoracic Society. Toronto, Ontario, Canada.
- 2015 Apr 19 **Invited Speaker.** The Emperor's Clothes: Integrating State of the Art Lung Cancer Care in Ontario. McMaster University Health Sciences. Niagara-on-the-lake, Ontario, Canada. 10th Annual Ontario Thoracic Cancer Conference.
- 2015 Apr 15 **Invited Speaker.** Challenges with drug access and navigation for private plan members: Focus Lung Cancer. Toronto, Ontario, Canada. DECLINED, due to time restraints.
- 2014 Jun 6 **Invited Speaker.** Advances in personalized medicine and impacts on clinical practice patterns. Ontario Lung Association and Ontario Thoracic Society. Toronto, Ontario, Canada. Lung Cancer Summit.
- 2014 Apr 27 **Invited Speaker.** Stage III NSCLC, Case presentations. 9th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2013 Oct 10 **Invited Speaker.** LHIN 4 meeting on Lung Cancer Diagnostic Pathway in 2013. CancerCare Ontario. Vineland, Ontario, Canada.
- 2013 Oct 4 **Invited Speaker.** Current Advances in Molecular Diagnosis and Targeted Therapy of Lung Cancer. Algoma District Cancer Centre. Sault Ste. Marie, Ontario, Canada.
- 2013 Sep 22 **Invited Speaker.** Diagnosing Lung Cancer in 2013. Ontario Association of Pathologists Annual General Meeting. Collingwood, Ontario, Canada.
- 2013 Sep 4 **Invited Speaker.** Lung Cancer Diagnosis in 2013. Algoma District Cancer Program. Sault Ste. Marie, Ontario, Canada.
- 2013 Apr 13 **Invited Speaker.** Novel Therapies for Squamous Cell Cancer. 8th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2013 Apr 5 **Chair.** Optimizing Management of Advanced NSCLC in the Toronto Region. Toronto, Ontario, Canada.
- 2012 Apr 21 **Invited Speaker.** Curative treatment for lung cancer in the elderly: Are you really as young as you feel? 7th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada.
- 2011 Nov 3 **Invited Speaker.** Diagnosis and Management of Lung Cancer. Lung Association-Ontario Respiratory Care Society "News and Reviews: the latest in respiratory care". Toronto, Ontario, Canada.
- 2011 Jun 14 **Invited Speaker.** Maintenance Therapy in NSCLC – Ready for Prime Time? OPTRA (Oncology Pharmacists). Toronto, Canada.
- 2011 Apr 20 **Invited Speaker.** State of the Art vs. the State of Ontario. Lung Cancer Scientific Meeting Series: Developments in Supportive Care and Beyond. London, Canada.
- 2011 Apr 10 **Invited Speaker.** What is the Future of Personalized Medicine. 6th Annual Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario, Canada. Panel Discussion.

Natasha LEIGHL

- 2009 Apr 19 Advances in Chemotherapy in Lung Cancer. 4th Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario. (Continuing Education).
- 2008 Mar 29 **Debate Chair.** Trimodality Therapy should be the Standard of Care for Stage 3A (N2) Non-small cell lung cancer. Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Canada. (Continuing Education).
- 2007 Jul 14 The Role of Abraxane in NSCLC. COMET Consultant Meeting. Muskoka, Ontario. (Continuing Education).
- 2007 Jun 7 ASCO 2007 Review – What’s new in NSCLC? Grand Rounds, Grand River Regional Cancer Centre. Kitchener, Ontario. (Continuing Education).
- 2007 Apr 1 New Drugs in NSCLC. 2nd Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario. (Continuing Education).
- 2006 Apr 6 Clinical Trials Opportunities. First Ontario Thoracic Cancer Conference. Niagara-on-the-Lake, Ontario. Apr 7-9/06. (Continuing Education).
- 2006 Mar 30 Incorporating Targeted Therapy in Lung Cancer. Grand Rounds, Grand River Regional Cancer Centre. Kitchener, Ontario. (Continuing Education).
- 2005 Oct 4 Management of Metastatic Breast Cancer. Training Meeting, Eli Lilly Canada. Cambridge, Ontario. (Continuing Education).
- 2005 Aug 25 Cancer-Related Anemia. Royal Victoria Hospital. Barrie, Ontario. (CHE-accredited). (Continuing Education).
- 2002 Nov 10 **Invited Speaker.** Quality of life and advanced nonsmall cell lung cancer. Chemotherapy – as good as it gets? Medical Oncology Educational Symposium. Niagara-on-the-Lake, Ontario, Canada.
- 2002 Nov 9 **Invited Speaker.** Update in the treatment of metastatic breast cancer. Medical Oncology Educational Symposium. Niagara-on-the-lake, Ontario, Canada.

Presented Abstracts

- 2023 Apr 15 **Presenter.** Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC. Ontario Thoracic Cancer Conference. Niagara-on-the-lake, Ontario, Canada. Presenter(s): **Natasha Leighl**. Senior author on behalf of Pilar Garrido, Nicolas Girard, Byoung Chul Cho, Joshua K Sabari, 4 Alexander I Spira, 5 Rachel E Sanborn, 6 Koichi Goto, 7 James Chih-Hsin Yang, 8 Joshua C Curtin, 9 Xuesong Lyu, 10 Andy He, 11 James Penton, 12 Joanne Edwards, 12 Grace Low, 13 Karen Xia, 9 Marc Chioda, 9 Meena Thayu, 9 Roland E Knoblauch, 9 Parthiv Mahadevia, 9, Natasha Leighl 14.

Presented and Published Abstracts

- 2015 Jun 11 **Presenter.** A knowledge translation intervention to improve awareness to molecular testing in NSCLC. Cancer Care Ontario-OICR/CCO Health Services Research Program 7th Annual Meeting. Toronto, Ontario, Canada. Oral Presentation.

Publication Details:

Authors: Zer A, Cutz JC, Sekhon H, Hwang D, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS Waddell T, Santos G, Patel M, Carter R, **Leighl NB**. A knowledge translation intervention to improve awareness to molecular testing in NSCLC. Proceedings of Cancer Care Ontario-OICR/CCO Health Services Research Program 7th Annual Meeting. 2016 Jun 11. **Senior Responsible Author.**

- 2014 Jun 16 **Senior Responsible Author.** A targeted intervention to improve awareness to molecular testing in NSCLC. Ontrario Institute for Cancer Research- Cancer Care Ontario. Toronto, Ontario, Canada. Oral and poster presentation at 6th Annual meeting OICR-CCO. (Trainee Presentation)

Publication Details:

Zer A, Cutz JC, Sekhon H, Hwant D, Sit C, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, Santos G, Patel M, Carter R, **Leighl NB**. A targeted intervention to improve awareness to molecular testing in NSCLC. Proceedings of 6th Annual meeting OICR-CCO. 2015 Jun 16. **Senior Responsible Author**.

2013 Apr 11 **Co-author/collaborator**. Homecare utilization and costs in colorectal cancer. OICR/CCO Health Services Research Program. Toronto, Ontario, Canada. Presenter(s): Oral/Poster Presentation. Mittmann N, Isogai PK, Saskin R, Liu N, Porter J, Cheung MC, **Leighl NB**, Hoch JS, Trudeau M, Evans WK, Dainty KN, Earle CC. 5th Annual Meeting OICR/CCO Health Services Research Program. Toronto, ON April 11, 2013. (oral/poster).

Publication Details:

Mittmann N, Isogai PK, Saskin R, Liu N, Porter J, Cheung MC, **Leighl NB**, Hoch JS, Trudeau M, Evans WK, Dainty KN, Earle CC. Homecare utilization and costs in colorectal cancer. Proceedings of 5th Annual OICR/CCO Health Services Research Program. 2013 Apr 11. **Coauthor or Collaborator**.

2013 Mar 7 **Co-author/collaborator**. Patient preferences: Understanding Risk-Benefit Trade-offs of Genomic Testing in Chemotherapy Treatment Decisions for Breast Cancer Patients. Ontario Institute for Cancer Research (OICR) Scientific Meeting. Toronto, Ontario, Canada. Poster Presentation.

Publication Details:

Marshall, D., Bombard, Y., Trudeau, M., **Leighl, N.**, Pykerman, K., Deal, K. Patient preferences: Understanding Risk-Benefit Trade-offs of Genomic Testing in Chemotherapy Treatment Decisions for Breast Cancer Patients. Proceedings of (OICR) Scientific Mtg March 2013. 2014 Mar 7. **Coauthor or Collaborator**.

2011 Feb 1 **Co-author/collaborator**. Access to and utilization of HER2 testing in early stage breast cancer in Ontario. Ontario Institute for Cancer Research/Cancer Care Ontario Health Services Research Program. Toronto, Ontario, Canada. Oral Presentation. (Trainee Presentation)

Publication Details:

Ferrusi IL, Trudeau M, Earle C, **Leighl NB**, Pullenayegum E, Cascagnette P, Marshall DA. Access to and utilization of HER2 testing in early stage breast cancer in Ontario. Proceedings of (OICR) 3rd Annual Scientific Mtg. 2011 Feb 1.

Other Presentations

2024 Jan 17 **Invited Speaker and Chair**. Ontario ctDNA Advisory Board. Astra Zeneca. Toronto, Ontario, Canada.

2022 Apr 23 **Invited Speaker**. Neoadjuvant therapy for early stage NSCLC. 15th Annual Ontario Thoracic Cancer Conference. Niagara on the Lake, Ontario, Canada.

2006 Mar 2 1) 2nd line therapy for NSCLC therapy: Improving Options; 2) Strategies for Managing Rash. Ontario Consultants Meeting at Canadian Oncology Winter Conference. Kamloops. (Continuing Education).

4. LOCAL

Invited Lectures and Presentations

2023 Nov 21 **Speaker**. Integration of the Diagnostic Process in Lung Cancer- Symposium. Hoffmann-La Roche. Mississauga, Ontario, Canada. DECLINED.

2023 Nov 17 **Co-Chair**. The Best of Lung Cancer Conference. Oncology Education. Toronto, Ontario, Canada. DECLINED.

- 2023 Sep 15 **Invited Lecturer.** Systemic Therapy in Lung Cancer. University of Toronto Division of Thoracic Surgery Educational Series. Toronto, Ontario, Canada.
- 2023 Sep 8 **Invited Speaker.** Systemic Therapy for Lung Cancer. Division of Thoracic Surgery, Toronto General Hospital. Toronto, Ontario, Canada. DECLINED.
- 2023 Jul 25 **Invited Speaker.** Amivantamab and other treatment for EGFR ex20 insertion mutant lung cancer. Janssen Canada. Toronto, Ontario, Canada. Presenter(s): **N. Leigh** and D. Zawisza.
- 2023 Jun 16 **Invited Speaker.** 47th Toronto Thoracic Surgery Refresher Conference. Division of Thoracic Surgery, U of T. Toronto, Ontario, Canada. DECLINED.
- 2023 Jun 16 **Chair.** Best of ASCO Toronto Conference 2023. DECLINED.
- 2023 May 15 **Invited Speaker.** MedOncNow Podcast (Episode 12): EGFR Exon20 Insertion Mutations. Stronach Regional Cancer Centre. Newmarket, Ontario, Canada.
- 2023 Feb 10 **Invited Speaker.** MRD in Stage I NSCLC: ctDNA Detect and RCT. Princess Margaret Cancer Centre Lung Disease Site Retreat. Toronto, Ontario, Canada.
- 2022 Nov 23 **Invited Speaker.** Accelerating Lung Cancer Diagnosis through Liquid Blospy. Princess Margaret Cancer Foundation. Toronto, Canada.
- 2022 Jul 6 **Speaker.** Introduction to Lung Cancer. PMH Medical Oncology Orientation Week. DECLINED.
- 2021 Dec 21 **Invited Speaker.** Clinical Trial Set-Up from an Investigator's Perspective. PMH Medical Oncology Research Month. Virtual.
- 2021 Jul 6 **Invited Speaker.** Early Stage Lung Cancer. PMH-Medical Oncology Training Program. Virtual.
- 2021 Jul 2 **Invited Speaker.** Introduction to Respiriology Course 2021- Lung Cancer. University Health Network. Not Required. Virtual.
- 2021 Jun 11 **Invited Speaker.** Is Surgery Dead for Stage IIIa? University of Toronto- Division of Thoracic Surgery, Department of Surgery-46th Toronto Thoracic Surgery Refresher Conference. Toronto, Ontario, Canada.
- 2021 May 28 **Invited Speaker.** Lung Cancer Molecular Testing at UHN. Princess Margaret Cancer Centre- Multidisciplinary Lung Oncology Rounds.
- 2020 Nov 2 **Invited Speaker.** Current Systemic Therapy SCLC. AstraZeneca Radiation Oncology Masterclass. Toronto, Ontario, Canada. Virtual Education Session.
- 2020 Apr 23 **Invited Speaker.** Update in mNSCLC. Merck Canada. Toronto, Ontario, Canada. CANCELLED due to COVID 19.
- 2019 Nov 29 **Invited Speaker.** Perioperative immunotherapy studies in lung cancer. Princess Margaret Cancer Centre- Lung Group Site- Multidisciplinary Clinical Rounds. Toronto, Ontario, Canada.
- 2019 Oct 4 **Invited Speaker.** The Emerging Role of Liquid Biopsies in Lung Cancer. UHN- Respiriology Research Rounds. Toronto, Ontario, Canada.
- 2019 Sep 19 **Invited Speaker.** New Hope in Lung Cancer Research. GO2 Foundation for Lung Cancer. Toronto, Ontario, Canada.
- 2019 Aug 9 **Invited Speaker.** Biomarkers and Challenges with Precision Medicine. Princess Margaret Cancer Centre- Trials Nurses Educational Session. Toronto, Ontario, Canada.
- 2019 Aug 1 **Invited Speaker.** Science 1st: From Early Prevention to Improved Treatment: Changing the Trajectory of Lung Cancer. JLABS @ Toronto. Toronto, Ontario, Canada.
- 2019 Jun 21 **Chair.** Best of ASCO 2019 Annual Meeting. Oncology Education. Toronto, Ontario, Canada. Presenter(s): Co-Chair Dr. Scott Berry.

Natasha LEIGHL

- 2019 Jun 7 **Invited Speaker.** Systemic Therapies in Lung Cancer: What's New? 45th Annual Toronto Thoracic Surgery Refresher Conference. Toronto, Ontario, Canada.
- 2019 May 24 **Invited Speaker.** Lung Cancer in 2019. Oncology Nurses Network. Toronto, Ontario, Canada.
- 2019 May 16 **Invited Speaker.** Lung Cancer 2019 and clinical trials at Princess Margaret Cancer Centre. 2019 Princess Margaret Research Retreat. Niagara-on-the-Lake, Ontario, Canada.
- 2019 May 10 **Invited Speaker.** Immunotherapy. COMRADS. Toronto, Ontario, Canada. DECLINED DUE TO TIME CONFLICT.
- 2019 May 6 **Invited Speaker.** The Changing Treatment Landscape in 1st Line Metastatic NSCLC. COMET. Toronto, Ontario, Canada.
- 2019 Apr 25 **Invited Speaker.** ROS1 and the value of precision medicine in NSCLC. University Health Network LMP. Toronto, Ontario, Canada.
- 2019 Apr 4 **Invited Speaker.** Lung Cancer in 2019. Princess Margaret Cancer Centre Pharmacy. Toronto, Ontario, Canada.
- 2019 Feb 15 **Invited Lecturer.** Non-EGFR (ALK/ROS/BRAF) Targeted Therapies in Lung Cancer. PMH DMOH Academic Half Day Talks. Toronto, Ontario, Canada.
- 2019 Feb 1 **Presenter.** Making things work. Lung Oncology Site Group Retreat Day 2019. Toronto, Ontario, Canada.
- 2018 Dec 4 **Invited Speaker.** Immunotherapy in Lung Cancer. The Centre for Innovation and Complex Care at UHN and The Lawrence S. Bloomberg Faculty of Medicine at the University of Toronto. Toronto, Ontario, Canada.
- 2018 Nov 9 **Session Chair.** Prevention, Screeing and Local Therapy. UHN 2018 Lung Oncology Research Day. Toronto, Ontario, Canada.
- 2018 Oct 4 **Invited Speaker.** Practice-Changing Studies from the 19th World Conference on Lung Cancer (WCLC) Conference. Combined DMOH/RMP Grand Rounds- Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Co-Speakers: Dr. Frances Shepherd, Dr. Gail Darling, Dr. Andrea Bezjak.
- 2018 Oct 4 **Invited Speaker.** Update on Lung Cancer: What a Respirologist Should Know. Boehringer-Ingelheim. Toronto, Ontario, Canada.
- 2018 Jan 19 **Invited Speaker.** Time to Abandon the RCT? Canada's Barriers to a Precision Approach in Lung Cancer. University of Toronto, Faculty of Medicine. Toronto, Ontario, Canada.
- 2018 Jan 12 **Invited Speaker.** Advanced Stage Lung Cancer. Lung Cancer Retreat- Translational Research. Toronto, Ontario, Canada.
- 2017 Mar 29 **Invited Speaker.** Progress in Lung Cancer - A medical oncologist's view. Peel Cancer Centre Grand Rounds. Mississauga, Ontario, Canada.
- 2016 Dec 13 **Invited Speaker.** Lung Cancer- A Tidal Wave of Progress. North York General Hospital. Toronto, Ontario, Canada. Medical Grand Rounds.
- 2016 Dec 1 **Invited Speaker.** Progress in Lung Cancer. Trinity College Life Sciences Society. Toronto, Ontario, Canada.
- 2016 Nov 25 **Invited Speaker.** Evolving Immunotherapy Landscape. Roche. Toronto, Ontario, Canada.
- 2016 Nov 23 **Invited Speaker.** What Family Doctors Should Know About Lung Cancer. UHN Primary Care Integration. Toronto, Ontario, Canada. Lung Cancer Support and Awareness.
- 2016 Nov 4 **Invited Chair.** Regional Reference Lab PDL-1 Testing. Merck. Toronto, Ontario, Canada.
- 2016 Oct 21 **Invited Chair.** Best of Lung Cancer. Oncology Education. Toronto, Ontario, Canada.

- 2016 Sep 24 **Invited Panelist.** Redefining Success in Oncology. Oncology Education. Toronto, Ontario, Canada. Immuno-oncology Update.
- 2016 Sep 22 **Invited Speaker.** Cost Effectiveness of ALK Inhibitors. University Health Network. Toronto, Ontario, Canada. Health Canada Preceptorship- DECLINED DUE TO TIME CONFLICT.
- 2016 Jul 15 **Invited Speaker.** Drug Access and Funding in Lung Cancer. RxMD. Toronto, Ontario, Canada.
- 2016 Jul 15 **Invited Speaker.** What Does the Future Look Like in Lung Cancer. RxMD. Toronto, Ontario, Canada.
- 2016 Jun 17 **Invited Speaker.** 42nd Annual Toronto Thoracic Surgery Refresher Course-Immunotherapy for Lung Cancer. University of Toronto. Toronto, Ontario, Canada.
- 2016 Apr 27 **Invited Speaker.** Leadership in Healthcare. U of T Medical Alumni Association. Toronto, Ontario, Canada. Medical Society Reunion- DECLINED DUE TO TIME CONFLICT.
- 2016 Apr 26 **Invited Speaker.** TKIs and Lung Cancer - RCT Data. Boehringer Ingelheim. Toronto, Ontario, Canada.
- 2016 Mar 2 **Invited Speaker.** Lung Cancer Diagnosis and Treatment. University of Toronto/UHN- Respirioly Trainees. Toronto, Ontario, Canada.
- 2016 Feb 24 **Invited Speaker.** Health Utility Estimation and Pharmacoeconomic Analyses. University Health Network/ Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Fellows Teaching 2016.
- 2015 Sep 18 **Chair.** The Advantages of Community: How We Work Better in Partnership. Oncology Continuing Education University of Toronto. Toronto, Ontario, Canada. Presenter(s): Dr. Paul Wheatley-Price, MD, MBChB. City Wide Rounds.
- 2015 Jun 26 **Senior Responsible Author.** Patients with advanced non-small cell lung cancer: Are research biopsies a barrier to participation in clinical trials? University of Toronto Division of Medical Oncology. Presenter(s): Charles Lim. Medical Oncology Research Day. (Trainee Presentation).
- 2015 Jun 26 **Senior Responsible Author.** Clinical outcomes of Asian versus non-Asian patients with EGFR mutant non-small cell lung cancer. University of Toronto Division of Medical Oncology. Presenter(s): Mike Sung. Medical Oncology Research Day. (Trainee Presentation).
- 2015 Jun 17 **Invited Speaker.** Moving Targets in Lung Cancer- Can We Keep Up". Sunnybrook Health Sciences Centre. Toronto, Ontario, Canada. Lung Rounds.
- 2015 Apr 28 **Speaker.** "A Review of Afatinib Clinical Experience (In Lung Cancer)". Sunnybrook Health Sciences Centre- Head and Neck Site Group. Toronto, Ontario, Canada.
- 2015 Apr 13 **Invited Speaker.** Lung Cancer 2015- Target Acquired? Department of Medical Imaging Mount Sinai Hospital and Department of Medical Imaging University of Toronto. Toronto, Ontario, Canada. The 9th Annual Marvin Steinhardt Lecture in Thoracic Imaging.
- 2015 Feb 2 **Invited Speaker.** Immunotherapy and Lung Cancer. University Health Network, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Personalizing Cancer Medicine in 2015.
- 2014 Nov 3 **Invited Speaker.** Personalizing Treatment in Advanced NSCLC. Best of Lung Cancer Summit. Toronto, Ontario, Canada.
- 2014 Oct 7 **Invited Speaker.** Genomic Profiling of Lung Cancer: What a Med Onc thinks a Radiologist needs to know. University of Toronto Medical Imaging Faculty. Toronto, Ontario, Canada. 29th Annual Organ Imaging Review.
- 2014 Apr 30 **Invited Speaker.** Pneumonitis Cases. PD-1 Inhibitor AE Management Tool Development. Toronto, Ontario, Canada.
- 2014 Feb 11 **Invited Speaker.** Recent advances in the treatment of non-squamous NSCLC from the Canadian perspective. AZ MSL National Meeting. Toronto, Ontario, Canada.

- 2014 Jan 31 **Invited Speaker.** Clinical impact of epidermal growth factor receptor (EGFR) mutation fraction and tumour sample cellularity on clinical outcomes. U of T, Division of Medical Oncology Research Half Day. Toronto, Ontario, Canada.
- 2013 Nov 12 **Invited Speaker.** Update in Treatment Options for Advanced NSCLC. Lung Cancer 2013: A Year in Review. Toronto, Ontario, Canada.
- 2013 Nov 11 **Invited Speaker.** What do medical oncologists and surgeons need from each other anyway? University of Toronto and McMaster Joint Division of Thoracic Surgery Retreat.
- 2013 Sep 5 **Invited Speaker.** Diagnosing Lung Cancer in 2013. University of Toronto Combined Chest Rounds. Toronto, Ontario, Canada.
- 2013 Jul 22 **Invited Lecturer.** Stage III Lung Cancer and Concurrent Chemo/Radiation. Princess Margaret Cancer Centre. Toronto, Ontario, Canada. In-Service.
- 2013 Jun 8 **Invited Speaker.** Multifocal lung nodules: when should a non-surgical approach be considered? 39th Annual Toronto Thoracic Surgery Refresher Course. Toronto, Ontario, Canada.
- 2013 Jun 8 **Invited Speaker.** Targeted therapy in lung cancer: what the surgeon needs to know. 39th Annual Toronto Thoracic Surgery Refresher Course. Toronto, Ontario, Canada.
- 2013 Apr 19 **Invited Speaker.** Diagnosing Lung Cancer in 2013 – it takes more than 2 cells. University of Toronto Faculty of Medicine Respiriology Grand Rounds. Toronto, Ontario, Canada.
- 2012 Nov 30 **Invited Speaker.** Best of Oncology Lung 2012. COMET. Toronto, Ontario, Canada.
- 2012 Nov 23 **Invited Speaker.** Role of EGFR and other Mutation Testing. University of Toronto, Division of Respiriology 7th Annual Day in Respiriology. Toronto, Ontario, Canada.
- 2012 Nov 23 **Invited Speaker.** Small Molecules, Big Bang: Targeted Therapies. Toronto Cancer Conference 2012. Toronto, Ontario, Canada.
- 2012 Oct 11 **Invited Speaker.** Challenges in Lung Cancer. Community Oncology CME. Toronto, Ontario, Canada.
- 2012 Sep 27 **Invited Speaker.** Crizotinib and ALK Testing at the University Health Network. Ontario Telemedicine Network. Toronto, Ontario, Canada.
- 2012 Jul 10 **Invited Speaker.** Advances in Targeted Therapy in NSCLC. Boehringer-Ingelheim Lunch and Learn. Burlington, Ontario, Canada.
- 2012 Jul 10 **Invited Speaker.** Targeting ALK in NSCLC. LHIN 7- CCO. Toronto, Ontario, Canada.
- 2012 May 17 **Invited Speaker.** Lung Cancer – Clinician Perspective. 2012 OCI Faculty Retreat. Huntsville, Ontario, Canada.
- 2012 Apr 3 **Invited Lecturer.** New Leaders. Toronto CLO Oncology Leadership Program. Toronto, Ontario, Canada.
- 2012 Jan 16 **Invited Speaker.** Maintenance Therapy in NSCLC. North York General Hospital Medical Oncology Group. Toronto, Ontario, Canada.
- 2011 Apr 21 **Invited Speaker.** State of the Art vs. the State of Ontario. Lung Cancer Scientific Meeting Series: Developments in Supportive Care and Beyond. Toronto, Canada.
- 2011 Mar 4 **Invited Speaker.** Oncology Drug Access in Canada. Boehringer Ingelheim. Burlington, Canada.
- 2011 Feb 11 **Chair.** Reviewing current standards and identifying future opportunities in advanced NSCLC in Canada. Lung Advisory Meeting. Toronto, Ontario, Canada.
- 2011 Jan 25 **Chair.** An International Perspective on Lung Cancer Treatment. AstraZeneca. Toronto, Ontario, Canada.
- 2010 Dec 4 **Invited Speaker.** The importance of Progression-Free Survival as an endpoint in NSCLC. Afatinib

Natasha LEIGHL

Advisory Meeting. Toronto, Ontario, Canada.

- 2010 Oct 29 **Invited Speaker.** What's new in lung cancer. Princess Margaret Hospital 2010 Conference. Toronto, Ontario, Canada.
- 2010 Jun 15 **Invited Speaker.** Personalized Medicine in Oncology – Can we afford not to? ROCHE Canada. Mississauga, Ontario, Canada.
- 2010 Feb 23 **Invited Speaker.** NSCLC Update – Early 2nd line Therapy. COMET. Toronto, Ontario, Canada. Case discussions.
- 2009 Jul 3 Lung Cancer in 2009. Drug Development Program Educational Series. Toronto, Ontario. (Continuing Education).
- 2009 Jun 16 2009 ASCO Update: Lung Cancer. Community Oncology of Metro Toronto Update Meeting. Toronto, Ontario. (Continuing Education).
- 2009 Apr 7 Moving towards Individualized Therapy in Lung Cancer – Identifying Cancer Risk Factors and Developing Individualized Therapy. Behind-the-Scenes Donor Appreciation Event, PMH Foundation. Toronto, Ontario. (Continuing Education).
- 2008 Oct 24 Lung and breast trials through the PMH Consortium. PMH Consortium 2008 Annual meeting. Toronto, Ontario. (Continuing Education).
- 2008 Oct 16 **Co-Chair.** Recent advances in lung cancer. The 8th Princess Margaret Hospital Conference. Toronto, Ontario. (Continuing Education).
- 2008 Jan 22 Abraxane in NSCLC. Regional Consultants Meeting in NSCLC. Toronto, Ontario. (Continuing Education).
- 2007 Nov 26 Advances in Lung Cancer. PMH Foundation. Toronto, Ontario. (Continuing Education).
- 2007 Nov 17 Locally Advanced NSCLC – Case Presentation. 7th PMH Conference. Toronto, Ontario. (Continuing Education).
- 2007 Oct 19 Lung Studies. 7th Annual PMH Phase II Consortium Meeting. Toronto, Ontario. (Continuing Education).
- 2007 Sep 13 Understanding Lung Cancer: Diagnosis, Treatment, Survivorship. Lung Cancer Canada/PMH Education Library Information Session, PMH. Toronto, Ontario. (Continuing Education).
- 2007 Jun 14 **Invited Speaker.** Post-ASCO 2007 Review – Targeted therapies in the treatment of advanced NSCLC: Today and tomorrow. COMET. Toronto, Ontario. (Continuing Education).
- 2007 Feb 7 The importance of breast cancer screening. Region of Peel Cancer Prevention Stakeholder Consultation. Mississauga, Ontario. (Continuing Education).
- 2007 Jan 11 **Invited Speaker.** Navigating the future in NSCLC. Second-line therapy in NSCLC – time for molecular selection? COMET. Toronto, Ontario. (Continuing Education).
- 2006 Nov 26 Drug Development in Breast Cancer. PMH Breast Site Group Research Retreat. Toronto, Ontario. (Continuing Education).
- 2006 Nov 7 **Invited Speaker.** Systemic Therapy of Lung Cancer in 2006. Lung Cancer Canada 3rd Annual Lung Cancer Information Fair. Toronto, Ontario. (Continuing Education).
- 2006 Oct 27 A Perspective on Lung Diseases COPD, Lung Cancer & Transplantation. Systemic Therapy in Lung Cancer in 2006. Toronto, Ontario. (Continuing Education).
- 2006 Oct 24 Chestmate: Controversies in Lung Cancer. Toronto, Ontario. (Continuing Education).
- 2006 Oct 5 Management of Small Cell Lung Cancer in 2006. 6th Princess Margaret Hospital Conference – New Developments in Cancer Management. Toronto, Ontario. (Continuing Education).

Natasha LEIGHL

- 2006 Jun 24 Decision Aids in Advanced Cancer. Multinational Association for Supportive Care in Cancer 18th International Symposium. Toronto, Ontario. (Continuing Education).
- 2006 Jun 22 **Chair.** Sexual Dysfunction and Fertility Issues. MASCC 18th International Symposium. Toronto, Ontario. Jun 22-24/06. (Continuing Education).
- 2006 May 12 Clinical Efficacy and Safety of Erlotinib. Advokit Meeting (Nursing Advisory Board). Toronto, Ontario. (Continuing Education).
- 2006 May 11 Targeted therapy in Cancer: Magic bullets at last? 3rd Canadian Therapeutics Congress. Toronto, Ontario. (Continuing Education).
- 2005 Oct 27 Advances in Lung Cancer: Erlotinib. PMH Pharmacy Rounds. Toronto, Ontario. (Continuing Education).
- 2005 Oct 6 Targeted Therapy in Lung Cancer – has the magic bullet arrived? Univ of Toronto Clinical Pharmacology Grand Rnds. Toronto, Ontario. (Continuing Education).
- 2005 Sep 23 Management of Breast Cancer in the Elderly. 5th Princess Margaret Hospital Conference – New Developments in Cancer Management. Toronto, Ontario. (Continuing Education).
- 2005 Sep 22 Angiogenesis Inhibitors in Lung Cancer. 5th Princess Margaret Hospital Conference – New Developments in Cancer Management. Toronto, Ontario. (Continuing Education).
- 2005 Aug 18 Lung Cancer in 2005. Lunch & Learn, Roche Canada. Toronto, Ontario. (Continuing Education).
- 2005 Jun 9 Lung Cancer and the Age of Aquarius. Behind the Scenes Donor Event for PMH Foundation. Toronto, Ontario. (Continuing Education).
- 2005 Jun 1 Post-ASCO Review 2005: What's new in metastatic breast cancer? Toronto, Ontario. (Continuing Education).
- 2005 Apr 7 **Invited Speaker.** Targeting lung cancer: Are EGFR inhibitors the magic bullet? Toronto General Hospital-Medical Grand Rounds. Toronto, Ontario, Canada.
- 2005 Feb 9 **Chair.** Post-San Antonio/St. Gallen Breast Cancer Conference Review. Toronto, Ontario. (Continuing Education).
- 2005 Jan 25 An Overview of Lung Cancer and its Treatment. Lung Cancer Discussion Series, Wellspring. Toronto, Ontario. (Continuing Education).
- 2004 Dec 14 Post 2004 SABC: Highlights of the 2004 San Antonio Breast Cancer Symposium – Targeted therapies in Breast Cancer. Toronto, Ontario. (Continuing Education).
- 2004 Dec 14 **Invited Speaker.** Targeted Therapies in Breast Cancer. Post 2004 SABC: Highlights of the 2004 San Antonio Breast Cancer Symposium. Toronto, Ontario, Canada.
- 2004 Nov 26 **Invited Speaker.** Drug Development in Breast Cancer. Princess Margaret Hospital Breast Site Group Research Retreat. Toronto, Ontario, Canada.
- 2004 Sep 24 Phase I study of GTI2040 in combination with docetaxel in advanced NSCLC. PMH Consortium Annual Meeting. Toronto, Ontario. (Continuing Education).
- 2004 Sep 23 Challenges and Strategies: a targeted approach to managing lung cancer. 4th Princess Margaret Hospital Conference: Lunchtime Satellite Symposium. Toronto, Ontario. (Continuing Education).
- 2004 Sep 23 Management of the elderly patients with lung cancer. 4th Princess Margaret Hospital Conference: New Developments in Cancer Management. Toronto, Ontario. (Continuing Education).
- 2004 Sep 23 Systemic therapy in non-small cell lung cancer – today and tomorrow. Oncology Rounds, Trillium Health Centre. Mississauga, Ontario. (Continuing Education).
- 2004 Jun 16 Post-ASCO Breast and Gynecologic Cancer Review: Breast Cancer. Toronto, Ontario. (CSIM accredited).

Natasha LEIGHL

Jun 15,16/04. (Continuing Education).

- 2004 May 28 Breast cancer prognostication. PMH Breast Cancer Education Series. Toronto, Ontario. (Continuing Education).
- 2004 Apr 30 COMET: Targeted therapy in lung cancer – EGFR TKIs. COMET/ABA Meeting. Toronto, Ontario. (Continuing Education).
- 2004 Mar 25 Systemic treatment of advanced NSCLC: is chemotherapy as good as it gets? PMH Pharmacy Rounds. Toronto, Ontario. (Continuing Education).
- 2003 Sep 12 Chemotherapy for Mesothelioma. 3rd Princess Margaret Hospital Conference: New Developments in Cancer Management. Toronto, Ontario. (Continuing Education).
- 2003 Jun 24 **Invited Speaker.** Post-ASCO 2003 Review. Toronto, Ontario, Canada.
- 2002 May 7 **Invited Speaker.** “The Role of Medical and Radiation Oncologists”. 12th Annual Hospice Palliative Care Conference. Toronto, Ontario, Canada.
- Chair.** Princess Margaret Cancer Centre Immunotherapy Toxicity Symposium. Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Presenter(s): **Leighl N.**

Presented Abstracts

- 2020 Feb 20 Using AI to Improve Precision Medicine: Real-World Impact of Biomarker Testing in Advanced Lung Cancer. Joint Princess Margaret/International Cancer Expert Corps (ICEC) 2020- Cancer AI and Big Data: Success through Global Collaboration. Toronto, Ontario, Canada. Presenter(s): Jennifer Law. Authors: Law J, Pettengell C, Le LW, Chen LG, Aviv S, Sung M, **Leighl NB.** Awarded Best Poster.

Presented and Published Abstracts

- 2010 Oct 26 **Co-author/collaborator.** Published Economic Evidence to Support Personalized Medicine Decision-Making: the Example of HER2-positive Early Breast Cancer. 32nd Annual Meeting of the Society for Medical Decision Making, October 26, 2010. Toronto, Ontario, Canada. Poster Presentation. (Trainee Presentation)

Publication Details:

Ferrusi I, Kulin NA, **Leighl N,** Marshall D. Published Economic Evidence to Support Personalized Medicine Decision-Making: the Example of HER2-positive Early Breast Cancer. Proceedings of 32nd Annual Mtg fo the Society for Medical Decision Making. 2010 Oct 26. **Coauthor or Collaborator.**

Media Appearances

- 2004 Feb 25 Iressa in advanced non-small cell lung cancer. Global TV Interview. Toronto, Ontario. (Continuing Education).
- 2003 Nov 12 Increasing awareness of breast cancer in the Southeast Asian Community. OMNI TV Interview. (Continuing Education).

Grand Rounds: ICU Noon Rounds (MSH/TGH/TWH)

- 2011 Feb 2 **Presenter.** A Complex Case of Bronchioloalveolar Carcinoma.

Preceptorship

- 2014 Nov 5 **Speaker and Organizer.** Introduction to Lung Cancer pathways and newer treatments. AstraZeneca Canada Inc. Toronto, Ontario, Canada. Presenter(s): Ta Y, Kamel-Reid S, Tsao M, Boerner S, Ali V,

Nouriany N, **Leighl NB**. Presentations/discussions in Princess Margaret Cancer Centre.

Video message

2013 Jan 28 **Invited Speaker**. Common lung cancer myths. Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Presenter(s): **Natasha Leighl**. World Cancer Day and social medial campaign.

Other Presentations

- 2009 Jul 3 Overview of lung cancer and its treatment. PMH. (Continuing Education).
- 2009 Feb 26 Preoperative Window Studies in Lung Cancer. Division of Medical Oncology and Hematology Grand Rounds, PMH. Toronto. (Continuing Education).
- 2007 Jun 9 New Drugs for Cancer: Is this the Dawning of the Age of Aquarius – Lung Cancer. Toronto. (Continuing Education).
- 2006 Oct 27 Lung studies. 6th Annual PMH Phase II Consortium. Toronto. (Continuing Education).
- 2006 Feb 7 The importance of breast cancer screening. Region of Peel Cancer Prevention Stakeholder Consultation. Mississauga. (Continuing Education).
- 2004 Sep 24 GTI-2040 and docetaxel Ph I study. 4th Annual PMH Phase II Consortium Meeting. Toronto. (Continuing Education).
- 2004 Jun 15 Post-ASCO Review of Breast and Gynecologic Cancers – Review of practice changing breast cancer phase III studies. Accredited Rounds (CSIM). Accredited Rounds (CSIM). (Continuing Education).
- 2004 Jun 1 A Glimpse of Tomorrow...Today. PMH Foundation - Behind-the-Scenes Donor Appreciation Event. Toronto. (Continuing Education).
- 2004 Apr 23 Systemic therapy in non-small cell lung cancer – today and tomorrow. Oncology Rounds, Trillium Health Centre. Mississauga. (Continuing Education).

5. OTHER

Invited Lectures and Presentations

2014 Jun 13 **Senior Responsible Author**. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-small Cell Lung Cancer. University of Toronto Division of Medical Oncology. Presenter(s): Charles Lim. Medical Oncology Research Day. (Trainee Presentation).

Presented and Published Abstracts

2009 Mar A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group.

Publication Details:

Goss G, Shepherd FA, Laurie S, Gauthier I, **Leighl NB**, Chen E, Feld R, Powers J, Seymour J. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. *European Journal of Cancer*. 2009 Mar;45(5):Page 782-788. **Coauthor or Collaborator**.

2008 May 30 **Senior Responsible Author**. Impact of clinical and molecular predictors of benefit from erlotinib in

advanced non-small cell lung cancer on cost-effectiveness. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)

Publication Details:

Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, **Leighl NB**. Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness. J Clin Oncol. 2008 May 20;20(26). (suppl; abstr 6531). **Senior Responsible Author**.

2008 May 30 **Senior Responsible Author**. Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer. American Society of Clinical Oncology 2008 Annual Meeting. Chicago, Illinois, United States. Poster Presentation. (Trainee Presentation)

Publication Details:

Horgan AM, Shepherd FA, Bradbury PA, Ng R, **Leighl NB**. Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer. J Clin Oncol. 2008 May;20(26). (suppl; abstr 8110). **Senior Responsible Author**.

2008 Treatment of Lung Cancer.

Publication Details:

Leighl N. Treatment of Lung Cancer. Critical Reviews in Oncology/Hematology. 2008;68(Suppl 12):S18. abstr F29. **Principal Author**.

2007 Sep 4 **Senior Responsible Author**. The impact of systemic therapy versus surgery on outcomes in multifocal bronchioloalveolar carcinoma. 12th World Conference on Lung Cancer. Seoul, Korea, Republic Of. Poster Presentation. (Trainee Presentation)

Publication Details:

Cheung WY, Hwang D, Chung T, Johnston M, **Leighl NB**. The impact of systemic therapy versus surgery on outcomes in multifocal bronchioloalveolar carcinoma. J Thorac Oncol 2. 2007;8(Suppl 4):PD4-1-1, S447. **Senior Responsible Author**.

2006 Oct 28 **Co-author/collaborator**. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the Canadian public health care perspective. ISPOR 9th Annual European Meeting. Copenhagen, Denmark. PCN 11Poster Presentation, Abst 13077.

Publication Details:

Cote I, **Leighl NB**, Gyldmark M, Maturi G. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the Canadian public health care perspective. Value in Health. 2006 Nov;9(6):A270. Abst 13077. **Co-Principal Author**.

2005 May 13 **Co-author/collaborator**. A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC): A COMET group study investigating sensitivity and specificity issues important in clinical decision making. American Society of Clinical Oncology 2005 Annual Meeting. Orlando, Florida, United States. Poster Presentation. Abstract 8134.

Publication Details:

Hollen PJ, Gralla RJ, Stewart JA, Chin C, Bizette A, **Leighl NB**, Kuruvilla PG, Meharchand JM, Solow H. A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC): A COMET group study investigating sensitivity and specificity issues important in clinical decision making. 2005 Proc ASCO. 2005. American Society of Clinical Oncology Annual Meeting, Orlando, June 2005. Abstract 8134. **Coauthor or Collaborator**.

2005 Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase 1 study in patients with

advanced non-small cell lung cancer (NSCLC).

Publication Details:

Wakelee H, Middleton G, Dunlop D, Kelly C, Ramlau R, **Leighl N**, Hao D, Zatloukal P, Loewen G, Cox K, Dziewanowska Z, Negro-Vilar A, Jacobs C. Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase 1 study in patients with advanced non-small cell lung cancer (NSCLC). 2005. Submitted to IASLC.

2004 Jun 5

Principle Author. Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: NCIC-CTG BR.18. American Society of Clinical Oncology 2004 Annual Meeting. New Orleans, Louisiana, United States. Poster discussion. Abstract 7038.

Publication Details:

Leighl N, Shepherd F, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Tu D, Galbraith S, Hann K, Seymour L. Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: NCIC-CTG BR.18. Journal of Clinical Oncology. 2004 Jun;22(14S). July 15 Supplement. Abstract 7038. **Principal Author.**

NCIC CTG IND.196: Phase I study of foretinib (GSK1363089) and erlotinib in patients with advanced pretreated NSCLC.

Publication Details:

Leighl N, Tsao M, Ho C, Shepherd F, Murray N, Goffin J, Nicholas G, Seymour L, Goss G, Bradbury P. NCIC CTG IND.196: Phase I study of foretinib (GSK1363089) and erlotinib in patients with advanced pretreated NSCLC. Eur J Cancer. 48(6):187. Poster presentation at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 6-9, 2012, Dublin, Ireland. Eur J Cancer 2012; 48(Suppl 6): 187 (abstr 607).

Patient Preferences: Understanding Risk-Benefit Trade-Offs of Genomic Testing in Chemotherapy Decisions for Breast Cancer Patients.

Publication Details:

Marshall, D., Bombard, Y., Trudeau, M., **Leighl, N.**, Pykerman K., Deal, K. Patient Preferences: Understanding Risk-Benefit Trade-Offs of Genomic Testing in Chemotherapy Decisions for Breast Cancer Patients. Value in Health. 16(3):A147-148. [Abstract PCN110]. **Coauthor or Collaborator.**

Media Appearances

Invited Speaker. Efficacy and Safety of Immuno-Oncology in Lung Cancer. CHECKPOINT Video. Toronto, Ontario, Canada. CME Education.

F. Teaching and Design

1. INNOVATIONS AND DEVELOPMENT IN TEACHING AND EDUCATION

- | | |
|-------------------------|---|
| 2020 Jan - present | Evidence Behind Genomic Profiling in Human Cancers, Continuing Education, CME supported by Roche Canada
<i>Content development.</i> |
| 2020 Dec 2 - 2020 Dec 4 | The Lung Cancer Patient Journey in Canada, Continuing Education, Faculty of Medicine, Princess Margaret Cancer Program, Lung Disease Site, Princess Margaret Cancer Centre
<i>Virtual Preceptorship over 3 days for 42 multidisciplinary members of thoracic oncology teams across Brazil with 13 PM Lung multidisciplinary faculty (Facilitated by Onc Info).</i> |

Natasha LEIGHL

- 2019 Jun 19 - 2019 Jun 20 Latin American Clinical Oncology Experience Program, Faculty Development, Faculty of Medicine, Dept of Medicine, Oncology (Medical)
21 attendees from 5 countries.
- 2019 Jun 5 - 2019 Jun 7 Princess Margaret Thoracic Oncology Clinical Observership Program, Faculty Development, Faculty of Medicine, Dept of Medicine, Oncology (Medical)
*Multidisciplinary collaboration between Princess Margaret Thoracic Site and the Polish Lung Cancer Group.
6 junior faculty from Poland (thoracic surgery, medical and radiation oncology, pathology and genomics).*
- 2015 Jul 1 - 2016 Jun 30 TARGET: Targeted Therapy in Lung Cancer, Continuing Education, Faculty of Medicine, Dept of Medicine
Faculty, CME Development.

G. Research Supervision

1. PRIMARY OR CO-SUPERVISION

Undergraduate Education

- 2019 May - 2022 Dec **Primary Supervisor.** B. Sc. Janice Li. *Smoking and anti-PD-1 response; VALUE; PD-L1 testing: Cytology versus pathology and immunotherapy response in lung cancer, Non-thesis Project.*
- 2018 May - 2018 Aug **Primary Supervisor.** Josh Morganstein. *Non-thesis Project.*
- 2017 May - 2017 Aug **Primary Supervisor.** Tanya Matthews. Supervisee Position: Summer Research Student, Supervisee Institution: Princess Margaret Cancer Centre. *Treatment Beyond Progression - ALK and IO, Non-thesis Project.*
- 2017 May - 2017 Aug **Primary Supervisor.** Alexandra Pavel. Supervisee Position: Summer Research Student, Supervisee Institution: Princess Margaret Cancer Centre. *Treatment Beyond Progression - ALK and IO, Non-thesis Project.*
- 2016 Sep - 2019 **Primary Supervisor.** B. Sc. Melissa Iazzi. Supervisee Position: research student. *Outcomes with malignant pleural mesothelioma in Ontario.*

Graduate Education

- 2023 Mar - present **Co-Supervisor.** MSc. Miguel Garcia.
- 2021 Jul - 2025 Jun **Primary Supervisor.** PhD. Roxana Tudor. *Molecular Testing in Lung Cancer: Provincial uptake, turnaround times, impact on patient outcomes.* Supervisor(s): Natasha Leighl.
- 2021 Jul - 2025 Jun **Primary Supervisor.** PhD. Roxana Tudor. Supervisee Position: PhD Candidate. *Impact of molecular testing on Ontario lung cancer patient outcomes and costs.*
- 2018 Jul - 2020 Jun **Primary Supervisor.** MSc. Kirstin Perdrizet. *Provincial outcomes of targeted therapy use in untargeted populations with advanced lung cancer (ICES database analysis), Non-thesis Project.* Supervisor(s): Natasha Leighl.
- 2018 Jul - 2020 Jun **Primary Supervisor.** MSc. Kirstin Perdrizet. *CancerLinq: Uptake of Molecular Testing and Targeted Therapy in the U.S. over Time, Non-thesis Project.* Supervisor(s): Natasha Leighl.
- 2017 Jul - 2018 Dec **Primary Supervisor.** MSc. Doreen Ezeife. Supervisee Institution: Princess Margaret Cancer Centre. *Establishing a Level Playing Field: Development of a Value Assessment Framework for Oncology Drugs.* Collaborator(s): Dr. Kelvin Chan.
- 2016 May - 2016 Nov **Primary Supervisor.** Nicole Lee, Pharmacology and Toxicology. Supervisee Position: Research Project Supervision, Supervisee Institution: University of Toronto. *Circulating DNA in EGFR+ lung cancer, Non-thesis Project.*

Undergraduate MD

- 2019 Jun - 2019 Aug **Primary Supervisor.** Ryan Chu. *Cost effectiveness of plasma EGFR T790M testing in acquired EGFR TKI resistance: CCT790M study, Non-thesis Project.*
- 2018 Jul - 2019 Jun **Primary Supervisor.** Year 1. Khizar Karim. *Non-thesis Project.*
- 2011 Jun - 2011 Aug **Primary Supervisor.** Year 2. Rick Chen. Supervisee Position: Summer Research Student. *1. Predictors of chemotherapy toxicity in elderly cancer patients – two objective markers of patient physical health.* Awards: CREMS \$2750. Collaborator(s): Dr. Tina Hsu.
- 2007 **Primary Supervisor.** Year 2. Michael Loreto, DOCH 2. *Efficacy of erlotinib or gefitinib compared to docetaxel as subsequent therapy in NSCLC.*

Postgraduate MD

- 2018 May - 2021 **Primary Supervisor.** Maisam Makarem. *Maximizing cost benefit of ROS1 testing in advanced NSCLC, Non-thesis Project.*
- 2017 Jan - 2022 Feb **Primary Supervisor.** Subspecialty. Kirstin Perdrizet. Supervisee Position: PGY4/5 Medical Oncology. *LU-NGS-2: NGS using the OncoPrint Array Panel, Non-thesis Project.*
- 2017 Jan - 2019 Dec **Primary Supervisor.** Subspecialty. Kirstin Perdrizet. Supervisee Position: PGY4/5 Medical Oncology. *LU-NGS-1: NGS as a routine diagnostic in the management of advanced NSCLC patients, Non-thesis Project.*
- 2015 May - 2022 **Primary Supervisor.** Mike Sung. Supervisee Position: research student. *Outcomes research in lung cancer, Non-thesis Project.*
- 2014 Jul - 2016 Jun **Co-Supervisor.** Catherine Labbe, Clinical Research Fellow. Supervisee Institution: Princess Margaret Cancer Centre. Supervisor(s): Dr. Frances Shepherd.
- 2014 Jul - 2015 Jul **Co-Supervisor.** Kevin Jao, Clinical Research Fellow. Supervisee Institution: Princess Margaret Cancer Centre. Supervisor(s): Dr. Frances Shepherd.
- 2014 Jul - 2015 Jun **Primary Supervisor.** Core Program. Charles Lim, PGY2. *"Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).* Awards: Accepted for oral presentation at 2014 CAMO Annual Meeting (May 1, 2014); Published in CAMO Annual Meeting Book of Abstracts. Best Resident Abstract 2014 CAMO Annual Meeting-certificate and honorarium.
- 2014 Mar - 2015 Jun **Co-Supervisor.** Pascale Tomasini. Supervisor(s): Dr. Frances Shepherd.
- 2013 Jul - 2015 Jun **Co-Supervisor.** Alona Zer, Clinical Research Fellow. Supervisee Institution: Princess Margaret Cancer Centre. Supervisor(s): Dr. Frances Shepherd.
- 2013 Jul - 2015 Jun **Co-Supervisor.** Mark Doherty, Clinical Research Fellow. Supervisee Institution: Princess Margaret Cancer Centre. Supervisor(s): Dr. Frances Shepherd; Dr. Jennifer Knox.
- 2013 Jul **Co-Supervisor.** Carol Ott, PGY4/5, Geriatrics Program, University of Toronto. *1. Longitudinal study of function and quality of life in older adults receiving chemotherapy for advanced non-small cell lung cancer.* Supervisor(s): Dr. Alibhai.
- 2013 Jan - 2014 Jun **Primary Supervisor.** Kitman Wong. Supervisee Institution: Princess Margaret Cancer Centre, Canadian Cancer Society Research Institute. Awards: Travel Award, 2000.00 CAD.
- 2012 Aug - 2014 Jul **Co-Supervisor.** Greg Korpanty, Clinical Research Fellow. Supervisor(s): Dr. Frances Shepherd.
- 2012 Aug - 2014 Jun **Primary Supervisor.** Donna Graham, Clinical Research Fellow. Supervisee Position: Fellow Medical Oncology, Supervisee Institution: Princess Margaret Cancer Centre. Awards: OICR Fellowship Grant (in support of ECCO-AACR-EORTC-ESMO Workshop) Workshop participant funding- 3000 Euro; Travel award-1600.00 CAD.
- 2012 Jul - 2014 Jun **Primary Supervisor.** Carmen Chung, PGY-5, Medical Oncology. Supervisee Position: PGY5, Medical Oncology, Supervisee Institution: Princess Margaret Cancer Centre. *Economic analysis of TORCH: Erlotinib vs. Cisplatin & Gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).* Awards: Annual Divisional Research and Awards Day, June 7, 2014.
- 2011 Sep - 2012 Aug **Primary Supervisor.** Clinical Fellow. Olusola Faluyi, Clinical Research Fellow. *Preoperative*

Metformin in Early stage Resectable NSCLC; Participant 14th Methods in Clinical Research.
Awards: OICR Fellowship Grant. Supervisor(s): Dr. Malcolm Moore and Dr. Frances Shepherd. Collaborator(s): Dr. Pamela Goodwin.

- 2011 Jul - 2012 Jun **Primary Supervisor.** Clinical Fellow. Petra Martin, Clinical Research Fellow. 1. *BIBW2992 in EGFR mutant NSCLC second-line. 2: EGFR mutation testing results, sample cellularity and treatment outcomes in Ontario.*
- 2011 Jul - 2012 Jun **Primary Supervisor.** Subspecialty. Dawn Ng, PGY 4, Medical Oncology. Supervisee Position: PGY5 Medical Oncology, Supervisee Institution: University of Toronto. 1. *Outcomes of male breast cancer, Ontario experience 2. HER2 adjuvant therapy and cardiac outcomes, Ontario experience.*
- 2010 Jul - 2015 Jun **Primary Supervisor.** Subspecialty. *Oncologists' Attitudes and Practices Regarding Physician-Patient Communication of Unfunded Cancer Therapies.*
- 2010 Jul - 2012 Jun **Primary Supervisor.** Subspecialty. Tina Hsu, PGY5, Medical Oncology. Supervisee Position: PGY5 Medical Oncology. 1. *Predictors of chemotherapy toxicity in elderly cancer patients – two objective markers of patient physical health.* Awards: 2011 Physicians Services Incorporated Foundation Research Award (\$4000).
- 2010 Jul - 2012 Jun **Primary Supervisor.** Maral Nadjafi. Supervisee Position: PGY4 Internal Medicine (Chief). 1. *Diagnostic patterns in advanced NSCLC – UHN experience.*
- 2010 Jul - 2012 Jun **Primary Supervisor.** Core Program. Adrian Sacher. Supervisee Position: IM PGY3, Supervisee Institution: University of Toronto. 1. *Pharmacoeconomic outcomes of advanced NSCLC therapy in Ontario 2. Shifting patterns of "positive" trials in advanced NSCLC 3. Inclusion of elderly patients in advanced NSCLC clinical trials. 4: SELECT: Surgery for early lung cancer treated with preoperative erlotinib.* Awards: 2010 American Society of Clinical Oncology Merit Award
2010 Novartis Young Canadian Investigator Award
2010 University of Toronto Division of Medical Oncology Annual Research Day - 1st Prize.
- 2010 Jan - 2010 Dec **Primary Supervisor.** Clinical Fellow. Arman Hasani, Research Clinical Fellow. 1. *Population outcomes in advanced mesothelioma treated with systemic therapy in Ontario 2. Pharmacoeconomic impact of systemic therapy in advanced mesothelioma in Ontario.*
- 2009 Jan - 2009 Mar **Primary Supervisor.** MD. Dawn Ng (PGY2). Supervisee Institution: University of Toronto. *Outcomes of patients over 70 with locally advanced non-small cell lung cancer.*
- 2009 **Primary Supervisor.** MD. Atia Haq (Medical Student). Supervisee Institution: University of Toronto. *Unfunded cancer therapy – physician survey.*
- 2008 Jul - 2010 **Primary Supervisor.** Clinical Fellow. Sara Taylor, Clinical Research Fellow. Supervisee Institution: University of Toronto. *Phase II study of pazopanib in breast cancer.*
- 2008 Jul - 2010 Jun **Co-Supervisor.** Clinical Fellow. Sara Taylor, Clinical Research Fellow. Supervisee Institution: University of Toronto.
- 2008 Feb - 2009 Dec **Co-Supervisor.** Clinical Fellow. Tom John, Clinical Research Fellow.
- 2008 Feb - 2009 Dec **Co-Supervisor.** Clinical Fellow. Linda Coate, Clinical Research Fellow.
- 2008 Jan - 2009 Jun **Co-Supervisor.** Clinical Fellow. Zarnie Lwin, Clinical Research Fellow. Supervisee Institution: University of Toronto.
- 2008 - 2010 **Primary Supervisor.** Clinical Fellow. Zarnie Lwin, Clinical Research Fellow. Supervisee Institution: University of Toronto. *Prognostic outcome of nodal extent and effusion in small-cell lung cancer.*
- 2008 - 2010 **Primary Supervisor.** Raymond Jang. Supervisee Institution: University of Toronto. 1. *Q-TwiST analysis of BR.10, adjuvant therapy in NSCLC; 2. EORTC QLQ-C30 and EuroQoL – valuation of utilities in NSCLC; 3. Willingness to pay for VEGF inhibitors in advanced NSCLC.* Awards: ASCO Merit Award, 2008
Novartis Young Canadian Investigator Award, 2008
PSI Resident Research Award 2008
Young Investigator Award, 13th World Conference on Lung Cancer.
- 2007 Jul - 2010 Jun **Co-Supervisor.** Clinical Fellow. Anne Horgan, Clinical Research Fellow.

- 2007 Jan - 2008 Dec **Co-Supervisor.** Clinical Fellow. Paul Wheatley-Price, Clinical Research Fellow. Supervisee Institution: University of Toronto.
- 2007 - 2009 **Primary Supervisor.** Clinical Fellow. Robert Goldberg, DOCH2 Medical Student. Supervisee Institution: University of Toronto. *1. Unfunded cancer therapy – patient perspective questionnaire; 2. Willingness to pay for VEGF inhibitors in advanced NSCLC.* Awards: 1st prize U of T Division of Medical Oncology Annual Research Day, Jun/09.
- 2007 - 2008 **Primary Supervisor.** Alyse Goldberg, DOCH2 Medical Student. Supervisee Institution: University of Toronto. *Unfunded cancer therapy – physician survey.*
- 2007 **Primary Supervisor.** Dr. Winson Cheung, PGY4/5. *Retrospective review of outcomes for patients with multifocal BAC treated with multiple modalities.*
- 2007 **Primary Supervisor.** Leena Hajra, PGY3. Supervisee Institution: University of Toronto. *Pilot testing of a decision aid for NSCLC patients considering adjuvant chemotherapy.*
- 2007 **Primary Supervisor.** Bianca Petrut, PGY3. Supervisee Institution: University of Toronto. *Psychosocial outcomes of waiting times for lung cancer therapy.* Collaborator(s): Co-supervisor Dr. Simron Singh, TSRCC.
- 2006 Aug - 2008 Jun **Co-Supervisor.** Clinical Fellow. Sheray Chin, Clinical Research Fellow.
- 2006 Jul - 2008 Jun **Co-Supervisor.** Clinical Fellow. Penny Bradbury, Clinical Research Fellow.
- 2006 Jul - 2007 Jun **Co-Supervisor.** Clinical Fellow. Martin Fruh, Clinical Research Fellow.
- 2006 - 2008 **Primary Supervisor.** Dr. Penelope Bradbury, Clinical Research Fellow. Supervisee Institution: University of Toronto. *Cost effectiveness analysis and cost-utility of erlotinib 2nd or 3rd line after chemotherapy failure in advanced NSCLC, NCIC CTG BR.21.* Awards: ASCO Merit Award
2008 Novartis Young Canadian Investigator Award, 2008.
- 2006 - 2007 **Primary Supervisor.** Meteb Al-Harbi (PGY3). *Management of local nodal recurrence in breast cancer.*
- 2006 **Primary Supervisor.** Dr. Leora Horn, Medical Oncology Resident, University of Toronto. *AZD2171 in locally advanced breast cancer.*
- 2006 **Primary Supervisor.** Jennifer Li, Year 2 Medical Student, University of Toronto. *Determinants of Community Health II Project Individual Learning Plan: Evaluation of a decision aid for patients with completely resected NSCLC considering adjuvant chemotherapy.*
- 2006 **Primary Supervisor.** Meteb Al-Foheidi (PGY2) – U of T. *Management of local nodal recurrence in breast cancer [supraclavicular lymph nodes and axillary lymph nodes].*
- 2005 Aug - 2006 Jul **Co-Supervisor.** Clinical Fellow. Carmela Pepe, Clinical Research Fellow.
- 2005 Jul - 2006 Jun **Primary Supervisor.** Kathryn Howe, Year 2 Medical Student, University of Toronto. *Determinants of Community Health II Project Individual Learning Plan: Determine the barriers for patients with completely resected stage 1B-11A non-small cell lung cancer (NSCLC) when considering adjuvant chemotherapy.*
- 2005 Jun - 2006 Jun **Co-Supervisor.** Clinical Fellow. Marie Florescu, Clinical Research Fellow.
- 2005 - 2010 **Primary Supervisor.** Clinical Fellow. Dr. Humberto Lara-Guerra, Thoracic Surgery Fellow. Supervisee Institution: University of Toronto. *1. Preoperative gefitinib in Stage 1A NSCLC; 2. Preoperative erlotinib in Stage 1-3 NSCLC.* Collaborator(s): Co-supervisor, Dr. Tom Waddell.
- 2005 - 2009 **Primary Supervisor.** Clinical Fellow. Dr. Carmela Pepe, Clinical Research Fellow. *Indirect costs of lung cancer – a patient survey.*
- 2005 - 2007 **Primary Supervisor.** Clinical Fellow. Dr. Raymond Ng, Clinical Research Fellow, University of Toronto. *1. BR10 cost effectiveness analysis; 2. Preoperative evaluation of bortezomib in early stage lung cancer; 3. Second-line chemotherapy vs EGFR TKI – review of single centre experience.* Awards: Novartis Young Canadian Investigator Award, 2006.
- 2004 Nov - 2005 Jan **Primary Supervisor.** Farrah Kassam (PGY2), University of Toronto. *1. Randomized trial of computer-based quality of life intervention in advanced non-small cell lung cancer (NSCLC) patients on chemotherapy; 2. Referral patterns for adjuvant chemotherapy in early stage NSCLC.*

Natasha LEIGHL

- 2004 Jul - 2008 Jun **Co-Supervisor.** Clinical Fellow. Anthony Joshua, Clinical Research Fellow.
- 2004 Jul - 2006 Jun **Co-Supervisor.** Clinical Fellow. Antonio Visbal, Clinical Research Fellow. Awards: selected for participation in the 7th FECS/AACR/ASCO Workshop on Methods in Clinical Cancer Research, Flims, Switzerland Jun/05.
- 2004 Jul - 2006 Jun **Co-Supervisor.** Clinical Fellow. Ali Al-Jubran, Clinical Research Fellow.
- 2004 Jul - 2005 Jun **Co-Supervisor.** Clinical Fellow. Srikala Sridhar, Clinical Research Fellow.
- 2004 Jul - 2005 Feb **Co-Supervisor.** Clinical Fellow. Elaine McWhirter, Clinical Research Fellow.
- 2004 May - 2007 Aug **Co-Supervisor.** Clinical Fellow. Raymond Ng, Clinical Research Fellow. Supervisee Institution: Princess Margaret Cancer Institute. *BR 10 cost effectiveness analysis*. Awards: 2006 Novartis Young Investigators Award.
- 2004 - 2009 **Primary Supervisor.** Clinical Fellow. Dr. Farrah Kassam, Internal Medicine Resident, University of Toronto. *1. Randomized trial of computerized QOL assessment in advanced lung cancer; 2. Referral patterns for adjuvant therapy in early stage NSCLC.*
- 2004 - 2006 **Primary Supervisor.** Clinical Fellow. Antonio Visbal, Clinical Fellow, University of Toronto. *Preoperative evaluation of novel therapies in NSCLC.*
- 2004 - 2005 **Primary Supervisor.** Eric Salomon, Radiation Technologist, University Health Network. *Cost effectiveness of CT screening.*
- 2004 - 2005 **Primary Supervisor.** Clinical Fellow. Dr. Milan Patel, Respiratory Fellow, University of Toronto. *Role of CT scanning in follow-up of Stage 3 NSCLC patients.*
- 2004 - 2005 **Primary Supervisor.** Clinical Fellow. Dr. Elaine McWhirter, Medical Oncology Fellow, University of Toronto. *Evaluating novel agents in advanced breast cancer, HDAC inhibitors.*
- 2003 Dec - 2004 Oct **Co-Supervisor.** Clinical Fellow. Ewan Brown, Clinical Research Fellow.
- 2003 Jul - 2006 Dec **Co-Supervisor.** Clinical Fellow. Janette Vardy, Clinical Research Fellow.
- 2003 Jul - 2004 Jun **Co-Supervisor.** Clinical Fellow. Kevin Jasas, Clinical Research Fellow.
- 2003 - 2004 **Primary Supervisor.** Dr. Simron Singh, Medical Oncology resident, University of Toronto. *Cost effectiveness study of 2nd line chemotherapy in lung cancer, cost effectiveness study of zoledronate in advanced NSCLC with bony metastases.*
- 2002 - 2004 **Primary Supervisor.** Clinical Fellow. Dr. Milan Patel, Respiratory Fellow, University of Toronto. *1. Needs assessment of patients with advanced lung cancer; 2. Role of CT scanning in follow up of lung cancer patients.*

Clinical Research Fellow (MD)

- 2021 Jul - 2023 Jun **Co-Supervisor.** Lucy Corke. *Impact of Liquid Biopsy on Patient Reported Outcomes, Non-thesis Project.* Supervisor(s): Natasha Leighl and Adrian Sacher.
- 2020 Oct - 2022 Sep **Primary Supervisor.** Miguel Garcia. *ACCELERATE: accelerating time to treatment in advanced NSCLC patients, Non-thesis Project.*
- 2020 Jul - 2022 Jun **Primary Supervisor.** Nicholas Meti. *LU-NGS-3: Comprehensive NGS in Routine Practice - Opportunities and Costs, Non-thesis Project.*
- 2020 Jul - 2021 Oct **Primary Supervisor.** Deirdre Kelly. *Intercept Cancer: ctDNA Lung Detect and RCT, Non-thesis Project.*
- 2020 Jul - 2021 Oct **Primary Supervisor.** Deirdre Kelly. *Phase III trials - are they always necessary in lung cancer?, Non-thesis Project.* Supervisor(s): Co supervisor: Dr. Peter Ellis, Juravinski Cancer Centre.
- 2020 Jul - 2021 Jun **Primary Supervisor.** Shelley Kuang. *LU-NGS-1: NGS as a routine diagnostic in the management of advanced NSCLC patients, Non-thesis Project.*
- 2020 Jul - 2021 Jun **Primary Supervisor.** Shelley Kuang. *TERAVOLT: Outcomes of Lung Cancer Patients with COVID-19, Non-thesis Project.*
- 2019 Jul - 2021 Jun **Primary Supervisor.** Sally Lau. *MET ex 14 mutant NSCLC: Correlative real world study of outcomes and MET protein expression, Non-thesis Project.*
- 2019 Jul - 2021 Jun **Primary Supervisor.** Sally Lau. *PD-L1 Cytology Validation: Treatment outcomes by cytology*

Natasha LEIGHL

- 2019 Jul - 2020 Jun *versus pathology, Non-thesis Project.* Supervisor(s): Co-supervisor Dr. Joerg Schwock, LMP.
Primary Supervisor. Andrea Fung. *Binimetinib plus Pemetrexed and Carboplatin as First line therapy in advanced lung cancer, Non-thesis Project.*
- 2019 Jul - 2020 Jun **Primary Supervisor.** Andrea Fung. Supervisee Position: PGY4/5 Medical Oncology. *LU-NGS-1: NGS as a routine diagnostic in the management of advanced NSCLC patients, Non-thesis Project.*
- 2019 Jul - 2020 Jun **Primary Supervisor.** Andrea Fung. *Binimetinib plus Pembrolizumab as First line therapy in advanced lung cancer with PD-L1 TPS>=50%, Non-thesis Project.*
- 2019 Jul - 2020 Jun **Primary Supervisor.** Marie Pier Gauthier. *Validation of Natural Language Processing Data Extraction in Advanced Lung Cancer Patients, Non-thesis Project.*
- 2017 Jul - 2018 Dec **Primary Supervisor.** Doreen Ezeife. Supervisee Institution: Princess Margaret Cancer Centre. *VALUE - integrating circulating DNA into standard of care in lung cancer.*
- 2017 Jul - 2018 Dec **Primary Supervisor.** Doreen Ezeife. Supervisee Institution: Princess Margaret Cancer Centre. *COST: evaluating financial toxicity in Canadian cancer patients.*
- 2016 Jul - 2019 **Primary Supervisor.** Grainne O'Kane. Supervisee Institution: Princess Margaret Cancer Centre. *Circulating DNA in advanced EGFR mutant NSCLC patients; Mechanisms of resistance to EGFR TKI in non-T790M mutated lung cancer, Non-thesis Project.*
- 2016 Jul - 2017 Jun **Co-Supervisor.** Mor Moskovitz. Supervisee Institution: Princess Margaret Cancer Centre. *Treatment Beyond Progression - ALK and IO, Non-thesis Project.*
- 2016 Jul - 2017 Jun **Primary Supervisor.** Tristan Barnes. Supervisee Institution: Princess Margaret Cancer Centre. *PDL-1 testing in FNA samples; Willingness to pay for circulating DNA testing for EGFR T790M mutations in lung cancer, Non-thesis Project.*
- 2016 Jul - 2017 Jun **Primary Supervisor.** James Kuo. Supervisee Institution: Princess Margaret Cancer Centre. *Correlates of Response and Resistance to Immune Checkpoint Inhibitors in Lung Cancer, Non-thesis Project.*
- 2015 Jul - 2020 Mar **Co-Supervisor.** Hamzeh Al-Baba. Supervisee Institution: Princess Margaret Cancer Centre. *Quality of Life as a Drug Registration Endpoint in Lung Cancer.* Supervisor(s): Dr. Leigh/Hedley.

Other

- 2018 May - 2018 Aug **Primary Supervisor.** Malcolm Ryan. *Non-thesis Project.*
- 2016 May - 2016 Oct **Primary Supervisor.** Kanwalpreet Walia. Supervisee Position: Undergraduate Summer Research Student, Supervisee Institution: University of Toronto. *Circulating DNA in EGFR+ lung cancer, Non-thesis Project.*

2. OTHER SUPERVISION

Undergraduate Education

Faculty Advisor

- 2003 - 2004 James Kennedy. *University of Toronto Medical School Pharmacology Handbook–Oncology Chapter.*
- 2003 - 2004 Adrianna Malicki. *University of Toronto Medical School Pharmacology Handbook–Oncology Chapter.*
- 2003 - 2004 Tripti Papneja (Yr 1). *University of Toronto Medical School Pharmacology Handbook–Oncology Chapter.*

Graduate Education

Secondary Supervisor

2003 - 2005

PhD. Dr. Eric Salomon, Health Sciences Program, Charles Sturt University, Australia (distance education). *Low dose CT screening for early detection of lung cancer on the Canadian Health Care System.* Collaborator(s): Primary Supervisors: Dr. T. & H. Roberts, U of T.

Thesis Committee Member

2022 Jan - 2025 Jun

PhD. Lara Chayab. Supervisee Position: PhD Candidate. *Effectiveness of ALK inhibitors in NSCLC.* Supervisor(s): William Wong.

2021 Jul - 2023 Jun

Graduate Diploma in Health Research (GDipHR). Karolina Gaebe. Supervisee Position: MSc Candidate. Supervisor(s): Sunit Das.

2020 Jul - 2022 Jan

MSc. Lara Chayab. Supervisee Position: MSc Candidate. *Effectiveness of ALK inhibitors in NSCLC.* Supervisor(s): William Wong/Murray Krahn.

2013 Jul - 2015

PhD. Pedro Reck dos Santos. Supervisee Position: Graduate Student, Supervisee Institution: IMS. *Modified isolated lung perfusion technique allows for prolonged perfusion without acute lung injury: A pre-clinical study of doxorubicin.* Supervisor(s): Dr. M. Cypel.

2013 Jul - 2014 Dec

MSc. Dolly Han, Pharmaceutical Sciences. Supervisee Position: MSc Candidate, Supervisee Institution: University of Toronto Lesley Dan Faculty of Pharmacy. *Real-world cost-effectiveness analysis of second-line pemetrexed versus docetaxel in the Ontario non-small-cell lung cancer population.* Supervisor(s): Jeffrey Hoch.

2012 Jul - 2014 Sep

PhD. Mallory Thao. Supervisee Institution: University of Toronto, Pharmaceutical Sciences, Lesley Dan Faculty of Pharmacy. *The Cost Effectiveness of Screening for Early Stage Lung Cancer and the Testing and Treatment of Disease Mutations Among Non-Small Cell Lung Cancer Patients in the Province of Ontario, Canada.* Supervisor(s): Jeffrey Hoch.

2008 Jan - 2014 Aug

PhD. Ilia Ferrusi. Supervisee Position: PhD Candidate, Health Research Methodology, Supervisee Institution: McMaster University. *A cost-effectiveness analysis of targeted therapy for HER2-positive breast cancer based on Canadian practice patterns.* Awards: Canadian Institutes of Health Research (CIHR) Frederick Banting & Charles Best Canada Doctoral Scholarship Recipient (2009-2011)

2010 McMaster Faculty of Health Science Excellence Award

2011 CAPT Best Student Presentation. Collaborator(s): Primary Supervisor: Professor D. Marshall, McMaster University.

Thesis Examiner

2021 Jul

PhD. Yong-Jin Kim, Pharmacology and Toxicology. *Comparative Clinical and Cost-Effectiveness Analysis of First- and Second-Line Therapies for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer in Ontario, Canada.* Supervisor(s): Sue Horton.

2020 Nov

PhD. Lucy Jane Gately. Supervisee Institution: Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne. *Clinical, Molecular and Psychological Profiling of Long-Term Survivors of Glioblastoma.*

2018 Jul

PhD. Anna Collins, Medical Science. Supervisee Position: University of Melbourne. *Towards the Integration of Palliative Care in Advanced Cancer: An Exploration of Patient, Family and Community Perceptions of Palliative Care and their Views of Communication.* Supervisor(s): Dr. Sue Ann McLachlan.

2015 Aug

MSc. Cameron Thompson. Supervisee Position: MSc in Applied Health Sciences Candidate, Supervisee Institution: Brock University. *Predicting the Risk of Lung Cancer in Never-smokers.* Supervisor(s): Dr. Martin Tammemagi.

2013 Jul - 2014 Dec

MSc. Dolly Han, Pharmaceutical Sciences. Supervisee Position: MSc Candidate, Supervisee Institution: University of Toronto Lesley Dan Faculty of Pharmacy. *Real-world cost-effectiveness analysis of second-line pemetrexed versus docetaxel in the Ontario non-small-cell lung cancer population.* Supervisor(s): Jeffrey Hoch.

Natasha LEIGHL

2012 Jul - 2014 Sep

PhD. Mallory Thao. Supervisee Institution: University of Toronto, Pharmaceutical Sciences, Lesley Dan Faculty of Pharmacy. *The Cost Effectiveness of Screening for Early Stage Lung Cancer and the Testing and Treatment of Disease Mutations Among Non-Small Cell Lung Cancer Patients in the Province of Ontario, Canada.* Supervisor(s): Jeffrey Hoch.

2008 Jan - 2014 Aug

PhD. Ilia Ferrusi. Supervisee Position: PhD Candidate, Health Research Methodology, Supervisee Institution: McMaster University. *A cost-effectiveness analysis of targeted therapy for HER2-positive breast cancer based on Canadian practice patterns.* Awards: Canadian Institutes of Health Research (CIHR) Frederick Banting & Charles Best Canada Doctoral Scholarship Recipient (2009-2011)

2010 McMaster Faculty of Health Science Excellence Award

2011 CAPT Best Student Presentation. Collaborator(s): Primary Supervisor: Professor D. Marshall, McMaster University.

Qualifying/Reclass Examiner

2022 Jan

PhD. Lara Chayab. Supervisee Position: PhD Candidate. *Effectiveness of ALK inhibitors in NSCLC.* Supervisor(s): William Wong.

2013 Jul - 2014 Jun

MSc. Erin Stewart, Medical Biophysics. Supervisee Position: MSc Candidate, Supervisee Institution: University of Toronto. *Modeling targeted therapy mechanisms and predictive biomarker discovery using patient-derived primary non-small cell lung cancer xenografts.* Supervisor(s): Ming Sound Tsao.

MSc Thesis Defence Chair

2021 Jun

MSc. Tanya Hauck. *Postoperative Buprenorphine Discontinuation In Continuously Treated Buprenorphine Patients: A Population Cohort Study.* Supervisor(s): Paul Kurdyak.

Postgraduate MD

Faculty Review Committee Member MOTP Research Month

2013 Jul - 2014 Jun

Subspecialty.

Other

2010 Jul - 2011 Jun

Clinical Fellow.

Other

Thesis Examiner

2016

PhD. Bianca Devitt. Supervisee Position: PhD Candidate, Supervisee Institution: University of Melbourne. *An examination of the dynamics and processes of multidisciplinary cancer meetings.* Supervisor(s): SueAnn McLachlan. Completed 2016.

2013

PhD. Belinda Emma Kiely. Supervisee Position: PhD Candidate, Supervisee Institution: University of Sydney. *Estimating Survival Duration and Communication of Prognostic Uncertainty in Patients with Incurable Cancer.* Supervisor(s): Martin Stockler.

2012

PhD. Rachel Fitz-Gerald Dear. Supervisee Position: PhD Candidate, Supervisee Institution: University of Sydney. *The potential of clinical trial registries to inform cancer care in Australia.* Supervisor(s): Martin Stockler.